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Abstract 
DNA, due to its double-helical structure, is subject to changes in topology due to the nature 
of transcription and replication. To overcome this, cells have processes and enzymes that 
ameliorate these changes. One such group of enzymes are the DNA topoisomerases, which are 
responsible for the maintenance of DNA topology. Despite this important role, these enzymes 
participate in illegitimate recombination (IR), which is genetic recombination between regions 
of DNA that share little or no homology. This can result in chromosomal rearrangements and is 
often a consequence of DNA-damaging agents. A consequence of topoisomerase-induced IR is 
thought to be therapy-related acute myeloid leukaemia (tAML). Analogously, there is evidence 
that exposure to sublethal concentrations of ciprofloxacin, a topoisomerase inhibitor, can cause 
resistance to non-quinolone antibiotics. This may work by a similar mechanism as that proposed 
for t-AML. This project centres around the examination of DNA gyrase-mediated IR focussing on 
the proposed subunit-exchange model. Using Blue-Native PAGE, I set up an assay to examine 
subunit exchange in topoisomerases. I have also characterised previously identified gyrase 
hyper-recombination mutations, known to increase the frequency of IR. Furthermore, I have 
investigated quinolone-induced antibiotic resistance and what the mechanism is. Here, I show 
that DNA gyrase can undergo subunit exchange, and that this seems to occur within higher-
order oligomers of the enzyme, which have not been investigated before. Biochemical 
characterisation of the hyper-recombination mutations shows that they impair DNA gyrase 
activity which, in vivo, may have downstream consequences that may lead to IR. Using an in vivo 
assay where E. coli is treated with subinhibitory levels of quinolones, I have seen resistance to 
other non-quinolone antibiotics. This is not seen when other antibiotics, including other 
topoisomerase inhibitors, are tested. Whole genome sequencing has revealed point mutations 
that explain the resistances seen, however other larger chromosomal modifications have been 
observed as well.
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Chapter 1: General Introduction 
During the cell cycle, DNA can be subject to a number of topological and structural changes. 
However, the integrity of DNA structure and sequence is vital to all cells. Large amounts of DNA 
damage and accumulations of mutations can cause apoptosis. However, changes to DNA 
sequence through homologous recombination can result in an important increase in genetic 
variation, whilst non-homologous recombination can provide important mutations that help 
organisms survive in hostile environments. During replication and transcription, the 
maintenance of sequence fidelity is important and cells have a number of repair systems to 
ensure this, as well as having processes in place to fix damaged DNA. In this introduction, the 
topological challenges involved with replication and transcription and how the cell ameliorates 
these challenges through the use of DNA topoisomerases will be described, as well as the 
problems that can arise when things go wrong, including the consequences of targeting these 
enzymes in antibiotic chemotherapy. 
1.1  Topology of chromosomes 
DNA compaction is essential for chromosomal DNA to fit inside the cell. It involves structural 
proteins and changes in DNA topology, in both prokaryotes and eukaryotes, to achieve this. The 
structural proteins involved include histones (eukaryotes), HU protein (prokaryotes) and SMC 
proteins (both) to help arrange the DNA into topological domains (Cobbe & Heck, 2000, Sherratt, 
2003, Luijsterburg et al., 2008, Vos et al., 2011). 
DNA, due to its double-helix structure, is subject to topological changes during processes 
such as replication and transcription, which require the two strands of the double helix to be 
separated (Watson & Crick, 1953a, Watson & Crick, 1953b). The DNA helix is considered to have 
topological properties due to the length and high frictional energy of chromosomes, the fact 
that plasmids and many chromosomes are circular, and that chromosomes are often anchored 
by biological membranes or other chromosomal scaffolds (Bates & Maxwell, 2005, Deweese et 
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al., 2009, Espeli & Marians, 2004). In addition to the fact that the linkages formed in DNA cannot 
change unless there is breakage and reunion (Bates & Maxwell, 2005, Lindsley, 2001). DNA 
topological conformations include supercoils, knots and catenanes (Bates & Maxwell, 2005, 
Lindsley, 2001, Seol & Neuman, 2016). Supercoiled DNA is a structural consequence of the two 
strands of DNA wrapped around each other in the double helix, which is then coiled upon itself. 
It can be found in two forms: plectonemic supercoils and solenoidal (toroidal) supercoils 
(Lindsley, 2001). DNA supercoiling is best described in terms of twist, writhe and linking number. 
Linking number (Lk) is a topological property applied to closed circular DNA (or constrained DNA) 
and it is defined as the number of times two DNA strands are wrapped around each other (Bates 
& Maxwell, 2005). It is the sum of the twist and writhe, which are the two geometric properties 
of DNA. Twist (Tw) is the number of helical turns in a molecule of DNA while writhe (Wr) is the 
number of superhelical turns (Bates & Maxwell, 2005). Supercoiled DNA is defined in the change 
in Lk (∆Lk) from a relaxed state (Lk = 0). Negatively-supercoiled DNA (underwound) is defined as 
a reduction in Lk (∆Lk < 0) and is accommodated by a reduction in Tw and the formation of 
negative (right-handed) Wr. Whilst positively supercoiled DNA (overwound) is defined as an 
increase in Lk (∆Lk > 0) which results in an increase in Tw and positive (left-handed) Wr (Bates & 
Maxwell, 2005, Seol & Neuman, 2016). Negatively-supercoiled DNA primarily forms 
plectonemes whilst toroidal supercoils, which are not normally found in free DNA, tend to be a 
result of packaging of DNA around structural DNA-binding proteins (Bates & Maxwell, 2005, 
Lindsley, 2001, Seol & Neuman, 2016). The DNA crossings in knots and catenanes are generally 
described in terms of nodes. In knots, the rotation direction defines whether the node is positive 
or negative, where as in catenanes this may be arbitrary depending on the similarity of the 
circles and the degree to which they can be orientated by DNA sequence (Bates & Maxwell, 
2005). 
Plectonemic supercoiling can compact the E. coli bacterial chromosome, which is about 4.6 
Mb long, by three orders of magnitude to fit inside the cell (Boles et al., 1990, Blattner et al., 
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1997, Holmes & Cozzarelli, 2000, Sherratt, 2003). This leaves most of the chromosome 
unconstrained by proteins (Holmes & Cozzarelli, 2000, Sherratt, 2003). However, the E. coli 
chromosome has been shown to be further organised into approximately 400 topological 
domains that are structurally maintained with the help of the SMC proteins (Deng et al., 2005, 
Postow et al., 2004). Despite the level of compaction, the structured nature of the chromosome, 
as well as the fact that the E. coli chromosome has a single replication origin, replication and 
segregation can be achieved in 20 min (Postow et al., 2004). As a result of the physical properties 
of the negatively-supercoiled DNA and the high level of spatial organisation within the 
chromosome, processes such as replication and transcription result in a number of topological 
challenges that have to be overcome for continued survival. 
1.2  Topological changes during replication and transcription 
Negative supercoiling has been shown to be important in bacteria (Holmes & Cozzarelli, 
2000), though, it has been shown to be more important in E. coli than in some others (such as 
in Salmonella sp.) (Higgins, 2016). Due to its physical properties, negative supercoiling allows for 
the denaturation of the DNA duplex on the initiation of replication at the origin (Holmes & 
Cozzarelli, 2000, Seol & Neuman, 2016). Moreover, negative supercoiling has been shown to be 
essential for replication to proceed (Funnell et al., 1986, Schvartzman & Stasiak, 2004). During 
replication, the binding of the replication machinery to single-stranded DNA requires the 
unwinding and separation of the DNA duplex. Replication initiation begins with the binding and 
subsequent oligomerisation of DnaA (Cunningham & Berger, 2005). This causes unwinding of 
the DNA duplex at oriC, followed by the recruitment of the helicase loader DnaC and the 
replicative helicase DnaB, in complex, onto single-stranded DNA (Duderstadt et al., 2014, 
Sherratt, 2003, Cunningham & Berger, 2005). Replication elongation begins with the 
concomitant dissociation of DnaC and recruitment of DnaG, the replication primase, which in 
complex with DnaB synthesises RNA primers. DNA polymerase III is then loaded onto the primed 
DNA with the help of the β-clamp and the clamp loader (Duderstadt et al., 2014, Katayama et 
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al., 1998, Graham et al., 2017). These events and replication fork progression causes positive 
supercoils to build up ahead of the fork (Postow et al., 2001, Schvartzman & Stasiak, 2004) 
(Figure 1.1). These positive supercoils need to be resolved as a build-up will cause a large amount 
of torsional stress (Seol & Neuman, 2016) that can stall replication. This stalling can cause 
replication fork regression (Postow et al., 2001) or double-stranded DNA breaks (Michel et al., 
2004). To relieve the torsional stress, the replication fork may rotate causing the development 
of precatenanes behind the fork (Figure 1.1) (Peter et al., 1998, Postow et al., 2001, Sogo et al., 
1999, Cebrián et al., 2015). These precatenanes can become tangled and knotted if left 
unresolved, leading to incomplete segregation at the end of replication. The conversion of 
positive supercoils into precatenanes by replication fork rotation is more likely towards the end 
of replication, where there is no longer space for the removal of positive supercoils ahead of the 
replication fork (Postow et al., 2001, Cebrián et al., 2015). Further to this, as replication forks 
converge towards the end of replication, the interwound (pre-catenated) DNA is then converted 
to catenated DNA which, if left, will stop chromosome segregation (Figure 1.1) (Schvartzman & 
Stasiak, 2004). At the termination of replication, occasionally a hemicatenane may form. This is 
a topological linkage where the two newly replicated DNA circles are still linked by a duplex of 
the parental strands (Figure 1.1) (Laurie et al., 1998, Vos et al., 2011). Alternatively, the positive 
supercoils ahead of the replication fork at the termination of replication may be resolved into 
Holliday Junctions that will need to be disentangled before segregation (Sherratt, 2003). Despite 
the topological stress that is associated with positive supercoils, the chromosomes of 
thermophiles have been shown to be positively supercoiled. This is most likely due to the higher 
melting point of positive supercoiling and thus greater stability at high temperatures (Forterre, 
2002, Forterre et al., 1985, Kikuchi & Asai, 1984). 
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Figure 1.1: Various topological products that form during replication. As the replisome 
moves along the DNA, it can cause a build-up of positive supercoils ahead of the fork and 
precatenanes behind, which if left unresolved can cause replication fork collapse or stalling 
and knotting of sister duplexes, which may cause missegregation, respectively. At fork 
convergence, hemicatenanes can be formed which can be resolved into catenanes, both of 
which, if left, can cause missegregation. Figure adapted from (Vos et al., 2011) with 
permission. 
DNA topology and the control of negative supercoiling has also been demonstrated to be 
important during transcription. In a similar way to replication, positive supercoils can build up 
ahead of RNA polymerase whilst negative supercoils can build up behind it (Figure 1.2). If left 
unresolved these can impede transcription (Dorman & Dorman, 2016, Lilley et al., 1996, Liu & 
Wang, 1987, Seol & Neuman, 2016). The degree of superhelical density of promoters has also 
been shown to influence gene expression. Additionally, the topological changes caused during 
transcription can locally affect the expression of other genes upstream or downstream (Dorman 
& Dorman, 2016, Lilley et al., 1996). 
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Figure 1.2: Topological problems arising during transcription. During transcription, as RNA 
polymerase unwinds the DNA, increased negative supercoils can form behind and positive 
supercoils can form ahead of the transcribed region. If left unresolved, this will result in 
stalling of RNA polymerase or failure of transcription. Figure adapted from (Vos et al., 2011) 
with permission. 
There is an added level of complication in bacteria and particularly in fast-growing species. 
Here replication and transcription are happening at the same time and collisions between the 
replication machinery and RNA polymerase occur frequently (McGlynn et al., 2012). These can 
be head-on collisions or co-directional where the replication machinery catches up with RNA 
polymerase which moves at a much slower rate (McGlynn et al., 2012, Hamperl & Cimprich, 
2016, Mangiameli et al., 2017). Head-on collisions have been shown to be the more devastating 
on fork progression. This can be either due to direct clashing of RNA polymerase with the 
replicative helicases or due to a build-up of positive supercoils between the converging 
processes (McGlynn et al., 2012, Hamperl & Cimprich, 2016). Therefore, the highly-transcribed 
genes in fast replicating bacteria, such as E. coli, have been demonstrated to be orientated such 
that co-directional collisions are more likely. However, this does not completely solve the 
problem with highly-transcribed genes consistently causing replication blockages (McGlynn et 
al., 2012, Hamperl & Cimprich, 2016). 
In terms of recombination, negative supercoiling has also been demonstrated to be 
important. This is most often seen with bacteriophage chromosomes, which need to be 
negatively supercoiled for integrase-type site-specific recombination to occur (Mizuuchi et al., 
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1978a, Nash, 1990). Another type of site-specific recombination involving resolvases (such as 
transposons), termed transposition site-specific recombination, can result in various knotted 
and catenated products. These products need to be resolved for continued survival of the cell 
(Bates & Maxwell, 2005). 
Overall, the maintenance of DNA topology is crucial for survival. Negative supercoiling needs 
to be maintained at approximately 20% of the normal mean value for continued growth in E. coli 
(Drlica, 1992, Deng et al., 2005). Loss of supercoiling can result in problems with chromosomal 
segregation (Hiraga et al., 1989, Holmes & Cozzarelli, 2000, Sawitzke & Austin, 2000) and issues 
with gene expression and replication (Deng et al., 2005, Zechiedrich et al., 1997). While 
increased DNA supercoiling can cause unwanted DNA structures that can affect transcription or 
cause stalling of replication forks (Deng et al., 2005, Higgins & Vologodskii, 2015). Like many 
other processes in biology, the interconversion of the various topological forms of DNA is 
maintained enzymatically. This maintenance of DNA topology is mediated by a group of diverse 
enzymes called DNA topoisomerases. 
 
1.3  DNA Topoisomerases 
  Topoisomerases are enzymes that catalyse the interconversion of different topological 
forms of DNA (Bates & Maxwell, 2005). They are found ubiquitously and are essential to all cells. 
Topoisomerases work by cleaving either one or both strands of DNA. They then allow one strand 
to rotate around the other (controlled rotation) or pass the uncleaved strand through the 
cleaved strand (strand passage) before resealing the DNA backbone. In fact, topoisomerases are 
classified by the type of cleavage they make with DNA (i.e. single-stranded or double-stranded 
breaks). Type I topoisomerases catalyse reactions by cleaving one strand of the DNA backbone 
whilst type II topoisomerases cleave both strands. During topoisomerase-catalysed reactions, 
the cleavage is transient and is formed by the creation of a phosphodiester bond between the 
  Chapter 1: General Introduction 
8 
 
catalytic tyrosine in the topoisomerase active site and the DNA backbone. These breaks in the 
DNA alter the linking number; type I topoisomerases alter the linking number by one per 
reaction cycle whilst type II topoisomerases alter the linking number by two. The respective 
reactions that each type of topoisomerase catalyses is depicted in Figure 1.3 and Figure 1.4 
(Champoux, 1981, Deweese et al., 2009, Liu et al., 1980, Schoeffler & Berger, 2008, Sissi & 
Palumbo, 2010, Vos et al., 2011). Type I topoisomerases typically catalyse ATP-independent 
reactions whilst type II topoisomerases require ATP for their catalytic cycles. Furthermore, many 
topoisomerases require a divalent metal ion cofactor for catalysis (Champoux, 1981, Schoeffler 
& Berger, 2008).  
Type I topoisomerases can be further subdivided into types IA, IB and IC whilst the type II 
enzymes are divided into types IIA and type IIB. These subdivisions are based on differences in 
mechanism, structure and evolution (Schoeffler & Berger, 2008, Vos et al., 2011). The specific 
types of reactions that the different topoisomerases have been shown to catalyse in vitro are 
indicated in Table 1.1. 
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Figure 1.3: Reactions performed by type I topoisomerases. Examples of specific type I 
topoisomerases that catalyse the indicated reactions are given above the arrows. It is 
important to note that in the decatenation/catenation reaction, the non-nicked plasmid may 
be supercoiled before decatenation/catenation occurs; for illustrative purposes it has been 
drawn as relaxed. Figure taken from EcoSal Plus (Bush et al., 2015) with permission. 
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Figure 1.4: Reactions performed by type II topoisomerases. Examples of specific type II 
topoisomerases that catalyse the indicated reactions are given above the arrows. It is 
important to note that in the decatenation/catenation reaction, the plasmids may be 
supercoiled before decatenation/catenation occurs; for illustrative purposes they have been 
drawn as relaxed. Although only relaxation of negative supercoils is indicated, type II 
topoisomerases can relax positively supercoiled DNA as well. Figure from EcoSal Plus (Bush et 
al., 2015) with permission. 
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Table 1.1: Properties of various DNA topoisomerases. Taken from EcoSal Plus (Bush et al., 2015) with permission 
Topoisomerase Type Enzyme 
structure 
No. of DNA strands 
cleaved 
5´ or 3´ bond 
formed 
Proposed 
mechanism 
ATP-
dependent 
Mg(II) 
dependent 
Activities: 
Catenation/ 
decatenation 
Knotting/ 
unknotting 
Relaxation Supercoiling 
-ve +ve -ve +ve 
Topo 
I 
Bacterial IA Monomer 1 5´ Strand passage No Yes Yesb Yesb Yes No No No 
Eukaryotic IB Monomer 1 3´ Controlled rotation No No Yesb Yesb Yes Yes No No 
Topo II IIA Homodimer 2 5´ Strand passage Yes Yes Yes Yes Yes Yes No No 
Topo III IA Monomer 1 5´ Strand passage No Yes Yesb Yes Yes No No No 
Topo IV IIA Heterotetramer 2 5´ Strand passage Yes Yes Yes Yes Yes Yes No No 
Topo V IB/ICa Monomer 1 3´ Controlled rotation No No Unknown Unknown Yes Yes No No 
Topo VI IIB Heterotetramer 2 5´ Strand passage Yes Yes Yes Unknown Yes Yes No No 
Topo VIII IIB Homodimer? 2 5´ Strand passage Yes Yes? Yes Unknown Yes Yes No No 
DNA gyrase IIA Heterotetramer 2 5´ Strand passage Yes Yes Yesc Yes Yes Yes Yes No 
Reverse gyrase IA Monomer 1 5´ Strand passage Yes Yes No No Yes No No Yes 
Notes: 
a Topo V was originally described as type IB but has been proposed to form a new class (IC) 
-ve indicates negatively-supercoiled DNA; +ve indicates positively supercoiled DNA 
b Possible only if one substrate is nicked or single-stranded 
c Decatenation by E. coli DNA gyrase is weak 
? – presumed 
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 Type I topoisomerases 
Type I topoisomerases are historically named with odd numbers. There are currently four 
known type I topoisomerases: topo I, topo III, topo V and reverse gyrase. The respective domain 
diagrams for these type I topoisomerases are shown in Figure 1.5. A brief appraisal of the type I 
topoisomerases follows (for a more extensive review, see (Schoeffler & Berger, 2008, Capranico 
et al., 2017)). 
 
Figure 1.5: Primary domain structures of type I topoisomerases. Black bars indicate 
catalytic residues. Y is the catalytic tyrosine which forms the covalent bond with the 
phosphodiester backbone of the cleaved single-strand of DNA (319 in E. coli topo I, 328 in E. 
coli topo III, 809 in A. fulgidus reverse gyrase, 723 in human topo I and 226 in M. kandleri topo 
V) (for full description of all catalytic residues see reference (Schoeffler & Berger, 2008)). Type 
IB: NTD is N-terminal domain; CTD is C-terminal domain. Type IC: HTH is helix-turn-helix; HhH 
is helix-hairpin-helix. Figure taken from EcoSal Plus (Bush et al., 2015) with permission. 
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Topo I was the first DNA topoisomerase to be discovered and was initially called ω protein 
(Wang, 1971, Wang, 2009). It is found in prokaryotes and eukaryotes; however, the bacterial 
and eukaryotic enzymes show mechanistic and structural differences (Table1.1) (Champoux & 
Dulbecco, 1972, Wang, 1971). Eukaryotic topo I is a type IB topoisomerase which is capable of 
relaxing both negative and positive supercoils by a controlled rotation mechanism (Stewart et 
al., 1998). In contrast, bacterial topo I is a type IA topoisomerase which only relaxes negative 
supercoils and this is by strand passage (Lima et al., 1994, Schoeffler & Berger, 2008). Both 
enzymes can catenate or decatenate DNA provided that one of the DNA strands is nicked (Tse 
& Wang, 1980). Topo I is non-essential in bacteria, except in species where it is the only type I 
topoisomerase such as in the Mycobacterium species. However, in topo I-inactivated strains, 
cold sensitivity and compensatory mutations in the DNA gyrase genes gyrA and gyrB can be 
found (Dinardo et al., 1982, Pruss et al., 1982, Richardson et al., 1984, Stupina & Wang, 2005). 
Although topo I is non-essential in many bacteria, it can cause double-stranded DNA breaks that 
lead to induction of the SOS response (Cheng et al., 2005). 
Topo III is a type IA topoisomerase that relaxes and decatenates DNA but has also been 
shown to catenate and decatenate RNA (Digate & Marians, 1989, Digate & Marians, 1992). Topo 
III has been identified in prokaryotes, eukaryotes and archaea and is well-conserved across 
evolutionary lineages (Schoeffler & Berger, 2008). It shares considerable homology to 
prokaryotic topo I (Digate & Marians, 1989) and like topo I is non-essential (Digate & Marians, 
1989); except in a topoisomerase IV temperature-sensitive background, where it is lethal (Lopez 
et al., 2005). Although topo III is capable of relaxation, it is thought that its primary function in 
the cell is the resolution of precatenanes, chromosome segregation as well as the resolution of 
some recombination intermediates (Digate & Marians, 1989, Lopez et al., 2005, Oakley & 
Hickson, 2002, Perez-Cheeks et al., 2012, Valenti et al., 2012). This may point to the reason 
behind the lethality of topB (topo III) deletions in a topoisomerase IV-depleted background. With 
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regard to recombination, RecQ helicases are often linked to topo III in the resolution of stalled 
and converging replication forks (Suski & Marians, 2008). 
Topo V is the only member of the type IC topoisomerases which has, to date, only been 
found in the archaeal genus Methanopyrus sp. (Slesarev et al., 1993). It was previously identified 
and classed as a type IB topoisomerase but has recently been reclassified based on structural 
and biochemical analyses (Rajan et al., 2010, Slesarev et al., 1993, Taneja et al., 2006). Topo V 
has been shown to relax both positively- and negatively-supercoiled DNA by controlled rotation 
(Taneja et al., 2007). It has recently been shown to participate in DNA repair as it was 
demonstrated to have AP lyase (apurinic/apyrimidinic) and deoxyribose-5-phosphate (dRP) 
lyase activities (Belova et al., 2002, Rajan et al., 2016, Taneja et al., 2006). 
Reverse gyrase is an unusual type IA topoisomerase as it is capable of introducing positive 
supercoils into DNA in an ATP-dependent reaction. It is also able to relax negatively-supercoiled 
DNA in an ATP-independent manner (Forterre et al., 1985, Shibata et al., 1987). The crystal 
structure has revealed a C-terminal that resembles a type IA topoisomerase but the N-terminal 
resembles a helicase (Confalonieri et al., 1993, Rodrıǵuez, 2002, Rudolph et al., 2013). 
Concurrently, if you delete the C-terminal domain, the enzyme has been shown to transiently 
unwind DNA (Ganguly et al., 2013). Additionally, the full-length enzyme has been shown to 
unwind DNA and it is thought that this capability directs strand passage in a positive supercoiling 
direction (Ganguly et al., 2013, Rodrıǵuez, 2002). Reverse gyrase is found in thermophilic and 
hyperthermophilic archaea, and eubacteria (Forterre, 2002, Forterre et al., 1985, Shibata et al., 
1987). 
Type II topoisomerases 
Type II topoisomerases are found in eukaryotes, prokaryotes and in archaea. They are 
typically named with even numbers and there are four currently characterised. These are topo 
II, topo IV, topo VI, topo VIII and DNA gyrase (Table 1.1). Their respective domain diagrams are 
shown in Figure 1.7 (excluding topo VIII). All type II topoisomerases operate through the same 
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basic mechanism, however, the process in DNA gyrase has been best characterised. The basic 
mechanism of relaxation is outlined below Figure 1.6). 
A gate (G) segment of DNA is bound and bent across the enzyme at the interface between 
the DNA-binding domain and the ATPase domain. The binding of ATP to the ATPase region 
results in the capture of a transport (T) segment. Hydrolysis of ATP to ADP triggers cleavage of 
the double-stranded G-segment DNA, with a 4-bp stagger between the cuts in the two strands. 
This is followed by the T-segment passing through the gap in the G-segment and into the cavity 
formed by the two C-terminal domains. Following strand passage, the two ATPase domains 
rotate around each other ensuring the unidirectional movement of the T-segment. The G-
segment is religated, and the T-segment passes out of the enzyme through the bottom gate. The 
release of the ADP molecules allows the enzyme to return to its original conformation (Bates et 
al., 2011, Schmidt et al., 2012). The exact timing of and sequence of ATP hydrolysis is yet to be 
fully determined. Variations to this mechanism will be discussed with reference to the respective 
enzyme. 
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Figure 1.6: Structure and mechanism of type II topoisomerases. Type IIA topoisomerase 
mechanism. Domains of the protein are indicated in colour. Yellow indicates the GHKL 
domain, orange the TOPRIM domain and blue the cleavage-religation domain. The T-segment 
(red/pink) is transported through the enzyme-stabilised double-stranded break in the G-
segment (green). b) Type IIB (topo VI) mechanism (note lack of C (exit)-gate). Figure adapted 
from (Bates et al., 2011).  
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Figure 1.7: Primary domain structures of type II topoisomerases. Black bars indicate 
catalytic residues. Y is the catalytic tyrosine which forms the covalent bond with the 
phosphodiester backbone of the cleaved strand of DNA (782 in S. cerevisiae topo II, 122 in E. 
coli DNA gyrase, 120 in E. coli topo IV, and 105 in M. mazei topo VI) (for full description of all 
catalytic residues see reference (Schoeffler & Berger, 2008)). GHKL is the ATPase domain, 
TOPRIM stands for topoisomerase/primase domain, WHD is winged-helix domain, CTD is C-
terminal domain, H2tH is helix-helix-turn helix domain, and Ig is an immunoglobulin type fold 
(not seen in all species). Figure taken from EcoSal Plus (Bush et al., 2015) with permission. 
Topo VI 
Topo VI is an archaeal type IIB topoisomerase that is found in all known archaea (Bergerat 
et al., 1997, Bergerat et al., 1994), however, it has also recently been found in plants (Hartung 
& Puchta, 2000) and in the apicomplexan parasite Plasmodium sp. (Aravind et al., 2003). In 
Arabidopsis thaliana it has been shown to be involved in endoreduplication (Hartung et al., 
2002, Sugimoto-Shirasu et al., 2002) whilst in Plasmodium sp. it is thought to play a role in 
schizogeny (Aravind et al., 2003). Topo VI is able to decatenate DNA and relax both positive and 
negative supercoils, and it acts as an A2B2 heterotetramer (Bergerat et al., 1997). Apart from 
three motifs in the ATPase domain and the topoisomerase-primase (TOPRIM) fold, topo VI 
shows little sequence homology to type IIA topoisomerases (Aravind et al., 1998, Bergerat et al., 
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1997). A number of structures from topo VI have been resolved including the topo VIA subunit 
(topo VIA) from Methanococcus jannaschii, the topo VIB from Sulfolobus shibatae in a variety of 
conformations involving a range of nucleotides, and the full structure of topo VI from 
Methanosarcina mazei (Corbett et al., 2007, Corbett & Berger, 2003, Corbett & Berger, 2005, 
Nichols et al., 1999). One major difference ascertained from these structures is the lack of a 
post-strand passage cavity, it has only two protein gates rather than three, which is unlike type 
IIA topoisomerases (Figure 1.6) (Corbett et al., 2007, Nichols et al., 1999). Another difference is 
the double-stranded breaks made by topo VI have a 2-bp stagger in contrast to the 4-bp stagger 
created by the type IIA topoisomerases (Buhler et al., 2001). As yet, topo VI has not been 
investigated in topoisomerase-mediated illegitimate recombination, however, the topo VIA 
protein has been identified as an orthologue of the meiotic recombination protein SpoII 
(Bergerat et al., 1997). More recently, in mice and A. thaliana a topo VIB-like protein has been 
identified as an associate protein of SpoII and demonstrated to be involved in initiating double-
strand breaks during meiosis (Robert et al., 2016a, Vrielynck et al., 2016, Robert et al., 2016b). 
Topo VIII 
A second type IIB topoisomerase, topo VIII has recently been discovered in silico (Gadelle et 
al., 2014). It has been found in a number of bacterial genomes, two bacterial plasmids and an 
archaeal plasmid and is thought to have originated from a conjugative plasmid or some other 
mobile genetic element (Gadelle et al., 2014). Unlike the other type IIB topoisomerases, the A 
and B subunits are fused and topo VIII is proposed to be a homodimer. It has been demonstrated 
to have both relaxation and decatenation activities, much like topo VI, although much weaker 
and the protein was far less stable (Gadelle et al., 2014). 
Topo II 
Topo II is a type IIA topoisomerase that can relax both positively and negatively-supercoiled 
DNA in an ATP- dependent manner. It can also catenate and decatenate DNA (Table 1.1) and has 
been found in all eukaryotes (Baldi et al., 1980, Bauer et al., 2012, Hsieh & Brutlag, 1980, Liu et 
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al., 1980). Topo II is also involved in the condensation, structural preservation and segregation 
of daughter chromosomes following DNA replication (Bauer et al., 2012, DiNardo et al., 1984). 
Higher eukaryotes generally contain two isoforms, termed topo IIα and topo IIβ (Drake et al., 
1989a), which appear to be expressed at different times in the cell cycle and in different cell 
types (Capranico et al., 1992, Gonzalez et al., 2011). The two isoforms share 72% homology in 
protein sequence with the greatest divergence at the N-terminal domain (NTD) and C-terminal 
domain (CTD) (Bollimpelli et al., 2017). Topo IIα is found in proliferating cell types, and 
expression peaks during the G2 and M phases of the cell cycle. Topo IIβ is found in all cell types, 
and its expression is constant throughout the cell cycle (Turley et al., 1997). Topo IIα also 
participates in chromosome condensation during apoptosis (Durrieu et al., 2000) and topo IIβ 
has also been shown to participate in cell differentiation and tissue development (Vávrová & 
Šimůnek, 2012). When topo IIα is deleted it results in embryonic death whilst a topo IIβ knock-
out results in death shortly after birth (Akimitsu et al., 2003, Yang et al., 2000). Topo II in yeast 
is also indicated to be cell cycle regulated (Clarke et al., 2006, DiNardo et al., 1984, Furniss et al., 
2013, Uemura et al., 1987). More recently, it has been demonstrated that double-stranded 
breaks induced by topo IIβ may be vital for transcriptional activation of some genes 
(Calderwood, 2016). 
Topo II shares many structural and mechanistic similarities with DNA gyrase and topo IV. 
The NTD of topo II aligns with the DNA gyrase subunit GyrB and the topo IV subunit ParE whilst 
the CTD aligns with GyrA and ParC (Figure 1.7). It is thought that topo II may have evolved 
following the fusion of the genes encoding the A and B subunits of gyrase (Lynn et al., 1986). 
Topo II does, however, differ significantly from topo IV and DNA gyrase at the C terminus. In 
DNA gyrase and topo IV, this domain is important mechanistically. Whereas in topo II it has been 
determined to have a regulatory role and includes nuclear localisation signals (Watt & Hickson, 
1994, Meczes et al., 2008, Nitiss, 2009a). The structure of residues 1-1177 (fully active construct) 
of S. cerevisiae topo II complexed with ADPNP (5′-adenylyl β,γ-imidodiphosphate, a non-
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hydrolysable ATP analogue) and DNA has been determined by X-ray crystallography (Figure 1.8) 
(Schmidt et al., 2012). It shows a homodimer with the NTDs in a domain-swapping conformation 
(the subunits wrapped around one another). A previous crystal structure of a 92 kDa fragment 
of the enzyme complexed with a nicked DNA oligonucleotide denoted a 150° bend in the DNA 
(Dong & Berger, 2007). These structural data, as well as data collected from the other type II 
topoisomerases, have provided information of a possible mechanism. Topo II (despite the 
enzyme having three protein interfaces) is thought to operate using the “two-gate” mechanism, 
as described above (Berger et al., 1996, Roca et al., 1996). 
 
Figure 1.8: Structure of truncated (amino acids 1-1177) S. cerevisiae topo II bound to DNA 
and ADPNP. One monomer is shaded grey the other coloured by functional region (see domain 
diagram Figure 1.7). WHD is winged-helix domain; TOPRIM is topoisomerase-primase domain. 
Black box indicates position of ADPNP and green indicates DNA. Figure taken from EcoSal Plus 
(Bush et al., 2015) with permission. 
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Topo IV 
Topo IV (Figure 1.9) is a type IIA topoisomerase that uses ATP hydrolysis (Peng & Marians, 
1993) to decatenate replication products (Levine et al., 1998), relax positive and negative 
(although less efficiently) supercoils (Crisona et al., 2000), and knot and unknot DNA (Table 1.1) 
(Deibler et al., 2001). Topo IV consists of two subunits, encoded by the parC and parE genes 
(Madhusudan & Nagaraja, 1996, Peng & Marians, 1993, Springer & Schmid, 1993). The E. coli 
ParC and the ParE subunits (84 kDa and 70 kDa respectively) are homologous to GyrA and GyrB 
(from DNA gyrase) both in sequence and in structure. However, there are some differences 
between the two enzymes, the principal being that topo IV is not capable of DNA supercoiling 
(Peng & Marians, 1995). Furthermore, although gyrase and topo IV share sequence similarities 
they have quite distinct cellular roles. Topo IV is the predominant enzyme responsible for 
decatenation and unknotting, whereas gyrase is responsible for supercoiling (Deibler et al., 
2001, Ullsperger & Cozzarelli, 1996, Zechiedrich & Cozzarelli, 1995, Zechiedrich et al., 1997). 
Topo IV also plays a major role in chromosome segregation after DNA replication with the help 
of motor proteins and cytoskeletal components (Adams et al., 1992). In particular, topo IV has 
been shown to interact with the SMC complex MukBEF in E. coli. It has been shown that MukBEF 
associates with topo IV at the origin of replication (Nicolas et al., 2014) and along with MatP and 
XerD/C ensures successful and timely decatenation at the replication termination site (Nolivos 
et al., 2016, El Sayyed et al., 2016). Furthermore, the interaction between MukB and topo IV has 
been shown to be important for DNA condensation with topo IV stabilising MukB on the DNA 
which increased the level of DNA compaction (Kumar et al., 2017). 
A number of structures of various full length and truncated forms of the ParE and ParC 
subunits have been solved (Bellon et al., 2004, Corbett et al., 2005, Hsieh et al., 2004, Laponogov 
et al., 2013, Laponogov et al., 2007). These structures have highlighted the differences and 
similarities between gyrase and topo IV and have also provided useful mechanistic insights. One 
particular difference they have highlighted is between the ParC and GyrA CTD. ParC CTD has 
been shown to be a broken five-bladed β-pinwheel (Figure 1.9D) (Corbett et al., 2005, Hsieh et 
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al., 2004) whereas GyrA CTD forms a six-bladed β-pinwheel (Corbett et al., 2004) (Figure 1.8C4). 
Additionally, the ParC CTD is anchored to the NTD, which would limit the movement of the 
domain (Corbett et al., 2005). In contrast, the GyrA CTD domain is connected to the NTD by a 
flexible linker, allowing movement (Corbett et al., 2005, Costenaro et al., 2005). These 
differences mean that topo IV cannot wrap DNA in the same way as DNA gyrase, providing an 
explanation for the inability of topo IV to negatively supercoil DNA (Kampranis & Maxwell, 
1998a). This is also confirmed by the fact that when the GyrA CTD is deleted it is converted into 
a topo IV-like enzyme (Kampranis & Maxwell, 1996). It has been proposed that the ParC CTD is 
important for substrate specificity as topo IV shows chiral discrimination between positively and 
negatively-supercoiled DNA (Corbett et al., 2005, Neuman et al., 2009, Stone et al., 2003). It has 
also been recently demonstrated to be able to discriminate between left-handed and right-
handed nodes in catenanes and knots that allow for the resolution of these topological forms 
without causing relaxation (Rawdon et al., 2016). 
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Figure 1.9: Structures of topoisomerase IV. (A) is the structure of the ParE- ParC55 fusion 
construct (Laponogov et al., 2013) (PDB: 4I3H). Yellow indicates the GHKL domain; orange the 
transducer domain; teal is the winged-helix domain (WHD); purple is the tower domain; and 
blue shows the coiled-coil domain (see Figure 1.7 for domain structure). (B) is the space-filled 
model of (A). (C) is the ParE 43 kDa N-terminal fragment complexed with ADPNP (black box) 
(PDB: 1S16) (Bellon et al., 2004). It is proposed that the open conformation of ParE as seen in 
(A) is the conformation pre-ATP binding whereas the conformation seen in (C) is the post-ATP 
binding conformation. (D) is the ParC C-terminal domain in two orientations (PDB: 1ZVT) 
(Corbett et al., 2005). Figure from EcoSal Plus (Bush et al., 2015) with permission. 
 
DNA gyrase 
DNA gyrase (Figure 1.10) is a type IIA topoisomerase that is unique in its ability to introduce 
negative supercoils in the presence of ATP into covalently-closed double-stranded DNA (Gellert 
et al., 1976a). Gyrase also uses ATP hydrolysis to relax positively supercoiled DNA in a reaction 
equivalent to the introduction of negative supercoils, even though this process is energetically 
favourable (Gellert et al., 1976b, Sugino et al., 1978, Brown & Cozzarelli, 1979). It has been 
demonstrated to be capable of decatenation and unknotting reactions in the presence of ATP 
as well (although not shown, it is also presumably capable of the converse reactions) (Kreuzer & 
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Cozzarelli, 1980, Liu et al., 1980, Marians, 1987, Mizuuchi et al., 1980). Furthermore, DNA gyrase 
can relax negatively-supercoiled DNA in an ATP-independent reaction (Gellert et al., 1979, 
Higgins et al., 1978). DNA gyrase is responsible for all processes in bacteria that require negative 
supercoiling, including chromosome compaction, origin firing and recombination. It is also 
responsible for the resolution of unwanted positive supercoils ahead of replication forks or 
ahead of RNA polymerase during transcription (Dorman & Dorman, 2016, Nollmann et al., 
2007a, Seol & Neuman, 2016, Wang, 2002). DNA gyrase works together with bacterial Topo I to 
maintain the levels of supercoiling in the cell (Drlica, 1992). In fact, the genome-wide 
recruitment of Mycobacterium tuberculosis DNA gyrase and topo I have recently been 
demonstrated to be closely coupled to transcription, with DNA gyrase shown to be recruited 
ahead of RNA polymerase and topo I behind it (Ahmed et al., 2017). 
DNA gyrases are ubiquitous in bacteria but have additionally been discovered in plants (Cho 
et al., 2004, Wall et al., 2004) and in apicomplexan parasites (Carucci et al., 1998, Dar et al., 
2007, Lin et al., 2015). However, they do not appear to be present in other eukaryotes. This, 
along with the fact that DNA gyrase is an essential bacterial enzyme, has made it a successful 
target for several antibacterial agents. E. coli DNA gyrase is made up of two 97 kDa GyrA subunits 
and two 90 kDa GyrB subunits encoded by the gyrA and gyrB genes, respectively, and organised 
as an A2B2 heterotetramer (Adachi et al., 1987, Klevan & Wang, 1980, Sugino et al., 1980, 
Swanberg & Wang, 1987). Transcription of the gyrA and gyrB genes themselves is controlled by 
the level of supercoiling in an autoregulatory feedback system (Menzel & Gellert, 1983, Snoep 
et al., 2002, Dorman & Dorman, 2016). 
The GyrA and GyrB subunits can each be split into two principal domains (Kampranis & 
Maxwell, 1998a, Reece & Maxwell, 1989). E. coli GyrB comprises a 43 kDa NTD and a 47 kDa 
CTD. The former is responsible for ATP binding and hydrolysis whilst the latter interacts with 
GyrA and DNA (Chatterji et al., 2000, Noble & Maxwell, 2002, Schoeffler et al., 2010, Wigley et 
al., 1991). The 47 kDa domain of GyrB may be further subdivided into two subdomains, the 
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TOPRIM domain and the tail (Costenaro et al., 2007, Fu et al., 2009). GyrA consists of a 59 kDa 
NTD responsible for DNA breakage (Horowitz & Wang, 1987) and a 35 kDa CTD that wraps DNA 
(Corbett et al., 2004). The 59 kDa domain can be further divided into the tower/shoulder, 
winged-helix, and coiled-coil domains in line with other type IIA topoisomerases (Berger et al., 
1996, Dong & Berger, 2007, Morais Cabral et al., 1997, Schoeffler & Berger, 2008). The structures 
of all of the gyrase domains have been resolved (Corbett et al., 2004, Fu et al., 2009, Hsieh et 
al., 2010, Morais Cabral et al., 1997, Piton et al., 2010, Ruthenburg et al., 2005, Schoeffler et al., 
2010, Tretter & Berger, 2012b, Wigley et al., 1991), but only individually in the form of truncated 
and fusion constructs. Thus, no full-length, high-resolution gyrase structure exists. There are, 
however, low-resolution structures of the whole protein obtained through small-angle X-ray 
scattering (SAXS) (Baker et al., 2011, Costenaro et al., 2005, Costenaro et al., 2007), 
supramolecular mass spectrometry and 3D cryo-electron microscopy (cryo-EM) (Papillon et al., 
2013). 
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Figure 1.10: Structures of DNA gyrase. (A) is a model of the full-length structure of DNA 
gyrase. Yellow indicates the GHKL domain; orange the transducer domain; teal is the winged-
helix domain (WHD); purple is the tower domain; blue shows the coiled-coil domain and pink 
indicates the CTD (see Figure 4 for domain structure). The full-length protein structure was 
modelled on the ATPase 43 kDa fragment (PDB: 1EI1); a B-A fusion construct (PDB: 3NUH) 
(Schoeffler et al., 2010) and the GyrA 35 kDa C-terminal domain (PDB: 3L6V). (B) is the space-
filled model of (A). Panel (C) shows the four principal domains of gyrase. (C1) is the E. coli GyrB 
43 kDa fragment complexed with ADPNP; (C2) is the E. coli GyrB TOPRIM domain; (C3) is the 
E. coli GyrA 59 kDa subunit; and (C4) is the E. coli GyrA C-terminal domain in two orientations 
(PDB: 1ZI0). Figure taken from EcoSal Plus (Bush et al., 2015) with permission. 
 
With the wealth of biochemical and structural data available on DNA gyrase, it is not 
surprising that its mechanism is the best described of all the type II topoisomerases. 
Furthermore, single-molecule experiments have served to verify these data and further extend 
our knowledge (Koster et al., 2010, Neuman, 2010, Nollmann et al., 2007a, Gubaev et al., 2009, 
Gubaev & Klostermeier, 2011, Gubaev & Klostermeier, 2014, Lanz & Klostermeier, 2011, 
Rudolph & Klostermeier, 2013, Basu et al., 2016). The proposed mechanism of negative 
supercoiling by gyrase (Figure 1.11) is outlined below. 
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Negative supercoiling occurs via a two-gate mechanism (see above, Figure 1.6) (Mizuuchi et 
al., 1980). The G-segment, binds across the top dimer interface of the GyrA NTDs (Gellert et al., 
1976b, Morais Cabral et al., 1997). The bound G-segment is bent at an angle of approximately 
70° (Papillon et al., 2013). Binding induces an upward movement of the GyrA CTDs, resulting in 
an adjacent section of the DNA becoming wrapped around the CTDs (Heddle et al., 2004, Lanz 
& Klostermeier, 2011, Basu et al., 2016). This wrapping positions the T-segment across the G-
segment at an angle of approximately 60° and it also provides gyrase with its unique ability to 
supercoil DNA (Heddle et al., 2004, Papillon et al., 2013, Ruthenburg et al., 2005). A conserved 
region on the CTD, termed the GyrA box, is proposed to orientate the T-segment in a positive 
node that favours DNA supercoiling (Kramlinger & Hiasa, 2006). The total length of DNA bound 
by gyrase is estimated to be between 120 and 150 bp (Fisher et al., 1981, Kirkegaard & Wang, 
1981, Morrison & Cozzarelli, 1981). DNA wrapping and the presentation of the T-segment has 
been demonstrated to occur in the absence of ATP, however, ATP (or ADPNP) is crucial for strand 
passage to occur (Sugino & Cozzarelli, 1980, Bates et al., 1996, Kampranis et al., 1999a, Basu et 
al., 2012). Following DNA binding and wrapping, ATP is bound to the NTDs of the two GyrB 
subunits, causing dimerisation and the closure of the clamp. This closure traps the T-segment in 
the complex (Basu et al., 2012, Kampranis et al., 1999a, Basu et al., 2016). In E. coli supercoiling 
is thought to be influenced by a small acidic tail on the GyrA CTD which has been shown to 
couple ATP binding to DNA binding (Tretter & Berger, 2012a, Lanz et al., 2014). 
The bound G-segment forms phosphotyrosine bonds with the active-site tyrosines, 
generating a double-strand break (DSB) with 4-bp overhangs (Horowitz & Wang, 1987, Morrison 
& Cozzarelli, 1981). Cleavage of the DNA strand requires two Mg2+ ions bound within the TOPRIM 
fold of GyrB (Noble & Maxwell, 2002). The top dimer interface (winged-helix domains) with the 
cleaved G-segment are pulled apart allowing the T-segment to pass through into the cavity 
formed by the GyrA NTDs (Morais Cabral et al., 1997). The G-segment is religated, and the T-
segment is released through the bottom gate of the GyrA NTDs. It has been proposed that the 
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unidirectional movement of the T-segment into the GyrA cavity may be driven by the closing 
and swivelling observed in the GyrB subunits (Gubaev & Klostermeier, 2011, Papillon et al., 
2013). ATP hydrolysis allows the resetting of the enzyme (Sugino et al., 1978, Kampranis et al., 
1999a), however, to date the mechanism that drives ATP hydrolysis is uncertain (Williams & 
Maxwell, 1999a, Bates & Maxwell, 2007, Bates et al., 1996). Despite this, the rate-limiting step 
of DNA supercoiling by DNA gyrase, like other type IIA topoisomerase, is proposed to be the rate 
of ADP and phosphate release (Baird et al., 2001). An alternative mechanism of negative 
supercoiling has recently been proposed by Gubaev et al. who have suggested that negative 
supercoiling by DNA gyrase occurs through a nick-closing mechanism and controlled rotation 
(Gubaev et al., 2016). This works by the T-segment being constrained by the GyrB subunit on 
the GyrA subunit after ATP binding, cleavage of one strand of the double-stranded DNA, 
followed by loss of the DNA wrap around the CTD thus rotation within the DNA saddle, followed 
by resealing. This results in a change in the linking number by -2 (Gubaev et al., 2016). Although 
this mechanism has been suggested, the widely-held view is that DNA supercoiling proceeds by 
the strand-passage mechanism outlined above and shown in Figure 1.11. 
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Figure 1.11: Model for negative supercoiling by DNA gyrase. The domains are coloured as 
follows: GyrB43 - dark blue; GyrB TOPRIM - red; GyrB tail - green; GyrA59 - orange; GyrA C-
terminal domain - light blue. The G and T DNA segments are coloured black and purple, 
respectively. 1) shows the subunits and DNA in their proposed free states in solution. Stars 
indicate the active-site residues for DNA cleavage and the circle indicates the ATP-binding 
pocket. 2) The G-segment binds across GyrA, at the dimer interface and the GyrA C-terminal 
domain wraps the DNA to present the T-segment in a positive cross over. 3) ATP is bound, 
which closes the GyrB clamp capturing the T-segment, and the G-segment is transiently 
cleaved. 4) Hydrolysis of one ATP molecule allows GyrB to rotate, the DNA gate to widen, and 
the transport of the T-segment through the cleaved G-segment. 5) The T-segment exits 
through the C-gate, and the G-segment is religated. The hydrolysis of the remaining ATP 
molecule resets the enzyme. The right panel shows the side view for 2 – 4. Figure taken from 
Cell (Costenaro et al., 2007) with permission. 
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The topoisomerases are a diverse class of enzymes both structurally and mechanistically, 
and given their essentiality, many of them are key targets for chemotherapy. In particular, gyrase 
and topo IV are well-validated targets for antibiotics. 
 
1.4  Antibiotic resistance 
Antibiotics are small molecules that selectively act against bacteria, either by killing them 
(bactericidal) or stopping them from growing (bacteriostatic). These molecules can be natural 
or synthetic in origin and are formed by a number of different chemical classes that target a 
number of different molecular processes. Antibiotic classes include: quinolones, β-lactams, 
sulphonamides, aminoglycosides, tetracyclines, amphenicols, lipopeptides, macrolides, 
oxazolidinones, glycopeptides, streptogramins, ansamycins, and lincosamides (Aminov, 2017). 
All of these classes broadly affect one or more of five main pathways or targets, including cell 
wall synthesis, protein synthesis, DNA replication or transcription, folate synthesis or membrane 
disruption (Figure 1.12) (Walsh & Wencewicz, 2016). 
Disrupting these targets leads to a number of cellular responses by the bacteria in order to 
ameliorate the damage done. These include, upregulation of the SOS response, DNA damage 
repair, and upregulation of stress-response pathways including those that manage reactive 
oxygen species. 
The SOS response is a bacterial stress-response pathway that involves about 40 genes, all 
regulated by RecA and LexA (in most bacteria) (Janion, 2008, Baharoglu & Mazel, 2014, Kreuzer, 
2013). It has been found to be upregulated in response to lethal and sublethal doses of a number 
of antibiotics, including quinolones, β-lactams, trimethoprim and aminoglycosides 
(aminoglycosides have been shown not to induce SOS in E. coli) (Baharoglu & Mazel, 2014, Cirz 
et al., 2007, Cirz et al., 2006, Miller et al., 2004). SOS induction is often caused by the 
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accumulation of single-stranded DNA (ssDNA) either from collapsed replication forks, or from 
resolution of double-stranded breaks (DSBs) caused by stalled replication forks or stalled RNA 
polymerase. This causes the recruitment of a number of DNA repair proteins or error-prone 
polymerases (Baharoglu & Mazel, 2014, Kreuzer, 2013). The SOS response can result in increased 
homologous recombination, mutagenesis and pathogenesis responses in bacteria (Baharoglu & 
Mazel, 2014, Kreuzer, 2013). It has also been demonstrated to play a role in various cell 
checkpoints and the rise in persistence (Dörr et al., 2009, Kreuzer, 2013). 
 
Figure 1.12: The five major clinically validated targets or pathways. Figure taken from The 
Journal of Antibiotics (Walsh & Wencewicz, 2014) with permission 
 
DNA repair proteins involved in DSB repair include various endonucleases and the RecBCD 
helicase (Dillingham & Kowalczykowski, 2008, Yeeles & Dillingham, 2010). These proteins are 
part of bacterial metabolism and are involved in the resolution of naturally occurring DSBs in 
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DNA. They are closely associated with other homologous recombination proteins and have been 
demonstrated to load RecA onto ssDNA (Dillingham & Kowalczykowski, 2008, Yeeles & 
Dillingham, 2010). Furthermore, they are usually the first response to exogenous sources of DSB 
and have been linked with non-SOS response recombination pathways in response to 
quinolones (Lopez & Blazquez, 2009, Lopez et al., 2007). Additionally, RecBCD has been shown 
to convert topo I- and DNA gyrase-DNA complexes into DSBs in preparation for induction of SOS 
response (Sutherland & Tse-Dinh, 2010). 
Other stress-response pathways include upregulation of those that ameliorate oxidative 
stress and general stress-response pathways. The role of oxidative stress in bacterial cell death 
(or programmed cell death) is controversial. A number of studies have suggested that the 
lethality and increased mutagenesis by antibiotics, and in particular that of β-lactams, 
aminoglycosides and quinolones, is due to an increase in ROS (reactive oxygen species) 
(Kohanski et al., 2010, Kottur & Nair, 2016, Zhao & Drlica, 2014, Zhao et al., 2015). Many of these 
studies have shown that there is a reduction in cell death when pathways that are involved in 
protection against ROS are perturbed; or they have used chemical probes to show an increase 
in various oxygen species. In response to these suggestions, other studies have disputed the role 
of ROS in the lethality of antibiotics (Fang, 2013, Imlay, 2015, Keren et al., 2013, Liu & Imlay, 
2013). These papers have argued that antibiotics are still lethal under anaerobic conditions 
where ROS are not formed, and that some of the dyes used to detect oxidation are readily 
transformed by antibiotics in the absence of oxygen. Furthermore, there have been few targets 
identified that increase susceptibility to antibiotics that are involved in scavenging ROS or 
involved in their formation (Tamae et al., 2008). Moreover, in catalase and peroxidase deficient 
E. coli no increase in susceptibility to ampicillin and kanamycin was observed and only modest 
increases in susceptibility norfloxacin was seen (Imlay, 2015). There are significant differences 
in the methods and procedures used in these studies which may be contributing to the 
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inconsistencies and differing results (Fang, 2013) and it seems as though the debate is set to 
continue. 
General stress-response factor RpoS has been shown to upregulate error-prone polymerase 
in response to DSBs and cell wall stress, such as with treatment with β-lactams (Gutierrez et al., 
2013, Koskiniemi et al., 2010, Rosenberg et al., 2012). It has been shown to work closely with 
the SOS response and protects cells from ROS damage (Baharoglu & Mazel, 2014). 
Ultimately, the bacterial response to antibiotics seems to be varied and complex and the 
relative stress and repair pathways in different bacterial species have been shown to respond in 
slightly different ways. For example, ROS formation has been shown in Vibrio cholerea whereas 
not in E. coli (Baharoglu et al., 2013) and there are also subtle differences in the SOS response 
pathway between bacterial species (Baharoglu & Mazel, 2014, Kreuzer, 2013). 
Since their introduction in the 1940’s, antibiotics have changed global medicine and been 
central to the reduction of the lethality of bacterial infections. However, resistance to antibiotics 
is rising and with it deaths as a result of drug-resistant infections (Figure 1.13) (Bush et al., 2011, 
Gelband et al., 2015, O'Neill, 2016). Coupled to this is the paucity of new classes of chemical 
compounds being discovered to tackle this problem and fewer pharmaceutical companies 
investing in the search for novel antibiotics (Figure 1.14) (Brown & Wright, 2016, Lewis, 2012, 
Walsh, 2003, Walsh & Wencewicz, 2016, Walsh & Wencewicz, 2014). Bacteria have been shown 
to be exposed to antibiotics in a number of environments, not just in a clinical or veterinary 
setting, but also in external and natural ecosystems (Andersson & Hughes, 2014). This constant 
barrage of chemical warfare is increasingly adding to the resistance problems and the effects of 
sublethal exposure to these antibiotics is progressively being shown to have far reaching 
consequences (see Chapter 6). 
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Figure 1.13: Rise in antibiotic resistance. a) Bar graphs showing % resistant E. coli isolates 
in various countries. Data collected between 2011 and 2015. Aminoglycoside (pink), 
Aminopenicillin (dark blue), Carbapenem (orange), Fluoroquinolones (light blue), 
Cephalosporin (green), Amoxicillin-clavulanate (turquoise), Piperacillin-tazobactams (yellow) 
and Macrolides (black). b) Shows the rise in resistant E. coli isolates in the United Kingdom to 
the Aminoglycosides (light blue), Cephalosporins (dark blue) and the Fluoroquinolones (pink). 
Isolates were collected from blood and cerebrospinal fluid from inpatients of all ages.  Figure 
was collated from http://resistancemap.cddep.org/resmap/resistance. 
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Figure 1.14: Timeline showing the “Golden Age” of antibiotic discovery and medicinal 
chemistry. The red Box highlights the innovation gap where no new structural classes of 
antibiotics were introduced. Figure adapted from (Walsh & Wencewicz, 2014) with 
permission. 
 
In general, resistance mechanisms are varied and are often as a result of the SOS- and stress-
response mechanisms described above and can be classed as molecular or genetic. The 
molecular mechanisms include modifications that reduce the uptake of the antibiotic such as in 
the alteration of the physical structures of porins or a reduction in the number of porins (Gram-
negative species organisms), the upregulation of efflux pumps, the acquisition or upregulation 
of enzymes that degrade or inactivate antibiotics, and modifications of the target of the 
antibiotic such that the activity is unaffected but the antibiotic is no longer effective (Walsh & 
Wencewicz, 2016). The genetic mechanisms involve the acquisition of resistance cassettes which 
are usually embedded within biosynthetic clusters. This occurs through transformation, 
transduction and conjugation. Another genetic mechanism is through mutation, which can 
result in modifications that can cause some of the molecular mechanisms of resistance, such as 
alterations in target proteins, or upregulation of quiescent resistance genes (Walsh & 
Wencewicz, 2016). 
  Chapter 1: General Introduction 
36 
 
Ultimately, better understanding of the resistance mechanisms and the target themselves 
will give us novel ways of tackling antibiotic-resistant infections. The DNA topoisomerases are 
one such group that are both well-validated targets for antibiotics and are linked with the 
development of resistance. 
1.5  DNA topoisomerase inhibitors 
As mentioned above, topoisomerases are clinically-relevant targets for antibacterials and 
other chemotherapeutic agents. DNA gyrase and topo IV are ideal targets for antibiotics as they 
are not found in humans (Collin et al., 2011). Furthermore, inhibitors of human topo I and both 
isoforms of topo II are currently used in cancer-related chemotherapy regimens (Jain et al., 
2017). 
Bacterial topo I, although not an established target for antibacterials, is a prospective new 
target with a number of studies investigating potential compounds and the viability of topo I as 
a target (Bansal et al., 2012, Cheng et al., 2007, Cheng et al., 2005, Tse-Dinh, 2009). This is 
particularly true in M. tuberculosis where topo I is essential (Godbole et al., 2015). Human topo 
I is the target of camptothecin, which is an anti-tumour alkaloid that functions by stabilising the 
cleavage complex (Hsiang et al., 1985, Pommier et al., 1998). 
Inhibitors of topo VI are not currently clinically-relevant and not many have been described. 
However, there is evidence that radicicol, a topo VI and HSP90 inhibitor, also inhibits human 
topo II. Conversely, a number of topo II inhibitors also inhibit topo VI (Gadelle et al., 2006). 
Furthermore, as this enzyme has been found in apicomplexan parasites (a group that contains a 
number of human pathogens) and in some plants, it would be an ideal target for drugs such as 
antimalarials or herbicides. 
Inhibitors of type IIA topoisomerases generally consist of two types of inhibitors: those that 
interfere with the catalytic cycle of the enzyme, or those that stabilise the cleavage complex (the 
covalent phosphotyrosine bond formed between the enzyme and DNA at the DSB). Although, 
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many known inhibitors will be mentioned, only those with relevance to this thesis will be 
expanded on. 
Competitive inhibitors of DNA topoisomerases 
Catalytic inhibitors are those that block DNA binding or compete with ATP binding. These 
include inhibitors such as the aminocoumarins, simocyclinones, cyclothialidines and the 
bisdioxopiperazines. Aminocoumarins and cyclothialidines bind partially in the ATP pocket and 
are thus competitive inhibitors of ATP hydrolysis (Gellert et al., 1976b, Lewis et al., 1996, 
Mizuuchi et al., 1978b), whilst the bisdioxopiperazines are non-competitive inhibitors of ATPase 
activity (Nitiss, 2009b). Simocyclinones are known to prevent DNA binding (Edwards et al., 2009, 
Edwards et al., 2011, Flatman et al., 2005). 
Aminocoumarin antibiotics (Figure 1.15) that target DNA gyrase were discovered as 
Streptomyces natural products in the 1950s and include novobiocin, clorobiocin and 
coumermycin A1 (Heide, 2009, Maxwell & Lawson, 2003). They bind to the ATPase (NTD) domain 
of GyrB and block the binding of ATP (Lewis et al., 1996, Wigley et al., 1991). Although the 
aminocoumarins do not resemble ATP, it was demonstrated that the novobiose sugar of the 
aminocoumarins overlaps the adenine-binding site in the ATPase pocket, thereby preventing the 
binding of ATP. Novobiocin also forms a hydrogen bond with R163 in GyrB which has been shown 
to prevent dimerisation of the GyrB NTDs (Ali et al., 1993, Lewis et al., 1996). 
Aminocoumarins have been demonstrated to be very effective inhibitors of gyrase and topo 
IV (Kampranis et al., 1999b). However, they have not had a high degree of success as clinical 
antibiotics with safety concerns having led to discontinuation of the use of these drugs (Mayer 
& Janin, 2014). Toxicity issues associated with these drugs may be due to the fact that they bind 
to the ATPase domain of GyrB/ParE, which is part of the GHKL ATPase/kinase superfamily (Dutta 
& Inouye, 2000). This means that secondary eukaryotic targets are likely, which was further 
demonstrated by Burlison et al. who reconfigured novobiocin to target a mammalian heat shock 
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protein (Hsp90) (Burlison et al., 2006). Furthermore, the aminocoumarins suffer from solubility 
issues, making it difficult to develop them as drugs. 
 
 
Figure 1.15: Chemical structures of various aminocoumarin topoisomerase inhibitors. 
 
Topoisomerase poisons 
Topoisomerase poisons are inhibitors that bind to type II topoisomerases and stabilise the 
cleavage complex. These include some of the most potent and clinically important inhibitors of 
topoisomerases. Inhibitors of the bacterial enzymes, DNA gyrase and topo IV, include the 
quinolones (Collin et al., 2011, Drlica & Malik, 2003), microcin B17 (Herrero et al., 1986, Vizan 
et al., 1991), CcdB (Miki et al., 1984a, Miki et al., 1992, Miki et al., 1984b) and albicidins (Birch 
& Patil, 1985). Topo II inhibitors include the anthracyclines (e.g. doxorubicin) (Binaschi et al., 
1997), and epipodophyllotoxins (e.g. teniposide and etoposide) (Baldwin & Osheroff, 2005, 
Hande, 1998), as well as mAMSA (Marshall et al., 1983), and merbarone (Drake et al., 1989b). 
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Quinolones 
The quinolones (Figure 1.16) are arguably the most successful class of topoisomerase 
inhibitors to date. They are synthetic antimicrobials with the initial compound, nalidixic acid, 
being discovered as a by-product of chloroquine synthesis in 1962 (Lesher et al., 1962, Bisacchi, 
2015). Nalidixic acid was released for clinical use in the late 1960’s for the treatment of 
uncomplicated urinary tract infections (UTI’s) (Correia et al., 2017). By the 1970’s several other 
quinolones, including oxolinic acid had been introduced to the clinic and these, along with 
nalidixic acid (although, technically, nalidixic acid is a 1,8 naphthyridone and not a true 
quinolone (Lesher et al., 1962, Bisacchi, 2015)), are the first-generation quinolones (Aldred et 
al., 2014b, Collin et al., 2011). The second-generation quinolones included a fluorine on the C6 
position, which led them to be called the fluoroquinolones, and a piperazine or methyl-
piperazine ring at C7 (Aldred et al., 2014b, Emmerson & Jones, 2003). The second-generation 
fluoroquinolones had better pharmacodynamic and pharmacokinetic properties, including 
broader spectrum activity, and better bioavailability. They were also less toxic and were less 
susceptible to single point mutations that led to high levels of resistance seen against the first-
generation quinolones (Emmerson & Jones, 2003, Correia et al., 2017). This class began with 
norfloxacin, however it was ciprofloxacin (CFX) that was the first quinolone that showed activity 
outside the urinary tract (Aldred et al., 2014b, Correia et al., 2017, Emmerson & Jones, 2003). 
CFX remains one of the most clinically important antibiotics to date, with the World Health 
Organisation classing it (amongst other fluoroquinolones) as a critically important antibiotic 
(WHO, 2017). The success of CFX led to a medicinal chemistry effort that produced a wide range 
of newer generation fluoroquinolones (third and fourth generations) that have even broader 
spectra of activity, greater efficacy and less resistance, including moxifloxacin, gatifloxacin and 
levofloxacin (Figure 1.16) (Aldred et al., 2014b, Collin et al., 2011, Emmerson & Jones, 2003). 
There is now potentially a fifth generation of quinolones in delafloxacin, which is a weak acid 
due to the loss of the strong base at C7, and it is chlorinated at C8 (Candel & Peñuelas, 2017).  
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Despite their success, some promising fluoroquinolones, such as trovafloxacin and 
grepafloxacin, have had to be removed from the clinic due to safety concerns (Emmerson & 
Jones, 2003). However, many have remained in clinic and are used in the treatment of UTI’s, 
pyelonephritis, gastroenteritis, sexually transmitted diseases such as Gonorrhoea, tuberculosis 
(moxifloxacin) (Gillespie, 2016), prostatitis, nosocomial infections, community acquired 
pneumonia, and skin and soft tissues infections (Oliphant & Green, 2002, Aldred et al., 2014b). 
Delafloxacin has also been demonstrated to be effective against quinolone- and methicillin-
resistant Staphylococcus aureus (Chan et al., 2014, Candel & Peñuelas, 2017). 
 
 
Figure 1.16: Chemical structures of a selection of quinolones. Quinolones are divided into 
generations based on their antibacterial spectrum. The first generation (e.g. nalidixic acid and 
oxolinic acid) are examples of older acidic (narrow spectrum) quinolones whereas the higher 
generations (e.g. ciprofloxacin, levofloxacin and gatifloxacin) are examples of the amphoteric 
fluoroquinolones (expanded-spectrum compounds). Figure taken from EcoSal Plus (Bush et 
al., 2015) with permission  
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The quinolones inhibit DNA supercoiling and relaxation by binding to both gyrase and DNA 
and stabilising the gyrase-DNA cleavage complex (Gellert et al., 1977, Sugino et al., 1977). This 
is also true for topo IV which has also been shown to be a target for quinolones, and the primary 
target in a number of Gram-positive species. However, this is often dependent on the specific 
quinolone, and some quinolones have been shown to target both enzymes equally (Aldred et 
al., 2014b, Ferrero et al., 1994, Khodursky et al., 1995, Redgrave et al., 2014, Correia et al., 2017). 
The quinolones have been shown to have interactions with both subunits of the enzyme (GyrA 
and GyrB for gyrase, and ParC and ParE for topo IV). Binding has been shown to be mediated by 
a Mg2+ ion via a “water-metal ion bridge” along with S83 and D87 in GyrA (amino acids in E. coli 
numbering) and the 3-carboxyl end of the quinolone. Interactions between position 466 in GyrB 
and the C7 ring of the quinolone are also important for binding of the compound (Aldred et al., 
2014a, Aldred et al., 2013, Mustaev et al., 2014, Hooper & Jacoby, 2015). The resulting 
quinolone-enzyme-DNA complex is the cause of the inhibition of DNA synthesis by quinolones 
which leads to the hindrance of cell growth (Hiasa et al., 1996, Wentzell & Maxwell, 2000, 
Willmott et al., 1994).  
DNA replication has been demonstrated to be promptly stalled when DNA gyrase is targeted 
with quinolone drugs which was suggested to be due to the collision of replication forks with 
quinolone-enzyme-DNA complexes (Snyder & Drlica, 1979). For example, norfloxacin has been 
shown to cause stalled replication forks in vivo; some of these were reversible and did not lead 
to cell death but others were not reversed and were lethal (Pohlhaus & Kreuzer, 2005). This 
stalling of replication is the likely cause of the bacteriostatic action of quinolones (Drlica et al., 
2008), however, the lethality is due to DNA breaks and chromosome fragmentation which 
induces the SOS response and leads to cell death (Drlica et al., 2008, Malik et al., 2006, Aldred 
et al., 2014b, Redgrave et al., 2014). Induction of the SOS regulon caused by quinolone-induced 
DSBs has been shown to be mediated by RecBC (Lewin et al., 1989, McDaniel et al., 1978, 
McPartland et al., 1980). The action of killing by quinolones appears to be dependent on the 
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chemical structure of the specific quinolone in question. The difference in chemical structure 
results in three pathways of quinolone killing: one that is dependent on aerobic growth and 
continued protein synthesis, one that is dependent only on continued protein synthesis and the 
third that can occur independently of aerobic growth or protein synthesis (Malik et al., 2007, 
Malik et al., 2006). Although the mode of action of quinolones in inhibiting DNA gyrase or topo 
IV is relatively straightforward, the lethality of quinolones to cells appears not to be. This is also 
evident by the minimum inhibitory concentrations (MIC) of quinolones being an order to two 
orders of magnitude lower (in vivo) than their IC50’s (in vitro) (Domagala et al., 1986, Gellert et 
al., 1977). This can be explained by the triggering the downstream processes that lead to cell 
death in response to a small amount of DNA damage. 
Bacterial resistance to quinolones is increasingly being reported. Mechanisms include 
upregulation of efflux pumps, a reduced ability to uptake the drug, plasmid-mediated resistance, 
or actual mutations in the DNA gyrase or topo IV genes (Figure 1.17) (Redgrave et al., 2014, 
Hooper & Jacoby, 2015). 
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Figure 1.17: Known quinolone-resistance mechanisms. Including a) point mutations in the 
GyrA/GyrB or ParE/ParC proteins of DNA gyrase and topo IV respectively; b) alterations of 
porins or the cell membrane that reduce the uptake of the quinolone; c) overexpression of 
efflux pumps; or d) plasmid-based resistance mechanisms. Figure taken from the Journal of 
Medical Microbiology (Correia et al., 2017) with permission. 
 
The mutations in gyrase that confer resistance to quinolones are often found in a region 
termed the quinolone resistance-determining region (QRDR) which is between amino acids 67 
and 106 of GyrA (E. coli numbering) or 63 and 102 in ParC (Yoshida et al., 1990). There is also a 
QRDR found in GyrB between amino acids 426 and 447 (E. coli numbering), with the two most 
common mutations found to be D426N and L447E (Avalos et al., 2015, Gensberg et al., 1995, 
Wohlkonig et al., 2010, Yoshida et al., 1991). However, the most prevalent quinolone resistance 
mutations are found in GyrA. These mutations cluster at the dimer interface, near the active-
site tyrosines (Morais Cabral et al., 1997). Due to their specific interactions with the quinolone 
through the water-metal ion bridge, the residues most commonly mutated in ciprofloxacin-
resistant strains are the serine and aspartic acid/glutamic acid on helix IV in GyrA/ParC (Aldred 
  Chapter 1: General Introduction 
44 
 
et al., 2014b, Correia et al., 2017, Hooper & Jacoby, 2015, Redgrave et al., 2014). Resistance-
conferring mutations outside the traditional QRDR have also been identified. For example, an 
A51V mutation results in a six-fold increase in ciprofloxacin resistance (Friedman & Court, 2001). 
Plasmid-mediated quinolone resistance have been found in some clinical strains (Hooper & 
Jacoby, 2015). This has been shown to be due to the expression of pentapeptide-repeat proteins 
which mimic DNA and bind gyrase and inhibit its activity. These include the Qnr’s (QnrA, QnrB 
and QnrS), MfpA and McbG (Aldred et al., 2014b, Correia et al., 2017, Hooper & Jacoby, 2015, 
Redgrave et al., 2014). Other plasmid-based resistance mechanisms include the efflux pumps 
OqxAB, QepA1, and QepA2, and aac(6′)-Ib-cr which is a variant of an aminoglycoside transferase 
which alters the structure of some quinolones, making them less effective (Aldred et al., 2014b, 
Correia et al., 2017, Hooper & Jacoby, 2015, Redgrave et al., 2014). 
Other chromosomal mutations that have been identified that confer quinolone resistance 
include those involved with uptake of the drug, upregulation of efflux pumps and in the regulons 
that control the expression of these. In Gram-negative bacteria, modifications of the bacterial 
membrane either structurally by the reduction of the number of porins (via OmpA and OmpX) 
in the cell membrane, or through the alteration of the porins themselves have been reported 
(Bolla et al., 2011, Correia et al., 2017, Fernández & Hancock, 2012). Additionally, 
overexpression of various efflux pumps (also found in Gram-positive species) can lead to 
increased resistance (Aldred et al., 2014b, Correia et al., 2017, Hooper & Jacoby, 2015, Redgrave 
et al., 2014). The overexpression of efflux pumps in E. coli is often linked to mutations in MarRA, 
SoxRS and Rob regulons, which are involved in the regulation of these efflux pumps, as well as 
many other pathways in the cell (Aldred et al., 2014b, Correia et al., 2017, Hooper & Jacoby, 
2015, Redgrave et al., 2014). 
Ultimately, the quinolones, despite being extremely successful antibiotics are coming under 
increasing pressure due to the rise in resistance. This resistance is multifactorial and 
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complicated. Likewise, the mode of action of the quinolones themselves appears to complex 
including the way cells respond to being challenged by them. 
One complexity associated with the quinolones, and other cleavage-stabilising compounds 
(such as those that target human topo II), is that they have been demonstrated to increase the 
frequency of topoisomerase-mediated illegitimate recombination. 
 
1.6  Topoisomerase-mediated illegitimate recombination 
Illegitimate recombination (IR) has been defined and is used here as recombination between 
DNA sequences that share little to no homology (Franklin, 1971, Weisberg & Adhya, 1977). It is 
distinct from general recombination as it is independent of general recombination pathways. IR 
can result in genomic rearrangements such as deletions, duplications, insertions, and 
translocations (Weisberg & Adhya, 1977). It is often a result of DNA damage, such as during UV 
irradiation (Weisberg & Adhya, 1977) and seems to occur during the repair of DSBs. 
In bacteriophage, IR is observed during generalised and specialised transduction (Franklin, 
1971). Transduction is defined as the transfer of bacterial DNA from one bacterial chromosome 
to another by bacteriophage (Franklin, 1971). Generalised transduction occurs when 
bacteriophage P1 and P22 phage package fragments of the bacterial chromosome instead of 
their own chromosomes (Ikeda & Tomizawa, 1965). Specialised transduction occurs when part 
of the bacterial chromosome is excised with part of the phage genome, this is then packaged 
into infective particles (Franklin, 1971). 
IR has been reported in viruses, prokaryotes and eukaryotes and has been suggested to be 
the major influence in the evolution of genomes (van Rijk & Bloemendal, 2003). In particular, it 
has been demonstrated to play a role in plant genome size variation (Michael, 2014), as well as 
in the size of LRR (Leucine-Rich Repeat) genes which are important in plant resistance to 
pathogens (Wicker et al., 2007). It has been implicated in chromosomal rearrangements that 
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has led to the divergence in the control of gene regulation in maize (Wicker et al., 2007). 
Furthermore, IR has been demonstrated to have facilitated the evolution of Pseudomonas 
aeruginosa as a human pathogen (Rau et al., 2012) as well as shaped bacterial evolution and 
plasticity in general (Darmon & Leach, 2014). It has also been demonstrated to play a role in 
exon shuffling that results in novel genes (Long, 2001, van Rijk & Bloemendal, 2003). 
Topoisomerases have been indicated to play a role in IR, although the mechanism is not known. 
Topo I-mediated IR 
Although not the main focus of this thesis, topo I has been implicated in IR (Kim & Jinks-
Robertson, 2017). Topo I from vaccinia virus has been shown to facilitate excisive recombination 
of λ prophage that is integrase-independent (Shuman, 1991). Topo I has also been shown to 
mediate strand transfer in HeLa cells (Halligan et al., 1982) and participate in the non-
homologous excision of SV40 from eukaryotic chromosomes (Bullock et al., 1985). Furthermore, 
topo I mediates integration of woodchuck hepatitis virus into cellular DNA in an IR reaction 
(Wang & Rogler, 1991). In spite of all of this, camptothecin, a human topo I cleavage-stabilising 
inhibitor, which induces DSBs, does not increase the frequency of non-homologous 
recombination in vivo (Aratani et al., 1996). 
DNA gyrase-mediated IR 
DNA gyrase was the first of the type II topoisomerases implicated in IR. Kobayashi and Ikeda 
(1977) developed an in vitro assay to study IR using a bacteriophage λ-based packaging assay 
developed by Hohn and Hohn (1974) (see Chapter 3). They found that when oxolinic acid was 
added to the in vitro assay, they saw a 13-fold increase in ampicillin-resistant transductants 
(Ikeda et al., 1980). This increase was abolished when the assay was run in the presence of both 
oxolinic acid and coumermycin A1, but was restored when the same assay was performed with 
packaging mixtures made from coumermycin resistant lysogens. The stimulation of 
recombination was also reduced when the assay was run in the presence of oxolinic acid but the 
packaging mixture was prepared from nalidixic acid-resistant (nalr) lysogens (Ikeda et al., 1980). 
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This indicated that the recombination induced by oxolinic acid was mediated by DNA gyrase. 
Furthermore, when the recombination step was separated from the packaging step in the assay, 
addition of exogenous gyrase showed a 50-fold increase in IR when compared to the reaction 
where no gyrase was added. This was increased a further 40-fold in the presence of both gyrase 
and oxolinic acid. Interestingly, it was shown that gyrase was unable to induce IR in the absence 
of cell extracts implying that some extra factor was needed (Ikeda & Shiozaki, 1984). Gyrase-
mediated IR has been determined to be independent of viral int and red functions, and of the E. 
coli homologous recombination (RecABCF) functions (Ikeda et al., 1980). When the structures of 
these recombination events were analysed, it was found that some were insertions of the 
ampicillin-resistance gene from pBR322 into λ whilst others were translocations (Ikeda et al., 
1982). Moreover, these events could occur at multiple sites in either of the DNA molecules 
(Naito et al., 1984). While most studies implicate gyrase in insertions and translocations, it has 
also been shown to participate in deletion events between direct repeats (Saing et al., 1988, 
Miura-Masuda & Ikeda, 1990). The recombination junctions at insertions and translocations 
have no sequence homology (Ikeda et al., 1982, Naito et al., 1984), although, in some later 
studies, some regions of short homology (<10 bp) were found (Kumagai & Ikeda, 1991, Shanado 
et al., 1998, Shimizu et al., 1995, Shimizu et al., 1997). In vivo studies have also implicated gyrase 
in IR. Gyrase has been demonstrated to increase the frequency of λbio transducing phage 
through oxolinic acid-induced abnormal excision of the prophage (Tomono et al., 1989, Kumagai 
& Ikeda, 1991, Shimizu et al., 1995). It appears that gyrase-mediated IR can be short-homology 
dependent (SHDIR) or short-homology independent (SHIIR). SHDIR is thought to occur more 
frequently in vivo in both chromosomal and plasmid DNA (Kumagai & Ikeda, 1991, Shimizu et 
al., 1997, Saing et al., 1988) whereas SHIIR seems to be linked with drug-induced IR (Naito et al., 
1984, Miura-Masuda & Ikeda, 1990, Ikeda et al., 1982, Shanado et al., 1998). Gyrase-mediated 
IR has also been shown to occur at preferred gyrase cleavage sites, however, a preferred 
cleavage site is not necessary for gyrase-mediated IR to occur (Ikeda et al., 1984). Temperature-
sensitive mutations in gyrase have been identified that confer a hyper-IR phenotype. These 
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mutations are in the breakage-reunion domain of the GyrA subunit and include a double mutant 
(I203V/I205V) in the α18 helix, and two single mutahons in the α10΄ helix (L488P, L492P) (see 
Chapter 4). These mutations are thought to result in religation defects in GyrA similar to that 
seen in quinolone-stabilised cleavage (Ashizawa et al., 1999). There is also some evidence for 
topoisomerase-mediated IR to be linked primarily with DNA replication (primarily shown in 
gyrase) (Ikeda & Shiozaki, 1984). E. coli HU protein, which is a DNA-binding protein that has been 
linked to the preservation of supercoiling in chromosomal and plasmid DNA, has been shown to 
supress gyrase-mediated IR and the SOS response (Shanado et al., 1998). 
Ikeda et al. (1982) have proposed a subunit-exchange model to explain gyrase-mediated IR 
based on the increase in IR during drug-stabilised cleavage (see Chapter 5). As for the deletions 
between direct repeats, Ikeda (1994) suggests that during DNA cleavage, the ends are processed 
by exonucleases resulting in DNA deletion upon religation. 
 
Topo II-mediated IR 
Like DNA gyrase, topo II has been shown to mediate IR. Bae et al. (1988) were the first to 
demonstrate this with calf thymus topo II. They found that calf thymus topo II-mediated IR was 
similar to gyrase-mediated IR except that this enzyme is capable of IR in the absence of any 
crude cell extracts. This suggests that unlike gyrase, topo II does not need any other factors for 
the reaction to occur. They suggested the subunit-exchange model as a possible mechanism of 
action. 
In a separate study, using a shuttle vector carrying three bacterial markers, ampr and kanr 
(two resistance genes), and galK, the topo II inhibitor teniposide (VM26) was shown to increase 
the frequency of deletion formation. This was done by growing the vector for a number of 
generations in monkey COS1 cells treated with or without teniposide (an epipodophyllotoxin), 
before purifying the vectors and transforming them into E. coli cells and scoring the number of 
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amps and galK – double mutants among the kanr cells (Bae et al., 1991). Further to this, Han et 
al. (1993) found that teniposide-induced deletion/duplication junctions strongly correlated with 
teniposide-induced topo II cleavage sites. However, they indicated that none of their mutants 
were likely to have been due to a subunit-exchange model (Han et al., 1993). Topo II has also 
been observed to induce the integration of SV40 (simian virus 40) into cellular DNA in an IR 
reaction in the presence of teniposide (Bodley et al., 1993). In concurrence with other studies, 
the recombination sites were associated with preferred teniposide-induced topo II cleavage 
sites. The topo II inhibitors etoposide, teniposide and ICRF-193 were also revealed to stimulate 
IR in vivo by 3–5-fold by integration of an exogenous aprt gene into adenine 
phosphoribosyltransferase-deficient (APRT–) CHO (Chinese hamster ovary) cells (Aratani et al., 
1996). Etoposide has also been demonstrated to increase IR in yeast cells through deletions on 
chromosome III (Asami et al., 2002). Although, in a different study, the primary repair pathway 
for etoposide-induced DSBs in yeast was shown to be through single-strand invasion, a 
homologous recombination repair pathway, and only to a lesser extent through IR (Sabourin et 
al., 2003). 
Cancer chemotherapy regimens that include the human topo II inhibitors such as etoposide 
and doxorubicin, have been implicated in the occurrence of therapy-related acute myeloid 
leukaemia (t-AML) (linked to the chromosomal translocations in band 11q23) (Pendleton et al., 
2014, Cowell & Austin, 2012). The topo II inhibitors mitoxantrone and epirubicin are also 
associated with t(15;17) rearrangements (translocations between the PML gene and the retinoic 
receptor α (RARA) gene causing promyelocytic leukaemia) (Pendleton et al., 2014). 
Furthermore, childhood leukaemias such as infant AML and acute lymphoid leukaemia, which 
are linked to the mixed lineage leukaemia gene translocations, have been associated with 
maternal consumption of genistein (a topo II poison found in soy products) (Azarova et al., 
2010). Furthermore, analysis of chromosomal breaks in an infant AML revealed potential topo II 
binding sites at the break points (Negrini et al., 1993) further implicating topo II in this kind of 
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IR. Alongside these, topo IIβ has been implicated in the fusion of two genes that lead to poor 
prognosis in prostate cancer (Ashour et al., 2015) and although not directly linked to 
topoisomerases, a number of other gene fusions and translocations are associated with various 
cancers and often, when connected with the gene fusions, poor prognosis (Mani & Chinnaiyan, 
2010, Mitelman et al., 2007). The role of human topo II in these genomic rearrangements is not 
yet fully elucidated, however, evidence is currently pointing to non-homologous end joining and 
homologous recombination, rather than through direct subunit exchange of the topo II 
homodimers (Ashour et al., 2015, Elguero et al., 2012). Alternatively, it has also been suggested 
that a number of different DNA repair and recombination pathways may be involved (Rocha et 
al., 2016). 
Other topoisomerases and IR 
The only other type II topoisomerase that has been shown to participate in IR is that of 
bacteriophage T4. Bacteriophage T4 topoisomerase-mediated IR is very similar to that mediated 
by gyrase. It was shown to be stimulated by oxolinic acid in the in vitro assay and it also needed 
crude cell extracts (that is, some other unknown factor) for the reaction to occur. Similarly, a 
subunit-exchange model has been suggested (Ikeda, 1986a). 
 
1.7  Summary and aims 
DNA topology in all types of cells is under constant flux due to many exogenous and 
endogenous processes. These changes in topology can be deleterious and thus there are a 
number of important pathways and enzymes that maintain DNA topology to ensure fidelity in 
DNA sequence and structure. These include the DNA topoisomerases and other DNA repair 
proteins. DNA topoisomerases are the targets for a number of chemotherapeutic agents, such 
as antibiotics. One class of antibiotics, the quinolones, have been extremely successful 
antibiotics, however more recently there has been growing problems with resistance against 
  Chapter 1: General Introduction 
51 
 
them. Due to this, understanding the mechanisms behind this has become increasingly 
important. The quinolones have been implicated in topoisomerase-mediated IR, which is a type 
of illegitimate recombination, which may play a role in this rise in resistance. 
The initial aims of my PhD were to determine the molecular details of the role that 
topoisomerases play in IR. In particular, investigating the subunit-exchange model, as well as 
identifying the other proteins/factors that may be involved in the process. When the initial 
experiments that involved confirming and repeating the published work on topo-mediated IR 
(Chapter 3) were unsuccessful, more focus was laid on investigating the subunit-exchange model 
and elucidation of whether this is possible with topoisomerases (Chapter 5). Two other lines of 
enquiry were also pursued. These were the purification and characterisation of three mutations 
in GyrA that were shown to have a hyper-recombination phenotype in vivo (Chapter 4) and how 
treatment with sublethal concentrations of quinolones are involved in the acquisition of 
resistance (Chapter 6). The hypothesis is that DNA topoisomerases are directly involved with the 
acquisition of resistance to quinolones and other antibiotics through their involvement in IR by 
subunit exchange. 
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Chapter 2: General Methods 
2.1 Bacterial and phage strains 
Table 2.1 shows the genotypes of the various Escherichia coli and bacteriophage λ strains 
used in this work. The source of these strains is indicated in the right-hand column. 
Table 2.1: E. coli and bacteriophage λ strains used in this work. 
Strain Genotype Source 
E. coli α-Select Gold F- deoR endA1 recA1 relA1 gyrA96 
hsdR17(rk-, mk+) supE44 thi-1 phoA 
Δ(lacZYA-argF)U169 
Φ80lacZΔM15λ- 
Purchased from 
Bioline 
    
 BH2688 F- λ[Eam4 b2 red3 imm434 cIts 
Sam7] recA3 IN(rrnD-
rrnE)1 rpsL200 
(Hohn, 1979) 
Obtained from 
DSMZ (#5451) and 
ATCC (#35131). 
    
 BHB2690 F- λ[Dam4 b2 red3 imm434 cIts 
Sam7] recA3 IN(rrnD-
rrnE)1 rpsL200 
(Hohn, 1979) 
Obtained from 
DSMZ (#5452). 
    
 BL21(DE3) B strain 
F– ompT gal dcm lon hsdSB(rB–mB–) 
λ(DE3 [lacI lacUV5-
T7p07 ind1 Sam7 nin5]) [malB+]K-
12(λS) 
(Studier & Moffatt, 
1986) 
Purchased from 
New England 
Biolabs® (NEB®) 
 
    
 BW25113 F- Δ(araB–D)567 Δ(rhaD–
B)568 ΔlacZ4787(::rrnB-
3) hsdR514 rph-1 
(Baba et al., 2006, 
Datsenko & 
Wanner, 2000, 
Grenier et al., 
2014) 
Gift from Peter 
McGlynn, 
University of York 
    
 C600 F– [e14– (McrA) or e14+ (McrA+)] thr
-1 leuB6 thi-1 lacY1 glnV44 rfbD1 
fhuA21 
(Appleyard, 1954) 
Lab strain 
    
 DH5α F– Φ80lacZΔM15 Δ(lacZYA-argF) 
U169 recA1 endA1 hsdR17 (rK–, 
mK+) phoA supE44 λ– thi-
1 gyrA96 relA1 
(Taylor et al., 1993) 
Lab strain 
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 LE392MP F– e14– (McrA–) ∆(mcrC-mrr) (TetR) 
hsdR514 supE44 supF58 lacY1 or 
∆(lacIZY)6 galK2 galT22 metB1 
trpR55 λ– 
Host strain supplied 
with Epicentre® 
MaxPlax™ 
packaging extracts 
    
 MA156 F- Δ(cod-lacI)265, λ-, IN(rrnD-
rrnE)1, rpsL200, Δhfl-150, zjf-
599::Tn10 
Obtained from 
CGSC (#6881). 
Cited in (Young & 
Davis, 1983) 
    
 MG1655 F- λ- ilvG- rfb-50 rph-1 (Blattner et al., 
1997, Guyer et al., 
1981) 
Used both a lab 
strain and a strain 
obtained from 
CGSC (#6300)  
    
 MLS83L MG1655 gyrA S83L (Parks, 2004) 
Lab strain  
    
 MM293 F- glnX44 λ- endA1 thiE1 hsdR19 (Meselson & Yuan, 
1968) 
Obtained from 
CGSC (#6337) 
    
 NEB® 5α F- fhuA2 Δ(argF-lacZ)U169 phoA 
glnV44 Φ80 Δ(lacZ)M15 gyrA96 
recA1 relA1 endA1 thi-1 hsdR17 
Purchased from 
NEB® 
    
 NGB345 MG1655 gyrA I203VS204RI205V This work 
    
 NM759 W3110 recA56, ∆(mcrA) e14, 
∆(mrr-hsd-mcr), (λimm434, clts, b2, 
red3, Dam15, Sam7)/λ 
Packaging extract 
lysogen supplied 
with Epicentre® 
MaxPlax™ 
packaging extracts 
    
 Y-Mel F- tyrT58 mel-1 (Ikeda et al., 1980, 
Kobayashi & Ikeda, 
1977, Rickenberg & 
Lester, 1955) 
Obtained from 
CGSC (#5032) 
    
Bacteriophage 
λ 
Temperature-
sensitive strain 
λ cI857 Sam7 (Goldberg & Howe, 
1969) 
Purchased as 
‘Lambda DNA’ from 
Sigma-Aldrich®  
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Spectinomycin 
-resistant 
strain 
λ lom::aadA (Fogg et al., 2010) 
Gift from Heather 
Allison via Andy 
Bates at the 
University of 
Liverpool 
CGSC is the Coli Genetic Stock Centre at Yale University; ATCC is the American Type Culture Collection; 
DSMZ is the Leibniz Institute DSMZ - German Collection of Microorganisms and Cell Cultures GmbH. 
 
2.2 Plasmids and DNA substrates 
Various plasmids and DNA substrates were used in this work (Table 2.2). Some were used in 
vitro as substrates for the various assays that were run and others were used in vivo, either as 
expression vectors or in recombineering. For the various maps see Appendix I. 
Table 2.2: Plasmids and other DNA substrates used in this work. 
Plasmid or 
Substrate 
Features Use Source 
Cam Fragment 1869 bp, Cam-
resistance cassette, 
Mu SGS, pBR322 SGS 
Linear substrate for non-
λ IR assay 
This work – 
synthesised by 
ThermoFisher using 
Gene strings 
application 
MiniCircle 1814 bp, Cam-
resistance cassette, 
Mu SGS, pBR322 SGS, 
AttR site 
Circular substrate for 
non-λ IR assay 
This work – 
Synthesised by 
Twister Biotech 
pACYC177 Kan resistance 
cassette, Amp-
resistance cassette, 
p15A origin 
PCR substrate for KanR 
linear fragment for non-λ 
IR assay 
(Chang & Cohen, 
1978) 
pBR322* High-copy number 
derivative of pBR322. 
Amp resistance, 
ColE1 origin 
Plasmid substrate for λ 
and non-λ IR assay, as 
well as DNA substrate for 
topoisomerase 
biochemical assays  
(Boros et al., 1984) 
This is a variant of 
the pBR322 in the 
refence as it has a 
deletion that 
inactivates the 
Tetracycline 
resistance gene. 
pGDV1 Bacillus subtilis 
plasmid – cannot 
replicate in E. coli. 
Cam-resistance 
cassette 
Plasmid substrate for 
non-λ IR assay 
(Sarkar et al., 1997, 
Bron, 1990) 
Obtained from 
BGSC (#1E60) 
pIR Derivative of pUC19 
with pSC101 origin, 
Plasmid substrate for 
non-λ IR assay – 
This work – 
synthesised by 
Chapter 2: General Methods 
 
55 
 
Cam-resistance 
cassette, Mu SGS, 
pBR322 SGS 
designed to have ColE1 
origin cut out 
ThermoFisher’s 
GeneArt plasmid 
construction service 
pKD46 pSC101 origin, Amp-
resistance cassette, λ 
Red genes: exo, beta, 
gam with ParaB 
inducible promoter 
ssOligo Recombineering 
plasmid, overexpresses λ 
recombination genes 
(Datsenko & 
Wanner, 2000) – 
obtained in E. coli 
MG1655 from 
CGSC, Yale 
University 
pPH3 Amp-resistance 
cassette, E. coli gyrA 
gene with Ptac 
promoter, pBR322 
origin 
E. coli GyrA over 
expression plasmid 
(Hallett et al., 1990, 
Maxwell & Howells, 
1999) 
pUC19 pMB1 origin, Amp-
resistance cassette, 
MCS, lacZα gene 
from E. coli 
Plasmid substrate for 
non-λ IR assay – used for 
Blue-white colony 
screening 
(Yansich-Perron et 
al., 1985) 
pI203V/I205V Amp-resistance 
cassette, E. coli 
gyrAG607G609G613 
gene with Ptac 
promoter, pBR322 
origin 
E. coli GyrA over 
expression plasmid with 
I203V/I205V hyper-
recombination 
mutations 
This work 
pL488P Amp-resistance 
cassette, E. coli 
gyrAC1463 gene with 
Ptac promoter, 
pBR322 origin 
E. coli GyrA over 
expression plasmid with 
L488P hyper-
recombination 
mutations 
This work 
pL492P Amp-resistance 
cassette, E. coli 
gyrAC1475G1476 
gene with Ptac 
promoter, pBR322 
origin 
E. coli GyrA over 
expression plasmid with 
L492P hyper-
recombination 
mutations 
This work 
Amp – Ampicillin, BGSC – Bacillus Genetic Stock Centre, Cam – is chloramphenicol, Kan – Kanamycin, MCS 
– multiple cloning site, SGS – strong-gyrase binding site 
 
DNA concentrations were measured using UV/Vis spectroscopy either using a NanoDrop or 
using a TrayCell (Hellma®Analytics) using a 1 mm path length. 
2.3 Primers and PCR 
Primers were synthesised by Sigma-Aldrich using their Standard DNA Oligo form. Oligos 
were ordered at 0.025 µmole scale with a desalting purification step. 
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Table 2.3: Primers and Oligo’s used in this work. 
Assay Primer Sequence (5´ - 3´) Notes 
Non-λ Kan100 F TGTGTCTCAAAATCTCTGATGTT 900bp product 
with Kan 
resistance 
cassette from 
pACYC177 
 Kan100 R TTAGAAAAACTCATCGAGCATC 
    
 Kan200 F TGCTTTGCCACGGAACGGTCTGC 1200bp 
product with 
Kan resistance 
cassette from 
pACYC177 
 Kan200 R ATCCAGCCAGAAAGTGAGGGAGCCACG 
    
 Kan400 F TTCGTAAGCCATTTCCGCTCGCCGCAG 1200bp 
product with 
Kan resistance 
cassette from 
pACYC177 
 Kan400 R ACATCACCTTCCTCCACCTTCATCCTCAGC 
    
 CamFragF GTCAGATTTCGTGATGCTTGTCAGG Primers for 
the 
amplification 
of the ~1800 
bp Cam Frag 
DNA substrate 
 CamFragR ATCATGCAGCTGGTTGGTCAGGTTC 
    
 pUC19AmpF CGTCAATACGGGATAATACCGC Primers from 
within the 
Ampicillin-
resistance 
gene of pUC19 
– used for 
primer walking 
by Eurofins 
 pUC19AmpR TAAATCTGGAGCCGGTGAGC 
    
Hyper-
recombination 
mutants - SDM 
I203VF GTATATTGATGATGAAGACGTGAG
CATTGAAGGGCTGATG 
Primers 
designed with 
PrimerXa 
online Protein-
based primer 
design tool  
I203VR CATCAGCCCTTCAATGCTCACGTCTTCATCAT
CAATATAC 
I205VF GATGAAGACATCAGCGTTGAAGGGCTGATG
G 
 
I205VR CCATCAGCCCTTCAACGCTGATGTCTTCATC  
    
 L488PF CTGGATCAGATCGCGGAACCGTTGCGTATTC
TTGGTAGCG 
Primers 
designed with 
PrimerXa 
online Protein-
based primer 
design tool 
 L488PR CGACCTAGTCTAGCGCCTTGGCAACGCATAA
GAACCATCG 
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 L492PF GAACTGTTGCGTATTCCGGGTAGCGCCGATC
GTC 
Primers 
designed with 
PrimerXa 
online Protein-
based primer 
design tool 
 L492PR GACGATCGGCGCTACCCGGAATACGCAACAG
TTC 
    
 TGM33 TGCATAATTCGTGTCGCTCAAGG Sequencing 
primers that 
cover the 
entire gyrA 
gene in pPH3. 
Designed by 
Thomas 
Germe (JIC) 
 TGM34 AAATCTGCCCGTGTCGTTGG 
 TGM35 TCGTCGCGGTATTGAAGAAGC 
 TGM36 TGGTTGCTAATCCGTGGCAG 
 TGM37 TGCCGCACGTATTAAAGAAGAAGAC 
 TGM38 AATGCTGTTCTCCGCTGAAGG 
    
Hyper-
recombination 
mutants - 
ssOligo 
recombineering 
I203V/I205V G*A*T*T*GCCGCCGTCGGGAAGTCCGGCCC
CGGGATGTGTTCCATCAGCCCTTCcaccctcacG
TCTTCATCATCAATATACGCCAGACAACC 
ssOligo 
designed with 
the help of 
MODESTb 
 
I203V/I205V 
wt 
CGGGATGTGTTCCATCAGCCCTTCAAT 
Colony PCR 
primers 
designed by 
MODESTb 
I203V/I205V 
mut 
GTTCCATCAGCCCTTCCACCCTCAC 
I203V/I205V
R500 
CCGTCGCGTACTTTACGCCATGAAC 
I203V/I205V
F 
CGGTACGGTAAGCTTCTTCAATAC Primers 
upstream and 
downstream 
from mutation  
I203V/I205V
R 
GACGTCATGCCAACCAAAATTC 
   
L488P C*T*G*T*TCACGAACCAGCTCCAGCTCTTCA
CGGATCACTTCCATCAGACGATCGGCGCTTCC
CAGGATGCGGAGcgGTTCCGCGATCTGATC 
ssOligo 
designed with 
the help of 
MODESTb 
L488P wt CGATCGGCGCTACCAAGAATACGCAAC Colony PCR 
primers 
designed by 
MODESTb 
L488P mut CGATCGGCGCTTCCCAGGATGCGGAGC 
L488P R400 GTCGTACTATTTTCGAACTGCGTAAAGCTCGC 
   
L492P T*C*C*A*GCTCTTCACGGATCACTTCCATCA
GACGATCCGCACTTCCcgGTATACGCAACAGT
TCCGCGATCTGATCCAGCAGCTCTTTGTAT 
ssOligo 
designed with 
the help of 
MODESTb 
 L492P wt CCATCAGACGATCGGCGCTACCA Colony PCR 
primers 
designed by 
MODESTb 
 L492P mut CCATCAGACGATCCGCACTTCCC 
 L492P R600 GTATGCGCATCGTGATTGAAGTGAAACGC 
a - http://www.bioinformatics.org/primerx/index.htm, b – MODEST online tool (Bonde et al., 2014) 
*indicates Phosphorothioate linkages 
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PCR reactions were run with 0.5 µM of each primer, 1 ng of template, 1 U of DNA 
polymerase, 200 µM dNTP’s (equimolar deoxynucleotide triphosphates, dGTP, dCTP, dATP and 
dTTP), 1 x PCR buffer and nuclease free water to the required volume. This is unless otherwise 
stated and specifics are outlined in individual Chapters. PCR reactions were incubated in an 
Eppendorf Mastercycler® nexus thermocycler. 
 
2.4 Gel electrophoresis 
Agarose gels 
Agarose (1% w/v) gels were made in TAE buffer (40 mM Tris-Base, 20 mM Acetic Acid, 1 mM 
Disodium EDTA). Gels were run between 80 – 100 V for between 1 and 3 h, unless otherwise 
indicated. Gels were then stained in a 1 µg/mL Ethidium Bromide (EtBr) bath for 10 min before 
destaining for a further 10 min in TAE buffer. Gels were then visualised on a Syngene G:BOX Gel 
Doc system. 
Blue-Native polyacrylamide gel electrophoresis (BN-PAGE) 
Proteins (normally between 0.1 µg and 2 µg) were added, along with relevant other factors, 
such as ATP, DNA and or antibiotics, native-PAGE sample buffer (2.5 µL of a 4 × solution) and 
ultrapure water (to a final volume of 10 µL) to a 10 or 15 well NativePAGE™ Novex® 4 – 16% 
gradient Bis-Tris Gel (Life Technologies). Gels were placed in a XCell SureLock™ Mini-Cell 
Electrophoresis System in the cold room (~7°C). The upper buffer chamber was filled with cold 
1 × Cathode buffer and the lower chamber filled with cold 1 × Anode buffer. The gels were run 
at 150 V, restricted to 8 mA (max 10 mA for 2 gels) for 60 min, after which the voltage was 
increased to 250 V, restricted to 2 mA per gel for a further 2 h. The gels were either stained with 
InstantBlue Coomassie (Expedeon) stain or transferred for Western Blotting. Gel pictures were 
taken using a Syngene G:BOX Gel Doc system. 
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Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE) 
Either purchased 12% Run Blue SDS PAGE (Expedeon) or homemade 12.5% SDS PAGE gels 
were run. The Run Blue SDS PAGE gels were run in the buffer supplied with the gels (TEO-tricine 
running buffer). The 12.5% SDS PAGE gels (0.75 mm thickness) were prepared as in Table 2.4 
and run in SDS PAGE running buffer. Initially gels were run at 120 V for 15 min, then at 180 V for 
1 h. The gels were either stained with InstantBlue Coomassie (Expedeon) stain and gel pictures 
were taken using a Syngene G:BOX Gel Doc system. 
Table 2.4: SDS PAGE gel components. 
 12.5% Resolving gel 3.75% Stacking gel 
30% Polyacrylamide (Severn Biotech Ltd, 
acrylamide:bisacrylamide 37.5:1) 
2.5 mL 0.75 mL 
Resolving Buffer (377 mM Tris.HCl pH 8.8, 0.1% 
SDS final concentration) 
2.0 mL - 
Stack Buffer (130 mM Tris.HCl pH 6.8, 0.1% SDS 
final concentration) 
- 2.25 mL 
TEMED (N,N,N´,N´-
tetramethylethylenediamine) (Sigma) 
10 µL 10 µL 
10% Ammonium Persulphate (Sigma) 100 µL 50 µL 
Ultrapure H2O 1.5 mL 3.0 mL 
 
2.5 Media, buffers and antibiotics 
LB 
Luria-Bertani broth (also known as Lysogeny Broth) (LB) was made using either a premade 
Formedium LB powder, or using Oxoid™ Tryptone power, Oxoid™ Yeast Extract and NaCl 
(Sigma). The composition of the broth either way is 10% tryptone, 5% yeast extract and 10% 
NaCl. This was made in Milli-Q® (Merck-Millipore) Ultrapure H2O and sterilised by autoclaving at 
121°C for 15 min at 15 psi. 
Chapter 2: General Methods 
 
60 
 
λB 
Lambda Broth (λB) was made using 10 % Oxoid™ Tryptone and 5% NaCl (sigma). Again, in 
Milli-Q® Ultrapure H2O and sterilised by autoclaving at 121°C for 15 min at 15 psi. 
NZM 
NZM broth was made using 10% Oxoid™ Tryptone, 5% NaCl, and 2% MgSO4 in Milli-Q® 
Ultrapure H2O and sterilised by autoclaving at 121°C for 15 min at 15 psi. 
SOC 
Super Optimal Broth with Catabolite repression (SOC) was made using a premixed 
Formedium powder. The composition of the broth is 2% tryptone, 0.5% yeast extract, 10 mM 
NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4 and 20 mM glucose. All but the MgCl2, MgSO4 
and glucose were suspended in Milli-Q® Ultrapure H2O and sterilised by autoclaving at 121°C for 
15 min at 15 psi. The other components were mixed together and filter sterilised (0.2 µm filter) 
before being added to the autoclaved components. 
Antibiotics 
Antibiotic stocks were made as per Table 2.5. Where applicable they were filtered through 
a 0.2 µm filter to ensure sterility before freezing in aliquots to avoid freeze thawing. 
Table 2.5: Antibiotics, their stock solutions and solvents used in this work. 
Antibiotic Solvent Stock Concentration (mg/mL) 
Ampicillin Ultrapure H2O 100  
Chloramphenicol 70% Ethanol 30 
Ciprofloxacin Ultrapure H2O 10 
Coumermycin A1 DMSO* 10 
Kanamycin Ultrapure H2O 50 
Moxifloxacin 0.1 N NaOH 10 
Norfloxacin Ultrapure H2O 10 
Oxolinic Acid 0.1 N NaOH 10 
Sparfloxacin 70% Ethanol 10 
Spectinomycin Ultrapure H2O 100 
Streptomycin Ultrapure H2O 100 
Tetracycline 70% Ethanol 15 
Triclosan 70% Ethanol 15 
RedX05931 DMSO* 5 
* was not filter sterilised. 
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TGED buffer 
This is the standard buffer used in purification of E. coli GyrA protein - 50 mM Tris.HCl (pH 
7.5), 1 mM EDTA, 2 mM DTT and 10 % (v/v) glycerol in Milli-Q® Ultrapure H2O. 
Supercoiling assay buffer (ScAB) 
ScAB is the standard assay buffer used in the topoisomerase biochemical assays that require 
ATP – 35 mM Tris.HCl, 24 mM KCl, 4 mM MgCl2, 2 mM DTT, 1.8 mM spermidine, 1 mM ATP, 6.5% 
(w/v) glycerol and 0.1 mg/ml albumin in Milli-Q® Ultrapure H2O. 
Enzyme buffer (EB) 
EB is the storage buffer for GyrA and GyrB proteins – 50 mM Tris.HCl (pH 7.5), 100 mM KCl, 
2 mM DTT, 1 mM EDTA, and 10% (w/v) glycerol in Milli-Q® Ultrapure H2O. 
Assay stop buffer (STEB) 
STEB is the standard stop buffer for enzymatic assays and for gel loading. It is made as a 2 × 
solution and used at 1 × - 40% (w/v) sucrose, 0.1 M Tris.HCl (pH 8.0), 0.1 M EDTA, and 0.5µg/mL 
bromophenol blue in Milli-Q® Ultrapure H2O. 
Sample application buffer (SAB) 
SAB is the standard SDS buffer SDS PAGE gel loading. It is made as a 5 × solution and used at 
1 × - 62.5 mM Tris.HCl (pH 6.8), 2% SDS, 10% glycerol, 5% β-mercaptoethanol and 0.001% 
Bromophenol Blue in Milli-Q® Ultrapure H2O. 
Native PAGE sample buffer 
Native-PAGE sample buffer is used as a gel loading buffer for BN-PAGE gels. It is made as a 
4 × solution and used at 1 × (pH 7.2) - 50 mM Bis-Tris, 6 N HCl, 50 mM NaCl, 10% (w/v) glycerol, 
and 0.001% Ponceau S in Milli-Q® Ultrapure H2O. 
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Cathode buffer 
This was the cathode buffer used in the BN-PAGE protocol – 50 mM Tricine, 15 mM Bis-Tris 
and 0.002% Coomassie G250 in Milli-Q® Ultrapure H2O. The pH was adjusted to 7.0 with HCl. 
Anode buffer 
This was the anode buffer used in the BN-PAGE protocol – 50 mM Bis-Tris (pH 7.0) in Milli-
Q® Ultrapure H2O. 
SDS PAGE running buffer 
This was the running buffer used with the SDS-Tris Glycine PAGE gels – 25 mM Tris.HCl (pH 
6.8), 192 mM glycine and 0.1% SDS in Milli-Q® Ultrapure H2O. 
 
2.6 Electroporation and transformation 
Electroporation 
Two microlitres (approximately 100 ng) of a DNA sample was added to 25 μL of 
electrocompetent E. coli cells (either purchased (see Table 2.1 or homemade by centrifuging 
through a glycerol/mannitol cushion (Warren, 2011) – unless otherwise stated). This was then 
transferred to precooled 1 cm electroporation cuvettes and electroporated at 1.7 kV with time 
constants between 4.5 and 5.5. After electroporation 975 μL of warm SOC was added to the 
samples and these were incubated at 37°C for 1 h with shaking. The samples were then 
centrifuged at 3000 g for 5 min and resuspended in 450 μL of LB before plating on 1.2% LB agar 
plates with appropriate antibiotics at suitable dilutions. 
Transformation 
Plasmid DNA (>100 ng) was incubated with 50 µL of chemically-competent E. coli cells on ice 
for 20 min before heat shocking at 42°C for 42 s. These were then returned to ice for 2 min 
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before 950 µL of prewarmed SOC was added. The samples were incubated at 37°C for 1 h with 
shaking before plating on 1.2% LB agar plates with appropriate antibiotics at suitable dilutions. 
2.7 Overexpression and purification of GyrA 
The pPH3 overexpression plasmid was transformed into the expression host E. coli BL21 
(DE3). A single colony was inoculated into 5 mL LB with 100 µg/mL ampicillin and incubated 
overnight at 37°C with shaking (unless otherwise stated). The following day all 5 mL of the 
overnight culture was inoculated into 500 mL of LB which was incubated at 30°C with shaking at 
220 rpm until an OD600 of about 0.6 was reached. Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
was added to 0.5 mM and the cultures were returned to the shaking incubator for a further 4 h 
or overnight. The cultures were centrifuged in 1 L pots in the SLC-4000 rotor at 7000 rpm for 10 
min. The pellet was resuspended in TGED and flash frozen in liq N2 before storing at -80°C. 
After incubation with IPTG, protein expression was identified using SDS PAGE. Samples were 
prepared by boiling 100 µL of the culture with 20 µL of 5 × SAB for five minutes. These were run 
on a 12.5% polyacrylamide resolving gel with a 4% polyacrylamide stacking gel initially at 135 V 
for 20 min then 180 V for 60 min, partially submerged in an SDS running buffer. 
The resuspended pellet was defrosted on ice and the cells lysed using either a Cell Disrupter 
(Constant Systems). The cell debris was removed by centrifugation at 18500 rpm for 30 min 
using a SS34 rotor in a RC 6+ Sorvall Centrifuge. Only the supernatant was retained and purified 
with an ÄKTA Pure FPLC system (GE healthcare). Firstly, the supernatant was applied to a HiLoad 
Q-Sepharose High Performance ion exchange column (GE Healthcare) and the protein eluted 
using a NaCl gradient (0 – 1 M NaCl in TGED). Fractions were collected and identified using SDS 
PAGE. The fractions that were identified as having the GyrA protein were pooled and (NH4)2SO4 
was added to 1 M. This was applied to a Phenyl-Superose column HR 5/5 (Pharmacia) and the 
protein eluted using a reverse (NH4)2SO4 gradient (1 M - 0 in TGED). Fractions were collected and 
identified using SDS PAGE. Again, the fractions that were identified as having the GyrA protein 
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were pooled before dialysing overnight in SnakeSkin™ dialysis tubing (ThermoFisher) at 4°C in 
TGED. The dialysed fractions were applied to a MonoQ column (Pharmacia 10/10) using the 
same ÄKTA FPLC protocol, however the desired fractions were dialysed overnight in TGED with 
100 mM KCl. 
Protein concentrations were determined using a calorimetric Bradford assay. Briefly 1 – 10 
µL of the protein (or made up to 10 µL in EB) was added to 90 µL of ultrapure H2O. This was 
added to 900 µL of Bradford reagent in a cuvette with a 1cm path length, briefly mixed and 
incubated at room temperature for 5 min. This was analysed at a 595 nm wavelength in a 
spectrophotometer against a pre-programmed standard curve. 
 
2.8 Supercoiling reactions 
The general supercoiling reactions were set up as follows. The relevant GyrA protein, GyrB 
(made by Thomas Germe, JIC), 0.5 µg relaxed pBR322* DNA, EB, 5 × ScAB, and Milli-Q® water to 
a final volume of 30µL (unless otherwise stated). GyrA and GyrB were mixed in equimolar 
concentrations and then diluted (see individual assays for specific concentrations). The pBR322* 
DNA, and supercoiling assay buffer were all supplied by Inspiralis Ltd. The supercoiling reaction 
was incubated at 37°C for 30 minutes. After incubation 30µL of 2 × STEB and 30µL chloroform-
isoamyl alcohol (24:1) were added and briefly vortexed before centrifuging at 13000 rpm for 1 
min. Samples were analysed by agarose gel electrophoresis at 80 V for 3 h or 16 V overnight. 
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Chapter 3: Topoisomerase-Mediated Illegitimate Recombination 
3.1 Introduction 
Bacteriophage λ (λ) is a temperate phage that infects E. coli (Hershey & Dove, 1971). It is a 
double-stranded DNA virus (Figure 3.1) that is encapsidated in an icosahedral head attached to 
a tubular tail (Kellenberger & Edgar, 1971). λ infects the bacterium by adsorbing to the host cell 
and injecting its DNA into the host. Once inside the host, the phage genome circularises and the 
phage can then multiply either by entering the lytic or the lysogenic phase of its life cycle (Figure 
3.2) (Hershey & Dove, 1971). 
The lytic cycle (also known as the productive or active phase) commences upon expression 
of the cro gene and N gene. The cro gene product negatively regulates the repressor gene cI 
whilst the N gene product provides positive regulation of the genes involved in replication, 
recombination and the Q gene. The Q gene product regulates the genes involved in capsid 
development and packaging of the DNA (Echols, 1971). The λ chromosome undergoes rolling 
circle replication resulting in concatemeric DNA that is packaged from cos end to cos end (Feiss 
& Becker, 1983) (Figure 3.1). Maturation of the head protein occurs upon packaging of the DNA 
(Hohn & Hohn, 1974). The newly packaged and assembled λ are released from the bacterium by 
lysis (Wilson, 1982). 
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Figure 3.1: Bacteriophage λ DNA map. A drawing of the molecular map of λ beginning and 
ending with the cos ends (cos – shown as overhangs). The scale is in kb. Gene functions and 
clusters are given above the brackets (in line with FUNCTION). Known promoters are shown 
with single-headed arrows (head denotes the direction of transcription; length is the extent 
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of the transcript) and indicated by p with the subscript indicating the point of origin: pI – int 
promoter; pE – cI promoter (Establishment); pM – cI promoter (Maintenance); pL – major 
leftward promoter; pR – major rightward promoter; pO – oop promoter; pR’ – late promoter. 
Areas of known deletion or substitution are indicated below the scale with gal substitutions 
denoting the position of the area of recombination during excision giving rise to gal 
transducing phage, likewise with bio giving rise to bio transducing phage. attP is the 
attachment site where the phage integrates into the bacterial chromosome and ori is the 
phage replication origin. Figure adapted from (Daniels et al., 1983). 
 
Lysogeny is a passive way for λ to multiply as it replicates as part of the bacterial 
chromosome (Hershey & Dove, 1971, Arber, 1983). The initial stages of infection are the same 
as in the lytic phase however the switch between lysis and lysogeny relies on the production of 
the repressor cI, cII and cIII proteins. The cro gene product competes with cI for occupation of 
the operator and each represses each other’s synthesis (Gussin et al., 1983) with cII stimulating 
the expression of cI (Friedman & Gottesman, 1983). Once the “decision” to enter lysogeny is 
taken, the circularised and supercoiled λ chromosome integrates into the bacterial 
chromosome. This is mediated by the int gene and the recombination generally occurs between 
the attB site on the E. coli chromosome and the attP site on the phage chromosome (Arber, 
1983). The infected E. coli bacterium is now referred to as a lysogen and the λ is now referred 
to as a prophage. In this lysogenic form enough cI is produced to maintain the prophage and 
alongside the production of cII and cIII will stop superinfection with another λ phage leading to 
the establishment of immunity (Kaiser, 1957, Eisen & Ptashne, 1971). The λ genome will 
passively replicate this way until some switch (such as induction of the SOS response) induces 
the lytic cycle, where upon the cI repressor is cleaved and the expression of the xis gene, which 
excises the phage genome from the bacterial genome to begin the lytic cycle (Echols, 1986). 
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Figure 3.2: Diagram of the life cycle of Bacteriophage λ. 1 – the phage (λ) adsorbs to a 
bacterium (E. coli) and 2 – injects its DNA into the cell. 3 – the DNA circularises and is 
supercoiled by DNA gyrase. 4 – it then either integrates into the bacterial chromosome (enters 
the Lysogenic phase) or it begins to replicate its genome by rolling circle replication and 
assembling the proteins necessary for making the capsid (Lytic phase). 5 – the concatemeric 
DNA (result of rolling circle replication) is packaged into the phage head capsid and the whole 
infective phage is assembled. 6 – the bacterial cell is lysed and 7 – the infective phage is 
released to start the cycle again. 8 – upon induction (such as during SOS response) the phage 
chromosome excises from the bacterial genome and begins the Lytic phase (steps 5 – 7). 
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As outlined in the Introduction (Chapter 1), IR is defined as recombination between DNA 
sequences that share little to no homology (Franklin, 1971, Weisberg & Adhya, 1977). It is 
distinct from general recombination as it is independent of general recombination functions. In 
bacteriophage, IR is observed during generalised and specialised transduction (Franklin, 1971). 
Transduction is defined as the transfer of bacterial DNA from one bacterial chromosome to 
another by phage (Franklin, 1971). Generalised transduction occurs when P1 and P22 phage 
package fragments of the bacterial chromosome instead of their own chromosomes (Ikeda & 
Tomizawa, 1965). Specialised transduction occurs when part of the bacterial chromosome is 
excised with the phage genome and packaged along with part of the phage genome (e.g. gal or 
bio specialised transducing phage) (Franklin, 1971). 
DNA gyrase was the first of the type II topoisomerases implicated in topoisomerase-
mediated-IR. Kobayashi and Ikeda (1977) developed an in vitro assay to study IR using a 
bacteriophage λ-based packaging assay (Figure 3.3) which was established by Hohn and Hohn 
(1974). This assay involved the incubation of two induced E. coli lysogens which have a large 
amount of endogenous concatenated λ DNA with a plasmid containing an antibiotic-resistance 
gene. These lysogens had amber mutations in either the D and FI genes or the E gene (λ cIts857 
Sam7 Dam15 FIam96B and λ cIts857 Sam7 Eam4). Amber mutations are part of a set of specific 
nonsense mutations that can be overcome by growing in a suppressor host, such as supF or supE 
(Brenner et al., 1965, Brenner & Stretton, 1964, Casali, 2003). 
The first of the two lysogens acts as an acceptor lysate whilst the latter acts as a donor lysate 
in a complementation reaction. The D gene mutant results in an acceptor that is defective in 
DNA packaging, and the FI mutant stops the creation of non-infectious particles by interfering 
with the head-tail attachment protein (the wild-type FI protein with the D mutant may yield 
complete particles lacking DNA) (Hohn & Hohn, 1974, Kellenberger & Edgar, 1971). The E mutant 
does not produce head particles (Kellenberger & Edgar, 1971) whilst the S mutant, seen in both 
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lysogens, stops lysis (Wilson, 1982). The S gene encodes a holin, which is a protein that provides 
a small hole in the inner membrane for the passage of small molecules, and the R gene encodes 
endolysin that lyses the cells and frees the newly-made phage (Wilson, 1982, White et al., 2010). 
Packaging of the λ DNA into the head is only efficient if the DNA length is 78% – 105% of the 
whole λ chromosome (~50 kb); meaning that neither the plasmid alone, nor the full-length 
plasmid and the λ DNA together, can be packaged efficiently (Feiss & Becker, 1983, Feiss et al., 
1977). 
 Once the reaction containing the packaging mixture and plasmid was complete, the newly 
packaged phage were released and used to infect an appropriate host. This was then plated onto 
media, with or without the respective antibiotic. The frequency of IR was calculated by the 
number of antibiotic-resistant transductants over the number of plaque forming units 
(Kobayashi & Ikeda, 1977). 
Although DNA gyrase and other topoisomerases have been shown to mediate IR (discussed 
in Chapter 1 – Introduction), the exact molecular mechanism behind this has not been 
investigated. In order to evaluate topoisomerase-mediated IR, I attempted to repeat the λ-based 
experiments done previously as well as develop a non-λ in vitro assay. 
 
 
3.2 Specific materials and methods 
λ – based assay 
This assay (Figure 3.3) was run in various ways in an attempt to repeat the work done 
previously. The basic outline is described below but more discussion on the variations is in the 
Results and Discussion section.  
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Figure 3.3: Diagram of the in vitro λ – based assay. Packaging extracts were prepared from 
two lysogens, one that cannot make the proteins required for packaging DNA (yellow lysogen) 
and the other the cannot make the capsid heads (red lysogen). These are mixed together along 
with concatemeric λ DNA and pBR322* as well as oxolinic acid. E. coli LE392MP is then infected 
by the newly packaged phage and assayed for the number of plaque forming units and for the 
number of ampicillin-resistant transducing phage. 
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Transfection 
λ cI857 Sam7 DNA (Sigma) was transfected into E. coli C600 (Table 2.1) using the protocol 
outlined in Davis et al. (Davis et al., 1980). Briefly, an overnight culture of C600 was diluted 1/100 
in LB (see Chapter 2) and incubated at 37°C until an OD600 of 0.6-0.7 was reached. Thymidine 
was added to 12 µg/mL at an OD600 of 0.3. Cells were sedimented at 5000 rpm at 4°C and 
resuspended in 50 mL ice-cold CT media (50 mM CaCl2 and 50 µg/mL thymidine). The 
resuspended cells were incubated on ice for 5 min before centrifuging again at 5000 rpm at 4°C 
before resuspending the sedimented cells in 5 mL ice-cold CT media. Two hundred microlitres 
of the resuspended cells was incubated with 100 µL of λ cI857 Sam7 DNA (100 ng maximum) in 
100 mM Tris. HCl pH 7.2 and 50 µg/mL thymidine for 60 min on ice before heat shocking at 45°C 
for 2 min and plating on room temperature plates with 2.5 mL LB-0.7% agar (soft agar). These 
were incubated, inverted, overnight at 42°C. 
Preparation of phage stocks: confluent lysis and plate lysis with scraping 
Freshly poured 9 cm LB agar plates were overlayed with 3 mL of soft agar with 200 µL of an 
E. coli strain, alone if it was a lysogen, or with 100 µL of a phage stock. These were incubated 
without inversion at either 37°C or 42°C (42°C for temperature-sensitive λ cI857 Sam7). 
Confluent Lysis – 5 mL of cold SM buffer (100 mM NaCl, 10 mM MgSO4, 50 mM Tris.HCl pH 
7.5) was added to the plate and incubated at 4°C on a shaking platform for 3 h. The SM buffer 
was pipetted off the plate and into a chloroform-resistant tube. One millilitre of fresh SM was 
added to the plate, gently swirled and left for 15 min, tilted for the SM to drain into one area. 
This was pipetted into the same chloroform-resistant tube. One hundred microlitres of 
chloroform was added to the harvested SM buffer and briefly vortexed before centrifuging at 
4000 g at 4°C for 10 min. The supernatant was placed in a fresh chloroform-resistant tube and a 
drop of chloroform was added. This was titered and stored at 4°C. 
Plate Lysis with scraping – 5 mL of cold SM buffer was added to the plate and the top soft 
agar was gently scraped into a sterile chloroform-resistant centrifuge tube. Two millilitres of SM 
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was added to the scraped plate and gently swirled to collect any remaining top agar before 
adding it to the rest of the soft agar in the centrifuge tube. One hundred microlitres of 
chloroform was added to the tube and the agar suspension was incubated at 4°C with gentle 
agitation for 15 min. This was then centrifuged at 4000 g at 4°C for 10 min. The supernatant was 
placed in a fresh chloroform-resistant tube and a drop of chloroform was added. This was titered 
and stored at 4°C. 
Titering 
Phage stocks or newly packaged phage were serially diluted from 10-2 to 10-9 in phage 
dilution buffer (10 mM Tris.HCl pH 8.3, 100 mM NaCl, 10 mM MgCl2). One hundred microlitres 
of the dilution was added to 100 µL of plating bacteria (grown in 50 mL LB with 10 mM MgSO4, 
and 0.2% maltose, to an OD600 between 0.8 and 1.0) and incubated at 30°C for 15 min before 
adding to 3 mL soft agar (at 48°C) and overlaying onto prewarmed 9 cm LB 1.2% agar plates. 
These were inverted and incubated overnight at 42°C. Plates with between 30 and 300 plaques 
were counted and the titer calculated by multiplying the number of plaques with the dilution 
factor and 1000 (to convert µL to mL) and dividing this number by the volume of phage plated 
(µL). This will yield a titer in PFU/mL. Alternatively, 200 µL of plating bacteria was added to the 
soft agar and overlayed onto LB 1.2% agar plates and left to set before 5 µL of each dilution was 
spotted onto the plate. These were incubated inverted at 42°C overnight. The titer is calculated 
as above in spots that have between 3 and 30 plaques visible in them. The plating bacteria used 
was E. coli LE392MP (Table 2.1) unless otherwise stated. Where LE392MP was used, all media 
was supplemented with 15 µg/mL tetracycline. 
Packaging extracts 
Either MaxPlax™ (epicentre®) commercially available lambda packaging extracts were used 
as per manufacturer’s instructions, or packaging extracts were prepared as described below. 
The packaging extracts were made from two E. coli lysogens, BHB2688 and BH2690 (Table 
2.1) using the method outlined in Sambrook et al. (1989). Briefly, the lysogens’ temperature-
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sensitive phenotype was confirmed by streaking onto two LB 1.2% agar plates and incubating 
one at 30°C and the other at 42°C. If there was little to no growth on the 42°C plate when 
compared to the 30°C plate, then the packaging extracts were made from a colony picked and 
grown in an overnight culture from each 30°C plate. The overnight cultures were diluted to an 
OD600 of 0.1 in 500 mL NZM media. The cultures were grown to an OD600 of 0.3 at which point 
they were induced by swirling in a 45°C water bath for 15 min. The induced cultures were then 
incubated at 39°C with shaking for 3 h before they were centrifuged at 4000 g for 10 min at 4°C. 
From here one lysogen was prepared by lysis, the other by sonication. 
For the BHB2688 lysogen which acts as the packaging protein donor, the pellet was retained 
and resuspended in a total of 3 mL of an ice-cold sucrose solution (10% sucrose in 50 mM Tris.HCl 
pH 8.0). The suspension was divided into chilled microfuge tubes (0.5 mL each) and 25 µL of ice-
cold Lysozyme solution (2 mg/mL lysozyme in 10 mM Tris.HCl pH 8.0) was added to each, gently 
mixed and flash frozen in liq N2. The tubes were then thawed on ice before 25 µL of packaging 
buffer (6 mM Tris.HCl pH 8.0, 50 mM spermidine, 50 mM putrescine, 20 mM MgCl2, 30 mM ATP 
and 30 mM β-mercaptoethanol) was added to each tube and briefly mixed. The contents of all 
the tubes was then combined into one tube and centrifuged at 45 000 g for 1 h at 4°C. This was 
then dispensed into 10 µL aliquots, flash frozen in liq N2 and stored at -80°C. 
For the BHB2690 lysogen the pelleted cells were resuspended in 3.6 mL sonication buffer 
(20 mM Tris. HCl pH 8.0, 1 mM EDTA and 5 mM β-mercaptoethanol). The suspension was then 
sonicated using a microtip probe at maximum amplitude in short bursts, 10 s on, 20 s off, until 
the solution cleared and was less viscous. This was then centrifuged at 12 000 g for 10 min at 
4°C. The supernatant was added to an equal volume of ice-cold sonication buffer and a sixth of 
the volume (500 µL) of packaging buffer. The solution was gently mixed and dispensed into 
microfuge tubes in 15 µL aliquots before flash freezing in liq N2 and storing -80°C. 
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For the packaging assay, one tube of each prepared packaging extract was thawed on ice 
and mixed together with up to 1 µg of concatemeric λ DNA. This was incubated at 30°C for 1 – 3 
h and the titer measured as described above. 
Packaging extracts of BHB2688 and BH2690 were also prepared as per Kobayashi and Ikeda 
(1977). Briefly, the lysogens were grown to an OD600 of 0.2, induced at 42°C for 15 min then 
incubated for a further hour at 37°C. Four hundred millilitres of each culture was cooled on ice 
and centrifuged at 5000 g for 5 min. The pellets were resuspended together in 10 mL 40 mM 
Tris.HCl pH 8.0 and 10 mM MgCl2. This was then centrifuged again and resuspended in 700 µL 
of 40 mM Tris.HCl pH 8.0, and 10 mM MgCl2 and 175 µL of a solution of 50% DMSO, 50 mM 
spermidine, and 7.5 mM ATP. Twenty five microlitre aliquots were dispensed into microfuge 
tubes and flash frozen in liq N2. 
Concatemeric DNA 
Bacteriophage λ was prepared by confluent lysis. Once clarified the lysates were treated 
with RNAse and DNAse in 10 mM CaCl2 for 1 h at 37°C before stopping the reaction with 10 mM 
EDTA. The phage were then precipitated by adding PEG8000 (10% w/v) and incubated for 1 h at 
4°C with constant but gentle stirring. The precipitated phage were then pelleted by centrifuging 
at 10 000 g for 10 min and the pellet was resuspended in 500 µL of 10 mM Tris.HCl pH 8.0. An 
equal volume of phenol-chloroform-isoamyl alcohol (25:24:1 v/v/v) was added, gently mixed 
then centrifuged at 10 000 g for 10 min. The upper phase was pipetted off, being careful not 
take-up any of the white precipitate, and added to an equal volume of phenol-chloroform-
isoamyl alcohol. This was repeated 5 times, or until no further white precipitate was visible at 
the interface between the upper phase and lower phase. After the final phenol extraction, an 
equal volume of chloroform was added, briefly mixed and centrifuged at 10 000 g for 1 min. The 
upper phase was retained and ethanol (EtOH) precipitation of the DNA was performed. Twice 
the volume of ice-cold 95% EtOH was added to the upper phase with 0.3 M NaOAc (sodium 
acetate) pH 5.2 and incubated at -80°C for 10 min. This was then centrifuged at 2500 g for 1 min 
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at 4°C. The pellet was washed gently with ice-cold 70% (v/v) EtOH before pelleting again at 1000 
g for 30 s at 4°C. The pellet was left to dry before resuspending in 10 mM Tris.HCl pH 8.0. The 
newly extracted λ DNA (200 – 500 µg) was incubated in TEK buffer (10 mM Tris.HCl pH 8.0, 50 
mM KCl, and 1 mM EDTA) at 65°C for 10 min then at 45°C for a further 2 h. Formation of 
concatemers was confirmed by HindIII digestion and gel electrophoresis (General Methods -
Chapter 2). 
In vitro recombination assay 
The IR assay was set up in variety of ways but the general protocol was as follows (Figure 
3.3). Concatemeric λ DNA (λ cI857 Sam7) (1 µg) was incubated with 25 µL packaging extracts, 
with and without 1 µg relaxed pBR322* (Table 2.2), 50 µg/mL oxolinic acid (OA) or DNA gyrase 
(25 ng). This was incubated for 1.5 h at 30°C before a further 25 µL of the packaging extract was 
added and incubated for 1.5 h at 30°C. After the incubation, 500 µL of phage dilution buffer and 
25 µL chloroform was added followed by very gentle vortexing. This solution was then titered to 
assay the number of PFU/mL whilst 100 µL was added undiluted to 100 µL of the plating bacteria 
(LE392MP unless otherwise stated; prepared as described above). This was incubated at 30°C 
for 15 min to 1 h before all 200 µL was plated onto 9 cm LB 1.2% agar supplemented with 20 
µg/mL ampicillin and incubated at 30°C overnight looking for ampicillin-resistant colonies 
(ampicillin-resistant transducing phage). 
In vivo recombination assay 
This was designed as a simpler in vivo version of the in vitro λ-based assay (Figure 3.4). The 
plasmid pBR322* was transformed into E. coli LE392MP. This transformant was grown in λB 
supplemented with 2 mM MgSO4, 0.2% (w/v) maltose, 10 µg/mL Tet and 100 µg/mL Amp 
overnight at 37°C. This overnight culture was inoculated into 50 mL λB supplemented with 2 mM 
MgSO4, 0.2% (w/v) maltose, 10 µg/mL Tet and 100 µg/mL Amp and incubated until an OD600 of 
0.4 was reached where 2 mL was removed and centrifuged at 3000 rpm for 15 min. The pellet 
was resuspended in 4.4 mL of λ cI857 Sam7 (0.6 × 109 PFU/mL, approximately a MOI of 5) and 
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incubated initially at 30°C for 15 min then for a further hour at 30°C with gentle shaking. This 
(200 µL) was plated onto λB 1.2% agar plates with 100 µg/mL Amp. Twenty colonies were 
selected and streaked onto two separate plates, λB 1.2% agar plates with 100 µg/mL Amp and 
10 µg/mL Tet, one was incubated overnight at 30°C and the other was incubated overnight at 
42°C. Lysogens were assumed to be colonies that were Amp resistant and temperature-
sensitive. The newly-made E. coli LE392MP (pBR322*)( λ cI857 Sam7) lysogen was grown 
overnight in LB with 10 µg/mL Tet and 100 µg/mL Amp at 30°C. One hundred microlitres of this 
overnight culture was inoculated into 10 mL LB with 20 µg/mL Amp with either no oxolinic acid 
(OA), 0.01 µg/mL OA, 0.1 µg/mL OA, 1 µg/mL OA or 10 µg/mL OA. These were incubated at 30°C 
with shaking for 2 h. The 1 µg/mL OA and 10 µg/mL OA samples were incubated overnight. After 
incubation, the samples were induced at 45°C for 15 min before a further 1 h incubation was 
performed at 38°C with gentle shaking. One hundred microlitres of chloroform was added to the 
cultures, gently vortexed and then centrifuged at 4000 g for 10 min. The supernatant was then 
titered and assayed for ampicillin transducing phage with an untransformed E. coli LE392MP. 
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Figure 3.4: Diagram of the in vivo λ – based assay. AmpR indicates ampicillin resistance 
(red line). The yellow line is the bacterial chromosome, and the navy line is the phage 
chromosome. 
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Non-λ assay 
This assay was originally developed by Richard Bowater (UEA) and then updated by myself 
(Figure 3.5). It works on a similar basis to the λ-based assay in that it involves the transfer of an 
antibiotic-resistance gene from one DNA molecule to another. Although, the assay was also run 
where the disruption of the lacZ gene in pUC19 was selected for (Figure 3.5b). The basic premise 
is a supercoiling reaction (as described in the General Methods) where relaxed pBR322* (or 
pUC19) is incubated in supercoiling assay buffer with another piece of DNA carrying a kanamycin 
or a chloramphenicol resistance cassette (see Table 2.2 and Appendix I for all substrates used), 
with up to 250 ng of DNA gyrase, 50 µg/mL OA and cell extracts. Post-incubation the samples 
were either cleaned-up and electroporated (see General Methods) into electrocompetent E. coli 
NEB® 5-alpha (see Table 2.1) or transformed (see General Methods) into chemically-competent 
α-Select Gold Efficiency E. coli (Bioline). These were plated onto LB 1.1% agar plates 
supplemented with 100 µg/mL ampicillin (Amp) or 50 µg/mL kanamycin (Kan) or 35 µg/mL 
chloramphenicol (Cam) (or both Amp and Kan, or both Amp and Cam). Any resistant colonies 
were cultured and the plasmids extracted using Qiagen Miniprep kits. These plasmids were then 
characterised using restriction digests or by PCR with primers (Table 2.3) designed from the 
origin or from within the resistance cassettes of the starting substrates (see General Methods). 
DNA substrates 
Relaxed pBR322* was purchased from Inspiralis Ltd. The linear Kan substrate was made by 
PCR (General Methods) from pACYC177 (Table 2.2 and Appendix I) using primers (Table 2.3) that 
included 100 bp, 200 bp or 400 bp flanking the kanamycin cassette (total length of 900 bp, 1200 
bp or 1500 bp). I designed a linear substrate with the Cam-resistance cassette flanked by 200 bp 
from pACYC184 (Table 2.2 and Appendix I) modified to include the strong-gyrase binding site 
(SGS) from pBR322 and the Mu SGS and to reduce secondary structure. This linear substrate was 
constructed by ThermoFisher using their GeneArt Strings Linear DNA fragments application. I 
also had a MiniCircle fabricated by Twister Biotech (Table 2.2 and Appendix I), that was a circular 
version of the linear Cam and I designed and had fabricated (ThermoFisher GeneArt) a plasmid 
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with the pSC101 origin of replication and a Cam-resistance cassette substrate (Table 2.2 and 
Appendix I). pGDV1 (Table 2.2 and Appendix I) is a Bacillus subtilis plasmid that cannot replicate 
in E. coli. It carries a Cam-resistance cassette and it was purchased from the Bacillus Genetic 
Stock Centre (Ohio State University). 
Cell extracts 
Cell extracts of NEB® 5-α cells or E. coli MM293 (Table 2.1) were grown in 10 mL LB with 0.05 
µg/mL OA at 37°C overnight. The cells were harvested by centrifugation and the pellet was 
resuspended in 100 µL 50 mM Tris. HCl pH 8.0. To this 10 µL of 10 mg/mL lysozyme was added, 
briefly mixed and subjected to two freeze thaw cycles where the samples were frozen in liq N2 
then slowly thawed on ice. After the second round of freeze-thawing, the lysates were either 
stored at -80 °C or they were clarified by centrifuging at 16 000 g for 30 min at 4°C. The 
supernatant was divided into 10 µL aliquots and flash frozen in liq N2 and kept at -80°C until 
required. 
Restriction digests 
Restriction enzymes ApaLI, AgeI, HindIII and NcoI were purchased from Roche or NEB® and 
were used as follows: 1 U of the enzyme was incubated with 100 ng of DNA at 37°C for 30 min 
to 1 h. The products of the digestion were then analysed using agarose gel electrophoresis. 
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Figure 3.5: Diagram of various ways the non-λ assay was performed. a) Diagram of non-λ 
assay with pBR322* and the linear fragment containing the kanamycin resistance cassette. b) 
Diagram of non-λ assay with pUC19 and the linear fragment containing the kanamycin 
resistance cassette. c) Diagram of non-λ assay with pBR322* and the pGDV1 B. subtilis plasmid 
containing the chloramphenicol resistance cassette. Cell lysate image is used with permission 
from Brian Jones (http://www.blog.bryanmjones.com/2013/12/cell-lysis-illustration.html). 
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3.3 Results and discussion 
λ-based assays 
I tried to detect IR following a number of variations of the procedure outlined in Figure 3.3. 
These included using different packaging extracts, both commercially available and made by 
myself. I tried different λ-phage and various E. coli hosts, including high frequency lysogeny hosts 
and phage with different selectable markers. Despite these attempts and the fact that IR has 
been demonstrated in repeated publications of this assay (Kobayashi & Ikeda, 1977, Ikeda et al., 
1980, Ikeda et al., 1982, Ikeda et al., 1984, Naito et al., 1984, Ikeda & Shiozaki, 1984), I have not 
been able to replicate the transfer of the Amp resistance to λ mediated by DNA gyrase. To date, 
I have seen one temperature-sensitive Amp-resistant transducing phage (Figure 3.6) which was 
found after incubation of the packaging extracts with λ cI857 Sam7 DNA and relaxed pBR322* 
in the presence of ATP, however no exogenous DNA gyrase or OA was added to this assay. From 
Figure 3.6, the transductant is temperature sensitive (no growth on the 42°C plate) and it is 
resistant to Amp (likely to have come from pBR322*) and Tet (from the host LE392MP). The 
cause of this is not known and I have also not been able to repeat this result. The transduction 
of resistance by phage is not uncommon and other groups have shown recombination between 
pBR322 and λ-phage in vivo (Pogue-Geile et al., 1980). 
There are quite a few possible reasons why I have not been able to reproduce the work done 
previously. I will deal with these individually below, explaining how I tried to address these 
challenges. 
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Figure 3.6: LB agar plates showing temperature-sensitive ampicillin transductants. a) Plate 
showing plaques from the assay containing the plasmid pBR322*, λ cI857 Sam7 DNA and 
packaging extracts at a 10-8 dilution. b) shows the isolated ampicillin-resistant colony that was 
grown overnight in LB with tetracycline and ampicillin then restreaked on two plates, one was 
incubated at 30°C (top left) and the other at 42°C (top right). The bottom plate shows the host 
streaked on LB and tetracycline and incubated at 42°C. This shows that this is an ampicillin-
resistant transductant of λ cI857 Sam7 as it is resistant to tetracycline (from the LE392MP 
host), ampicillin (likely from the pBR322*) and is temperature-sensitive (from the phage). 
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Substrates, packaging extracts, and hosts. 
To start with it was difficult to find the original E. coli host (Y-Mel – Table 2.1), λ strain (E. 
coli 594 lysogen) and packaging extracts from the initial publications (Kobayashi & Ikeda, 1977, 
Ikeda et al., 1980, Ikeda et al., 1982, Ikeda et al., 1984, Naito et al., 1984, Ikeda & Shiozaki, 1984). 
Thus, I tried to obtains hosts and strains for packaging extracts that were not too dissimilar from 
the original work. I did manage to find extracts used in other IR publications and tried those. 
The first assay where the Amp transductants induced by the addition of OA were identified 
used packaging extracts made from E. coli lysogens 594 (λ cI857 Dam15 FIam19B Sam7) and 594 
(λ cI857 Eam4 Sam7) (Ikeda et al., 1980, Ikeda et al., 1982). These extracts work in the same way 
as the ones I used (BHB2688 and BHB2690) except the λ prophages were able to excise from the 
genomes upon induction, thus the concatemeric DNA was endogenous to the packaging 
extracts. In some of the later publications (Ikeda et al., 1984, Naito et al., 1984, Ikeda & Shiozaki, 
1984), the lysogens were switched to similar lysogens carrying the b2 mutation which causes 
the prophage to be defective in excision (Gottesman & Yarmolinsky, 1968), meaning that there 
would be very little endogenous concatemeric DNA present in the packing extracts. In these 
cases, exogenous λ cI857 Sam7 DNA that had been annealed to make concatemers was added 
to the assay along with the pBR322*. I was unfortunately unable to acquire these lysogens to 
make packaging extracts. I did not think this would be a problem as in later publications (Ikeda, 
1986a, Ikeda, 1986b, Bae et al., 1988, Saing et al., 1988, Tomono et al., 1989, Chiba et al., 1989, 
Bae et al., 1991, Kumagai & Ikeda, 1991, Shimizu et al., 1995, Shimizu et al., 1997, Shanado et 
al., 1998, Ashizawa et al., 1999) the BHB2688 and BHB2690 packaging extracts were used. 
Although, these assays were slightly different from the original assays (the formation of Spi- 
phage instead of the formation of Amp transductants was used as a measure of IR - see Chapter 
4) (Ikeda et al., 1980, Ikeda et al., 1982, Ikeda et al., 1984, Naito et al., 1984, Ikeda & Shiozaki, 
1984), I thought that these packaging extracts should work. To try and make packaging extracts 
that more closely resembled the original protocol that identified the DNA gyrase-mediated IR 
(Ikeda et al., 1980), I also used a helper phage to excise the prophages from the BHB2688 
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lysogens, however, this did not make a difference. The commercial MaxPlax™ packaging extracts 
use the BHB2688 lysogen and another lysogen NM759 (see Table 2.1) and seem to be prepared 
in a similar way to the Sambrook packaging extracts (Sambrook et al., 1989). 
I attempted to prepare packaging extracts following the protocol outlined in Kobayashi and 
Ikeda (1977), as all reported packaging extracts used in the DNA gyrase-mediated IR papers cited 
this method. These packaging extracts didn’t yield plaques, however, on subsequent inspection 
of my protocol, I had not grown the lysogens sufficiently prior to induction due to a 
miscalculation on my part (the paper called for 1.5 × 108 cells, and I was using 3 × 107 cells). This 
factor of 5 difference in cell number, combined with my lack of experience with this protocol 
could explain why this protocol did not work in my hands. The importance of working with these 
extracts is that they are made with high percentages of DMSO. There is some suspicion that the 
topoisomerase-mediated IR may be an artefact of the assay and may be a result of the DMSO. 
DMSO has been shown to affect the efficiency of type II topoisomerases in vitro (Alison Howells 
(Inspiralis) and Thomas Germe (JIC) Personal Communication and personal observation) 
although the mechanism behind this is not known. 
In order to remove the packaging extracts from the equation, I designed the λ-based in vivo 
assay. This involved transforming E. coli LE392MP with pBR322* and then infecting it with λ 
cI857 Sam7 and selecting for lysogens (Figure 3.7). This lysogen carrying the pBR322* plasmid 
was then exposed to various amounts of OA, before the prophage was induced. The newly-made 
phage were separated from the bacterial lysates by centrifugation and used to infect an 
untransformed host. Ampicillin-resistant transducing phage were selected for but a number of 
false positives were obtained. The false positives were clustered in patches, seemingly where I 
had added the cultures for plating (Figure 3.8). None of the isolated colonies regrew on Amp. 
Upon discussion with other members in the lab, it was suggested that these were due to 
carryover of the beta lactamase produced by the pBR322* plasmid. This was confirmed when 
the strange Amp-resistant colonies disappeared when the phage were purified from the lysates 
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through a glycerol step gradient before infection. Ultimately, this assay requires further 
optimisation as no Amp-transducing phage were isolated. However, this also implied that the 
packaging extracts were not necessarily the primary problem. 
 
 
Figure 3.7: λ cI857 Sam7 lysogens of LE392MP (pBR322*). An overnight culture of LE392MP 
(pBR322) was grown in λB supplemented with 10 mM MgSO4, 0.2% maltose (w/v) and 100 
µg/mL ampicillin. One hundred microlitres of this culture was mixed with λ cI857 Sam7 with a 
multiplicity of about 5. This was incubated for 15 min at 30°C then incubated with gentle 
shaking for a further hour at 30°C. Dilutions were then plated on λB (see General Methods) 
1.2% agar with 100 µg/mL ampicillin at 30°C overnight. Twenty colonies were selected and 
each streaked on two λB 1.2% agar with 10 µg/mL tetracycline and 100 µg/mL ampicillin. One 
was incubated at 30°C and the other at 42°C. Colonies were selected based on those that grew 
at 30°C but not 42°C. Colony 5 was taken forward. 
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Figure 3.8: Ampicillin-resistant colonies from λ-based in vivo assay. a) spot titer and b) 
ampicillin-resistant colonies from no oxolinic acid (OA) sample from λ-based in vivo assay. 
LE392MP (λ cI857 Sam7)(pBR322*) was incubated at 30°C with various concentrations of OA 
(including a no OA control) before induction at 42°C for 15 min. After induction, the cultures 
were incubated for 1 h at 38°C. One hundred microlitres of chloroform was added and briefly 
vortexed. The lysates were clarified by centrifugation at 10 000 g for 10 min and the 
supernatants were retained. a) 200 µL LE392MP, grown to OD600 of 1.0 in λB with 10 µg/mL 
tetracycline, 10 mM MgSO4 and 0.2% (w/v) maltose, was added to molten λB 0.7% agar and 
poured over λB 1.2% agar + 10 µg/mL tetracycline and left to set. The clarified lysates were 
serially diluted (10-1 – 10-8) and 5 µL of each dilution (plus an undiluted sample) was spotted 
onto the set plate and left to dry for 30 min. These were then incubated overnight at 42°C. The 
plate shown is the one from the no added OA control. The 10-6 spot contains 21 plaques. b) 
100 µL of an overnight culture of LE392MP, grown in λB with 10 µg/mL tetracycline, 10 mM 
MgSO4 and 0.2% (w/v) maltose, was added to 100 µL of phage lysate (MOI of between 2-3) 
and incubated for 15 min at 30°C. λB was added to 1 mL and the culture was incubated for a 
further hour at 30°C with shaking at 110 rpm. This was then diluted 1 in 10 and plated on λB 
1.2% agar with 100 µg/mL ampicillin. The plate shown is the no added oxolinic acid control. 
The ampicillin-resistant colonies can be seen arranged in 5 groups. 
 
I eventually found the E. coli Y-Mel strain from the Coli Genetic Stock Centre (CGSC) at Yale 
University, however, when I infected it with λ cI857 Sam7, I didn’t get any plaques. 
Unfortunately, I ran out of time to follow this up. 
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Another potential pitfall was the λ strain. The λ cI857 Sam7 DNA was purchased from Sigma 
and is primarily sold to make DNA ladders. Thus, I am not sure that this strain is completely to 
type and is capable of all the expected phenotypes of the genotype. However, I am able to 
package the DNA which implies that it is the correct length, and the cos ends are intact. The 
packaged phage are able to form plaques on the appropriate host (supF), which suggests that 
the packaging proteins, capsid proteins and all proteins necessary for the lytic phase are 
functional. Furthermore, I have been able to identify lysogens that are temperature-sensitive 
and, upon induction, produce infective phage (from the in vivo assay) (Figures 3.7 and 3.8). This 
suggests that all the genes necessary for lysogeny and induction of prophage are functional. 
However, to address this separately, I also began setting up the assay to use the spectinomycin-
resistant λ lom::aadA (Fogg et al., 2010) (a gift from Heather Allison and Andy Bates at the 
University of Liverpool) (see Table 2.1), but I ran out of time to use it in the assays. 
Concatemeric DNA 
From discussions with Maggie Smith at York University, it seemed that concatemeric DNA 
was an important step in the assay. I had thought I was using concatemeric λ cI857 Sam7 DNA 
as there was a large amount of DNA remaining in the well of the gel after electrophoresis (Figure 
3.9a) however, when I switched to using the λ lom::aadA strain, I checked if I was making 
concatemers by digesting the newly annealed DNA with the restriction enzyme HindIII. If 
concatemeric DNA was being made, the band at about 4 Kb would be lost due to the annealing 
of the cos ends (Figure 3.9c). However, as seen in Figure 3.9b, there is no difference between 
the bands pre- and post- annealing and the banding pattern reflects that of the predicted 
banding pattern for the non-catemeric sample (left-hand side of Figure 3.9c). Unfortunately, I 
ran out of time to fully investigate this problem. 
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Figure 3.9: Concatemeric λ DNA. a) 0.7% agarose gel of λ cI857 Sam7 DNA post annealing. 
Arrow indicates large amount of remaining in the well. b) HindIII digest (+) of λ lom::aadA 
genome pre (λ lom::aadA pre) and post (λ lom::aadA post) annealing. c) is a predicted band 
pattern of the linear λ lom::aadA (left-hand side) and the predicted band pattern of the 
circular/concatemeric λ lom::aadA (right-hand side), the red box indicates the band at around 
4 Kb, which is not visible on the predicted concatemeric sample. On the gel the lower band 
can’t be seen. Predicted banding pattern was produced on ApE 2.0.47, a plasmid editor by M. 
Wayne Davis, Utah University. Hyper ladder VI is best used for PFGE and the upper band runs 
at around 48 Kb. The sizes of the visible bands are indicated down the left-hand side of a). 
 
Lysogeny 
As well as the concatemeric DNA, in discussions with Maggie Smith at York University, the 
importance of the frequency of lysogeny also became apparent. The ability to see the Amp 
transductants relies on enough lysogens being formed to reveal them. I was expecting to see 
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recombination rates of around 10-7 Amp transductants per PFU (Ikeda et al., 1980). This meant 
that I needed to have 107 lysogens to see one transductant. Although I was making lysogens 
(Figure 3.7), I was seeing at most 65% lysogeny at worst it was 5%, this would translate to about 
108 colony forming units (CFU)/mL. Although this rate should have revealed transductants, I still 
was not seeing any. The number of lysogens was also not constant across assays. In order to 
improve my protocols to ensure I was getting a high enough and consistent number of lysogens, 
I switched to the λ lom::aadA phage. This spectinomycin-resistant phage provides a better 
selectable marker than the temperature-sensitive repressor. I also found a strain of E. coli 
MA156 (Table 2.1) that carries the hfl mutations which stands for high frequency of lysogeny. 
Lambda forms lysogens at a high frequency (99% lysogeny) in this host as the mutations cause 
an accumulation of cII, which selects for lysogeny (Wullff & Rosenberg, 1983). Unfortunately, I 
ran out of time to test this host in the assay. 
Ultimately, alongside the issues outlined above, my lack of experience of working with λ 
likely contributed to the lack of outcomes where this part of my project was concerned. Despite 
this, I still think that the λ-based assays should be reproducible and given more time, I would 
have been able to overcome the challenges associated with the assays. 
Non-λ assay 
This assay has not been published before and was originally designed by Richard Bowater 
(UEA) and Tony Maxwell (JIC). Figure 3.5a shows the first iteration of this assay, where a linear 
900 bp double-stranded PCR product from pACYC177 was incubated with pBR322*. Here I was 
looking for the transfer of the Kan resistance into pBR322*. I tested these DNA substrates with 
and without DNA gyrase, ATP (which is in the supercoiling assay buffer), cell extracts (from E. 
coli MG1655) and OA. With this assay, I found a higher than expected number of Kan resistant 
and Amp and Kan resistant colonies. When I tested just the Kan PCR product with and without 
the various other components, the resistance, including the Amp resistance, remained (Table 
3.1). Unfortunately, I discovered that the PCR product still contained the parental plasmid in it, 
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which gave false positives as the pACYC177 plasmid carries both an Amp-resistance cassette and 
a Kan resistance cassette. I tried to gel extract the fragment but unfortunately this did not yield 
enough DNA to run the experiment. I was also concerned that the 100 bp flanking region was 
not sufficient to allow DNA gyrase to bind and potentially mediate exchange the whole Kan 
cassette from within those 100 bp regions. Especially considering the footprint of DNA gyrase 
on DNA was found to be about 120 bp (Fisher et al., 1981, Rau et al., 1987, Kirkegaard & Wang, 
1981, Morrison & Cozzarelli, 1981, Orphanides & Maxwell, 1994). I designed two sets of primers; 
one set to make the flanking regions 200 bp and the other to make the flanking regions 400 bp. 
This, however, would not solve the pACYC177 contamination issue. To overcome this issue, I 
decided to gel extract the PCR fragment then reamplify the fragment with the original primers. 
The 400 bp fragment would never reamplify after gel extraction but this solved the 
contamination issue. However, I still did not observe any recombinants. 
 
Table 3.1: Number of colonies that were ampicillin resistant, kanamycin resistant or both 
after transformation with 900 bp Kan PCR product. 
 Number of colonies 
Sample No drug Amp (100 
µg/mL) 
Amp (100 µg/mL) + Kan 
(50 µg/mL) 
Kan (50 µg/mL) 
No DNA Millions 0 0 0 
pUC19 n.d. 30 0 0 
K-PCR only n.d. 296 0 2 
K-PCR + ScAB n.d. 18 0 2 
K-PCR + RxAB n.d. >500 0 0 
K-PCR + ScAB + 
DNA gyrase 
n.d. 210 0 3 
K-PCR + RxAB + 
DNA gyrase 
n.d. 42 0 6 
K-PCR + ScAB + 
DNA gyrase + OA 
n.d. 10 0 7 
K-PCR + RxAB + 
DNA gyrase + OA 
n.d. 0 1 1 
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K-PCR + ScAB + DNA gyrase + CE n.d. 140 0 4 
K-PCR + RxAB + DNA gyrase + CE n.d. 54 0 5 
K-PCR + ScAB + DNA gyrase + OA + CE n.d. 1 0 8 
K-PCR + RxAB + DNA gyrase + OA + CE n.d. 48 0 8 
K-PCR is the 900 bp Kan PCR product from pACYC177; ScAB is supercoiling assay buffer; RxAB is 
relaxation assay buffer; OA is oxolinic acid; CE is crude cell extracts from E. coli MG1655; K-PCR is the 
kanr gene PCR product. n.d. is not done 
 
In order to increase the chance of seeing a recombination event, I decided to switch to 
looking for the disruption of a gene, instead of the transfer of a resistance cassette. This resulted 
in the second iteration of this assay (Figure 3.5b) where pUC19 (Figure 3.10a) containing the lacZ 
gene was incubated with the 1200 bp Kan fragment (with the 200 bp flanking regions). The idea 
was to use blue/white colony screening to look for disruption of the lacZ gene. Initially, I still had 
contamination with pACYC177, however, I managed to get rid of the contamination and got a 
white colony from a sample that had DNA gyrase, topoisomerase IV, ATP, pUC19, the Kan 
fragment and 0.1 µg/mL OA. We sent this plasmid for primer walking at Eurofins Genomics with 
the initial primer starting from within the pUC19 Amp-resistance gene cassette (Table 2.3). The 
sequence showed that this colony was a result of a recombination event in the pUC19 plasmid, 
that interrupted the lacZ gene, however, it was not a result of topoisomerase-mediated IR but 
was a DDE transposase (Figure 3.10b). The insert has separated the lac operator from lacZ and 
is stopping the production of β-galactosidase. 
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Figure 3.10: Maps of pUC19 and the plasmid from the isolated white colony. a) Plasmid 
map of pUC19 showing the relative positions of the ColE1 origin (grey), the Ampicillin-
resistance cassette (AmpR in pink), the lacZ gene with its operator (Blue), the position of the 
M13 primer binding site (turquoise and green) and the position of the three ApaLI restriction 
sites. b) is the plasmid isolated from the white colony with matching features seen in a) except 
the DDE transposase insert is shown in orange. The AmpR cassette was not fully sequenced as 
the primer walking started from within the AmpR cassette. The dotted lines indicate the area 
that was not sequenced but is thought to contain the rest of the AmpR cassette. 
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I decided at this point to redesign the assay again. As attempts to make a longer (>1200 bp) 
linear DNA fragment had failed, I designed a fragment (Cam fragment) that was 1896 bp long 
(Table 2.2 and Appendix I), which contained the chloramphenicol resistance (Cam) cassette as 
well as two strong-gyrase binding sites (SGS) (one from Mu phage (Pato, 1994), the other from 
pBR322 (Lockshon & Morris, 1985). The strong-gyrase binding site was identified by 
fragmentation and sodium dodecyl sulphate (SDS) trapping of the plasmid pBR322 in OA-treated 
E. coli. The SGS was identified by Lockshon and Morris (Lockshon & Morris, 1985) and was 
identified as: 5’ RNNNRNR(T/G)↓GRYC(T/G)YNYN(G/T)NY 3’ when averaged across 19 identified 
sites. N represents any nucleotide, R is a purine, and Y is a pyrimidine. The arrow represents the 
cutting site. Subsequent investigations have surmised that DNA gyrase cleavage specificity does 
not always adhere to this sequence (Cove et al., 1997) but alteration of the SGS has been shown 
to reduce DNA binding by DNA gyrase (Oram et al., 2006). The Cam fragment was fabricated as 
a linear DNA fragment which could be amplified by PCR. Alongside the Cam fragment, I designed 
and had fabricated a plasmid with the linear fragment and the pSC101 temperature-sensitive 
origin (pIR, Appendix I) using GeneArt’s plasmid constructor. I also had a MiniCircle made by 
Twister Biotech (Appendix I) with the same features. This would give two different types of 
substrate to use in the assay (linear and circular). One with a temperature-sensitive origin and 
the others without replicons, which mean they cannot replicate in E. coli. I also decided to alter 
my protocol to ensure that I was getting high enough transformation efficiencies to see all 
potential recombination events. I did this by cleaning up the DNA with phenol-chloroform before 
buffer exchanging to get rid of any salts and electroporating into high efficiency 
electrocompetent E. coli (Figure 3.5). 
The work done with the Cam fragment was completed with the help of an undergraduate 
Lister summer student, Shannon McKie, who spent 10 weeks working on this assay. Despite 
removing the pACYC177 from the equation, we still had problems with false positives in this 
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assay including contamination with two other plasmids. The assay is very sensitive due to the 
high efficiency of the electrocompetent E. coli NEB 5α (> 1010 CFU/µg of pUC19) and it picks up 
contaminating plasmids very easily. The other plasmids were identified as pLysS and pIR (Figure 
3.11a and b) (see Appendix I). From Figure 3.11, the digestion patterns from separate plasmids 
from three Cam-resistant colonies appears to be similar to those of the contaminating plasmids 
shown in Figure 3.11a. The second plasmid in Figure 3.11b also appears to have a second plasmid 
present, which is evident by the extra larger DNA bands seen in lane 3 as opposed to the lane 3 
of the pBR322* sample seen in Figure 3.11a. The pIR was believed to have been a cross 
contaminant picked up during DNA quantification. The pLysS was presumed to be a contaminant 
from the E. coli expression host that was used in the expression of the DNA gyrase subunits. It 
did not appear in every sample containing DNA gyrase but the only source of this plasmid in the 
lab comes from the expression host JM109 pLysS, in which the subunits of DNA gyrase are 
expressed. 
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Figure 3.11: Restriction digests of chloramphenicol-resistant plasmids. a) ApaLI (2) and 
AgeI (3) digests of the parental plasmid pBR322* and two potential contaminating plasmids 
pIR and pLysS. Undigested plasmid is 1. b) Representative ApaLI and AgeI digests of plasmids 
isolated from 3 separate chloramphenicol-resistant colonies from non-λ assay. A 1 Kb (NEB) 
ladder was used with the sizes of the bands in Kb indicated on the left-hand side of a). All 
samples were resolved on a 1% agarose gel at 90 V for 2 h. 
 
The MiniCircle proved to be unfeasible in the assay as well because of contamination. These 
MiniCircles are made by using λ recombinase to excise the MiniCircle from a larger plasmid (Fogg 
et al., 2006). This larger plasmid has a functional replication origin and when we added the 
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MiniCircle to the assay we got a large number of Cam-resistant colonies. We could not see the 
larger plasmid on a 1% agarose gel prior to electroporation, but when we extracted the plasmid 
from one of the Cam-resistant colonies there was a very large plasmid of over 10 Kb (Figure 
3.12). We presumed this was the parent plasmid as there was no other source of a plasmid of 
that size carrying Cam resistance, and it is bigger than a potential fusion between pBR322* and 
the MiniCircle (this would be ~ 6000 bp). 
 
Figure 3.12: Contamination by MiniCircle parent plasmid. MiniCircle (lane 1) and 
suspected parental plasmid (lane 2). A 1 Kb (NEB) ladder was used with the sizes of the bands 
in Kb indicated on the left-hand side of a) and d). All samples were resolved on a 1% agarose 
gel at 90 V for 2 h. 
 
The other source of false positives were double transformants. The high efficiency of the 
electrocompetent cells allowed for more than one plasmid to be transformed (Figure 3.13, also 
see Figure 3.11). From Figure 3.11 and 3.13, two plasmids are visible in the uncut lanes 
(numbered 1). The pBR322* plasmid is a high-copy number plasmid whereas, pLysS is a low copy 
number plasmid and this is reflected in the relative amounts of each plasmid present on the 
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agarose gel. This added to the confusion by making the Cam-resistant colonies resistant to Amp 
as well. 
 
Figure 3.13: Representative ApaLI (left-hand side) and NcoI (4 – right-hand side) digests of 
a plasmid isolated from a chloramphenicol-resistant colony that also showed ampicillin 
resistance as a result of cotransformations of pBR322* and pLysS from non-λ assay. A 1 Kb 
(NEB) ladder was used with the sizes of the bands in Kb indicated on the left-hand side of a) 
and d). All samples were resolved on a 1% agarose gel at 90 V for 2 h. 
 
A further problem experienced in all iterations of the assay was much lower transformation 
efficiencies in samples treated with cell extracts. The cell extracts were added to try and 
identify/provide the extra factor that is needed in DNA gyrase-mediated IR. Previous work 
indicated that DNA gyrase could not mediate IR alone and some other factor from the packaging 
extracts was needed for the recombination to occur (Ikeda & Shiozaki, 1984). It is likely to be a 
factor that is produced during the SOS response which often induced upon phage induction 
(Greer, 1975, Campoy et al., 2006). A consequence of this is a lower probability of seeing any 
recombination events and is possibly a result of endonucleases in the cell extracts (Figure 3.12). 
To ameliorate this problem, I selected DH5α (Table 2.1), an E. coli strain that is endA 
(endonuclease-deficient, often used in cloning strains) to make the cell extracts. However, this 
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strain also has mutations in gyrA and recA which means that it is resistant to OA. For that reason, 
I switched to using E. coli MM293 which are wild type for gyrA and recA but are have an 
endonuclease mutation. With these cell extracts I maintained the same or similar 
transformation efficiencies in all samples. 
 
 
Figure 3.14: Effect of endonuclease-competent strain on transformation efficiencies. a) 1% 
agarose gel showing the DNA after concentrating with the Amicon concentrators, before 
electroporation from 3 assays, 1 and 3 have no cell extracts added, 2 has cell extracts from E. 
coli MG1655 added. Although, all started with the same initial amount of DNA, sample 2 had 
the cell extracts added and seems to have less DNA present b) is the resulting number of Amp-
resistant colonies all diluted 10-5 from the transformations with the DNA from a). 2 clearly has 
fewer colonies present. 
 
Whilst preparing the pIR plasmid for use in the assay, a Bacillus subtilis plasmid (pGV1) that 
is not capable of replicating in E. coli was brought to my attention (Table 2.2, Appendix I) (Sarkar 
et al., 1997). This plasmid also carries a Cam-resistance gene and had been used in a similar 
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assay before with no false positives (Dr. Abhimanyu Sarkar JIC, personal communication, 2015). 
This substrate would likely be a better option than pIR due to the incompatibility of pGDV1 with 
E. coli and would help solve the problem of cotransformants. In all of the original (λ-based) work 
done on topoisomerase-mediated IR, the substrates used were all greater than 4 Kb, not linear 
and were likely to have some degree of supercoiling (Bae et al., 1988, Ikeda, 1986a, Ikeda, 1986b, 
Ikeda et al., 1984, Ikeda et al., 1980, Ikeda & Shiozaki, 1984). To this effect, I believed a circular 
substrate would be a much more likely substrate to see recombination with. Hence, the 
investment in the pIR plasmid and the MiniCircle. Thus, the last iteration of this assay was run 
with pGDV1 as a substrate. These assays gave colonies that were resistant to Cam and both Cam 
and Amp but had no contamination with pIR, however there was still some very minor 
contamination with pLysS. There was no pGDV1 visible. Samples that came from the assay run 
with supercoiled pBR322*, pGDV1, ATP, OA and DNA gyrase yielded colonies that were Amp and 
Cam resistant but the plasmid present did not resemble pBR322* or any of the contaminants. 
Unfortunately, I did not have time to continue working on this assay but Monica Agarwal (JIC) 
has continued this work and she has found colonies that confer Amp and Cam resistance. When 
she extracts the plasmids, she does seem to see more than one plasmid present in the sample. 
To resolve this, she has gel extracted specific bands from the gel and transformed those in to E. 
coli. These gel-extracted plasmids still confer Cam resistance. However, primers designed from 
the pGDV1 Cam-resistance gene, do not form a product with these plasmids. Neither do primers 
from within the Amp-resistance gene of pBR322*. One of these plasmids was been sent for 
sequencing with a primer walking service from Eurofins. Preliminary data suggests that it is 
possibly pLysS. 
The non-λ assay has been plagued with contamination issues and has had a big problem with 
false positives. Although Monica’s work has yielded some unexplained results, the potential 
problem of cotransformation could be a significant issue with this assay. If a recombination 
event does occur, it may be contransformed with other plasmids that are wild type or with a 
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range of plasmids that all have different recombination events. These may be, at best, difficult 
to disentangle. Equally, it is important to use high efficiency competent cells to ensure that 
transformation efficiencies are high enough to see prospective transformants (potentially 
around 10-7 recombinants per CFU) (Ikeda et al., 1980). This is one way that the λ-based assays 
are in theory advantageous as there is certainty that any transfer of resistance is due to infection 
with a single phage unit. This is due to the immunity against superinfection by other λ phage 
(Kaiser, 1957) and the fact that λ phage can only package between 78% – 105% of its genome 
length (Feiss et al., 1977). 
 
3.4 Conclusions 
These assays have unfortunately not been fruitful in the investigation of topoisomerase-
mediated IR. The λ-based work has proven more difficult to replicate than originally anticipated 
and the non-λ based assays have been optimised to a point where we may be observing IR, but 
these events are proving difficult to disentangle. 
λ-based assay 
With the difficulties reproducing the λ-based assay, the legitimacy of the work has come in 
to question, however, due to the extensive publications on this subject (Asami et al., 2002, 
Ashizawa et al., 1999, Bae et al., 1991, Bae et al., 1988, Chiba et al., 1989, Ikeda, 1986a, Ikeda, 
1994, Ikeda, 1986b, Ikeda et al., 1982, Ikeda et al., 1984, Ikeda et al., 1980, Ikeda et al., 1995, 
Ikeda & Shiozaki, 1984, Kato & Ikeda, 1996, Kobayashi & Ikeda, 1977, Kumagai & Ikeda, 1991, 
Miura-Masuda & Ikeda, 1990, Naito et al., 1984, Sabourin et al., 2003, Saing et al., 1988, 
Shanado et al., 1998, Shimizu et al., 1997, Shimizu et al., 1995, Tomono et al., 1989) as well as 
many collaborations with external laboratories (Bae et al., 1988, Ikeda et al., 1984, Sabourin et 
al., 2003), I doubt that it is a fabrication. It may possibly be an artefact due to the high amount 
of DMSO present in the packaging extracts but further work is necessary to investigate this as 
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there is currently no experimental evidence to support this. There are also still many lines of 
enquiry that have not been fully resolved to explain why this assay has not been reproducible, 
such as the concatemeric DNA and consistent levels of lysogeny. 
non-λ assay 
The non-λ assay, although theoretically sound, has proven to be difficult to optimise, mostly 
due to the sensitivity of the assay. Despite there being no scientific record of this assay working, 
with some further optimisations, it may still work. The biggest problem I see is the potential for 
cotransformants. The best way to deal with this would be to use a mini-F’ plasmid or something 
similar where only one plasmid is present in the cell due to compatibility (see Chapter 4). Thomas 
Germe (JIC) is working on a suicide substrate where only an IR event would result in a plasmid 
that would not kill the cell. This however, has not been tested yet, but could, in theory, solve 
this problem. 
Unfortunately, time required me to put both the λ and non-λ assays to one side to focus on 
other assays that were producing more promising results. However, I do feel that given enough 
time, the challenges that have been described for these assays would be overcome. Particularly 
where the λ assay is concerned. 
 
3.5 Future work 
λ-based assay 
I would like to continue trying to reproduce this assay. First, I would resolve the issues 
around making concatemeric DNA, then I would like to optimise a method which would result 
in a consistent number of lysogens being produced per infection. Thirdly, I would investigate 
why the λ phage did not produce plaques in the E. coli Y-Mel host. I would also work on 
recreating the packaging extracts using the method outlined by Kobayashi and Ikeda (Kobayashi 
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& Ikeda, 1977). Once all of these issues were addressed (and hopefully resolved), I would then 
reattempt to run the assay again. 
non-λ assay 
With this assay, I may try and redesign the assay with a mini-F’ plasmid, which is a low copy 
number plasmid (1 or 2 per cell) (Kato & Ikeda, 1996). I would incubate this with the pGDV1 
plasmid and look for recombinants. I would also purify DNA gyrase subunits from a non-pLysS 
strain to eliminate this as a source of false positives. This assay has become a collaborative 
endeavour between myself, Monica Agarwal (JIC) and Thomas Germe (JIC) and between us, a 
non-λ, in vitro assay could be optimised to study topoisomerase-mediated IR. 
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Chapter 4: DNA Gyrase Hyper-Recombination Mutants 
4.1 Introduction 
Mutations in GyrA have been found that increase the frequency of illegitimate 
recombination (Ashizawa et al., 1999, Shimizu et al., 1997). These mutations caused the 
aberrant excision of the λ prophage in the presence of the mutagenized gyrA gene. They were 
identified using a plasmid shuffling method developed by Kato and Ikeda (1996). This method 
uses mini-F plasmids, which are low copy number plasmids (1 – 2 copies per cell) that, due to 
their stringent copy number control, allows for one mini-F plasmid to easily be replaced by 
another carrying a different selection marker. In this instance, the gene of interest, gyrA, was 
disrupted in the presence of a mini-F plasmid carrying a functional wild-type gene. The 
disruptant is then transformed with another mini-F plasmid that carries a mutated gyrA gene 
and a different selection marker (Figure 4.1). 
Shimizu et al. (1997) mutagenized the gyrA gene by PCR in the presence of Mn2+ before 
ligating the product into a mini-F plasmid carrying ampicillin resistance (AmpR). From 10 000 
AmpR transductants, 130 temperature-sensitive colonies were isolated and the corresponding 
mini-F plasmid was transformed into a strain with the disrupted gyrA gene and carrying a λ cI857 
lysogen. These were then tested for their ability to induce spontaneous illegitimate 
recombination by the formation of λ bio transductants (Figure 4.1). These transductants were 
identified by their capacity to form plaques on E. coli P2 lysogens (Spi- phenotype) (Shimizu et 
al., 1997, Ashizawa et al., 1999). 
 
 Chapter 4: DNA Gyrase Hyper-Recombination Mutants 
105 
 
 
Figure 4.1: Diagram showing plasmid shuffling system set up by Kato and Ikeda. Briefly, 
the wild-type gyrA gene is disrupted by a chloramphenicol resistance cassette in the presence 
of a mini-F plasmid carrying a functional wild-type gene. A mini-F plasmid containing a 
mutagenized gyrA gene and an ampicillin-resistance (AmpR) cassette is transformed into the 
disruptant (gyrA::CmR) (orange E. coli) and temperature-sensitive AmpR transductants are 
selected. The associated mini-F plasmid is then transformed into a λ cI857 lysogen with the 
disrupted gyrA gene (green E. coli). Illegitimate recombination is measured by the number of 
λ cI857 bio transductants that are formed. These transductants have the Spi- phenotype 
meaning they can form plaques on E. coli P2 lysogens. The black lines indicate the position of 
the λ cI857 on the E. coli genome, flanked by the gal and bio genes. att indicates the att sites 
where the λ genome integrates into the E. coli genome. 
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Occasionally during induction of the lytic phase of the λ life cycle (described in the 
introduction to Chapter 3), aberrant excision of the prophage can result in specialised 
transducing phage (Campbell, 1971). This is a type of illegitimate recombination where a portion 
of the E. coli genome is excised along with the λ genome whilst a portion of the λ genome 
remains in the chromosome. The resulting phage must be able to be packaged into the λ head 
(it must be a suitable length for packaging to occur) and the cos ends must be maintained 
(Franklin, 1971). This generally results in the transduction of either the E. coli gal or bio genes. 
The concomitant loss in the λ genome with bio transductants includes red-, γ- and δ- genes and 
the lack of these genes enables the λ bio transductants to form plaques on P2 lysogens (Zissler 
et al., 1971). This was also shown to be stimulated by oxolinic acid treatment (Tomono et al., 
1989). 
Of the 130 temperature-sensitive colonies that were identified, five showed an increase in 
temperature-induced formation of bio transducing phage at frequencies of 74, 53, 30, 30 and 
28-fold over wild type. These were GyrA D216G, L492P, L488P, N165S/P215L and I203V/I205V 
respectively (Ashizawa et al., 1999). However, when these mutations were introduced into mini-
F AmpR plasmids by PCR and transformed into E. coli HI2487 gyrA::Cmr λ cI857 only three 
showed an increase in the frequency of spontaneously induced bio transducing phage. These 
were GyrA I203V/I205V, L488P and L492P at 3.4, 2.5 and 12.5-fold increase over wild type 
respectively (Ashizawa et al., 1999). When the recombinant junctions were sequenced, all the 
mutants were shown to induce recombination at greater frequencies at non-hotspot sites over 
wild type and the junctions were shown to share less than 1 bp homology (Ashizawa et al., 1999). 
The “hyper-recombination” alleles where shown to be dominant over wild type for the 
spontaneous induction of λ bio transducing phage, however, although they were shown to 
increase the spontaneous induction of wild-type λ, the mutant alleles were not dominant in this 
case (Ashizawa et al., 1999). 
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Figure 4.2 shows the position of the mutations on GyrA. The mutations are located on the 
59 kDa N-terminal domain of GyrA which is the domain responsible for the breaking and 
religating of the double-stranded DNA during the DNA gyrase reaction cycle (Horowitz & Wang, 
1987). Specifically, the I203V/I205V mutations are in the winged-helix domain, on the α18 helix, 
and the two single mutations (L488P, L492P) are on the α10 helix on the coiled-coil domains 
(Morais Cabral et al., 1997, Berger et al., 1996, Dong & Berger, 2007, Schoeffler & Berger, 2008). 
 
Figure 4.2: Structure of truncated DNA gyrase (GyrA 55; PDB: 4CKK) (grey) with hyper-
recombination mutations highlighted. Pink show the residues 203 and 205 from the 
I203V/I205V double mutant. Green shows the 488 residue from the L488P mutant and orange 
shows the 492 residue from the L492P mutant. 
 
Ashizawa et al. (1999) purified the GyrA L492P mutant and characterised its supercoiling 
activity alongside the formation of cleavage complexes during supercoiling. They found that 
under non-permissive conditions a higher amount of cleaved complex was visible (Figure 4.3). 
They proposed that this indicated that these proteins were either deficient in their ability to 
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religate DNA or in dimer formation and this would result in double-stranded breaks (DSB) in the 
chromosome which could confer the hyper-recombination phenotype. 
 
Figure 4.3: Figure from Ashizawa et al. (Ashizawa et al., 1999) showing the supercoiling 
reaction with L492P mutant (GyrA63).  (Original Legend: Cleavage of DNA by the GyrA63 
protein. (a) – (not shown here) The GyrA+ and GyrA63 proteins were subjected to SDS/12% 
polyacrylamide gel electrophoresis and stained with Coomassie brilliant blue R250. (b) and (c) 
Relaxed pACYC184 was incubated with various amounts of (b) GyrA+ or (c) GyrA63 proteins 
and with a fixed amount (200 ng) of GyrB+ protein at 42°C for 30 minutes. The reaction 
products were analysed by agarose gel electrophoresis). 
 
Given that the in vitro activity of only one of these hyper-recombination mutants had been 
partially investigated, I set out to investigate the in vitro characteristics of all three mutations in 
order to clarify why they would confer a hyper-recombination phenotype in vivo. I did this by 
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analysing their supercoiling, relaxation, and cleavage activities under various conditions and by 
evaluating their ability to form complexes in vitro. I also attempted to move these mutations 
into the E. coli MG1655 chromosome to further investigate their phenotype in vivo (see Chapter 
6). 
 
4.2 Specific materials and methods 
Site-Directed Mutagenesis 
Site-Directed Mutagenesis (SDM) uses mismatched synthetic oligonucleotides that will 
insert specific mutations into your gene of interest during PCR (Carter, 1986). Using the SDM 
primers listed in Table 2.3 I set up PCR reactions with pPH3 (GyrA over expression plasmid 
(Hallett et al., 1990)) as the template, Phusion DNA polymerase (NEB®), Phusion HF buffer 
(NEB®) in 50 µL PCR reactions, using the PCR conditions in Table 4.1 (see Chapter 2 for more 
information). The I203V/I205V mutant was made step-wise with the I205V mutation made first. 
Following this, the I203V mutant was made in the plasmid carrying the I205V mutant. The 
products were analysed using gel electrophoresis. Any positive hits were digested with DpnI for 
1 h at 30°C before transforming into Bioline α-Select (Table 2.1 for genotype) Gold efficiency 
chemically-competent E. coli as per manufacturer’s instructions. Fifty microlitres of the 
transformations were plated onto 9 cm diameter LB 1.1% agar plates with 100 µg/mL ampicillin, 
as pPH3 has an AmpR-cassette. Three to five colonies from each mutant were selected and 
inoculated into 5 mL LB media with 100 µg/mL ampicillin with a sterile toothpick. These were 
incubated overnight at 30°C. From these overnight cultures, I extracted the plasmids using a 
Qiagen QIAprep Spin Miniprep Kit, using the manufacturer’s instructions. The DNA 
concentrations were ascertained using UV absorbance and sent for Sanger sequencing by 
Eurofins Genomics using their overnight Mix2Seq kits. The sequencing primers used are in Table 
2.3 and cover the whole gyrA gene in pPH3 including the genes’ flanking regions and were 
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designed by Thomas Germe (JIC). Plasmids containing the correct sequences were taken forward 
for expression trials. 
 
Table 4.1: Polymerase Chain Reaction conditions for Site-Directed Mutagenesis of gyrA 
gene. 
Step Temperature Time No. of cycles 
Initial Denaturation 98°C 30 s 1 
Denaturation 98°C 10 s 35 
Annealing 59°C 10 s 35 
Extension 72°C 8 min 35 
Final Extension 72°C 10 min 1 
 
Supercoiling reactions 
The standard supercoiling reaction is run as follows: 0.25 μg of relaxed pBR322* was 
incubated at either 30°C (permissive) or 42°C (non-permissive) with ScAB (see Chapter 2) and 
varying concentrations (0 – 44.33 nM) of either wild-type GyrA (wtA) or the mutants in a 15 µL 
volume. Each sample was made up as a 30 µL sample and then halved after the addition of the 
enzyme. The GyrA subunits (WT and mutants) were mixed with the WT GyrB subunit at a 
concentration ratio of 1:1. After 30 min an equal volume of chloroform:isoamyl alcohol (24:1) 
and 15 μL of 2 × STEB was added and then briefly vortexed. The samples were then centrifuged 
at 16000 g for 1 min and 10 μL was analysed by gel electrophoresis at 90 V for 2 – 3 h or at 16 V 
overnight. The standard supercoiling reaction was also stopped with SDS as a repetition of the 
assay performed by Ashizawa et al. (Ashizawa et al., 1999). The assay was run as above except 
after the 30 min incubation, 3.75 µL of a 1% (w/v) SDS solution (0.25% final concentration) was 
added, briefly vortexed before the addition of 10 × Invitrogen Loading Buffer (to a final 
concentration of 1 ×) and 15 µL of chloroform:isoamyl alcohol (24:1). 
A supercoiling time course was run in a similar way to the standard supercoiling reaction at 
both 30°C and 42°C, except that 60 ng/15 µL (10.64 nM) of enzyme (WT and mutants) was added 
to each reaction and a 15 μL sample was taken at the following time points: 0 s, 10 s, 30 s, 1 min, 
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2 min, 5 min, 10 min, 15 min, 30 min, 1 h and 2 h. All supercoiling reactions were repeated at 
least 3 times. 
 
Relaxation reactions 
These were run in much the same way as the supercoiling reactions except 0.25 µg 
supercoiled pBR322* (purchased from Inspiralis Ltd) was incubated with relaxation assay buffer 
(35 mM Tris.HCl (pH 7.5), 24 mM KCl, 4 mM MgCl2, 2 mM DTT, 6.5 % (w/v) glycerol, and 0.1 
mg/ml albumin) which does not have spermidine or ATP in it. Again, all samples were made up 
as 30 µL reaction volumes and then halved after the addition of the enzyme. In the relaxation 
time course, 100 ng/15 µL (17.73 nM) of enzyme (A2B2 – both wtA and mutants) was added and 
samples were taken at 0 s, 30 s, 1 min, 2 min, 5 min, 10 min, 15 min, 30 min, 1 h and 2 h. Titrations 
of the wild-type enzyme and L488P mutant were done in the relaxation assay from 0 - 600 ng 
and 0 - 1.2 µg for each respectively over a 1 h incubation. The wild type titration was also 
analysed on a 1% agarose gel with 1 µg/mL chloroquine. The relaxation time courses were 
repeated at least three times and the titration with L488P was only performed once. 
Cleavage reactions 
A number of different cleavage reactions were performed. For the drug-induced cleavage 
reactions 0.25 µg supercoiled pBR322* was incubated with relaxation assay buffer (or relaxation 
assay buffer with 1 mM ATP for the +ATP reactions) and 50 µM of either ciprofloxacin (CFX) or 
oxolinic acid (OA) along with either wtA or the mutants in 15 µL reactions. These were incubated 
at 30°C and 42°C for 30 min. SDS (3.75 µL of 1% (w/v) solution) was added to each reaction, 
briefly vortexed, and 1.5 µL of 10 mg/mL proteinase K was added before briefly vortexing again. 
These were then returned to either 30°C or 42°C (i.e. back to their original incubation 
temperature) for a further 30 min. Following this incubation an equal volume of 
chloroform:isoamyl alcohol (24:1) and 15 μL of 2 × STEB was added and then briefly vortexed. 
The samples were the centrifuged at 16000 g for 1 min before loading 10 μL onto a 1% agarose 
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gel which was run at 90 V for 2 – 3 h or at 16 V overnight. For the CFX – induced cleavage 150 ng 
(13.3 nM) of either WT or mutant enzyme was added in a 30 µL reaction which was halved after 
the first incubation. To one set, EDTA was added to 8 mM and vortexed briefly before the 
addition of the SDS and proteinase K. 
For the Mg2+ - mediated cleavage, 0.25 µg of relaxed pBR322* was incubated with relaxation 
buffer without the MgCl2 (35 mM Tris.HCl (pH 7.5), 24 mM KCl, 2 mM DTT, 6.5 % (w/v) glycerol, 
and 0.1 mg/ml albumin), 375 ng (66.49 nM) of enzyme (WT and mutant), 1 mM ATP, and 
increasing concentrations of MgCl2 (0, 1 mM, 2 mM, 4 mM, 8 mM, 16 mM and 32 mM) in 15 µL 
reaction volumes. The 1% agarose gels were run with 0.5 µg/mL EtBr in the gel and running 
buffer and thus were imaged without needing to be stained. Gel scans were performed using 
SynGene Gene Tools software using the manual band quantification. The mean pixel value minus 
background was acquired for all DNA bands present. The percentage of linear DNA was 
ascertained as a percentage of the total DNA present. A binomial best fit line was generated in 
Microsoft Excel 2016. 
The Ca2+-induced cleavage was run as per the Mg2+-mediated cleavage except a fixed 
concentration of CaCl2 (4 mM) was added to the samples and 0.5 µg or 1.5 µg of enzyme was 
added. 
Cleavage induced by the non-hydrolysable ATP analogue 5'-adenylyl-β,γ-imidodiphosphate 
(ADPNP) was set up as per the Mg2+ and Ca2+ - based assays except relaxation buffer was used 
with the MgCl2 present and ADPNP was added to 1 mM. 
All cleavage reactions were performed in triplicate, except for the cleavage assays done in 
the presence of Mg2+, which were run twice, and the assay with OA, which was only done once. 
Circular Dichroism 
 Circular Dichroism (CD) is a spectroscopic technique that uses the differential absorption 
of left and right-handed polarised light to examine the secondary structure of proteins in 
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solution (Figure 4.4) (Kelly et al., 2005). CD spectra can be used to assess whether a protein is 
folded correctly and give insight into the overall secondary structure of a protein (Kelly et al., 
2005). 
 
Figure 4.4: Far UV CD spectra associated with various types of secondary structure. Solid 
line, α-helix; long dashed line, anti-parallel β-sheet; dotted line, type I β-turn; cross dashed 
line, extended 31-helix or poly (Pro) II helix; short dashed line, irregular structure. From (Kelly 
et al., 2005) with permission from publisher 
 
The purified wtA and mutant hyper-recombination GyrA proteins were buffer exchanged in 
20 mM sodium phosphate buffer (pH 7.5) using ultrafiltration in Amicon® Ultra 0.5 mL 
centrifugal filters with a 30 kDa cut off. The proteins were diluted to 200 µg/mL. Far UV spectra 
were obtained using a Chirascan-Plus CD spectrometer (Applied Photophysics) at 30°C and 42°C. 
This was done with in a quartz glass cell with a 0.5 mm path length, using wavelength scans 
between 180 nm and 260 nm using a 2 nm bandwidth, 0.5 nm steps and a time per point of 1 s. 
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The spectra were collected over four repeats and averaged then converted to mean residue 
ellipticity [ϑ] using the following equation: 
[θ], = MRW × /(10 ×  × ) 
Where MRW is the mean residue weight (molecular mass/no. of peptide bonds), θλ is the 
observed ellipticity (degrees) at wavelength λ, d is the path length (cm), and c is the concentration 
(mg/ml). 
 
4.3 Results and discussion 
Expression and purification 
The hyper-recombination mutations were made by site-directed mutagenesis of the GyrA 
overexpression plasmid pPH3 and were confirmed by Sanger sequencing (Figure 4.5). The 
plasmids were transformed into the E. coli expression strain BL21(DE3) (Table 2.1) and the 
proteins were expressed in LB with induction by IPTG. Purification of the wild type and mutant 
proteins involved an initial Q-Sepharose column, followed by a Phenyl Superpose column and 
finally a MonoQ column (Figure 4.6). For the I203V/I205V and L488P mutants, the MonoQ and 
Phenyl-Superose steps were reversed. The L492P protein was purified twice to check that the in 
vitro activity of the enzymes was similar across preparations. No difference in activity was visible 
(data not shown). All proteins used had approximately the same level of purity (~70%) (Figure 
4.6e). 
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Figure 4.5: Sequencing Chromatograms of gyrA mutations in pPH3 aligned with the wild-
type sequence. WT is the wild-type pPH3 gyrA sequence. Mut is the mutated pPH3 gyrA 
sequence. Red boxes indicate the position of the mutations. a) is the I203V/I205V mutations. 
b) is the L488P mutation and c) shows the base changes of the L492P mutations. 
 
 Chapter 4: DNA Gyrase Hyper-Recombination Mutants 
116 
 
 
Figure 4.6: Purification GyrA L492P mutant. LMW is the low molecular weight protein 
marker; Load is a sample of the extract loaded onto the column, FT is the flow through from 
the column, i.e. the fraction that did not stick to the column. * indicates the fractions (and the 
fractions between) pooled. a) Overexpression of the protein. Briefly E. coli BL21(DE3) 
transformed with the overexpressing plasmid was grown in LB media until an OD600 of 0.4 was 
reached. A 1 mL sample was removed (-IPTG) and incubated separately. IPTG (IPTG+) was 
added to the remaining culture and incubated for 18 h before analysis with SDS PAGE. b) Q-
Sepharose. After overexpression, the cell extract was applied to a Q-Sepharose and fractions 
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collected over a NaCl gradient. Alternative fractions were analysed by SDS PAGE. c) Phenyl-
Superose. Ammonium sulphate was added to 1 M to the pooled fractions from the Q-
Sepharose column and applied to a Phenyl-Superose column. Fractions were collected over a 
reverse (NH4)2SO4 gradient and alternate fractions analysed by SDS PAGE. d) MonoQ. Pooled 
fractions were dialysed in TGED over night before loaded onto a MonoQ column. Fractions 
were collected over a NaCl gradient and fractions analysed by SDS PAGE. e) Shows 1 µg of the 
purified proteins (concentration based on Bradford Assay measurements). wtA is the wild-
type GyrA subunit, I203V/I203V, L488P and L492P are the hyper-recombination mutants, 
amino acid changes are referred to by their single letter codes. 
 
Structural information and complex formation 
To check if the mutant proteins were folded correctly CD spectra between 180 nm and 260 
nm were measured. As these mutants were identified in a temperature-sensitive screen, the 
spectra were collected at both permissive (30°C) and non-permissive (42°C) temperatures. From 
Figure 4.7, there appears to be no difference in the overall shape of the spectra between the 
wild type and the mutants as well as any difference between the temperatures. This suggests 
that the mutants have no significant deviations in structure or folding in comparison to wild type 
or at non-permissive temperatures. 
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Figure 4.7: Far UV (190 nm – 260 nm) CD spectra of wild-type GyrA and the GyrA hyper-
recombination mutants. WtA is the wild-type protein, I203V/I203V, L488P and L492P are the 
hyper-recombination mutants, amino acid changes are referred to by their single letter codes. 
30 and 42 indicate the spectrum at either the permissive or non-permissive temperature (30°C 
or 42°C respectively). 
 
Ashizawa et al. (1999) suggested that one reason that these hyper-recombination mutants 
present this phenotype may be because they are flawed in subunit dimerisation. To address this, 
I looked at the native complexes of the subunits using Blue-Native PAGE (BN-PAGE) (Figure 4.8). 
From the BN-PAGE it appears that like the wild-type GyrA, the hyper-recombination mutants 
appear to be primarily dimers and do form complexes with GyrB. This is evident as there is no 
band where a GyrA monomer would run and they seem to have the same banding pattern as 
the wild type. However, they do not seem to form the higher tetrameric species (A4) in 
comparison to the wild-type protein. From the gels, it is apparent that the molecular weights of 
the marker and the protein complexes do not match up. This is probably because of the 
limitations of BN-PAGE in ascertaining molecular mass for water soluble proteins with isoelectric 
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points (pI) below 8.6 (Schagger et al., 1994, Wittig et al., 2006). The measured pI for GyrA is 
between 4.5 – 5.5 (calculated pI is 4.98) and GyrB is about 6 (calculated pI is 5.52) (Reece & 
Maxwell, 1991a) and can result in up to a 20% deviation from the actual molecular mass 
(Schagger et al., 1994). Estimated pI’s were calculated using the IPC (Isoelectric Point Calculator) 
tool online (Kozlowski, 2016). There is also no difference is banding patterns at the different 
temperatures. 
 
Figure 4.8: Blue-Native PAGE of GyrA wild-type and hyper-recombination mutants. 
Samples were incubated at 30°C or 42°C for 40 min, either alone or with GyrB (+B samples) 
before running on a 4-16% gradient polyacrylamide gel. WtA is the wild-type protein, 
I203V/I203V, L488P and L492P are the hyper-recombination mutants, amino acid changes are 
referred to by their single letter codes. The High Molecular Weight native size marker (HMW) 
is indicated on the left-hand side in kDa. A2 shows the GyrA dimer, A4 is the GyrA tetramer. B 
is the GyrB monomer, B2, B3 and B4 show the GyrB dimer, trimer and tetramer. A2B2 is the full-
length DNA gyrase (GyrA, GyrB tetramer). * is likely a contaminant as it does not show up in a 
western blot probing with antiGyrA monoclonal antibodies (data not shown). 
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The BN-PAGE data along with the CD spectra suggests that there are no structural reasons, 
in terms of folding or complex formation, for these proteins to show a hyper-recombination 
phenotype. 
Supercoiling activity 
To investigate the hyper-recombination mutants’ in vitro activity, I initially looked at their 
supercoiling activity. Supercoiling is an ATP-dependent activity and involves the wrapping of the 
DNA around the enzyme to present a T-segment in a positive node. This T-segment is then 
passed through a G-segment which is bound along the GyrA/GyrB interface and is cleaved during 
the reaction cycle. 
I repeated the assay Ashizawa et al. (1999) ran with the L492P mutant (GyrA63 in Figure 4.3) 
where the enzyme is titrated into the assay and the enzyme-DNA complex is trapped with SDS 
before analysis on an agarose gel. This should give an indication of the DNA damage caused by 
the enzyme during the reaction cycle. If the enzyme is inefficient in DNA religation activity a 
greater amount of cleaved (linear or OC) DNA should be visible. In Figure 4.9, there is no such 
increase over wild type by any of the mutants, at either permissive or non-permissive 
temperatures. This contrasts with the conclusions drawn by Ashizawa et al. (1999) who 
suggested that there is an increase in linear DNA present (Figure 4.3). However, I do not entirely 
concur with their analysis of the gel (Figure 4.3). I would not say that the mutant shows a 
significant increase in linear DNA over wild type, and further analysis is needed. Ultimately, this 
assay does not suggest that these hyper-recombination mutants have hyper-cleavage activity. 
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Figure 4.9: SDS-trapping of DNA during supercoiling by DNA gyrase with hyper-
recombination mutations. Cleavage activity during supercoiling of the three hyper-
recombination GyrA mutants were compared to wild-type GyrA, all with equimolar wild-type 
GyrB, with between 15 ng and 500 ng (1.33 nM and 44.33 nM) of enzyme at permissive (30°C) 
and non-permissive (42°C) temperatures. The reactions were stopped by adding 0.25% (w/v) 
SDS before analysing samples on a 1% agarose gel. OC indicates the open-circular or nicked 
DNA, linear indicates the cleaved or linear DNA, Sc indicates the supercoiled DNA and Rel 
indicates the relaxed topoisomers. No Enz is the no enzyme control. wtA and wtA2 are two 
separate wild-type GyrA controls. I203V/I205V, L488P and L492P are the respective GyrA 
hyper-recombination mutants. 
 
Under normal supercoiling activity, it appears that the mutants are marginally less active 
than wild type. When the enzymes are titrated into the assay, the I203V/I205V and L492P 
mutants do not show much difference to wild type, and the L488P mutant is slightly less active 
(Figure 4.10). When a time course is run where the amount of enzyme is fixed at 60 ng (10.64 
nM), and the wild type shows full supercoiling after 30 min (Figure 4.11), the mutants are less 
active with the L488P and I203V/I205V mutants only reaching full supercoiling after 30 min and 
only after 1 h with the L492P mutant. This suggests that the enzymes are slower at supercoiling 
than wild type. 
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In all three of these assays, all the enzymes, wild type included, show lower activity at 42°C. 
This is clear in the time course where the wild type activity is greatly reduced at the non-
permissive temperature. This indicates that the mutant enzymes are no more temperature 
sensitive in their in vitro supercoiling activity than wild type. In the previous work (Ashizawa et 
al., 1999), the L492P mutant was only tested at the non-permissive temperature so no 
comparison at the permissive temperature can be done. From their data, it seems that these 
purified enzymes are slightly less active than the Ashizawa et al. (1999) GyrA63 at the relevant 
concentrations. This may be due to the different purification techniques or the slightly different 
assay conditions. 
 
Figure 4.10: Supercoiling activity at increasing concentrations of DNA gyrase with hyper-
recombination mutations. Supercoiling activity of the three hyper-recombination GyrA 
mutants were compared to wild-type GyrA, all with equimolar wild-type GyrB, at enzyme 
concentrations between 5 ng and 500 ng (1.33 nM and 44.33 nM) at permissive (30°C) and 
non-permissive (42°C) temperatures. Samples were analysed on a 1% agarose gel. OC indicates 
the open-circular or nicked DNA, Rel indicates the relaxed topoisomers and Sc indicates the 
supercoiled DNA. No Enz is the no enzyme control. wtA is the wild-type GyrA control. 
I203V/I205V, L488P and L492P are the respective GyrA hyper-recombination mutants. 
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Figure 4.11: Supercoiling activity time-course of GyrA hyper-recombination mutants. 
Supercoiling activity of the three hyper-recombination GyrA mutants were compared to wild-
type GyrA, all with equimolar wild-type GyrB, over 2 h at a fixed enzyme concentration (60 ng 
or 10.64 nM) at permissive (30°C) and non-permissive (42°C) temperatures. Samples were 
analysed on a 1% agarose gel. OC indicates the open-circular or nicked DNA, Rel indicates the 
relaxed topoisomers and Sc indicates the supercoiled DNA. The time points are indicated 
below each lane. wtA is the wild-type GyrA control. I203V/I205V, L488P and L492P are the 
respective GyrA hyper-recombination mutants. 
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DNA supercoiling has been shown to affect transcription in vivo (Bagel et al., 1999, Lilley et 
al., 1996) with different levels of chromosomal supercoiling affecting protein expression in 
bacteria (Bagel et al., 1999, Webber et al., 2013). Alteration of the superhelical density by 
perturbations in the expression of topoisomerase I or inhibition of DNA gyrase in vivo has been 
shown to effect site-specific recombination in the fimA promoter (Dove & Dorman, 1994). 
Although supercoiling activity in vitro does not directly correlate to the superhelical density of 
the chromosome in vivo, a mutation that shows much lower supercoiling activity would 
presumably also have an effect in vivo. These mutants are less active than the wild type which 
may have an effect in vivo, however, the in vivo activity of these mutants would have to be 
evaluated to draw any conclusions. 
Relaxation activity 
Relaxation of negative supercoils by DNA gyrase is an ATP-independent process (Gellert et 
al., 1976b, Higgins et al., 1978, Nollmann et al., 2007b). It is thought to occur by reverse strand-
passage (or bottom-up strand passage) (Williams & Maxwell, 1999b). 
A relaxation activity time course (Figure 4.12) shows that the I203V/I205V mutant is not to 
dissimilar to wild type, conversely the L488P and L492P mutants appear to have no relaxation 
activity. This lack of relaxation activity has not been consistent across all repetitions of the 
relaxation time-course assay; in some replications, these enzymes have both shown complete 
relaxation by a mid-timepoint (data not shown). The cause of this effect is not clear. The L488P 
mutant was titrated into the assay to see if any relaxation could be seen (Figure 4.13), it takes 
nearly 6-fold more enzyme to achieve full relaxation. 
The ATP-independent relaxation by DNA gyrase may not be biologically relevant as it is 
unlikely that there would be no ATP present in the cell. However, it can give us insights into the 
structural or functional integrity of the C-gate or exit gate. Williams and Maxwell (1999b) have 
shown that when the exit gate is cross-linked, the enzyme is no longer able to relax negatively-
supercoiled DNA. The L488P and the L492P mutants are not completely deficient in relaxation 
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but at times have shown very poor relaxation activity. These two mutations are found on the α-
helix of the coiled-coil domains near the exit gate (Figure 4.2). The introduction of a proline in 
the helix could result in a kink in the helix due to the specific structure and chemistry of the 
amino acid. Altogether, this implies that the L488P and L492P mutants affect the normal 
functioning of the exit gate. 
 
Figure 4.12: Relaxation activity time-course of GyrA hyper-recombination mutants. ATP-
independent relaxation activity of the three hyper-recombination GyrA mutants were 
compared to wild-type GyrA, all with equimolar wild-type GyrB, over 2 h at a fixed amount of 
enzyme (200 ng or 17.73 nM) at permissive (30°C) and non-permissive (42°C) temperatures. 
Samples were analysed on a 1% agarose gel. OC indicates the open-circular or nicked DNA, Rel 
indicates the relaxed topoisomers and Sc indicates the supercoiled DNA. The time points are 
indicated below each lane. wtA is the wild-type GyrA control. I203V/I205V, L488P and L492P 
are the respective GyrA hyper-recombination mutants. 
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Figure 4.13: Relaxation activity at increasing concentrations of DNA gyrase with L488P 
hyper-recombination mutation. ATP-independent relaxation activity of the L488P hyper-
recombination GyrA mutant, with equimolar wild-type GyrB, at enzyme concentrations 
between 0.04 µg and 1.2 µg (3.55 nM and 106.38 nM), at permissive (30°C) and non-permissive 
(42°C) temperatures. These were incubated for 1 h before samples were analysed on a 1% 
agarose gel. OC indicates the open-circular or nicked DNA, Rel indicates the relaxed 
topoisomers and Sc indicates the supercoiled DNA. 
 
Cleavage activity 
Cleavage assays allow us to see the trapped transient DSBs caused by the enzyme. The 
cleavage-religation domain has been shown to be primarily in a closed conformation (Gubaev et 
al., 2009) and double-stranded cleavage is thought to be extremely transient, unless it is 
stabilised by drugs or denaturants (Maxwell, 1997, Chan et al., 2017). Ashizawa et al. (1999) 
suggested that the hyper-recombination phenotype was due to these mutations causing 
religation defects. To directly test this, I looked at cleavage with different metal ions, ADPNP-
induced cleavage and drug-induced cleavage using quinolone antibiotics (Figure 1.16) that 
stabilise the cleavage complex between the enzyme and DNA. 
I first analysed drug-induced cleavage with oxolinic acid (OA) as it is the quinolone that Ikeda 
et al. (1980) used to identified DNA gyrase-mediated IR with. Figure 4.15 shows the cleavage 
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assay with OA. With OA, the hyper-recombination mutants do not show more cleavage than 
wild type. All enzymes show a concentration-dependent increase in linear DNA, with wild type 
showing the most cleavage at the highest enzyme concentration. Again, all enzymes showed 
much less activity at 42°C. 
 
Figure 4.14: Oxolinic acid-induced cleavage by GyrA hyper-recombination mutants. a) ATP-
dependent (+ATP) oxolinic acid (OA)-induced cleavage activity of the three hyper-
recombination GyrA mutants were compared to wild-type GyrA, all with equimolar wild-type 
GyrB, at permissive (30°C) and non-permissive (42°C) temperatures. Samples were analysed 
on a 1% agarose gel. OC indicates the open-circular or nicked DNA, Linear indicates the cleaved 
DNA and Sc indicates the supercoiled DNA. b) Column Graph showing percentage of linear 
DNA present. The mean pixel value minus background was acquired for all DNA bands present 
from the samples in the 30°C assay gel. The percentage of linear DNA (% Linear) was 
ascertained as a percentage of the total DNA present. wtA is the wild-type GyrA control. 
I203V/I205V, L488P and L492P are the respective GyrA hyper-recombination mutants. 
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Figure 4.15: Ciprofloxacin-induced cleavage by GyrA hyper-recombination mutants. a) 
ATP-dependent (+ATP) and independent (-ATP) ciprofloxacin (CFX)-induced cleavage and 
resealing activity of the three hyper-recombination GyrA mutants were compared to wild-type 
GyrA, all with equimolar wild-type GyrB, at permissive (30°C) and non-permissive (42°C) 
temperatures. L492P* is the L492P mutant at a quarter of the wild-type concentration. b) is 
ATP-dependent (+ATP) CFX-induced cleavage and resealing activity of the L492P hyper-
recombination GyrA mutant (at the same concentration as wild-type GyrA) compared to wild-
type GyrA. EDTA was added (+EDTA in panel a, and + in panel b) to samples pre-trapping with 
SDS to strip out the Mg2+ ions that mediate the stabilisation of the cleavage complex with CFX 
in order to test the enzymes ability to reseal cleaved complexes. Samples were analysed on a 
1% agarose gel. OC indicates the open-circular or nicked DNA, Linear indicates the cleaved 
DNA and Sc indicates the supercoiled DNA. wtA is the wild-type GyrA control. I203V/I205V, 
L488P and L492P are the respective GyrA hyper-recombination mutants. 
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CFX-induced cleavage was tested in a similar way to the OA-induced cleavage, except the 
enzymes ability to religate drug-induced cleavage was also measured. CFX is believed to poison 
via the water-metal ion bridge (Aldred et al., 2016, Aldred et al., 2014a, Aldred et al., 2013) and 
thus when EDTA is used to strip out the metal ion (Mg2+), the drug can no longer stabilise the 
cleavage complex and the enzyme can religate the DNA (Gellert et al., 1977, Sugino et al., 1977, 
Drlica et al., 2014). If these mutants were defective in religation then they would likely show 
more cleavage after the drug-induced cleavage was repaired. 
In the presence of ATP, both the L488P and L492P mutants show more CFX-induced cleavage 
than wild type (Figure 4.16), at both permissive and non-permissive temperatures, while the 
I203V/I205V shows slightly less. Without ATP, the differences are not as striking and all enzymes 
show less cleavage. This is not unexpected as ATP has been shown previously to accelerate CFX-
induced cleavage (Li & Liu, 1998, Chan et al., 2017). Cleavage induced by norfloxacin (Figure 
1.16), another fluoroquinolone, has also been shown to increase in the presence of ATP (Shen 
et al., 1989). Considering the poor supercoiling and relaxation activity, it may be expected that 
the mutants show reduced cleavage activity. This is not necessarily the case as DNA cleavage 
induced by the quinolones has been shown to be independent of the normal activity of the 
enzyme (Kampranis & Maxwell, 1998b). Furthermore, when the drug is bound, it favours a 
conformational change that results in a slow religation step (Kampranis & Maxwell, 1998b). To 
determine whether the decreased drug-induced cleavage seen with the I203V/I205V mutant is 
due to the reduced activity of the enzyme overall, or if it is only affecting cleavage activity would 
require further investigation. 
Looking at the effect of the mutations on the enzymes’ ability to religate drug-induced 
cleavage, the L488P and L492P mutations at 30°C, have slightly more linear DNA present after 
the addition of EDTA but only in the presence of ATP (Figure 4.16). This implies the mutations 
either cause the enzyme to release the double-stranded ends, or they have a reduced religation 
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activity. With the former it could indicate that the dimers are coming apart and so the religation 
cannot happen, or with the latter, that the DSBs are more stable than with wild type and thus 
take longer to reseal. The best way to probe these interactions would be to look at the cleavage 
and resealing kinetics. 
Although drug-based cleavage can reveal alterations in conformational changes, the drugs 
themselves can affect the natural conformations during reaction cycle. Thus, the natural 
cleavage activity was investigated. This was done by titrating Mg2+ into the assay and trapping 
the enzyme/DNA complexes with SDS (Figure 4.17), by substituting Mg2+ ions for Ca2+ ions in the 
reaction mix (Figure 4.18), and trapping the whole enzyme with ADPNP (Figure 4.19). 
When Mg2+ is titrated into the assay there is concentration-dependent increase in linear 
DNA to 16 mM with the wild type and the I203V/I205V mutant (Figure 4.17 and 4.18). Whereas, 
the L488P and L492P mutants have much lower levels of cleavage and the amount of linear DNA 
appears to reach a maximum at 2 mM for the L488P mutant and 8 mM with the L492P mutant 
(Figure 4.17 and 4.18). However, this maximum is about 6-fold lower than both the wild type 
and the I203V/I205V mutant. Lane 4 in Figure 4.17 is the reaction with 4 mM MgCl2 which is the 
standard concentration of Mg2+ in the assay buffers. There is less linear DNA present with the 
I203V/I205V mutant (~3%) and both the L488P and the L492P mutants (~0.5 and 1% 
respectively) in comparison to wild type (~6%) (Figure 4.18). I was unable to perform gel scans 
on the 42°C samples as they had an extra, unidentified band running below the open-circular 
band. The differences with 4 mM MgCl2 show that under standard assay conditions, all three 
mutants show less cleavage activity in comparison to wild type. 
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Figure 4.16: Cleavage activity of GyrA hyper-recombination mutants in the presence of 
increasing concentrations of Mg2+. The effect of increasing Mg2+ ions (0 – 32 mM MgCl2) on the 
cleavage activity of the three hyper-recombination GyrA mutants were compared to wild-type 
GyrA, all with equimolar wild-type GyrB, at permissive (30°C) and non-permissive (42°C) 
temperatures. Samples were analysed on a 1% agarose gel with 0.5 µg/mL Ethidium Bromide. 
OC indicates the open-circular or nicked DNA, Linear indicates the cleaved DNA and Rel/Sc 
indicates the supercoiled and relaxed DNA. wtA is the wild-type GyrA control. I203V/I205V, 
L488P and L492P are the respective GyrA hyper-recombination mutants. 
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The lack of Mg2+ concentration-dependent increase seen with the L488P and L492P mutants 
could be a result of their lower activity, or it could imply that they are defective in cleavage. It 
has been shown that cleavage (opening of the DNA-gate) and opening of the C-gate are mutually 
exclusive, so that the C-gate does not open if the DNA-gate is open (preventing the enzyme from 
falling apart) (Rudolph & Klostermeier, 2013). Thus, if these mutations affect the normal 
functioning of the C-gate, then it is likely that it would affect the DNA-gate (and cleavage) as 
well. This suggests that the C-gate possibly spends more time in an open conformation, which 
would result in the DNA-gate spending more time closed. This in turn would cause the enzyme 
to be unaffected by the increase in Mg2+ as it is not rate-limiting. 
 
Figure 4.17: Proportion of double-stranded cleavage by GyrA hyper-recombination 
mutants in the presence of increasing concentrations of Mg2+. The effect of increasing Mg2+ 
ions (0 – 32 mM MgCl2) on the cleavage activity of the three hyper-recombination GyrA 
mutants were compared to wild-type GyrA. The mean pixel value minus background was 
acquired for all DNA bands present from the samples in the 30°C assay gel. The percentage of 
linear DNA (% Linear) was ascertained as a percentage of the total DNA present. wtA is the 
wild-type GyrA control. I203V/I205V, L488P and L492P are the respective GyrA hyper-
recombination mutants. 
 Chapter 4: DNA Gyrase Hyper-Recombination Mutants 
133 
 
 
 
Figure 4.18: Cleavage activity of GyrA hyper-recombination mutants in the presence of 
Ca2+. Ca2+-induced cleavage activity of the three hyper-recombination GyrA mutants were 
compared to wild-type GyrA (at 1.5 µg in 30 µL or 132.98 nM), all with equimolar wild-type 
GyrB, at permissive (30°C) and non-permissive (42°C) temperatures. a) and b) are the same 
except for the concentration of the L492P mutant. L492P* indicates the L492P mutant but 
used at a quarter of the wild type concentration. c) is the same as a) except 0.5 µg of enzyme 
was used. Samples were analysed on a 1% agarose gel with 0.5 µg/mL Ethidium Bromide. OC 
indicates the open-circular or nicked DNA, Linear indicates the cleaved DNA and Rel/Sc 
indicates the supercoiled and relaxed DNA. d) Column Graph showing percentage of linear 
DNA present in c). The mean pixel value minus background was acquired for all DNA bands 
present from the samples in the 30°C assay gel. The percentage of linear DNA (% Linear) was 
ascertained as a percentage of the total DNA present. wtA is the wild-type GyrA control. 
I203V/I205V, L488P and L492P are the respective GyrA hyper-recombination mutants. 
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Ca2+ has been shown to stabilise cleavage with DNA gyrase (Reece & Maxwell, 1989, 
Kampranis & Maxwell, 1998a, Hockings & Maxwell, 2002) and it can support negative DNA 
supercoiling, although at a much lower rate (Noble & Maxwell, 2002). From Figure 4.19 we can 
see a similar result to cleavage with Mg2+. The I203V/I025V mutant does not show as much 
cleavage with Ca2+ as wild type but it is not as deficient as the L488P and L492P mutants 
(wtA>I203V/I205V>L488P>L492P). This supports the idea that these mutants affect the closing 
of C-gate. In a study by Williams and Maxwell (1999a), when the DNA-gate was cross-linked, 
Ca2+-based cleavage was only 10% of wild-type. When the C-gate was cross-linked it too was 
shown to have reduced Ca2+-induced cleavage but it was much higher, 60% of wild type, than 
when the DNA-gate was cross-linked (Williams & Maxwell, 1999b). There was no effect of 
temperature with equal amounts of cleavage visible at both permissive and non-permissive 
temperatures. 
ADPNP (5´-adenylyl-β,γ-imidodiphosphate) is a non-hydrolysable analogue of ATP. It has 
been shown to support negative supercoiling by DNA gyrase, although at a lower efficiency and 
is dependent on the topological state of the DNA (Sugino et al., 1978, Bates et al., 1996). ADPNP 
is thought to effectively stall the enzyme (due to the slow off rate), allowing a single round of 
supercoiling (Tamura et al., 1992, Kampranis et al., 1999a). 
The L488P and L492P mutants show very little to no ADPNP-mediated cleavage (Figure 4.20). 
In effect, it takes three times more enzyme to see any cleavage over background with the L488P 
mutant and the L492P mutant doesn’t show any increase cleavage over background, even with 
three times more enzyme. The I203V/I205V mutant does show cleavage with ADPNP, but it is 
less than wild type (Figure 4.20). Again, there is less cleavage at the non-permissive 
temperatures with all enzymes. 
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Figure 4.19: ADPNP (5´-adenylyl-β,γ-imidodiphosphate)-induced cleavage by GyrA hyper-
recombination mutants. ADPNP-induced cleavage activity of the three hyper-recombination 
GyrA mutants were compared to wild-type GyrA, all with equimolar wild-type GyrB, at 
permissive (30°C) and non-permissive (42°C) temperatures. wtA and I203V/I205V were added 
to 0.5 µg (44.33 nM) and L488P and L492P were added to 0.5 and 1.5 µg (44.33 and 132.98 
nM). Samples were analysed on a 1% agarose gel with 0.5 µg/mL Ethidium Bromide. + 
indicates samples containing 1 mM ADPNP. OC indicates the open-circular or nicked band, 
Linear indicates the cleaved band and Sc indicates the supercoiled band * indicates bands 
associated to the L492P gels only. No Enz is the no enzyme control. wtA and wtA2 are two 
separate wild type GyrA controls. I203V/I205V, L488P and L492P are the respective GyrA 
hyper-recombination mutants. 
 
The hyper-recombination mutants were identified as temperature-sensitive alleles 
(Ashizawa et al., 1999, Shimizu et al., 1997). In spite of this, in vitro, none of them appear to be 
more sensitive to the non-permissive temperature than wild type (Figures 4.9 – 4.20). However, 
they are all less active at the non-permissive temperatures, this may be due to the in vitro 
ATPase activity of the GyrB protein being affected at the higher temperature (Maxwell & Gellert, 
1984). Another gyrase mutation, a GyrB mutation R436S was also identified in a temperature-
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sensitive screen (Gari et al., 1996) however, when the enzyme was characterised in vitro it was 
found not to be temperature sensitive (Pang et al., 2005). It was shown to have a poor kcat 
relative to wild type and upon further in vivo investigations was shown not to be temperature 
sensitive at all, i.e. the enzyme was shown to be functional at the higher temperature. However, 
this poorer activity was demonstrated to cause supercoil disruption near the terminus of the 
replication dif site. The authors argued that at the higher temperature where replication rates 
are faster, this would have many implications downstream such as replication fork collapse and 
refiring of the origins, which could then lead to release of DSBs and induction of SOS response 
(Pang et al., 2005). This ‘Terminal Chaos’ hypothesis could be applied to the hyper-
recombination mutants as well, however, it would not explain the particular hyper-
recombination phenotype observed (Ashizawa et al., 1999, Shimizu et al., 1997). 
4.4 Conclusions 
 
Table 4.2: Summary of the biochemical data from the hyper-recombination mutants. 
Values are in relation to wild type. 
  I203V/I205V L488P L492P 
Supercoiling  titration NSD ~3-fold lower NSD 
 time course# ~3-times slower ~3-times slower ~3-times slower 
Relaxation  NSD deficient deficient 
Cleavage  OA*1 ~2-fold lower ~3-fold lower ~4-fold lower 
 CFX1 ~2-fold lower NSD NSD 
 Mg2+1 NSD ~5-fold lower ~5-fold lower 
 Ca2+1,2 NSD ~4-fold lower ~3-fold lower 
 ADPNP1 2-fold lower 20-fold lower 17-fold lower 
NSD – not significantly different; # based on time point that wtA reached ~50% supercoiling; * at 
150 ng of enzyme; 1 – differences based on mean pixel values from gel scans; 2 – at 0.5 µg of enzyme. 
 
Ashizawa et al. (1999) and Shimizu et al. (1997) suggested the hyper-recombination mutants 
were causing DSBs in the chromosome and this was inducing illegitimate recombination in the 
form of spontaneous excision of specialised λ bio transducing phage and induction of 
spontaneous excision of λ prophage. They proposed this based on limited biochemical data from 
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one of the mutants showing an increase in linear DNA during the mutant’s reaction cycle. From 
the biochemical characterisations I have performed on all three mutants, it seems that the 
I203V/I205V mutations do not have a large effect on the enzyme (Table 4.2) and the L488P and 
L492P mutations seem to affect the operation of the C-gate. 
 Taken together, it appears that the I203V/I205V mutations result in slightly defective DNA 
gyrase (Table 4.2). This is most evident from all the cleavage assays (Figures 4.15-4.20) where it 
always seems to show lower levels of cleavage than wild type, although this is marginal. In the 
gyrase reaction cycle, ATP hydrolysis, not cleavage, is thought to be rate limiting (Tamura et al., 
1992, Bates et al., 1996, Kampranis et al., 1999a, Bates & Maxwell, 2007), which explains why 
the I203V/I205V mutant would appear to be competent in supercoiling whilst having a slower 
or defective cleavage activity. Relaxation, despite the weaker cleavage activity, would appear to 
be near wild type levels as ATP-independent relaxation of negative supercoils by DNA gyrase is 
a much less efficient process than supercoiling (Higgins et al., 1978). A similar GyrA mutant, 
G214E, was identified in vivo which resulted in resistance to the bacterial toxin CcdB (Miki et al., 
1992). This mutant and the G214A mutant were purified and their activity was analysed (Smith 
& Maxwell, 2006). The G214E mutant was shown to be mostly misfolded but the G214A mutant 
was said to have equivalent supercoiling activity as well as comparable cleavage in the presence 
of CcdB and CFX. This raised questions as to why this mutant would confer in vivo resistance to 
CcdB (Smith & Maxwell, 2006). This is similar to the I203V/I205V mutants in that the biochemical 
assays do not reveal an in vitro phenotype that would explain the in vivo phenotype. 
Conversely, the L488P and L492P mutations appear to be affecting the C-gate of DNA gyrase. 
A mutation thought to destabilise the C-gate (GyrA T467S – Salmonella Typhimurium 
numbering) has been shown to rescue a GyrB mutation in Salmonella Typhimurium (Blanc-
Potard et al., 2005). The GyrB mutation was shown to be resistant to nalidixic acid, 
hypersensitive to novobiocin and have reduced supercoiling activity in vivo. The mutation in 
GyrA (T467S) reduced the sensitivity to novobiocin and partially restored the supercoiling 
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activity to the enzyme but increased the resistance to nalidixic acid. This could confirm 
destabilisation of the C-gate as it would likely show lower activity. However, the in vitro activity 
of this enzyme was not analysed making it difficult to evaluate how the mutation really affected 
the activity of the enzyme. Another C-gate mutation GyrA R462C, which was identified as a CcdB-
resistance mutation in vivo (Bernard & Couturier, 1992, Bernard et al., 1993) and shown to 
obstruct binding of the bacterial toxin in vitro (Kampranis et al., 1999c, Dao-Thi et al., 2005), was 
demonstrated to have normal supercoiling and drug-induced cleavage activities but the 
relaxation and natural cleavage activity was not investigated (Smith & Maxwell, 2006). This 
would mirror the L488P and L492P mutations which did not really affect the supercoiling or drug-
based cleavage activity (Table 4.2). 
Overall the C-gate in DNA gyrase appears to be vital for the stability of DNA gyrase and 
attempts to delete it have been unsuccessful (Maxwell and Mitchenall, unpublished data). 
Martinez-Garcia et al. (2014) have successfully made a topoisomerase II with a truncation in the 
C-gate (83 amino acids between L1039 and W1122), although this enzyme was shown to be 100-
fold less active than wild type. Here I have shown that the L488P and L492P mutants have 
reduced relaxation activity, and reduced Mg2+, Ca2+ and ADPNP-induced cleavage activity (Table 
4.2). This may suggest that that these mutations are destabilising the C-gate. Upon discussion 
with David Lawson (Structural Biologist, JIC), the leucine to proline substitution in the α-helix 
could disrupt hydrogen bonding that could result in a kink in the helix (however, the true 
structural effects of these mutations could only be determined by crystallography). If this were 
the case, it could result in a situation where the gate either doesn’t open efficiently, doesn’t 
close effectively or cause a problem transducing information between the C-gate and the DNA-
gate. Notionally, if the C-gate were to dwell in an open conformation, this could intrinsically 
cause the DNA-gate to remain closed maintaining the stability of the enzyme, which could result 
in reduced relaxation activity (reverse strand-passage) and lower cleavage activity. If the C-gate 
was predominantly in a closed conformation, it is unlikely that there would be reduced cleavage 
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activity under these conditions, as demonstrated by Williams and Maxwell (1999b) who showed 
cleavage activity with Ca2+ when the C-gate was cross-linked. Further to this, they showed that 
CFX-mediated cleavage can still occur when the DNA-gate is cross linked (Williams & Maxwell, 
1999a). Similarly, the L488P and L492P mutants also showed wild-type levels of CFX-mediated 
cleavage (Figures 4.15 and 4.16). This indicates that CFX-induced cleavage may work by 
disrupting the cleavage-religation equilibrium of the enzyme, rather than stopping religation. 
Moreover, DNA cleavage has been shown to not be essential for drug binding (Critchlow & 
Maxwell, 1996). The slightly increased amount of cleavage with the L488P and L492P mutants 
in comparison to wild type after religation demonstrated in Figure 4.16 could be a result of the 
subunits coming apart as a result of the lack of stability in the C-gate during cleavage. This could 
also occur when a T-segment is captured and the DNA-gate doesn’t open, the subunits could be 
forced apart and cause double-stranded DNA breaks. This is evident by the increase in ADPNP 
cleavage demonstrated by Williams and Maxwell (1999a) when the DNA-gate is permanently 
closed by cross-linking. However, this is in contrast to my data which shows reduced ADPNP-
dependent cleavage by the L488P and L492P mutants to wild-type. An explanation for this is 
that the DNA-gate in these mutants is not permanently shut so this would occur at a much-
reduced frequency than that seen by Williams and Maxwell (1999a). It would be difficult to 
resolve how much of the ADPNP-induced cleavage seen with the mutants was due to the 
presence of the nucleotide favouring cleavage (Kampranis et al., 1999a) or how much was due 
to the subunits coming apart. However, this could explain the in vivo hyper-recombination 
phenotype. 
 
4.5 Future work 
To confirm this hypothesis, I would do further analysis of these mutations in vivo by moving 
them into the E. coli chromosome; this has been attempted and is discussed in Chapter 6. By 
evaluating their supercoiling activity as well as replication fork collapse, it may give more insight 
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into the effect these mutants could be having in vivo. It would also be good to directly probe for 
DSBs during log and stationary phases. I would also like to finish the in vitro characterisation of 
the mutants by looking at their cleavage and resealing kinetics and to evaluate the L488P and 
L492P effects on dimer stability when treated with CFX and ADPNP. It may also be interesting to 
use single-molecule techniques, such as FRET to investigate the opening of the C-gate of the 
L488P and L492P mutations. Further biochemical characterisations should include analysis of 
relaxation of positively supercoiled DNA by these mutants and further characterisation of the 
anomalous relaxation activity. 
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Chapter 5: Subunit Exchange 
5.1 Introduction 
Subunit exchange is often essential for the stability of molecular machines, allowing them 
to work continuously. It has been demonstrated in various systems and across species. This has 
been demonstrated during replication where the of Pol III* subassembly in E. coli was shown to 
frequently undergo subunit exchange with free subunits in vivo (Beattie et al., 2017). Similarly, 
subunit exchange in E. coli Pol V allows for the error-prone polymerase to be in an inactive state 
when not needed (Shen et al., 2003). In flagellar motor proteins, the rotor subunits FliN and FliM 
have been demonstrated to undergo subunit exchange with free FliN and FliM subunits, even 
while the rotor is functioning (Fukuoka et al., 2010). In plants, the subunits of two docecameric 
small heat shock proteins from wheat and pea have been shown to undergo subunit exchange 
(Sobott et al., 2002) and exchange of the αA- and αB-/crystallin with other small heat shock 
proteins have been shown to alter chaperone activity as a result of physiological heat stress 
(Bakthisaran et al., 2015). Defective subunit exchange has also been implicated in disease, 
including cataracts (Fujii et al., 2001), amyloidosis (Keetch et al., 2005), and Neuropathies such 
as Alzheimer’s, Parkinsons, Huntingindon’s, Creutzfeldt–Jakob disease and Amyotrophic Lateral 
Sclerosis (Sun & MacRae, 2005, Shi et al., 2016). It has also been suggested to be a potential 
mechanism behind certain cancers caused by chromosomal translocations (Ahuja et al., 2000, 
Aplan, 2006). 
The role of subunit exchange in site-specific recombination has been well studied in the 
Serine Recombinases. These enzymes, including the λ integrase and the cre recombinases, form 
tetramers and work by cleaving double-stranded DNA. Each subunit forms a phosphodiester 
bond with the 5´ end of the double-stranded DNA with 2 bp overhangs, before one dimer rotates 
180° relative to the dimer, causing a crossover when the DNA is religated (Xiao et al., 2016, Stark, 
2014) (Figure 5.1). These enzymes play various roles from antigenic variation, to the movement 
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of mobile genetic elements, to phage integration and phage host range specificity (Johnson, 
2015). 
 
Figure 5.1: Cartoon demonstrating proposed subunit exchange of serine recombinases. 
Subunit exchange is thought to occur by rotation of one dimer 180° relative to the other 
resulting in a crossover when the DNA is religated. Figure Taken from (Stark, 2014) with 
permission 
In order to explain topoisomerase-mediated IR, Ikeda et al. (1982) proposed a subunit 
exchange model. They suggested that when DNA gyrase binds and transiently cleaves DNA 
during the cleavage-religation reaction, it could be possible that another gyrase molecule in a 
similar position in the reaction cycle, but on an adjacent molecule of DNA, could bind to the 
original gyrase complex in an A4B4 conformation. Occasionally, when this intermediate 
dissociates, one subunit could be exchanged for the other resulting in a concomitant exchange 
of DNA strands followed by the religation reaction. Alternatively, subunit exchange may occur 
by the dissociation of the A2B2 complex resulting in heterodimers attached to DNA that could 
reassociate with another heterodimer in a similar situation, but attached to a different strand 
of DNA, leading to recombination (Figure 5.2) (Ikeda, 1994, Ikeda et al., 1982, Ikeda et al., 2004). 
Although this model was suggested, they never verified it experimentally. However, it has been 
suggested that it may be the mechanism behind the translocations associated with t-AML and 
some childhood leukaemias (Ahuja et al., 2000, Azarova et al., 2010). Although, this too has not 
been demonstrated. 
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Figure 5.2: The proposed gyrase subunit-exchange model for illegitimate recombination. 
Each rectangle represents the AB heterodimer of DNA gyrase, composed of one gyrase A 
subunit and one gyrase B subunit. Two combined rectangles constitute the complete 
heterotetramer (A2B2) of the functional enzyme. The gyrase-DNA complex (b) assembles with 
another gyrase-DNA complex, forming the A4B4 conformation (c). The dissociation of the A4B4 
conformation to the heterotetramer results in the subunit exchange that leads to the 
exchange of DNA strands (d). Figure taken from (Ikeda et al., 1982) with permission from 
publisher 
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Given that the subunit-exchange model of topoisomerase-mediated IR was never fully 
examined, and because the λ-based assays were proving unsuccessful, a more direct 
investigation into subunit exchange was taken. This was done by examining the complexes 
formed by the GyrA subunits and trying to see if they are perturbed during the reaction cycle. I 
did this using native PAGE to look at how the complexes changed after incubation either alone 
or with various components of a supercoiling reaction (see Chapter 4 for method). We also 
looked at the complexes using native electrospray ionization mass spectrometry (ESI-MS) in 
collaboration with Prof. Justin Benesch at the University of Oxford. 
 
5.2 Specific materials and methods 
Native PAGE 
Native polyacrylamide gel electrophoresis is a non-denaturing technique using tris-glycine 
polyacrylamide gels to look at native protein complexes. Discontinuous gels were run with a 7% 
resolving gel with a 3% stack (Table 5.1). Unless otherwise stated, 1 µg of protein in 1 x 
nondenaturing sample buffer (50% glycerol, 0.1 M Tris.HCl pH 6.8 and 0.002% bromophenol 
blue) was loaded into the stacking gel and samples were run partially submerged in a 
nondenaturing running buffer (50 mM Tris.HCl pH 8.9, 380 mM glycine), at 110 V for 2 h. Blue-
Native PAGE gels are described in the General Methods (Chapter 2). 
Table 5.1: Native PAGE gel components. 
 7% Resolving gel 3% Stacking gel 
30% Polyacrylamide (Severn Biotech Ltd, 
acrylamide:bisacrylamide 37.5:1) 
1.4 mL 0.3 mL 
1 M Tris.HCl (pH 8.9) (377 mM final) 2.6 mL - 
1 M Tris.HCl (pH 6.8) (130 mM final) - 0.39 mL 
TEMED (N,N,N´,N´-tetramethylethylenediamine) 
(Sigma) 
10 µL 10 µL 
10% Ammonium Persulphate (Sigma) 100 µL 50 µL 
Ultrapure H2O 2 mL 2.31 mL 
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Denaturation and refolding of GyrA and GyrA59 
This is a modification of the protocol outlined in Hockings and Maxwell (Hockings & Maxwell, 
2002). Wild-type GyrA and the truncated form, GyrA59, were diluted to 1 mg/mL in EB buffer 
without glycerol. Two millilitres of each protein were pooled together (4 mL final volume). To 
the pooled proteins, as well as 2 mL of each protein individually, Guanidine.HCl was added to 
8.6 M before incubating at 37°C for 3 hours. Glycerol was added to 10% and then all three 
samples were transferred to SnakeSkin™ dialysis tubing. These were dialysed against 2 L of EB 
with 8 M urea overnight at 4°C. The dialysis was then transferred to 2 L of EB at room 
temperature for two rounds of 4 h, each round with fresh EB. A final dialysis step was performed 
overnight in 2 L of EB at 4°C. The refolded proteins were then analysed by native PAGE (7% 
resolving and 3% stack) and SDS PAGE (12.5% resolving and 4% stack). 
Assays 
Full-length wild-type GyrA or the truncated GyrA59 were either incubated alone or together, 
with or without: GyrB, pBR322* (relaxed or supercoiled), supercoiling assay buffer (see Chapter 
4), 50 µM CFX (ciprofloxacin). Incubation times ranged from 30 min to 14 days at 37°C. Native 
sample buffer (see General Methods) was added before loading and resolving on Blue-Native 
PAGE gels (see General Methods). The hyper-recombination mutants were also analysed in a 
similar way, except they were only incubated for 48 h. 
A supercoiling reaction (titration) was performed as described in Chapter 4 except an 
acetate-based assay buffer, AcAB, was used (250 mM Ammonium acetate, 4 mM magnesium 
acetate (pH 7.4)) with 1 mM ATP. Before this assay was run, GyrA and GyrB proteins were buffer 
exchanged into 1 x AcAB using ultrafiltration in Amicon® Ultra 0.5 mL centrifugal filters with a 
30 kDa cut off. GyrA and GyrB were used at equimolar concentrations. 
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2D-PAGE 
Bands from BN-PAGE (first dimension) were excised from the BN-PAGE gel and soaked in a 
solution of 1% SDS and 1% β-mercaptoethanol (Sigma) for 45 min before being briefly washing 
with H2O. SDS PAGE gels were made as described in Chapter 2 except, 1.5 mm gels were poured 
with a single well comb in the stack and the denatured 1st dimension strip was cast in the stacking 
gel. Gels were run at 90 - 100 V for 3 h. 
Western blot 
Polyacrylamide gels were transferred to PVDF membranes using the BioRad Trans-Blot® 
Turbo™ system at 20 V, 2.5 mA, for 15 min. After transfer, membranes were briefly washed with 
Ponceau S then rinsed with ultrapure MilliQ H2O. The membrane was blocked in TBS-T (50 mM 
Tris.HCl pH 7.6, 150 mM NaCl, 0.1% Tween-20) with 5% milk solids (Marvel Dry Skimmed Milk 
powder) for 10 min before incubating at 4°C overnight with monoclonal antibody (either anti-
GyrA-CTD – 4D3 or anti-GyrB-CTD – 9G8; a gift from Alison Howells, Inspiralis) diluted 1/1000 in 
TBS-T 5% milk. The membrane was then rinsed briefly with TBS-T before washing three times 
for 10 min each at room temperature. The membrane was then incubated at room temperature 
for 1 h with secondary antibody (1/5000); rabbit polyclonal antimouse-HRP conjugate (Dako). 
This was then washed as described above. The membrane was flooded with Pierce™ ECL 
Western Blotting Substrate and left for 1 min at room temperature before covering with 
Clingfilm and exposed for 5 – 10 min onto Amersham Hyperfilm ECL Auto Radiography film 
before developing in a Konica Minolta SRX101A developer. 
Native ESI-MS 
This was performed and analysed by Justin Benesch at the University of Oxford. Native mass 
spectra were obtained on a Q-ToF 2 (Waters UK, Ltd) according to a protocol described 
previously (Kondrat et al., 2015). Samples were infused by nanoelectrospray in 200 mM 
ammonium acetate, at protein concentrations in the range of 20-40 µM. Instrument conditions 
were as follows. Capillary: 1.7 kV, sample cone 200 V, extractor cone 20 V, accelerating potential 
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into the collision cell 50-150 V, collision cell pressure 35 µbar (argon), and backing pressure 0.007 
mbar. All spectra were calibrated externally (using CsI as a reference) and processed using 
MassLynx software (Waters UK Ltd), and are displayed without background subtraction, and 
with minimal smoothing. 
Glossary 
Table 5.2: Glossary of terms used to describe various oligomers and samples of GyrA, 
GyrA59 and GyrB 
Term Definition 
A + A59* The denatured and refolded GyrA and GyrA59 which made the heterodimer 
A & A59 The GyrA and GyrA59 subunits mixed together 
A2 The GyrA dimer 
A592 The GyrA59 dimer 
(AA59) The heterodimer 
(AA59) + A2 A heterotetramer of the GyrA dimer and the heterodimer 
 (AA59) + A592 A heterotetramer of the GyrA59 dimer and the heterodimer 
A4 The GyrA tetramer 
A594 The GyrA59 tetramer 
(AA59)2 A tetramer of the heterodimer (or a tetramer and the GyrA and GyrA59 
dimers) 
B GyrB 
A2B2 DNA gyrase heterotetramer 
* contains GyrA and GyrA59 homodimers in the sample as well. 
 
5.3 Results and discussion 
To investigate whether the subunit-exchange model of topoisomerase-mediated IR is valid, 
I set up an assay looking for the creation of heterodimers of the full-length GyrA subunit and a 
C-terminal deletion (38 kDa), GyrA59 (Reece & Maxwell, 1991b, Kampranis & Maxwell, 1996) 
(Figure 5.3). In all assays, the GyrA and GyrA59 proteins were more than 95% pure (Figure 5.4). 
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Figure 5.3: Model of proposed heterodimer of GyrA and GyrA59. The coloured subunit is 
the full-length wild-type GyrA subunit (GyrA). The grey subunit is the truncated GyrA59, it has 
the 38 kDa C-terminal domain deleted (pink domain on GyrA). 
 
Figure 5.4: SDS PAGE of GyrA, GyrA59 and GyrB proteins used. a) is the GyrA and GyrA59 
proteins at about 1 µg. GyrB is about 2 µg based on Bradford measurements. LMW is the low 
molecular weight marker with the sizes indicated on the left. b) is another preparation of 
GyrA, also at 1 µg. This GyrA was used for everything except the denaturing and refolding 
experiment. The molecular weights of the Broad Range, Color Prestained Protein Standard 
(New England BioLabs®Inc) are indicated to the left. 
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To start with I made the heterodimer by denaturing in Guanidine.HCl and Urea and then 
refolding the GyrA and GyrA59 subunits together (Figure 5.5). From the native PAGE gel, you can 
see the appearance of a new band between the GyrA dimer and the GyrA59 dimer. The GyrA 
dimer is about 194 kDa, the heterodimer should be 156 kDa and the GyrA59 dimer is about 118 
kDa. This gel indicates that the heterodimer was stable as a dimer and that the heterodimer was 
easily resolved from the GyrA and Gyr59 dimer by native PAGE. However, I found that the 
discontinuous native PAGE was not consistent as when I reran the heterodimer sample; 
sometimes the GyrA dimer or the GyrA59 dimer would not be visible on the gel. GyrB also did 
not show up on the gel occasionally (data not shown). It was for these reasons that I switched 
to running Blue-Native PAGE (BN-PAGE). 
 
Figure 5.5: 7.0% Native PAGE gel with refolded GyrA and GyrA59 proteins after 
denaturation in 8.6 M Guanidine.HCl and 8 M urea.  A is the GyrA subunit alone, A59 is the 
GyrA59 subunit alone, A+A59 is a mixture of the GyrA and GyrA59 subunits. HMW is the Native 
high molecular weight marker and the sizes of the bands in kDa are down the left side. 
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Figure 5.6 shows the GyrA, GyrA59, the refolded heterodimer and GyrB on a BN-PAGE gel. 
In this figure, you can see that there are a number of bands associated with all samples (see 
Table 5.2 for glossary). That is, dimers and tetramers with GyrA and GyrA59 and various 
complexes with GyrA/GyrA59 (Figure 5.6 b). I believe these are likely higher-order species of the 
samples as these proteins were greater than 95% pure (Figure 5.4). They are also present in the 
western blot when the Gyr(AA59) sample was probed with the anti-GyrA-CTD monoclonal 
antibody (Figure 5.6c). As the GyrA59 protein has the GyrA-CTD deleted (Figure 5.4) it will not 
be detected by the antibody thus the A592 or A594 complexes will not be seen. These higher 
complexes have also been seen previously, by me and others (Edwards, 2009) on the 7% native 
PAGE gels (data not shown). Again, it is important to note that with BN-PAGE, there can be as 
much as a 20% discrepancy between the actual molecular weight and the molecular weight 
observed on the gel (Schagger et al., 1994, Wittig et al., 2006) (discussed in Chapter 4). 
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Figure 5.6: Blue-Native PAGE and Western blot of the GyrA/GyrA59 heterodimer. a) is a 
BN-PAGE of the GyrA (A), GyrA59 (A59), the refolded heterodimer (A+A59) and GyrB (B) run 
on a 4-12% gradient gel. HMW is the high molecular weight marker with the size of each band 
in kDa down the left-hand side. b) shows the refolded heterodimer with the higher-order 
complexes highlighted alongside, with their predicted molecular weights. c) is the refolded 
heterodimer stained with coomassie alongside the western blot probing for the GyrA-CTD 
(exposure time 10 min). The arrow indicates the domain the antibody was raised against on 
the heterodimer (panel in the grey box) with the GyrA-CTD highlighted by the red box. A4 is 
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the GyrA tetramer, A594 is the GyrA59 tetramer, (AA59)2 is the GyrA/GyrA59 heterotetramer, 
(AA59) is the heterodimer, A2 is the GyrA dimer, A592 is the GyA59 dimer. 
 
These higher-order complexes have also been demonstrated by native ESI-MS in 
collaboration with Justin Benesch (Figure 5.7). Figure 5.7a shows that DNA gyrase is still active 
in AcAB (as compared with normal supercoiling assay buffer) which was used in the native ESI-
MS experiments. In Justin’s data, it can be seen that the GyrA and GyrA59 associate into dimers, 
tetramers, hexamers and octamers (Figure 5.7b) and that GyrB associates in dimers, trimers, 
tetramers and pentamers (Figure 5.6 and 5.7c). From the data (Figure 5.6 and 5.7), it can be seen 
that GyrA and GyrA59 are primarily dimers in solution, agreeing with previously published data 
and crystal structures (Klevan & Wang, 1980, Morais Cabral et al., 1997) but will associate into 
multimeric complexes in steps of two (Figure 5.7b). GyrB is primarily a monomer in solution in 
BN-PAGE, agreeing with previously published data (Liu & Wang, 1978, Ali et al., 1993, Ali et al., 
1995, Costenaro et al., 2007). In the spectra we can see it associates in dimers, but it does also 
appear to form multimeric complexes but seemingly only in steps of one (Figure 5.7c). Higher 
oligomeric species have also been demonstrated with yeast topoisomerase II, which was shown 
to form multimeric complexes up to octamers (Vassetzky et al., 1994); these authors also 
showed that these multimeric complexes either associated in aggregates or in more regular 
rosette structures. From Figure 5.8, it is evident that the refolded GyrA/GyrA59 higher-order 
oligomeric species seen by BN-PAGE is also evident by ESI-MS. In this figure, the spectra show 
oligomeric species up to hexamers and various mass species can be resolved that reveal diverse 
associations between the GyrA and GyrA59 subunits, such as a tetrameric species consisting of 
the heterodimer (AA59) and the GyrA dimer A2 (A3:A591 in Figure 5.8). This corroborates the 
data obtained from the BN-PAGE (Figure 5.6). 
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Figure 5.7: Electrospray ionization mass spectra from subunits of DNA gyrase. a) DNA 
gyrase supercoiling assay in acetate buffer, amount of enzyme (A2B2) added is in µg above. OC 
is the position of the nicked or open-circular band, Rel indicates the relaxed topoisomers, Sc 
indicates the supercoiled band. b) Mass spectra of GyrA and GyrA59 showing the different 
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oligomeric species. c) Mass Spectra of GyrB showing higher-order oligomers. ESI-MS was 
performed and the graphs assembled by Justin Benesch, University of Oxford. 
 
Figure 5.8: Electrospray ionization mass spectra from the refolded GyrA/GyrA59 subunits. 
Mass Spectra of the denatured and refolded GyrA + GyrA59 sample showing higher-order 
oligomers. ESI-MS was performed and the figure assembled by Justin Benesch, University of 
Oxford. 
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Seeing that the various complexes, including the heterodimer could be resolved using BN-
PAGE, I incubated GyrA, GyrA59 and GyrB under supercoiling assay conditions (Figure 5.9) to 
investigate whether subunit exchange occurs during strand passage. Again, the antibody used 
in the blot in Figure 5.8b will only bind the full-length GyrA protein. 
Firstly, from this figure in the A & A59 lane, we can see a band where we would expect to 
see the GyrA/GyrA59 heterotetramer ((AA59)2 in the refolded heterodimer, Figure 5.6) 
however, this could be A2A592 as opposed to (AA59)2 (Table 5.2). Despite this, we don’t see the 
formation of the heterodimer, in either the subunit-only samples or under assay conditions (1 
or 3). Secondly, we can see that A2B2 forms high molecular weight aggregates visible by the 
smears running high up on the gel, which are also visible in 1, 2 and 3 on both western blots. In 
Figure 5.9a, in 1 and 3 we do see a band between where the GyrA dimer and GyrA/Gyr59 
heterotetramer run (indicated by arrows on the figure), this is also present in Figure 5.9b but 
not seen in Figure 5.9c. Based on the proposed oligomers outlined in Figure 5.6, I suggest it is 
potentially a heterotetramer of (AA59) + A592. Further to this on the antiGyrA-CTD blot (Figure 
5.9b), in samples 1 and 3 there is a band between the GyrA/Gyr59 heterotetramer and the GyrA 
tetramer (indicated by the asterisk) which is present in the refolded heterotetramer sample 
(sample A+A59 in the figure). This could be a heterotetramer of the GyrA dimer and GyrA/Gyr59 
heterodimer, that is (AA59) + A2. This could indicate that subunit exchange is occurring. 
However, it is not definitive as with the band indicated by the arrow ((AA59) + A592), we don’t 
see an equivalent band in the refolded heterodimer (A+A59) sample. This may be due to the 
addition of GyrB which seems to have shifted the banding profile of the heterodimer sample, 
meaning the (AA59) + A592 heterotetramer in the refolded heterodimer sample may have 
formed other complexes with GyrB causing the original complex to be below detection levels. 
Again, we don’t see any GyrA, or GyrA59 monomers. 
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Figure 5.9: Blue-Native PAGE and western blots of gyrase subunits under supercoiling 
assay conditions. a) Coomassie stained 4-12% gradient BN-PAGE gel. HMW is the native high 
molecular weight marker. Native mark is the NativeMark™ Protein Ladder with the respective 
molecular weights down the right-hand side in kDa. b) & c) Western blots probing with the 
anti-GyrA-CTD monoclonal antibody and anti-GyrB-CTD monoclonal antibody respectively. A 
5-min exposure time was done for both blots. A & A59 is GyrA and GyrA59 subunits together, 
A + A59 is the refolded GyrA/GyrA59 heterodimer sample, B is GyrB, 232 is the band at 232 
kDa, 1 and 3 is A & A59 with B, relaxed plasmid pBR322*, and ATP (supercoiling assay buffer). 
2 is the refolded heterodimer sample A + A59 with B, relaxed plasmid pBR322*, and ATP 
(supercoiling assay buffer). Samples were incubated for 2 h at 37°C. The arrows indicate the 
band seen between the GyrA dimer and GyrA/Gyr59 heterotetramer. * indicates the new 
band between the GyrA/Gyr59 heterotetramer and the GyrA tetramer. 
 
As no GyrA/GyrA59 heterodimers or monomers were seen after a two-hour incubation, a 
longer time course was performed. It was run over 14 days, with and without GyrB, relaxed 
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pBR322*, ATP (supercoiling assay buffer) and CFX, taking samples at various time points (Figure 
5.10). 
 
Figure 5.10: Effect of long-term incubation on subunit exchange. a) BN-PAGE experiment 
run over 14 days with samples taken at time points indicated above the double arrows. D is 
sample with GyrA and GyrA59 (A & A59) only; E is the sample with A & A59 and GyrB; F is the 
sample with A, A59, GyrB with ATP and relaxed pBR322* (DNA); G is the sample with A, A59, 
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B, ATP, DNA and 50 µM ciprofloxacin (CFX). b) is a diagram of a), it shows the A&A59 sample 
at different time points up to 14 days, then the samples taken of E, F, and G at the 14-day time 
point. The arrow indicates the position of the heterodimer. 1 – 8 indicate the proposed 
GyrA/GyrA59 species. HMW is the native high molecular weight marker. 
 
From Figure 5.10 we can see the appearance of the heterodimer in the GyrA and GyrA59 
only and the GyrA, GyrA59 and GyrB samples at 18 h, while it is only evident at two days when 
ATP, DNA and CFX are present. With the GyrA and GyrA59 only and GyrA, GyrA59 and GyrB 
samples (lanes 1 (D) and 2 (E) from each time point), at 14 days they appear to have a very 
similar banding pattern to the refolded heterodimer, indicating that there could be some 
subunit rearrangement occurring. To confirm this a 2D PAGE was run with the 14-day time point 
of GyrA and GyrA59 only sample (Figure 5.11). 
Blue-Native-SDS 2D PAGE has been shown to be a useful techniques in studying membrane 
protein complexes and protein assembly (Schagger et al., 1994, Wittig et al., 2006, Reisinger & 
Eichacker, 2007). The premise is that protein complexes that have been resolved by BN-PAGE 
can be further refined into their subunits in the second dimension using SDS PAGE. Analysis of 
the second dimension separates the complexes by size allowing us to see which subunits are in 
the complexes observed in the BN-PAGE (Reisinger & Eichacker, 2007). The lane containing the 
GyrA and GyrA59 only sample at 14 days was cut out of the BN-PAGE gel and resolved in the 
second dimension on a 12% Tris-glycine-SDS gel (Figure 5.11). The SDS PAGE shows two distinct 
bands, one at around 100 kDa, and the second at around 58 kDa. Based on their sizes they would 
be GyrA (97 kDa) and GyrA59 (59 kDa) respectively. This is confirmed by the GyrA59 dimer from 
the BN-PAGE only showing a band at about 58 kDa in the second dimension. There are bands 
visible at around 35 kDa which could be the GyrA-CTD indicating that the full-length GyrA may 
be degrading over time. This is clear from the A4 band (1 in Figure 5.11) which has a small amount 
of GyrA59 and a concomitant band at 35 kDa. For the bands containing both GyrA and GyrA59, 
the 2D PAGE further corroborates the suggested complexes (numbered in the box in Figure 5.11) 
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as the amounts of each subunit present on the 2D PAGE appear to be proportional to the ratio 
of subunits in the complex it is suggested to be in. That is, there is more GyrA59 present on the 
gel than GyrA from the band suspected to be the (AA59) + A592 heterotetramer. 
Again, in Figure 5.9, we do not see the dimers dissociating to form monomers. This is not 
surprising as previous work on the related yeast topoisomerase II enzyme showed that this 
enzyme is a stable dimer and their work suggested that no subunit exchange occurs in the 
enzyme (Tennyson & Lindsley, 1997). In other work, conversely, heterodimers of the two 
isoforms of the human enzymes, topoisomerase IIα and topoisomerase IIβ have been shown to 
exist in HeLa cell lines and in other mammalian cells (Gromova et al., 1998). However, these are 
thought to be associating during expression and were shown not to be due to subunit exchange 
(Biersack et al., 1996). 
 
Figure 5.11: 2D-PAGE of GyrA and GyrA59 incubated over 14 days. The first dimension was 
the 14-day time point from the GyrA and GyrA59 only sample resolved on BN-PAGE. This lane 
was excised from the BN-PAGE gel and soaked in a solution of 1% SDS and 1% β-
mercaptoethanol before running in the second dimension on a denaturing 12% Tris-glycine 
SDS PAGE gel with a 4% stack and stained with coomassie. The original BN-PAGE sample is 
shown above. The molecular weights of the Broad Range, Color Prestained Protein Standard 
(New England BioLabs®Inc) are indicated on the left. The suggested complexes from the BN-
PAGE are in the box on the right. A indicates GyrA, and A59 indicates GyrA59. CTD is C-terminal 
domain. 
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In Figure 5.10, the samples with ATP and DNA, and ATP, DNA and CFX (lanes 3(F) and 4(G) 
from each time point) by 14 days do not show the level of rearrangement that is seen with the 
sample with just the subunits. This suggests that the presence of ATP and DNA reduce exchange, 
even in the presence of CFX which we would assume would cause more exchange considering 
the increase in IR seen by Ikeda et al. (Ikeda et al., 1982, Ikeda et al., 1984, Ikeda et al., 1980) in 
the presence of oxolinic acid. To further investigate this, a time course was done over 7 days 
with the three subunits (GyrA, GyrA59, and GyrB) with and without DNA and CFX. Samples with 
ATP were run in duplicate over 48 h (Figure 5.12). 
 
Figure 5.12: Effect of DNA, ATP and ciprofloxacin on subunit exchange. a) BN-PAGE subunit 
exchange experiment run over 7 days with samples taken at time points indicated above the 
double-headed arrows. E is GyrA & GyrA59 with GyrB; H is A, A59, GyrB with relaxed pBR322* 
(DNA); I is A, A59, B, 50 µM ciprofloxacin (CFX), and J is A, A59, B, with DNA and CFX. b) BN-
PAGE of 48 h experiment with is A, A59, B, and ATP (indicated by K). c) 0.5 µg of relaxed 
pBR322* (rpBR322) run on a BN-PAGE gel then stained with ethidium bromide for 30 mins. 
The arrow indicates the position of the heterodimer. HMW is the native high molecular weight 
marker with the molecular weights of each band in kDa on the left-hand side. 
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From Figure 5.12, it is evident that the DNA doesn’t reduce the formation of the heterodimer 
and it is also clear that CFX has no effect on heterodimer formation. However, ATP reduces the 
amount of heterodimer formed (Figure 5.12b). The reduction in exchange by ATP may suggest 
an additional role that ATP has during the reaction cycle. DNA gyrase uses the free energy of 
ATP binding and hydrolysis to introduce negative supercoils into DNA (Bates & Maxwell, 2007, 
Bates et al., 1996). Here it also suggests that it may have some role in reducing subunit exchange. 
Vassetzky et al. (1994) found that ATP increased the presence of multimers of yeast 
topoisomerase II. This does not seem to be the case here, as the addition of ATP to the subunits 
did not seem to affect the formation of the complexes, with dimers and tetramers remaining as 
the major species on the BN-PAGE. 
Figure 5.12c shows where the relaxed pBR322* DNA runs on the BN-PAGE. It is unlikely that 
the observed bands seen in the gels stained with coomassie or in the western blots are due to 
the protein binding to DNA. Particularly as there is a band evident with coomassie staining where 
the DNA runs, with the no DNA samples. 
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Figure 5.13: Subunit exchange with the hyper-recombination mutants. BN-PAGE with 
wild-type GyrA and the hyper-recombination mutants with GyrA59, all added to 1 µg. Samples 
were incubated at 37°C and removed from incubation at various time points up (indicated 
above the double arrows) up to 48 h. HMW is the high molecular weight marker with the 
molecular weights of the bands indicated on the left in kDa. wtA is the wild-type protein, 
I203VI203V, L488P and L492P are the hyper-recombination mutants, amino acid changes are 
referred to by their single letter codes. * is likely a contaminant as it does not show up in a 
western blot probing with anti-GyrA monoclonal antibodies (data not shown). 
 
The hyper-recombination mutants discussed in Chapter 4 were also tested in the subunit 
exchange assay. None of them showed any increase over wild type in subunit rearrangement 
and, again (see Figure 4.8), they seem to form the higher oligomeric forms at a lower frequency. 
Interestingly, the subunit rearrangements seen in Figure 5.9 is not visible in Figure 5.13. The 
difference here is that half the amount of protein was used in the assay in Figure 5.13. This may 
suggest that the subunit rearrangement is dependent on concentration, although a significant 
effect by two-fold change in concentration is improbable. Thus, whether, in this particular 
situation, this is due to subunit exchange being concentration-dependent or whether it is below 
detection levels due to the lower starting concentrations, remains to be investigated. Vassetzky 
et al. (1994) showed that in yeast topoisomerase II, the appearance of the multimers was 
concentration dependent. Thus, to see the rearrangements and the higher-order oligomeric 
  Chapter 5: Subunit Exchange 
163 
 
species, higher concentrations of the proteins or a longer incubation period may be necessary. 
Further to this, where the hyper-recombination mutants are concerned, it may be necessary to 
have these mutations in the GyrA59 subunit to get a clear idea about whether these mutations 
could increase subunit rearrangements. 
The data presented here may at first appear to conflict with work done by Gubaev et al. 
(2016) and Tennyson and Lindsley (1997). However, the assays and conditions used may explain 
the contrasting outcome. Both of these papers have looked for subunit exchange using a 
fluorescence based assay and biochemical assays using inactivated subunits. Gubaev et al. 
(2016) used FRET and fusion proteins that either had a cleavage defective GyrA subunit, or an 
ATPase deficient GyrB subunit. If subunit exchange occurred the resulting complexes would be 
inactive for either cleavage or ATPase activity, rendering the enzymes catalytically dead. Both 
the FRET and activity assays indicated that no subunit exchange was taking place. However, the 
assays presented were only run for 5 min (Gubaev et al., 2016). Tennyson and Lindsley (1997) 
used cleavage inactivated yeast topoisomerase II and incubated it with wild-type protein up to 
48 h. Here, they looked for a reduction in activity as the cleavage-deficient subunit recombined 
with the wild-type subunit, the pool of active enzyme would be decreased. They also used an 
immunotagged subunit exchange assay with two yeast topoisomerase II, one His-tagged, the 
other Ha-tagged. These were incubated together for up to two weeks before the samples were 
bound to a Ni2+-chelating spin column. The eluted fraction was then immunoblotted. Here only 
complexes that had both the His-tag and the Ha-tag would be detected. Neither of these 
experiments showed any subunit exchange (Tennyson & Lindsley, 1997). Both Tennyson and 
Lindsley and Gubaev et al. looked for subunit exchange under assay conditions with ATP present. 
In fact, Tennyson and Lindsley (1997) used an ATP-regeneration mixture of 
phosphoenolpyruvate, pyruvate kinase, NADH, and lactate dehydrogenase in their assays. This 
would mean that the effect of ATP in the assay would be constant. In my assays, ATP reduced 
subunit rearrangements which could explain why no subunit exchange was evident in Tennyson 
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and Lindsley’s work, even after two weeks. This is still not to say that it doesn’t happen, it may 
just be below detection level in the assays presented. 
 
5.4 Conclusions 
Quaternary structure in proteins in the form of dimers and the formation in multimers is 
ubiquitous in biology (Marianayagam et al., 2004). It has been shown to regulate function and 
activate enzymes. It plays an important role in the assembly of big protein complexes such as 
transmembrane channels or cell-surface receptors. Many DNA-binding proteins such as those 
involved in recombination, replication, transcription and DNA repair are functional as dimers or 
higher-order multimers (Marianayagam et al., 2004). 
It is well established that DNA gyrase functions as an A2B2 heterotetramer (Higgins et al., 
1978, Sugino et al., 1980, Klevan & Wang, 1980, Maxwell & Gellert, 1986, Reece & Maxwell, 
1991a). Here, I present data that suggests that DNA gyrase may associate in higher-order 
complexes (Figures 5.6 – 5.13 and Figure 5.14) such as tetramers, hexamers and octamers as 
well, although the predominant species is always the dimer. This would concur with published 
work by Vassetzky et al. (1994) who found that multimers of yeast topoisomerase II were 
enzymatically active. 
In this work, I have demonstrated that full-length GyrA can reassociate with the truncated 
GyrA59 to form heterodimers (Figure 5.14). However, in all of the work done to date on DNA 
gyrase, including that done here, GyrA has not been reported as a monomer. This may be 
because the monomeric species is too transient to be seen with the methods used to date. 
However, I believe that subunit exchange is occurring in the higher-order oligomers formed by 
DNA gyrase. Whether this is a direct subunit exchange as seen with serine recombinases (Stark, 
2014, Xiao et al., 2016) or whether it is due to rearrangements within the oligomers, is yet to be 
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determined. It also appears that the rearrangements may be concentration dependent (Figure 
5.13), although further work needs to be done to confirm this. 
The presence of plasmid DNA seems to have no protective effect against these 
rearrangements, however, ATP does (Figure 5.11 and Figure 5.14). Since it is unlikely that a cell 
would not have ATP available, whether this is biologically relevant may be up for debate. This 
subunit exchange may reflect a labile quaternary structure, especially considering it is stabilised 
by ATP. This may also suggest an additional role for ATP; as well as driving the reaction cycle, it 
may also have a protective role, ensuring that rearrangements of the subunits does not occur 
during the reaction cycle. 
Addition of CFX did not show any increase in rearrangement of the subunits (Figure 5.11 and 
Figure 5.14). Although at first this may be surprising as quinolones have been shown to increase 
DNA gyrase-mediated IR (Ikeda et al., 1982, Ikeda et al., 1984, Ikeda et al., 1980), however, the 
quinolones themselves may have no bearing on the actual subunit rearrangement. CFX would 
however, stabilise a cleaved-DNA state on the protein which could result in DNA recombination 
during subunit rearrangement. 
In summary, I have demonstrated that subunit exchange is possible with DNA gyrase 
although it seems to occur in higher-order oligomers, not through the dissociation of the dimers. 
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Figure 5.14: Summary Diagram of formation of heterodimers and oligomeric species. Top 
two lines shows the various species seen. The bottom three lines show the species observed 
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with a) just the GyrA and GyrA59 subunits (D from Figure 5.10) or with DNA (H from Figure 
5.12), CFX (I from Figure 5.12) or DNA and CFX (J from Figure 5.12) incubated long term (arrow 
with time above). b) with ATP (K from Figure 5.12). The blue shows the GyrA59 subunit and 
the orange is the GyrA subunit. 
 
5.5 Future work 
In future work, I would like to investigate the concentration dependence of the 
rearrangements, either using BN-PAGE and immunodetection or by ESI-MS. It would be good to 
assess whether subunit rearrangements occur with the hyper-recombination mutations if more 
protein is used, and if the mutations in GyrA59 would increase the rearrangements. It would be 
interesting to see if I get a similar result to Tennyson and Lindsley  by having an ATP regenerating 
system during the long-term incubation of these proteins. Alternatively, to see if ADP stimulates 
the rearrangements. We have also recently made GyrA subunits that are fluorescently tagged 
which may provide an alternative way of investigating subunit exchange with both the species 
being full-length GyrA subunits. I also feel it is important to further investigate if the higher-
order oligomers are also seen in vivo and to try and ascertain whether this model is biologically 
relevant. 
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Chapter 6: Quinolone-Induced Antimicrobial Resistance 
6.1 Introduction 
Antibiotic resistance is a growing global threat with resistance to all classes of antibiotics 
now reported worldwide. This issue is compounded by a lack of innovation and few new 
structural classes of antibiotics brought to the clinic (see Chapter 1) (Bush et al., 2011, Walsh & 
Wencewicz, 2014, Lewis, 2012). To tackle antibiotic resistance, we need to review our antibiotic 
stewardship and discover new antibiotics that are not susceptible to known resistance 
mechanisms. Additionally, we need to understand how resistance develops and how bacteria 
evolve under the selection pressure of antibiotic killing. Many complex biochemical and 
physiological processes are involved in the development of resistance and often our 
fundamental understanding of these processes is lacking (Davies & Davies, 2010). 
Another complexity is the effect sublethal doses have on the development and selection of 
resistance. There are a number of studies and reviews (Andersson & Hughes, 2014, Gullberg et 
al., 2011, Hughes & Andersson, 2012) describing and discussing the mutagenic effect of low 
concentrations of antibiotics on bacteria. They have shown that sublethal doses of antibiotics 
can select for resistance by promoting homologous recombination (Lopez & Blazquez, 2009) and 
horizontal gene transfer (Laureti et al., 2013), by induction of the SOS response (Blázquez et al., 
2012, Thi et al., 2011), or by RpoS induction (Gutierrez et al., 2013). Exposure to sublethal 
concentrations of antimicrobials has also been shown to increase the number of persister cells 
(Dörr et al., 2009, Goneau et al., 2014), as well as to the enrichment of resistance genes within 
the population (Gullberg et al., 2011). Bacteria can be subjected to subinhibitory levels of 
antibiotics in a variety of environments. These include concentration gradients due to spatial 
variation within a human body (Hermsen et al., 2012), excretion of unabsorbed antibiotics into 
the natural environment (Pletz et al., 2004, Mathieu et al., 2016) or as a result of non-medical 
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uses of antibiotics, such as the agricultural use (ter Kuile et al., 2016, Hughes & Andersson, 2012) 
or through effluent from pharmaceutical plants (Andersson & Hughes, 2014). Bacteria are also 
often exposed to natural environmental concentration antibiotic gradients produced by other 
bacteria and fungi (Andersson & Hughes, 2014). There is also the effect that long-term use of 
antibiotics in prophylactic treatment of recurrent infections has had on the rise of antibiotic 
resistance (Goneau et al., 2015, Sethi et al., 2010). 
As discussed more widely in the introduction (Chapter 1), quinolones are a potent class of 
synthetic antibiotics that target DNA gyrase and DNA topoisomerase IV. They are the most 
successful class of topoisomerase inhibitors with fluoroquinolones being widely prescribed in 
the United States of America and Europe (Linder et al., 2005, Pitiriga et al., 2017). This, however, 
has led to an increase in resistance to quinolones including upregulation of efflux pumps, 
plasmid-based resistance or mutations in the gyrase or topo IV genes (Hooper, 2003, Redgrave 
et al., 2014). This widespread resistance has resulted in revised stewardship for quinolones 
(Pitiriga et al., 2017) as well as the WHO categorizing quinolones as a highest priority ‘Critically 
Important Antimicrobial’ (WHO, 2017). 
Although the rise of quinolone resistance is well-documented (discussed in Chapter 1), there 
is also evidence that subinhibitory treatment with quinolones can lead to multidrug and non-
quinolone resistance. However, this is not well-documented and the cause is not yet fully 
established. One study shows an increase in the resistance of quinolone-susceptible methicillin-
resistant Staphylococcus aureus to nafcillin when exposed to subinhibitory doses of ciprofloxacin 
or levofloxacin (Tattevin et al., 2009). A later study by Kohanski et al. (Kohanski et al., 2010) 
demonstrated that treatment of E. coli MG1655 with norfloxacin led to increased resistance to 
kanamycin and ampicillin. The authors suggest that the mechanism behind this resistance is due 
to an increase in mutagenesis as a result of oxidative stress caused by the antibiotic. The 
legitimacy of this has been discussed directly by two other papers (Keren et al., 2013, Liu & Imlay, 
2013) (discussed further in Chapter 1). Along with this continued argument on the mechanism 
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behind this quinolone-induced resistance, further evidence is provided in a paper on E. coli 
isolates from preweaned dairy calves. These were treated with enrofloxacin or the 
cephalosporin ceftiofur for diarrhoea and respiratory diseases. They found that in the isolates 
from the quinolone-treated calves, 77% showed resistance to 3 or more antimicrobials. These 
included ciprofloxacin, streptomycin, tetracycline, ampicillin, cetiofur and chloramphenicol. The 
cetiofur-treated isolates also showed resistance to 3 or more antibiotics. These included 
ampicillin, cetiofur, cefoxitin, chloramphenicol, neomycin, streptomycin, tetracycline and 
trimethoprim sulfamethoxazole (Pereira et al., 2014). A similar study in Spain on the effect of 
enrofloxacin on the commensal E. coli populations in healthy chickens found that after 
treatment with the quinolone there was an increase in the number of isolates resistant to 
doxycycline and amoxicillin as well as the enrofloxacin (Jurado et al., 2015). Although these 
papers provide evidence (although not very robust evidence) for quinolone-induced antibiotic 
resistance, there are other papers that show that sublethal treatment with quinolones increases 
mutation rates, mutation frequencies and recombination (Lopez & Blazquez, 2009, Lopez et al., 
2007, Cirz et al., 2007, Cirz et al., 2006, Gillespie et al., 2005, O'Sullivan et al., 2008). Some of 
these papers looked for specific single point mutations in specific genes that would confer 
resistance to rifampicin or trimethoprim, further indicating the potential of fluoroquinolone-
induced resistance. The cause of the increase in mutation rates has been linked to induction of 
the SOS response and concomitant derepression of the error-prone polymerases (Ysern et al., 
1990, Cirz et al., 2007, Cirz et al., 2006, Cirz & Romesberg, 2006, Thi et al., 2011, Tattevin et al., 
2009), however, not all of the mutations observed have been linked to this, with some shown 
to be independent of the SOS response (Lopez & Blazquez, 2009, Lopez et al., 2007, Song et al., 
2016). 
Many of these papers suggest that treatment with subinhibitory levels of quinolones could 
have significant effects on general antibiotic resistance but within the literature, no one seems 
to have engaged the question directly. There is also a question of whether the use of CFX may 
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induce chromosomal rearrangements similar to those seen with etoposide (Negrini et al., 1993, 
Lovett et al., 2001, Baldwin & Osheroff, 2005). To try and address these, I have designed an in 
vivo assay looking at the effect of treating E. coli MG1655 with sublethal concentrations of 
antibiotics. 
 
6.2 Specific materials and methods 
Number of CFU’s from OD600 
The number of colony forming units (CFU’s) was determined for OD600 of 1.0. A single colony 
of E. coli MG1655 (see Table 2.1) was inoculated into 5 mL of LB under sterile conditions and 
incubated at 37°C overnight. Fifty microlitres of this was inoculated into two universals 
containing 10 mL LB in each. These were incubated at 37°C. The OD600 was measured at intervals 
and samples were removed at ODs of around 0.6, 0.8 and 1.0. The samples were diluted 10-5, 
10-6, and 10-7, and 50 µL of these dilutions were plated onto 9 cm LB 1.5% agar plates. The plates 
were incubated at 37°C overnight. The colonies were counted and plates that had between 30 
and 300 colonies were kept. The CFU/mL was calculated from these at each OD600 and averaged 
across the replicates. The CFU/mL for all samples were converted to CFU/mL at an OD600 of 1.0 
and an average CFU/mL was calculated as well across the 6 replicates. 
MIC testing 
Broth and solid-agar MICs were ascertained using the method in Andrews (2001), which is 
an updated version of the BSAC Guide to Sensitivity Testing (1991). Except, instead of 
IsoSensitest agar or broth, LB (General Methods) was used. Briefly, under sterile conditions, a 
single colony of the E. coli strain was inoculated into 10 mL of LB and incubated overnight at 
37°C (unless otherwise stated). Either the OD600 of the overnight culture was ascertained and 
then diluted or 50 µL of the overnight culture was inoculated into 10 mL of LB and incubated for 
2 – 3 h before the OD600 was read. The OD600 was converted to CFU/mL based on the measured 
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CFU/mL for and OD600 of 1.0 (see above – about 1.5 × 108 CFU/mL). For the solid-agar MICs, the 
cultures were diluted to between 107 and 108 CFU/mL whilst for the broth dilution MICs, the 
inoculum was diluted to 105 CFU/mL. Once the cultures were prepared, they were used within 
30 min. Each antibiotic or strain was tested in triplicate, for the broth MICs, these were 
microdilution broth MICs were done in 96-well microtitre plates. For the solid-agar MICs, the LB 
1.5% agar supplemented with the appropriate antibiotics at specific dilutions were prepared in 
square 10 cm petri dishes (Sterilin™). Dilutions of the antibiotics were done based around 
reported MICs for E. coli ATCC 25922 and thus were slightly different for each antibiotic. Stock 
solutions of the antibiotics were made up as directed in Andrews (Andrews, 2001), these were 
aliquoted and stored at -20°C. Each antibiotic stock was only used once. From these stocks, the 
antibiotic was diluted appropriately and added to the microtitre plate (or added to warm (<50°C) 
LB 1.5% agar for solid MICs). For the solid MICs, once the plates were poured and dried, 2 µL of 
the prepared inoculum was added in triplicate to each plate. For the broth MICs, the 8 dilution 
points were made up in 75 µL of LB each and added to the plates in triplicate with 4 wells of 12 
set aside for controls. These were two sterile controls (LB only) and 2 growth (0 antibiotic) 
controls per replicate. For the growth controls and the antibiotic dilutions, 75 µL of the prepared 
inoculum was added to each well, whilst 75 µL of LB was added to the sterile controls. The lid 
was placed on the microtitre plate and these were incubated at 37°C (unless otherwise stated) 
for between 18 – 20 h. For the solid MICs, the ‘drops’ were left to dry before the plates were 
inverted and incubated at 37°C for between 18 – 20 h. The MICs were determined by eye as the 
lowest antibiotic concentration where visible growth was inhibited. 
Quinolone-induced antimicrobial resistance assay 
An overview of this assay is depicted in Figure 6.1. A colony from an E. coli strain was 
inoculated into 5 mL of LB and incubated overnight at 37°C (unless otherwise stated). Fifty to 
100 µL (50 µL for incubations >24 h, 100 µL for 7 h incubations) of the overnight culture was 
inoculated into 50 mL of LB with either 0, 0.25×, 0.5×, or 1× MIC of an antibiotic. If DMSO was 
 Chapter 6: Quinolone-Induced Antimicrobial Resistance 
173 
 
the solvent that the antibiotic was made in, then it was added to all samples at the same 
percentage as the highest percentage used with addition of drug. With the plasmid-based hyper-
recombination mutants, the GyrA proteins were overexpressed in the presence 0.5 mM IPTG, 
thus an extra control was run where no drug but 0.5 mM IPTG alone was added. These samples 
were also run with 20 µg/mL Amp for the maintenance of the plasmid. The samples were 
incubated at 37°C (unless otherwise stated) for 7 or 24 h (although with CFX it was up to 72 h). 
After incubation, 12.5 mL of the cultures was decanted into sterile 50 mL centrifuge tubes 
(Corning™ Falcon™) and centrifuged for 30 min at 3000 g. The supernatant was discarded and 
the pellet resuspended in 2.5 mL LB. This resuspended culture was used within 30 min of 
preparation. Serial dilutions were made from 10 µL of this prepared culture (10-2 – 10-8) and 100 
µL of the dilutions (usually 3, i.e. 10-6, 10-7 and 10-8) were plated onto 9 cm LB 1.5% agar plates. 
The remaining resuspension was plated (400 µL per plate ~ 108 – 1010 cells) on 15 cm LB 1.5% 
agar plates supplemented with either 50 µg/mL Amp, 50 µg/mL Kan, 30 µg/mL Cam, 12 µg/mL 
Tet, 10 - 15 µg/mL Tri or 0.35 µg/mL CFX (usually about 20× the measured MIC, although for 
some, concentrations were used at those suggested for selection during cloning). All the plates 
were incubated for 22 – 24 h at 37°C (unless otherwise stated). After the incubation, at 37°C, 
the plates were left on the bench (~ 22°C) for a further 8 – 20 h. Any colonies that appeared on 
the selection plates were restreaked back onto the antibiotic that they were identified on to 
confirm resistance using sterile 0.5 -10 µL tips before incubating for 20 – 22 h at 37°C. The plates 
without antibiotic were used to calculate the number of colonies that survived the incubation, 
any plate that had between 30 and 300 CFU were counted using a ProtoCOL 3 Colony Counter 
(Synbiosis). To calculate resistance frequencies, the number of colonies that survived the 
restreaking step were divided by the number of colonies on the LB only plates multiplied by the 
dilution factor, multiplied by 4 (to scale the amount plated to 400 µL). 
For some of the assays, the restreaked colonies were then also streaked onto the other 
antibiotics to check for cross resistance. To check whether the resistance was due to mutation 
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or persistence, selected resistant colonies were inoculated into 5 mL of LB and incubated at 37°C 
for 18 h, after which 50 µL of this was inoculated into 5 mL of LB and incubated at 37°C for a 
further 8 h. I then took 50 µL of this and inoculated it into 5 mL of LB and incubated at 37°C for 
a further 18 h. The cells were subcultured again and incubated for a further 8 h as before. These 
cultures were then streaked back onto the antibiotic that they were identified on and incubated 
overnight at 37°C. Any colonies that survived were assumed to have some fixed mutation that 
conferred the resistance. 
 
Figure 6.1: Diagram showing in vivo quinolone-induced antibiotic resistance assay. E. coli 
MG1655 (or another E. coli strain) is incubated with 0, 0.25×, 0.5×, and 1× MIC of an antibiotic 
at 37°C for 4 – 72 h. The cells are the concentrated and diluted in fresh LB before plating on 9 
cm LB 1.5% agar plates at various dilutions (between 10-6 – 10-8) to check the number of CFU 
(cell survival) and then on 15 cm LB 1.5% agar with various antibiotics (~108 – 1010 cells plated) 
to check for any antibiotic resistance. Amp is ampicillin, Tri is triclosan, Kan is kanamycin, Cam 
is chloramphenicol, and Tet is tetracycline. 
 
Whole genome sequencing 
Resistant colonies and non-selected colonies (colonies from dilution plates) where sent for 
whole genome sequencing (WGS). This was performed by MicrobesNG 
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(http://www.microbesng.uk), which is supported by the BBSRC (grant number BB/L024209/1). 
The colonies were prepared according to MicrobesNG’s specifications. Colonies that were sent 
for sequencing were streaked out onto the antibiotic they were identified on or just LB if there 
was no selection. A singly colony from the restreaked plate was resuspended in 100 µL of sterile 
PBS (phosphate buffered saline – see Chapter 4). This was streaked onto an LB 1.5% agar plate 
with 1/3 of the plate as a lawn and then streaks from this lawn to single colonies were done to 
ensure the culture is pure. These were incubated overnight at 37°C. A large sterile loop was then 
used to take all of the bacterial culture off the plate, which was mixed into the microbead tubes 
supplied by Microbes NG. These were sent to MicrobesNG for DNA extraction and library 
preparation. Sequencing was done on either Illumina® MiSeq or Hiseq 2500 platforms. 
Bioinformatics 
The bioinformatics was done with support from and in collaboration with Bernardo Clavijo 
(Earlham Institute). The trimmed reads were used for analysis. These were assembled against 
the published E. coli MG1655 sequence (Blattner et al., 1997). The GenBank and Fasta files of 
the reference sequence were downloaded from GenBank (NCBI - Accession: NC_000913.3) 
(Benson et al., 2013). Assemblies and variant calling were performed using Snippy v3.1 (Seeman 
T., 2015) (https://github.com/tseemann/snippy) using Perl v5.16.2, BioPerl v1.6.923, SamTools 
v1.3.1, bwa-mem v0.7.5, and Java v7.21. Assemblies and alignments were visualised using Tablet 
(v1.17.08.17; 17th August 2017) (Milne et al., 2013). A further set of assemblies on two of the 
samples was done using W2rap Contigger (https://github.com/bioinfologics/w2rap) (Clavijo et 
al., 2017) using the -gfa dump option. Bandage v0.8.1 was used to visualise these assemblies 
(https://github.com/rrwick/Bandage) (Wick et al., 2015). Specific nodes of the assemblies done 
with W2rap were run in BLAST® (NCBI) using their nucleotide blast tool (BLASTN v2.7.0+) using 
the default settings (run on the 17th of August 2017 and 30th if August 2017) (Zhang et al., 2000, 
Morgulis et al., 2008). All information about the various genes identified with mutations was 
obtained from EcoCyc database online (accessed 2017) (Karp et al., 2014). 
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ssOligo recombineering 
 I attempted to make the hyper-recombination mutants (Chapter 4) in the E. coli MG1655 
genome by ssOligo recombineering. This is a method based on λ- red recombineering (Datsenko 
& Wanner, 2000) which uses a single or double-stranded DNA oligo to insert or delete genetic 
sequences, or introduce nucleotide polymorphisms into bacterial chromosomes. Double-
stranded DNA recombineering uses the λ Exo, Beta and Gam proteins to introduce these novel 
mutations. Single-stranded recombineering only requires Beta and uses a single-stranded oligo 
(ssOligo) which pairs with the lagging strand during replication, mimicking an Okazaki fragment 
(Wang & Church, 2011). ssOligo recombineering can be a quick and scarless way to make 
mutations in the chromosome. The most important step of the ssOligo recombineering protocol 
is that of the design of the nucleotide to evade the mismatch repair (MMR) mechanisms in the 
bacteria. The oligo needs to match the lagging strand (in terms of replication) of the area of the 
genome you wish to mutate, it should be between 40 and 90 nt in length and it should have a 
folding energy of no less than -12.5 kcal/mol (as predicted by MFold (Markham & Zuker, 2005)) 
(Sawitzke et al., 2011, Wang & Church, 2011), . 
I designed the hyper-recombination mutation ssOligo’s using an online program called 
MODEST (Bonde et al., 2014). The oligos that were designed by MODEST were then further 
optimised to evade MMR. The oligos (Table 2.3) were synthesised by Sigma-Aldrich using a 
desalting purification only and contained four phosphorothioated bases on the 5' end to stop 
them from being degraded by exonucleases in the cell. 
The rest of the protocol was essentially as described by Wang and Church (2011) apart from 
the following exceptions: 
• E. coli MG1655 carrying the recombineering plasmid pKD46 (Table 2.2 and Appendix 
I) (Datsenko & Wanner, 2000) was used. 
• 30 mL Sterilin™ Polypropylene 30mL Universal Containers were used instead of glass 
culture tubes and were incubated in a shaking incubator at 300 rpm. 
 Chapter 6: Quinolone-Induced Antimicrobial Resistance 
177 
 
• Standard colony PCR was used instead of genotyping by multiplex allele specific 
colony PCR verification. 
Colony PCR was set up with the primers shown in Table 2.3. Between 47 and 63 colonies 
were selected from the colony isolation plates and one colony from the “no oligo” (wild type) 
control plate (E. coli MG1655 (pKD46) without electroporation of any oligo) for each mutation. 
The colonies were resuspended in 8 µL sterile water in 96-well plates. PCR reactions were set up 
using GoTaq™ Green mix (Promega), which is a ready-to-use premix of Taq polymerase, dNTPs 
and MgCl2, with either the wild-type GyrA gene forward primer (wt) or the mutant forward 
primer (mut) as well as the same reverse primer (R400, R500 or R600) for both (Table 2.3), and 
1 µL of the resuspended colony. Thus, for each colony, two PCR reactions were set up; one with 
the primers for the wild-type sequence and one with the primers for the mutant sequence. The 
PCR reactions were set up in 96-well plates and run using the PCR conditions in Table 6.1. For 
each colony selected, after addition to the PCR reaction, the colony was restreaked onto another 
plate and incubated at 30°C overnight. 
Table 6.1: Polymerase Chain Reaction conditions for colony PCR. 
Step Temperature Time No. of cycles 
Initial Denaturation 94°C 2 min 1 
Denaturation 94°C 1 min 25 
Annealing 65°C 1 min 25 
Extension 72°C 1 min 25 
Final Extension 72°C 10 min 1 
 
The colony PCR reactions were analysed using the QIAxcel Advanced System using a High-
Resolution Kit and the ML400 program. Any colonies that showed a band with the mutant 
primers or no band with the wild type primers, were reconfirmed by colony PCR. Any confirmed 
colonies underwent colony PCR with primers upstream from the mutation (see Table 2.3) and 
this PCR product was sent for sequencing. Any colonies that had the desired mutations were 
then cured of the pKD46 plasmid by growing them in liquid culture for 24 hours at 37°C without 
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the ampicillin selection. The culture was then diluted and plated on LB agar plates and incubated 
overnight. Individual colonies were then selected and streaked on two LB agar plates, one with 
ampicillin and one LB only. Any colony that grew on the LB only plate but not on the LB with 
ampicillin were believed to no longer carry the pKD46 plasmid. 
 
6.3 Results and discussion 
MICs 
Microbroth MICs for the antibiotics used in the assay were determined for the E. coli 
MG1655 strain (Table 6.2). For the other E. coli strains used, only the MIC of CFX was ascertained 
(Table 6.3). All MICs were done in triplicate and the MIC used was an average of the triplicates. 
For the E. coli MG1655, solid-agar MICs (Table 6.4) were also determined for CFX, OA, Amp, Tet, 
Kan, and Cam. The MIC for CFX against MG1655 was determined to be 0.016 µg/mL, which is 
almost the same as the published MIC for E. coli ATCC 25922 which was 0.015 µg/mL (Andrews, 
2001). It was also within a factor of 2 from another study measuring the CFX MIC of MG1655 
(Cirz et al., 2005) and it was the same as the MIC reported in (Mo et al., 2016), except that study 
used the resazurin method to determine MICs. The other MICs measured either matched 
reported (if applicable) MICs or they were within a factor of 2; except for the BW25113 strain, 
which, in my hands, had a 4-fold lower MIC than previously reported (Tamae et al., 2008). The 
solid-agar MICs were calculated from two separate iterations (apart from the OA solid MIC, 
which was only run once). With the solid MICs, a sheen of growth or individual colonies were 
ignored in the analysis as prescribed in Andrews (Andrews, 2001). 
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Table 6.2: Minimum Inhibitory Concentrations (MICs) for all antibiotics used in the QIAR 
assay against E. coli MG1655. 
 MIC (µg/mL) 
E. coli Strain CFX SFX MFX NFX OA* 5931 CouA1 Amp* Kan* 
MG1655 0.016 0.016 0.032 0.032 0.4 1.0 16.0 6.0 4.0 
* these were solid-agar MICs; CFX – ciprofloxacin, SFX – sparfloxacin, MFX – moxifloxacin, NFX – 
norfloxacin, OA – oxolinic acid, 5931 – REDX05931, CouA1 – coumermycin A1, Amp – ampicillin, Kan – 
kanamycin 
 
Table 6.3: Minimum Inhibitory Concentrations (MICs) for ciprofloxacin (CFX) used in the 
QIAR assay. Broth-based MICs were determined for CFX used in the QIAR assay against all E. 
coli strains used. 
E. coli Strain MIC (µg/mL)         
MLS83L 0.256         
BW25113 0.004         
NGB345 0.008         
MG1655 (pPH3)a 0.004         
MG1655 (pI203V/I205V) 0.004         
MG1655 (pL492P) 0.004         
MG1655 (pL488P) 0.004         
 a – brackets indicate the strain with a plasmid. 
 
Table 6.4: Solid-agar minimum inhibitory concentrations (MICs) for antibiotics used in the 
QIAR assay. 
 Solid-agar MIC (µg/mL) 
 Kan Amp Cam Tet CFX OA 
E. coli MG1655 4.0 6.0 8.0 4.0 0.016 0.4 
CFX – ciprofloxacin, Amp – ampicillin, Kan – kanamycin, Tet – tetracycline, Cam – chloramphenicol, OA – 
oxolinic acid 
 
QIAR assay 
This assay investigated the effect of CFX on different E. coli hosts (for genotypes see Table 
2.1) as well as the effect of other quinolone and non-quinolone antibiotics on E. coli MG1655 
alone. Whole genome sequencing was only performed on colonies that arose during the assays 
with MG1655. The number of times the assay was performed with each strain or antibiotic is 
detailed in Table 6.5. Due to time constraints, some of the strains or antibiotics were only tested 
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once or twice. This means that some of the data is not as robust as hoped, it also means that 
the conclusions drawn do not have statistical support. 
Table 6.5: Number of times the QIAR assay was run with each strain or antibiotic for each 
incubation period (h). 
E. coli Strain Antibiotic 
No. of times performed for each incubation period 
7 h 24 h 48 h 72 h 
MG1655 CFX 3 7 1 1 
 Amp 2 1 - - 
 CouA1 1 1 - - 
 5931 1 3 - - 
 Kan 1 1 - - 
 OA 1 1 - - 
 SFX - 1 - - 
 MFX 1 1 - - 
 NFX - 1 - - 
MLS83L CFX 1 1 - - 
BW25113 CFX 1 2 - - 
NGB345 CFX - 1 - - 
MG1655 (pPH3) CFX 1 3 - - 
MG1655 
(pI203V/I205V) 
CFX 
- 1 - - 
MG1655 (pL488P) CFX - 2 - - 
MG1655 (pL492P) CFX - 1 - - 
- is not determined; CFX – ciprofloxacin, SFX – sparfloxacin, MFX – moxifloxacin, NFX – norfloxacin, OA – 
oxolinic acid, 5931 – REDX05931, CouA1 – coumermycin A1, Amp – ampicillin, Kan – kanamycin 
 
With E. coli MG1655 
I chose E. coli MG1655 for these assays as it is a non-virulent, near wild-type E. coli K12 strain 
that has a fully annotated genome sequence available (Blattner et al., 1997). When this strain 
was incubated with sublethal concentrations of CFX for 7 h or more, resistant colonies were 
isolated on the non-quinolone antibiotic selection plates. Many (between 20% and 100%; on 
average ~60%) of these colonies survived when they were restreaked back onto the antibiotic 
they were identified on; an example of these in shown in Figure 6.2. Analysis of all replicates of 
the assay showed that when MG1655 was treated with sublethal concentrations of CFX, there 
was an increase in the frequency of resistance to all non-quinolone antibiotics tested (Table 6.6 
and 6.7). The most common non-quinolone resistance identified was to Cam and Kan. Resistance 
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to Amp and Tet were not as common, and resistance to Tri was only really identified once (see 
below). This resistance was also shown not to be due to contaminating plasmids as after plasmid 
preparations (see General Methods) were performed on selected colonies with Amp, Kan and 
Cam resistance, no plasmids were observed by gel electrophoresis (data not shown). 
 
 
Figure 6.2: Example of restreaked colonies isolated on selection plates post incubation 
with sublethal ciprofloxacin (CFX). All kanamycin (Kan) resistant colonies (KanR) isolated from 
a Kan selection plate after a 24 h incubation with sublethal CFX (0, 0.004, 0.008 and 0.016 
µg/mL) were streaked back onto a LB 1.5% agar plate supplemented with 50 µg/mL Kan and 
incubated for 20 h at 37°C. 
 
Table 6.6: Range of antibiotic resistances identified for all assays run with E. coli MG1655 
Treatment Selection Antibiotic 
 n Kan Amp Cam Tet Tri CFX CouA
1
 OA 5931 SFX MFX NFX 
CFX 7             
Kan 2  0 0 0 0 0       
Amp 2   0 0 0 0       
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CouA
1
 2  0 0 0 0 0       
 OA 2   0 0 0        
5931 4  0  0 0        
SFX 1  0   0        
MFX 2  0 0 0 0        
NFX 1  0  0 0        
 - present; 0 – absent; if blank, then it was not determined; CFX – ciprofloxacin, SFX – sparfloxacin, MFX 
– moxifloxacin, NFX – norfloxacin, OA – oxolinic acid, 5931 – REDX05931, CouA1 – coumermycin A1, Amp 
– ampicillin, Kan – kanamycin, Cam is chloramphenicol, Tet is tetracycline, and Tri is triclosan 
 
Table 6.7: Frequency of antibiotic resistance per CFU (×10-10) for E. coli MG1655 treated 
with sublethal antibiotics over a 24 h incubation. 
Treatment Antibiotic Resistance/CFU (×10-10) 
             
Antibiotic ×MIC Kan Amp Cam Tet CFX CouA1 5931 OA SFX MFX NFX 
CFXa 0 34 0.4 0 0 0       
 0.25 86 0 0.7 0 0       
 0.5 806 0 63 0 1480       
 1.0 25 16 203 0.2 60       
             
Kan 0 98 0 0 0 0       
 0.25 79 0 0 0 0       
 0.5 921 0 0 0 0       
 1.0 3176 0 0 0 0       
             
Amp 0 0 0 0 0 0       
 0.25 0 0 0 0 0       
 0.5 0 0.8 0 0 0       
 1.0 0 0 0 0 0       
             
CouA1 0 5 0 0 0 0 0      
 0.25 22 0 0 0 0 14      
 0.5 0 0 0 0 0 0      
 1.0 0 0 0 0 0 0      
             
5931a 0 62 0 0 0 0  1     
 0.25 145 0 0 0 0  >167     
 0.5 312 0 7 0 46  >288     
 1.0 57 0 69 0 >117  >217     
             
OA 0 77 0 0 0 0   8    
 0.25 109 3 0 0 0   3    
 0.5 83 5 0 0 0   0    
 1.0 0 0 0 0 17   97    
             
SFX 0 44 0 0 0     0   
 0.25 67 0 0 0     0   
 0.5 62 0 0 0     0   
 1.0 27 0 218 17     62   
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MFX 0 162 0 0 0      0  
 0.25 118 0 0 0      0  
 0.5 44 0 0 0      0  
 1.0 89 0 0 0      0  
             
NFX 0 15 0 0 0       0 
 0.25 15 0 0 0       0 
 0.5 27 0 0 0       2 
 1.0 223 0 2 0       49 
a – these are averages across replicates, CFX = average across 6 replicates, 5931 = average across 3 
replicates. All the others are single data points. If blank, then it was not determined; CFX – ciprofloxacin, 
SFX – sparfloxacin, MFX – moxifloxacin, NFX – norfloxacin, OA – oxolinic acid, 5931 – REDX05931, CouA1 
– coumermycin A1, Amp – ampicillin, Kan – kanamycin 
 
Some of the resistant colonies were tested for multidrug resistance by streaking onto all 
antibiotics used. Those tested did not show cross resistance to the other antibiotics, that is 
colonies identified as Kan resistant were only resistant to Kan and not any other antibiotic tested 
(data not shown). However, testing for cross resistance was only performed twice, and thus 
instances of multidrug resistance could have been missed, especially considering some of the 
WGS data (see below). 
Several resistant colonies were incubated without selection (in LB only) over 3 days, with 
subculturing twice daily (18 h incubation followed by an 8 h incubation for 3 days). The cultures 
were then streaked back onto the antibiotic the original colony was identified on, in order to 
determine whether the resistance was maintained over generations. Some of the colonies did 
not retain resistance, some showed reduced resistance while with others the resistance was 
maintained (Figure 6.3). This indicated that in some cases the resistance was heritable and 
unlikely to be due to tolerance or epigenetic factors. 
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Figure 6.3: LB agar plates showing that resistance is still maintained after growth in LB 
only. Several resistant colonies were inoculated into LB and incubated for 3 days, with 
subculturing into LB twice daily (after 8 h and 18 h). The resultant culture was then streaked 
back onto the antibiotic they were originally identified on. a) Examples of cultures that 
maintained resistance; AmpR indicates a colony that was resistant to ampicillin (Amp) and is 
still resistant to Amp, likewise with KanR, CamR, TriR, and CFXR (kanamycin, chloramphenicol, 
triclosan and ciprofloxacin respectively). b) Example of a colony that was initially Kan resistant 
but upon subculturing only showed partial Kan resistance. c) Example of a colony that was 
initially Cam resistant but upon subculturing is now no longer resistant. 
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From Table 6.7, the 0.5 × MIC (0.004 µg/mL) treatment appears to have the greatest effect 
over a 24 h period with highest frequency of resistance/CFU observed. Here resistance 
frequencies of 8.0 × 10-8 were seen for Kan, and 1.4 × 10-7 for CFX, as opposed to the 0.25 × MIC 
and 1 × MIC samples where the greatest frequency observed was 2 × 10-8 for Cam. However, a 
greater diversity in the resistance profile is seen with the 1 × MIC (0.016 µg/mL) samples, with 
resistance to all antibiotics tested observed at least once across the 7 iterations (Table 6.6 and 
6.7). The treatment with 0.5 × MIC has been previously reported to have greater effect on 
recombination and mutation rates (Lopez et al., 2007, Thi et al., 2011). Increased frequencies of 
resistance with sublethal CFX treatment have been demonstrated previously and concurs with 
the results seen here. In particular, incubation of methicillin-susceptible S. aureus with sub-MIC 
CFX has been shown to increase resistance to methicillin (Tattevin et al., 2009). Gullberg et al. 
(2011) (reviewed in (Hughes & Andersson, 2012)) have also demonstrated an increase in 
fluoroquinolone resistance when E. coli was incubated with 0.1 × MIC of CFX. Subinhibitory levels 
of CFX have also been shown to increase the mutation rates in E. coli and Mycobacterium 
fortuitum (Gillespie et al., 2005, Mo et al., 2016, Song et al., 2016). 
In Table 6.6 and Figure 6.3, resistance to triclosan (Tri) is seen but it is not reported in Table 
6.7. Despite this biocide being used for selection of resistance in all assays, resistance was only 
ever isolated in one of the assays run over both the 7 h and 24 h incubations, and it was isolated 
from the no-CFX control (as well as in the 0.5 × MIC and 1 × MIC treatments). In this particular 
assay, I did not see colonies on the LB only (non-selective) plates at the dilutions I plated the 1 × 
MIC sample on. This was either due to an error in plating or the inappropriate dilutions being 
plated. This meant that I could not work out a frequency of resistance for this assay and thus it 
was left out of the analysis for Table 6.6. I expected to see the Tri resistance again, however, in 
later assays, I increased the amount of Tri to 15 µg/mL (in error) which may explain why I didn’t 
see any other Tri resistance. The colony isolated from the 1 × MIC treated sample was sent for 
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WGS (see below) and it did align to the no-CFX control except for a single point mutation, 
indicating that it is unlikely to be a contaminant. Recently, mutations that confer quinolone 
resistance in DNA gyrase were shown to increase resistance to Tri (Webber et al., 2013, Webber 
et al., 2017). This was found to be upregulation of stress-response genes due to the altered 
supercoiling caused by these mutations (Webber et al., 2017). Thus, here, it was expected that 
with increasing CFX-resistant mutations in GyrA could lead to more Tri resistance. 
Although the data is incomplete (the total number of times the assay was incubated for the 
various time periods is not the same, i.e. 7 times for 24 h vs 3 times at 7 h), there does seem to 
be a greater number of resistant colonies after the 24 h period as opposed to the 7 h period 
(Table 6.8). However, to fully evaluate the effect that incubation time has on the rise in 
resistance, time courses should be run. 
Table 6.8: Average number of resistant colonies identified per assay for E. coli MG1655 
treated with sublethal CFX after various incubation times. 
 Incubation Time  
×MIC 7 ha 24 hb 
0 7 11 
0.25 5 12 
0.5 4 42 
1.0 3 15 
a – is an average of 3 replicates, b – is an average of 7 replicates 
 
Indications from the literature, suggested that multidrug resistance could be induced by a 
non-quinolone antibiotics as well (Kohanski et al., 2010), so to ascertain whether this was a 
general characteristic of treatment with subinhibitory levels of antibiotics, the assay was run 
with Amp and Kan. The same variety of resistance induced by sub-MIC CFX treatment is not seen 
when the assay is run with sub-MIC concentrations of Amp or Kan (Table 6.5 and 6.6). Resistant 
colonies were isolated with these two antibiotics but the colonies were only resistant to the 
incubation antibiotic (i.e. only Amp-resistant colonies were seen with the treatment with 
sublethal Amp). This is in contrast to previous work, that showed the rise of multidrug resistance 
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after incubation with sublethal levels of Amp and increased mutation rates when treated with 
Amp or Kan (Kohanski et al., 2010). Other studies have shown that β-lactam antibiotics such as 
Amp increase mutations either via induction of the RpoS regulon, leading to an increase in 
resistance to fosfomycin, Tet, and rifampicin (Gutierrez et al., 2013), or via induction of the SOS 
response (Shaw et al., 2003, Miller et al., 2004), both of these pathways can result in the 
upregulation of the error-prone polymerase Pol IV (dinB) (Pérez-Capilla et al., 2005). The 
discrepancies between my work and published work may be down to experimental differences, 
such as with Kohanski et al. (Kohanski et al., 2010), they were looking for an increase in MIC (I 
was looking for resistant colonies at a fixed selection concentration), and with their mutation 
assays they left their plates at 37°C for 48 h, whereas at most my incubations were for 22 h at 
37°C (although occasionally, I left the plates for a further 18 h at 22°C). This is also true for study 
conducted by Gutierrez et al. (2013) who also only scored colonies after a 48-h incubation at 
37°C. 
When the assay was run in the presence of a non-cleavage-stabilising DNA gyrase inhibitor 
CouA1, there was also no increase in resistance except to CouA1 itself (Table 6.5 and 6.6). 
Coumermycin A1 is a non-quinolone antimicrobial that targets the GyrB protein of DNA gyrase 
and competitively inhibits the ATPase reaction (Gellert et al., 1976b). The Kan resistance seen in 
Table 6.6 and 6.7 is shown in Figure 6.4 not to be greatly different to the no-CouA1 control. 
Coumermycin was shown by Ikeda et al (Ikeda et al., 1980) to reduce the frequency of IR both 
in the presence (down by 20%) and absence (down 70%) of OA. Another aminocoumarin 
antibiotic novobiocin has also been shown to inhibit the SOS response, in the presence and 
absence of CFX, and it reduced the frequency of recombination in S. aureus (Schröder et al., 
2013). This all implies that merely inhibiting DNA gyrase does not cause an increase in resistance 
indicating that it may be due to the stabilisation of the cleavage complex. 
To address this, and in collaboration with my CASE partner Redx Anti-Infectives, I tested a 
compound, RedX05931 (5931), which inhibits DNA gyrase by stabilising the cleavage complex 
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but is not a quinolone antibiotic and does not seem to share the quinolone-binding site (Savage 
et al., 2016a, Savage et al., 2016b). This compound did show resistance to other antibiotics as 
well as to itself, specifically Cam and CFX (Table 6.6 and 6.7) and possibly Kan (I will deal with 
this separately), but across the four iterations, the levels of resistance and the extent of the 
resistance were not equivalent to that of CFX (Table 6.6 and 6.7). This drug has been shown to 
have a lower frequency of resistance in S. aureus, which may suggest that doesn’t induce the 
formation of spontaneous mutations to the same level as CFX. This raised the question of 
whether the effect seen is peculiar to CFX or whether it is common to all quinolones? 
For that reason, I tested OA, SFX, MFX and NFX. All but MFX showed resistance to at least 
two other antibiotics (Table 6.6 and 6.7). Due to time constraints, the other quinolones were 
only tested once for each incubation period (OA and MFX) or only once over 24 h (SFX and NFX). 
Looking at OA first, resistance was seen to Kan, Amp, CFX and to itself. Although, the increased 
resistance to CFX is not surprising as certain types of quinolone resistance are often effective to 
some degree across all quinolones (Yoshida et al., 1990). Oxolinic acid is the antibiotic that Ikeda 
et al. (1980) identified DNA gyrase-mediated IR with. He saw a 13-fold increase in IR when he 
added OA to his assay. Oxolinic acid is a first-generation quinolone whilst CFX, SFX and MFX are 
second third and fourth-generation fluoroquinolones respectively (see Chapter 1). Sparfloxacin, 
although only tested once showed increased resistance to Kan, and resistance to Cam and Tet 
(Table 6.6, 6.7 and Figure 6.4). This is in contrast to MFX which did not show any increase in 
resistance to Kan over a 24 h period, and no resistance to any other antibiotic, including itself 
(Table 6.6). When the assay was run over a 7 h incubation period, however, one MFX-resistant 
colony was identified with the 1 × MIC sample. This is in line with other studies that have 
demonstrated that resistance is less frequently isolated against MFX (Malik et al., 2012, Dalhoff, 
2012, Dong et al., 1998, Sethi et al., 2010). Against E. coli, MFX was shown to have a mutation 
rate 100-fold less than that seen with CFX at 4 × MIC (Schedletzky et al., 1999). This may be 
because MFX has been shown to target both topo IV and DNA gyrase equally in Streptococcus 
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pneumoniae and thus two mutations are required to cause resistance (Houssaye et al., 2002). 
Further to this, in S. aureus, gatifloxacin, which like MFX is an 8-methoxyfluoroquinolone, was 
also shown to target both topo IV and DNA gyrase equally (Ince & Hooper, 2001). Despite MFX 
apparently showing decreased induction of resistance in this work, it has been shown to increase 
the selection of resistant mutants in comparison to the β-lactam ceftriaxone when tested 
against S. pneumoniae, although in this same study, it had the lowest selection frequencies in 
comparison to the other quinolones tested (Browne et al., 2002). 
Norfloxacin has been used extensively to study the effect that subinhibitory concentrations 
of antibiotics have on resistance. This is despite NFX having been demonstrated to affect killing 
in cells by a different mechanism than most other fluoroquinolones (Drlica et al., 2008, Drlica et 
al., 2009). Specifically, killing with NFX appears to be sensitive to Cam and it has been suggested 
to upregulate ROS which results in cell death. However, it has also been shown to be lethal under 
anaerobic conditions making the mode of killing by this quinolone complex (Malik et al., 2007). 
Considering the debate surrounding the hypothesis that the lethality of antibiotics is due to ROS 
killing and the role that NFX has played in that, I felt it was necessary to test this quinolone in 
my assay. However, due to time constraints, I was only able to run the assay once with a 24 h 
incubation period. Thus, preliminary results do not suggest that this antibiotic is too different to 
SFX or CFX in initiating an increase in the frequency of resistance when MG1655 was treated 
with sublethal concentrations (Table 6.6 and 6.7). It does show the third greatest increase in Kan 
resistance after Kan and CFX (Figure 6.4). Unfortunately, due to time constraints the colonies 
obtained were not assessed for cross resistance. 
The Kan resistance profile of the assay changed in February of this year (2017). Before 
February the only time Kan resistance was seen with the no-drug control was when the assay 
was run in the presence of DMSO. After February, however, despite repeated decontamination, 
making fresh Kan stocks from a new stock of kanamycin sulphate (Sigma), and streaking out 
MG1655 from a separate glycerol, the colonies repeatedly appeared in the no-drug control. 
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Many of these colonies did not survive restreaking (on average - 0 × MIC = 48% survival, 0.25 × 
MIC = 62% survival, 0.5 × MIC = 84% survival, and 1 × MIC = 54% survival). The ones that did 
survive would often not grow in liquid culture, regardless of whether there was Kan in the media 
or not. In order to use the Kan data, I took the number of colonies that survived restreaking and 
calculated the frequency of resistance per CFU. I then calculated the fold change in resistance 
to the no-drug control. That meant the no-drug control gave a fold-change value of 1.0, in other 
words, no change. In Figure 6.6, the red line indicates this value, that is, a fold-change value of 
1.0. Any bars above this red line indicate a greater change in the frequency of resistance whilst 
any bars below this red line indicate a lower frequency of resistance than the no-drug control. 
From Figure 6.4, it is evident that CFX, Kan and NFX show the greatest increase in frequency of 
Kan resistance over the other antibiotics tested. However, it is important to note that the CouA1, 
SFX and NFX data is from a single experiment with a 24 h incubation period. 
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Figure 6.4: Fold change in the frequency of kanamycin resistance to the no-drug control. 
E. coli MG1655 was treated with sublethal antibiotics over a 7 h and a 24 h period before 
selection of LB 1.5% agar plates supplemented with 50 µg/mL kanamycin (Kan). Resistant 
colonies were isolated and restreaked back on to Kan. Colonies that regrew were used to 
calculate the frequency of resistance per CFU and the fold change in resistance was calculated 
in respect to the no-drug control. The red line shows the fold change in the frequency of 
resistance of one, i.e. no change over the no-drug control. a is data that was calculated as an 
average over 2 replicates of the 7 h and 6 replicates of the 24 h period incubation. b is data 
that was calculated as an average over a 7 h incubation period and 3 replicates of the 24 h 
period incubation. c indicates data that was calculated as an average of a single run of the 7 h 
and 24 h results. CouA1, SFX and NFX sample data was calculated from a single experiment 
incubated over 24 h. CFX is ciprofloxacin, CouA1 is coumermycin A1, SFX is sparfloxacin, MFX 
is moxifloxacin, NFX is norfloxacin, OA is oxolinic acid and 5931 is RedX05931. 
 
With other E. coli hosts 
To investigate whether DNA gyrase was involved in this increase in resistance, the 
quinolone-resistant E. coli strain MLS83L (see Table 2.1) was used in the assay with CFX. This 
strain has the clinically-relevant quinolone-resistant GyrA S83L mutation in the MG1655 
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background (Parks, 2004). From Table 6.9 and 6.10 and Figure 6.5, it is evident that the MLS83L 
strain treated with sublethal CFX does not seem to show the same increase in antibiotic 
resistance as observed with MG1655 and CFX (shown above in Table 6.6, 6.7 and Figure 6.4). 
This may confirm that DNA gyrase is involved in the observed increase in resistance, however 
further replicates of the assay with this strain are needed. It also suggests that the effect is 
stimulated by DNA gyrase rather than topo IV in this strain. I tested this strain using the MIC of 
the susceptible strain (0.016 µg/mL). Although I did not have the time to test this, I would predict 
that I would observe an increase in resistance if I ran the experiment with this strain using 0.25, 
0.5 and 1 × its own MIC (0.064, 0.128 and 0.256 µg/mL respectively). 
 
Table 6.9: Range of antibiotic resistances identified when E. coli MG1655, MLS83L and 
BW25113 were treated with sublethal concentrations of ciprofloxacin. 
 Selection Antibiotic 
E. coli strain n Kan Amp Cam Tet Tri CFX 
MG1655 7       
MLS83L 2  0 0 0 0  
BW25113 3  0   0  
 - present; 0 – absent; if blank, then it was not determined or it was not applicable; CFX – ciprofloxacin, 
Amp – ampicillin, Kan – kanamycin, Cam is chloramphenicol, Tet is tetracycline, and Tri is triclosan 
 
Table 6.10: Frequency of antibiotic resistance per CFU (×10-10) for E. coli strains MG1655, 
MLS83L, and BW25113 treated with sublethal CFX over a 24 h incubation 
Treatment Antibiotic Resistance/CFU (×10-10) 
       
E. coli strain ×MIC Kan Amp Cam Tet CFX 
MG1655a 0 34 0.4 0 0 0 
 0.25 86 0 0.7 0 0 
 0.5 806 0 63 0 1480 
 1 25 16 203 0.2 60 
       
MLS83Lb 0 28 0 0 0  
 0.25 37 0 0 0  
 0.5 5 0 0 0  
 1 39 0 0 0  
       
BW25113c 0 17 0 0 0 0.8 
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 0.25 18 0 0 0 7 
 0.5 31 0 32 0 96 
 1 11 0 0 3 3 
a – average across 6 replicates, b – data from a single experiment, c – average across 2 replicates. If blank, 
then it was not determined; CFX – ciprofloxacin, Amp – ampicillin, Kan – kanamycin, Cam is 
chloramphenicol, and Tet is tetracycline. 
 
 
Figure 6.5: Fold change in the frequency of kanamycin resistance to the no-drug control 
for E. coli strains MG1655, MLS83L and BW25113 treated with sublethal concentrations of 
ciprofloxacin (CFX). Strains were treated with sublethal CFX over a 7 h and a 24 h period before 
selection on LB 1.5% agar plates supplemented with 50 µg/mL kanamycin (Kan). Resistant 
colonies were isolated and restreaked back on to Kan. Colonies that regrew were used to 
calculate the frequency of resistance per CFU and the fold change in resistance was calculated 
in respect to the no-drug control. The red line shows the fold change in the frequency of 
resistance of one, i.e. no change over the no-drug control. The data presented from MLS83L is 
an average of the 7h and 24 h incubation data, BW25113 is an average over the 7 h and 2 
replicates of the 24 h incubation data and MG1655 is calculated as an average over 2 replicates 
of the 7 h and 6 replicates of the 24 h period incubation. 
 
E. coli BW25113 (see Table 2.1) is the parental strain that all deletion mutations were made 
from in the Keio collection (Baba et al., 2006). The ultimate aim was to use specific strains from 
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the Keio collection to investigate the other proteins or genes involved in the increase in 
resistance caused by sublethal treatment with CFX. Unfortunately, I ran out of time to attempt 
any of this but I did use the parent strain, BW25113, as a further control to test whether the 
same effect was visible with another strain of E. coli. This strain had an MIC lower than that 
measured for MG1655 (0.004 µg/mL). However, colonies were isolated that were resistance to 
Cam (0.5 × MIC, frequency of 3.2 × 10-9), Tet (1 × MIC, frequency of 3 × 10-10) and CFX (0 – 1 × 
MIC) (Table 6.9 and 6.10) but did not show the same increase in resistance to Kan (Figure 6.5). 
This implies that the increase in resistance may not be peculiar to MG1655 but it would be good 
to test clinically-isolated strains and other species of bacteria to see if it is relevant in a clinical 
setting. Overall the BW25113 strain was more resistant to CFX with CFX resistance identified in 
the no-drug control (frequency of 0.8 × 10-10). 
 
With the hyper-recombination mutants 
The hyper-recombination mutants were identified by Ashizawa et al. (1999) as mutations in 
GyrA that increase the frequency of illegitimate recombination in vivo (see Chapter 4). In order 
to test their in vivo phenotype and to see if they affect the increase in the frequency of 
resistance, I transformed the overexpression plasmids (made by site-directed mutagenesis of 
pPH3) that were used to produce the proteins in Chapter 4, into MG1655 (pPH3 – wild-type 
GyrA, pI203V/I205V - GyrA I203V/I205, pL488P – GyrA L488P and pL492P – GyrA L492P). I also 
attempted to move these mutations into the MG1655 gyrA gene on the chromosome by ssOligo 
Recombineering. Regrettably, I was unable to make the L488P or the L492P mutations due to 
time constraints. Although I managed to move the I203V/I205V mutations into the 
chromosome, I accidently added an extra mutation leaving me with I203V/S204R/I205V (E. coli 
NGB345 – Table 2.1) (Figure 6.6). This was due to a mistake in the oligo (Table 2.3) not as a result 
of spontaneous mutation. 
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Figure 6.6: Sequencing chromatogram of the E. coli MG1655 gyrA mutations 
(I203V/S204R/I205V) after ssOligo recombineering aligned with the expected sequence 
(I203V/I205V) and the wild-type (WT) sequences. Red boxes indicate the positions of the base 
changes and the star indicates the erroneous base. Amino acid changes are referred to by their 
single letter codes. 
 
Although these assays were only run once for the hyper-recombination mutants, the 
preliminary results suggest that overexpressing the GyrA subunit with the hyper-recombination 
mutants appears to have little effect on the frequency of mutation when compared to the WT 
MG1655 (Table 6.11 and Figure 6.7). There is no increase in the frequency of resistance with 
NGB345 when compared with WT MG1655. There is also very little difference in the frequency 
of resistance observed with the overexpressed hyper-recombination mutants in comparison 
with the overexpressed wt-GyrA (pPH3). In terms of the range of resistances seen, the MG1655 
(pL492P) showed resistance is against Kan, Cam and CFX whilst with MG1655 (pI203V/I205V) 
resistance is seen to Kan, Cam and Tet. With MG1655 (pPH3) resistance was observed against 
Kan and Cam, however only Kan resistance was obtained with the MG1655 (pL488P) mutant. 
Overall with these mutants, less resistance to CFX was observed (Table 6.11). The frequency of 
resistance appears to be higher with the pI203V/I205V than that of the strain NGB345 (especially 
at 1×MIC) (Table 6.11 and Figure 6.7). This may be because the extra mutation (S204R) has 
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altered the effect the other two mutations have on the protein or that overexpression of this 
mutation is needed to see the effect. This protein would have to be tested in vitro to see what 
effect the extra mutation has on the activity of the enzyme. All things considered, the actual 
I203V/I205V, L488P and L492P mutations need to be made in MG1655 to definitively assess the 
in vivo phenotypes with regards to sublethal treatment with CFX. Furthermore, these assays 
would need to be repeated to get a realistic idea of the effect these mutations could be having. 
Moreover, these assays were run at permissive temperatures and increasing the temperature 
may yield very different results. Ultimately, further work with these mutations in this assay is 
needed to fully explore whether they do increase IR in this assay. 
 
Table 6.11: Frequency of antibiotic resistance per CFU (×10-10) for E. coli strains MG1655, 
NGB345, and MG1655 carrying the wt-GyrA and hyper-recombination overexpression 
plasmids, all treated with sublethal CFX over a 24 h incubation. 
Treatment Antibiotic Resistance/CFU (×10-10) 
       
E. coli strain ×MIC Kan Amp Cam Tet CFX 
MG1655a 0 34 0.4 0 0 0 
 0.25 86 0 0.7 0 0 
 0.5 806 0 63 0 1480 
 1 25 16 203 0.2 60 
       
NGB345b 0 52 0 0 0 0 
 0.25 15 0 0 0 2 
 0.5 48 0 0 0 0 
 1 30 0 6 0 0 
       
MG1655 (pPH3)b 0 19  0 0 0 
 +IPTG 10  0 0 0 
 0.25 13  1 0 0 
 0.5 40  2 0 0 
 1 26  7 0 0 
       
MG1655 (pI203V/I205V)b 0 6  9 0 0 
 +IPTG 4  0 0 0 
 0.25 2  0 0 0 
 0.5 3  0 0 0 
 1 186  46 23 0 
       
MG1655 (pL488P)b 0 1  0 0 0 
 +IPTG 0  0 0 0 
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 0.25 14  0 0 0 
 0.5 2  0 0 0 
 1 386  0 0 0 
       
MG1655 (pL492P)b 0 9  0 0 0 
 +IPTG 12  1 0 0 
 0.25 55  0 0 0 
 0.5 75  0 0 0 
 1 6  3 0 3 
a – average across 6 replicates, b – data from a single experiment; if blank, then it was not determined; 
CFX – ciprofloxacin, Amp – ampicillin, Kan – kanamycin, Cam is chloramphenicol, and Tet is tetracycline. 
 
 
Figure 6.7: Frequency of kanamycin resistant colonies per CFU (×10-10) for the E. coli strains 
MG1655, NGB345, and MG1655 carrying the wt-GyrA and hyper-recombination 
overexpression plasmids treated with sublethal concentrations of ciprofloxacin (CFX). Strains 
were treated with sublethal CFX over a 7 h (CFX only) and a 24 h period before selection of LB 
1.5% agar plates supplemented with 50 µg/mL kanamycin (Kan). Resistant colonies were 
isolated and restreaked back on to Kan. Colonies that regrew were used to calculate the 
frequency of resistance per CFU. On the X-axis, the 0, 0.25, 0.5 and 1 are × MIC and the +IPTG 
is the sample that had 0.5 mM IPTG added but no CFX. A indicates that the data presented 
from MG1655 is calculated as an average over 2 replicates of the 7 h and 6 replicates of the 24 
h period incubation. NGB345, and MG1655 carrying the wt-GyrA and hyper-recombination 
overexpression plasmids sample data was calculated from a single experiment incubated over 
24 h. pPH3 is the plasmid carrying the wild-type gyrA gene; pI203V/I205V, pL488P and pL492P 
are the hyper-recombination mutations of gyrA in pPH3. 
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Whole genome sequencing 
A variety of strains from the assays run with E. coli MG1655 and sublethal CFX were sent for 
WGS. A total of 24 strains were sent and included resistant and non-selected strains. The non-
selected strains were those that had been incubated with 0.25, 0.5, or 1 × MIC CFX but were 
taken from the LB only plates and therefore had not been selected on any antibiotic. Control 
strains were sent from LB only plates from samples that had been incubated without any CFX 
and one parental strain was sent that had not been run in the assay. 
Firstly, from Table 6.12 it is evident that there are specific mutations that are found in all of 
the strains sent for sequencing. These include a CC deletion (bp 2173360) in gatC, a G insertion 
(bp 3560455) in glpR and a CG insertion (bp 4296380) in a repeat region that is non-coding. 
These are all known variants of this strain (Freddolino et al., 2012, Graves Jr et al., 2015). Two 
different sources of MG1655 were used in these assays. Initially, a lab strain of MG1655 was 
used (assays from October 2015 until January 2016) before the strain from CGSC arrived. This 
initial lab strain had a SNP in yieP and it was found to have a 4.5 kb deletion (confirmed by PCR) 
from bp 1397239 – 1401771 across ynaJ, uspE, fnr, ogt, agbT and rrlD (data not shown). The 
resistant strains that were sent for sequencing that were derived from this parent include the 
Amp, and Tri strains, a CFX strain (CFX-1 – Table 6.12), a Cam strain (Cam-1 – Table 6.12) and a 
Kan strain (Kan with 0.5 × MIC in Table 6.12). Whether the deletions in this parental strain has 
played a role in the development of the resistance or the associated chromosomal deletions 
(∆marR or ∆leuP) is unknown. The strain obtained from CGSC developed a spontaneous SNP in 
dppD (probably during the preparation of the strain for sequencing) and later also had one in 
nfo (possibly developed in the process of making the initial glycerols of the strain for long-term 
storage). This mutation may have more serious consequences as the nfo gene codes for 
endonuclease IV. This mutation resulted in an amino acid change from valine to phenylalanine 
on β-sheet 6 at position 176, which appears to be a conserved residue in the protein, however 
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it does not appear to be in or near the active site of the enzyme (Hosfield et al., 1999, Daley et 
al., 2010). Endonuclease IV is one of the apurinic/apyrimidinic (AP) endonucleases that is 
involved in the DNA repair of oxidative damage. It removes apurine or apyrimidine bases during 
base excision repair. Mutations at AP sites are often A>T transversion mutations with E. coli 
mutants deficient in AP site repair also showing an increase in A>T transversion mutations (Daley 
et al., 2010). In all of the unique mutations found when this parent MG1655 was used in the 
assays, only one (out of the 11 SNPs) showed an A>T transversion (Kan resistant without CFX, 
Table 6.12). This may suggest that the majority of the SNPs seen may not have been influenced 
by this mutation. Ultimately the effects of this nfo mutation are not really known and although 
endonuclease IV has not been shown to play a significant role in the repair of DNA damage by 
CFX, I cannot say for certain that it has not affected the outcomes of this assay. Suffice to say 
that an increase in the frequency of resistance was observed regardless of the parental strain 
used and the hallmark A>T transversion mutation of AP sites was not a considerable contributor 
to the SNPs seen (11% of the SNPs). Furthermore, it is also unlikely that the mutation in 
endonuclease IV would affect the large genome mutations (e.g. the large deletions) that have 
been observed. Having said that, all of this should be repeated with a wild-type nfo strain. 
 
Table 6.12: All variants and mutations identified from whole genome sequencing of 24 E. 
coli MG1655 strains from QIAR (quinolone-induced antibiotic resistance) assay. 
Resistance Mutation 
type 
Genotype Chromosome 
position 
Gene Notes  
Reference Strain 
 
 
None - No 
incubation 
deletion ACCC AC 2173360 gatC known MG1655 
variant 
insertion CC CGC 3560455 glpR known MG1655 
variant 
SNP G  A 3703260 dppD dipeptide ABC 
transporter 
insertion AC  ACGC 4296380 Non-
coding 
RIP321 element 
(repetitive 
extragenic 
palindromic)        
deletion ACCC AC 2173360 gatC 
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None - 
Incubated 
without 
CFX - 4 
strains 
SNP G T 2251365 nfo Endonuclease IV 
- V176F 
insertion CC CGC 3560455 glpR 
 
insertion AC  ACGC 4296380 Non-
coding 
 
       
None - 
Incubated 
with 0.25 
or 0.5 × 
MIC - 4 
strains 
deletion ACCC AC 2173360 gatC 
 
SNP G T 2251365 nfo 
 
insertion CC CGC 3560455 glpR 
 
insertion AC  ACGC 4296380 Non-
coding 
 
       
None - 
Incubated 
with 1 × 
MIC - 2 
strains 
deletion ACCC AC 2173360 gatC 
 
SNP G T 2251365 nfo 
 
SNP G A 2339173 gyrA DNA gyrase A 
subunit S83L – 
known 
resistance 
insertion CC CGC 3560455 glpR 
 
insertion AC  ACGC 4296380 Non-
coding 
 
       
Amp - 
incubated 
with 0.5 × 
MIC 
deletion ACCC AC 2173360 gatC 
 
insertion CC CGC 3560455 glpR 
 
SNP C  A 3941164 yieP f Predicted 
transcriptional 
regulator 
insertion AC  ACGC 4296380 Non-
coding 
 
SNP A T 4379035 frdD Lies within the 
promoter of 
ampC        
Tri - 
incubated 
with 0.5 × 
MIC 
SNP C A 1350762 fabI G93V - known 
Tri resistance 
mutation 
SNP C T 1351063 Non-
coding 
 
deletion ACCC AC 2173360 gatC 
 
insertion CC CGC 3560455 glpR 
 
SNP C  A 3941164 yieP 
 
insertion AC  ACGC 4296380 Non-
coding 
 
       
Tet - 
incubated 
with 1 × 
MIC 
deletion CTC CC 458566 clpX ClpX ATP-
dependent 
protease 
specificity 
component and 
chaperone 
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deletion GAA GA 459223 lon Protease 
insertion GAAAAAA
AT 
GAAA
AAAA
AT 
468358 Non-
coding 
 
SNP C T 1619468 marR DNA-binding 
transcriptional 
repressor 
deletion ACCC AC 2173360 gatC 
 
SNP G T 2251365 nfo 
 
insertion CC CGC 3560455 glpR 
 
insertion AC  ACGC 4296380 Non-
coding 
 
       
CFX-1 - 
incubated 
with 1 × 
MICa 
deletion ACCC AC 2173360 gatC 
 
SNP G C  2339173 gyrA S83W 
insertion GTGGTCA GTGGT
CTGGT
CA 
2664136 suhB Inositol-
phosphate 
phosphatase 
insertion CC CGC 3560455 glpR 
 
SNP C  A 3941164 yieP 
 
insertion AC  ACGC 4296380 Non-
coding 
 
       
CFX-2 - 
incubated 
with 1 × 
MICb 
SNP G T 1619370 marR 
 
deletion ACCC AC 2173360 gatC 
 
SNP G T 2251365 nfo 
 
SNP G A 2339173 gyrA S83L 
insertion CC CGC 3560455 glpR 
 
insertion AC  ACGC 4296380 Non-
coding 
 
       
Cam - 
incubated 
with 0.5 × 
MIC 
complex N/A N/A 883585 - 
932177 
 
possible loop or 
amplification 
See Figure 6.11 
deletion ACCC AC 2173360 gatC 
 
SNP G T 2251365 nfo 
 
insertion CC CGC 3560455 glpR 
 
insertion AC  ACGC 4296380 Non-
coding 
 
       
Cam-1 - 
incubated 
with 1 × 
MICc 
deletion N/A N/A 1619098 - 
1619552 
∆marR See Figure 6.10 
SNP A T 1792432 nlpC 
 
insertion CC CGC 3560455 glpR 
 
SNP C  A 3941164 yieP 
 
insertion AC  ACGC 4296380 Non-
coding 
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Cam-2 - 
incubated 
with 1 × 
MICd 
complex N/A N/A 870751 - 
899202 
 
possible loop or 
amplification 
See Figure 6.12 
deletion N/A N/A 1196375 - 
1211411 
e14 
prophage 
Excision of 
cryptic phage 
SNP C T 1619468 marR 
 
deletion ACCC AC 2173360 gatC 
 
SNP G T 2251365 nfo 
 
insertion CC CGC 3560455 glpR 
 
insertion AC  ACGC 4296380 Non-
coding 
 
       
Cam -3 - 
incubated 
with 1 × 
MICe 
SNP T G 883616 Non-
coding 
found between 
mdfA and its 
promoter 
SNP T G 1619370 marR 
 
deletion ACCC AC 2173360 gatC 
 
SNP G T 2251365 nfo 
 
insertion CC CGC 3560455 glpR 
 
insertion AC  ACGC 4296380 Non-
coding 
 
       
Kan - 
Incubated 
without 
CFX 
SNP C A 516710 fetB putative iron 
ABC exporter 
deletion ACCC AC 2173360 gatC 
 
SNP G T 2251365 nfo 
 
SNP G A  3471539 fusA elongation 
factor G - 
known Kan 
resistance gene 
insertion CC CGC 3560455 glpR 
 
SNP A T 4104443 cpxA sensory 
histidine kinase 
– part of CpxAR 
two-component 
signal 
transduction 
system 
insertion AC  ACGC 4296380 Non-
coding 
 
       
Kan - 
incubated 
with 0.5 × 
MIC 
deletion ACCC AC 2173360 gatC 
 
SNP G C  2400681 nuoF NADH:quinone 
oxidoreductase 
subunit F 
SNP G A 3471686 fusA 
 
insertion CC CGC 3560455 glpR 
 
SNP C  A 3941164 yieP 
 
insertion AC  ACGC 4296380 Non-
coding 
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deletion N/A N/A 4606166 - 
4606314 
∆leuP tRNA – see 
Figure 6.10        
Kan - 
Incubated 
with 1 × 
MIC 
SNP T G 1619370 marR 
 
deletion ACCC AC 2173360 gatC 
 
SNP G T 2251365 nfo 
 
insertion CCTGC CCTGC
TGC 
3471824 fusA 
 
insertion CC CGC 3560455 glpR 
 
deletion CTG CG  3991578 cyaA adenylate 
cyclase - 
suggested to 
play a role in 
persistence 
insertion AC  ACGC 4296380 Non-
coding 
 
0.25, 0.5 and 1 × MIC CFX is 0.004, 0.008 and 0.016 µg/mL respectively. Grey blocks indicate unique 
mutations. a & b are different strains identified from different replicates that share CFX resistance. c - e 
are different strains identified from different replicates that share Cam resistance. f the variant of yieP 
was found in all resistant strains from the first batch of WGS, the parental MG1655 strain these assays 
were run with was a lab strain that likely carried this variant. 
 
The strains that were incubated with CFX but were not selected against another antibiotic 
did not show any other mutations other than the SNP mutations in gyrA seen when MG1655 
was incubated with 1 × MIC CFX (Table 6.12). This perhaps is not surprising considering the 
chance of selecting of selecting a colony with various mutations at random is quite low 
considering the low frequencies of resistance (1 in 107 for CFX-resistant mutations, 1 in 1010 for 
Tet-resistant mutations). However, having said that, this does raise the question about whether 
the non-CFX mutations arise during the initial incubation with sublethal CFX or if they are a result 
of the secondary selection. This would imply that pre-exposure to CFX makes bacteria more 
predisposed to becoming resistant when exposed to a secondary antibiotic. To the best of my 
knowledge, there is no evidence in the literature that this has been directly tested, however, 
Torres-Barceló et al. (2015) have argued that the induction of the SOS-induced response by CFX 
does not increase evolvability, but competitive fitness, implying that for mutations to become 
fixed in the population, continued selection is needed. This was also demonstrated by Gullberg 
et al. (2011) who showed in competition experiments that continued selection with sublethal 
antibiotics gave individuals with resistance mutations a competitive advantage over those 
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without. Despite these studies however, there are papers that show that sublethal treatment 
with CFX increases recombination between homologous sequences (Lopez & Blazquez, 2009) 
and between non-homologous sequences independently of the SOS response (Lopez et al., 
2007), implying that treatment with CFX is enough to cause significant chromosomal 
modifications. 
The CFX-resistant mutations seen here are in the gyrA gene (at bp 2339173), and all lead to 
the mutation of the S83. Mutations that cause this residue to be mutated are well known (Collin 
et al., 2011, Aldred et al., 2014b). It is the residue that is involved in the binding of CFX through 
the water-metal ion bridge (Aldred et al., 2014a, Aldred et al., 2013, Hooper & Jacoby, 2015) 
and the S83L and S83W mutations identified here are well characterised (Redgrave et al., 2014). 
For the Amp- and Tri- resistant strains, both contain SNPs that explain the resistance 
phenotype (Table 6.12). The Amp resistance comes from an A>T transversion (bp 4379035) 
mutation in the promoter region of ampC. This promoter in E. coli overlaps with the end of the 
frdD gene (Grundström & Jaurin, 1982) and is not generally inducible (Livermore, 1995) resulting 
in Amp susceptibility in E. coli. However, there are examples of mutations in this promoter 
region that increase the production of this gene which encodes a β-lactamase (class C 
cephalosporinase) including an amplification of the ampC gene (Normark et al., 1977, Briñas et 
al., 2002, Corvec et al., 2002). The Tri resistance comes from a known C>A transversion mutation 
(bp 1350762) in fabI resulting in the G93V amino acid change (Heath et al., 1999). 
The Tet resistance appears to be a synergistic outcome of two mutations, the deletion in the 
lon gene (∆A at bp 459223), and the C>T transition mutation in marR (bp 1619468) as neither of 
the individual mutations would have been enough to see the observed resistance (Nicoloff & 
Andersson, 2013, Nicoloff et al., 2007). This may explain why only low levels of Tet resistance 
have been seen in this assay as the probability of the formation of two mutations is much lower 
than that of just one mutation. Mutations in lon have also been demonstrated in Pseudomonas 
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aeruginosa when treated with sublethal CFX (Brazas et al., 2007). Lon protease has also been 
suggested to be involved in the repair of quinolone-induced DNA damage (Drlica et al., 2009). 
 
Figure 6.8: Large-scale (> 100 bp) deletions from antibiotic-resistant strains obtained after 
sublethal treatment with ciprofloxacin (CFX). Trimmed reads were assembled and aligned to 
the published E. coli MG1655 sequence and scanned by eye for large-scale genomic changes 
in Tablet (Milne et al., 2013), with deletions indicated by gaps in coverage (double-headed 
arrows). KanR is a kanamycin-resistant strain with a deletion of leuP (red box ∆leuP), CamR are 
chloramphenicol-resistant strains, one showing a deletion of marR (red box ∆marR) and the 
other the excision of the cryptic prophage e14. 
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Cam resistance was often obtained after MG1655 treatment of sublethal CFX and 4 of the 
24 strains sent for WGS were Cam resistant. Three of those had mutations in marR, including 
the complete deletion of the gene (Figure 6.8b) and two SNPs, one C>T transition (bp 1619468) 
and one T>G transversion (bp 1619370). All of these marR mutations were identified from 
MG1655 treated with 1 × MIC CFX. The Mar operon (Multiple Antibiotic Resistance) contains 3 
genes marR, marA, and marB. MarR is the transcriptional repressor of marA and marB and 
derepression of these results in multidrug resistance through MarA which itself regulates a 
number of efflux pumps and porins. Mutations in marR are known to give rise to resistance to 
various antibiotics including tetracycline, chloramphenicol and fluoroquinolones (Cohen et al., 
1993, Alekshun & Levy, 1997, Alekshun & Levy, 2007). Considering these mutations should give 
multidrug resistance, I should have seen resistance to more than just Cam when I tested for 
cross resistance, however, there may have been a decreased susceptibility of these strains to 
the other antibiotics that was not visible at the concentrations of the antibiotics that were used. 
If MICs were performed on these strains, I expect that higher MICs would be obtained for all of 
the antibiotics tested. The high number of marR mutations obtained, particularly with treatment 
at 1 × MIC CFX, may imply that the resistance is induced to reduce the effects of the CFX, and 
the Cam resistance may be a secondary effect observed. Especially as specific resistance to 
fluoroquinolones mediated by marOR mutations have been identified in E. coli isolated from 
patients with urinary tract infections (UTI’s) that were treated with various fluoroquinolones 
(Komp Lindgren et al., 2003) and demonstrated under treatment with sub-MIC NFX (Long et al., 
2016). 
One of the strains with a marR SNP and the Cam-resistant strain from the 0.5 × MIC 
treatment showed a large jump in coverage after assembly with Snippy (Figures 6.9a and 6.10a) 
(1 × MIC CamR – CV jump from ~50 to ~450; 0.5 × MIC CamR – CV jump from ~50 to ~250). In 
order to try and address whether or not this was a sequencing or PCR error, Bernardo 
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reassembled the reads from these two strains using W2rap Contigger. When the newly 
assembled reads were visualised in Bandage, both of the assemblies had large loops visible that 
mapped to the same area as the previously assemblies (Figures 6.9b and 6.10b). The small 
unitigs from the loops (398 bp unitig and 394 bp unitig from Figures 6.9b and 6.10b) were then 
run in BLAST. The sequences in these unitigs aligned to the edges of the “duplications” with 
exactly half of the sequence aligning to the front end of the area with high coverage and the 
other half to the far end (Figures 6.9c and 6.10c). This suggests that this is a loop or plasmid or 
it is an amplification made up of a number of concatemers of this region. This still needs to be 
confirmed by PCR or sending these strains for further sequencing using a long-read sequencer 
such as PacBio® or MinION. The interesting thing about this duplication is that in both strains it 
contains the mdfA gene, also known as the cmr gene. This gene encodes a transmembrane 
ATPase multi-drug efflux pump (Edgar & Bibi, 1997) which was initially identified by its ability to 
confer resistance to Cam when over expressed (Nilsen et al., 1996). It has also been found to 
increase resistance to a number of molecules as well as several clinically-relevant antibiotics 
including fluoroquinolones (Edgar & Bibi, 1997), however, clinically significant increases in 
resistance to fluoroquinolones has been shown to require over expression of more than one 
efflux pump, such as mdfA and acrAB (Swick et al., 2011). With the Cam-resistant isolate from 
the 0.5 × MIC CFX treatment, this amplification of the mdfA gene is the only genetic explanation 
for the Cam resistance that is observed. Here is appears that the copy number of this gene has 
increased 9-fold in the 1 × MIC CamR isolate and 5-fold in the 0.5 × MIC CamR isolate. 
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Figure 6.9: Putative plasmid or duplications of bp 883585 – 932177 in a chloramphenicol-
resistant strain isolated after treatment with sublethal (0.5 × MIC) ciprofloxacin. a) Trimmed 
reads were assembled and aligned to the published E. coli MG1655 sequence (using Snippy) 
and scanned by eye for large-scale genomic changes in Tablet (Milne et al., 2013), with the 
duplication/plasmid indicated by a large jump in coverage (double-headed arrows). Important 
genes and the flanking genes are shown above the assembled reads. b) The assemblies were 
redone using W2rap Contigger (Clavijo et al., 2017) and visualised using Bandage, with the 
duplications/plasmid indicated by the 48605 bp and 398 bp unitigs. c) The 398 bp unitig was 
run in BLASTN. The query sequence aligned to E. coli sequences in two places, splitting the 
query sequence in half and these are graphically presented here (screen shots of the BLAST 
graphic). 
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Figure 6.10: Putative plasmid or duplications of bp 870751 – 899202 in a chloramphenicol-
resistant strain isolated after treatment with sublethal (1 × MIC) ciprofloxacin. a) Trimmed 
reads were assembled and aligned to the published E. coli MG1655 sequence (using Snippy) 
and scanned by eye for large-scale genomic changes in Tablet (Milne et al., 2013), with the 
duplication/plasmid indicated by a large jump in coverage (double-headed arrows). Important 
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genes and the flanking genes are shown above the assembled reads. b) The assemblies were 
redone using W2rap Contigger (Clavijo et al., 2017) and visualised using Bandage, with the 
duplications/plasmid indicated by the 28450 bp and 394 bp unitigs. c) The 394 bp unitig was 
run in BLASTN. The query sequence aligned to E. coli sequences in two places, splitting the 
query sequence in half and these are graphically presented here (screen shots of the BLAST 
graphic). 
 
Gene duplications and amplifications (GDA) have been suggested to be found frequently in 
bacteria populations (including those not under any selection (Brochet et al., 2008, Roth et al., 
2006)) and have been implicated in resistance previously in a number of bacterial species 
(Andersson & Hughes, 2009, Conrad et al., 2009, Hjort et al., 2016, Slager et al., 2014, Sun et al., 
2009) including some clinical isolates (Gao et al., 2015, McGann et al., 2014). In particular, 
MG1655 was shown to have gene duplications of 12 kb – 140 kb after short-term laboratory 
evolution experiments in lactate minimal media. Here they demonstrated a 1 – 4-fold increase 
in coverage in their assemblies in areas of the amplifications (Conrad et al., 2009). The first 
reported gene amplification that was linked with resistance was found in an ampicillin-resistant 
E. coli that had amplifications of the ampC gene (Normark et al., 1977). Slager et al. (Slager et 
al., 2014) showed that antibiotics that target DNA replication increased gene dosage near oriC 
in S. pneunomiae which was a result of stalled replication forks and refiring of the replication 
origin. Tandem duplications of 98 kb were found in MRSA clinical isolates as well as 20 kb 
amplifications that included mprF that confers resistance to antimicrobial peptides were 
identified in vancomycin-intermediate S. aureus (Gao et al., 2015). Due to GDA being found in a 
population of bacteria under no particular selection, it has been suggested that these mutations 
are often the first selected for when a selection pressure is applied (such as antibiotics) 
(Andersson & Hughes, 2009, Roth et al., 2006). Further to this, GDA may be a short-term solution 
(as GDA’s have been shown to generally be unstable in a population (Hjort et al., 2016)) to a 
selection pressure until a stable mutation is established. Thus, GDA’s may facilitate antibiotic 
resistance by allowing populations time to accumulate point mutations that may confer stable 
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resistance (Andersson & Hughes, 2009). GDA’s have been demonstrated to arise through RecA-
dependent and -independent routes (Andersson & Hughes, 2009). The RecA-dependent routes 
include non-equal homologous recombination between long directly repeats (Anderson & Roth, 
1981), transposable or insertion elements (Nicoloff et al., 2007) or repeat regions (Shyamala et 
al., 1990). The RecA-independent routes include DNA secondary structure (Trinh & Sinden, 
1993) or crossovers between sister chromatids (Lovett et al., 1993) that may direct 
recombination between direct repeats or through illegitimate recombination by DNA gyrase 
(Ikeda et al., 2004). Alternatively, they could happen as a result of double-strand DNA breaks 
and rolling circle replication (Andersson & Hughes, 2009). There is no evidence that transposons 
or insertion elements played a role in the amplifications demonstrated here and the closest 
repeat is 400 bps away (most are >1 kb away) nor are there any repeat regions in the join points 
(Figure 6.9c and 6.10c). This suggests that these amplifications occurred via a RecA-independent 
pathway, however this would need further analysis and experimentation to confirm this. 
All of the Kan-resistant isolates have mutations in the elongation factor G gene fusA (Table 
6.12). These include an insertion of a TGC at bp 3471824 in the fusA gene causing the addition 
of an alanine at position 564 and two separate G>A transition mutation (bp 3471539 and 
3471686 respectively) causing FusA P658L (Kan-resistant isolate from incubation without CFX) 
and P610L (Kan-resistant isolate from 0.5 ×MIC CFX treatment) respectively. The P610L mutation 
has been identified previously (Mogre et al., 2014) and the amino acid 658 has been shown to 
lie within a set of conserved residues on the C-terminus of the protein (Hou et al., 1994). Overall 
many mutations in fusA resulting in Kan resistance have been reported in both E. coli (Lázár et 
al., 2013) and in S. aureus (Norström et al., 2007). Two other mutations that have been shown 
to contribute to Kan resistance are also seen in the Kan-resistant isolate that had no incubation 
with CFX and in the 1 × MIC CFX treatment isolate. These are the A>T transversion mutation (bp 
4104443) in cpxA and the single bp deletion in cyaA respectively (Lázár et al., 2013, Mogre & 
Seshasayee, 2017). Mutations in these genes, alongside the fusA genes have been shown to 
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increase MIC of Kan, however, the study by Mogre and Seshasayee (Mogre & Seshasayee, 2017) 
has not been published in a peer-reviewed journal, only in the Cold Spring Harbour Laboratory 
hosted BioRxiv. The other mutation of note, is the 148 bp deletion of leuP in the Kan-resistant 
isolate from the 0.5 × MIC CFX treatment (Figure 6.8a). 
Large genomic deletions have been demonstrated here with the deletion of marR in the 
Cam-resistant 1 × MIC CFX-treated isolate and the deletion of leuP in the Kan-resistant 0.5 × MIC 
CFX-treatment isolate (Figure 6.8a and b). Another deletion in another Cam-resistant 1 × MIC 
CFX-treated isolate (Figure 6.8c) was identified to be a potential excision event of the cryptic 
e14 prophage. The excision of this prophage in response to treatment with sublethal norfloxacin 
has been demonstrated by Long et al. (Long et al., 2016). The e14 prophage is a defective 
prophage with important phage-related functional genes having been deleted since integration 
(Mehta et al., 2004). Despite this, the e14 prophage has been shown to excise from the genome 
if the SOS response is induced (Brody et al., 1985, Wang et al., 2010). The sequence length of 
e14 prophage is 15.4 kb long (Mehta et al., 2004) which is a bit longer than the deletion seen in 
the Cam-resistant strain (15.036 kb). This is not too surprising considering the e14 prophage has 
been demonstrated to form a 14.4 kb circle after excision (Brody et al., 1985). This prophage 
seems to provide some protection to the bacterium making it more tolerant to nalidixic acid, 
and acid stress (without the phage there was a 90-fold reduction in % cell survival after pH 2.5 
for 30 min), probably due to its role in biofilm formation (Wang et al., 2010). The other genomic 
deletions are more difficult to explain and to the best of my knowledge no large deletions (>100 
bp) have been reported as a response to sublethal treatment with CFX previously. Salmonella 
enterica has been previously shown to naturally decrease the size of its genome over time by a 
RecA-independent mechanism with deletions from 1 bp to 212 kb reported (Nilsson et al., 2005). 
However, the deletions seen here though seem to be in response to treatment with antibiotics 
so it is unlikely to be a natural mechanism of genome size reduction. Sublethal treatment with 
fluoroquinolones have been demonstrated to induce small deletions (>19 bp) in E. coli 
 Chapter 6: Quinolone-Induced Antimicrobial Resistance 
213 
 
previously (Long et al., 2016, Song et al., 2016) and these were suggested to be independent of 
the SOS response-induced error-prone polymerases. Translesion polymerases (error-prone 
polymerases) have been shown to introduce spontaneous deletions in Salmonella enterica 
Typhimurium as a result of double-strand break repair. However, the size of these deletions was 
not discussed (Koskiniemi & Andersson, 2009). Ultimately, the mechanism behind how these 
deletions have formed is not known. 
With all of the SNP mutations present, the vast majority (44%) are G>A or C>T transition 
mutations. This has been shown to be the dominant type of spontaneous mutation in E. coli 
(Foster et al., 2015). However, an increase in this kind of SNP mutation has also been linked with 
an increase in 8-oxo-G- and deamination-damage due to ROS (Lind & Andersson, 2008, Foster 
et al., 2015). However, in another study, an increase in G>A and C>T transition mutations under 
treatment with norfloxacin was shown not to be as a result of oxidative damage (Long et al., 
2016). Studies that have looked at the effect of sublethal antibiotics on the development of 
mutation, have shown that genes involved in the SOS response are responsible for the elevated 
mutation rate under sublethal treatment with CFX; including recA which when deleted showed 
reduced mutation rates when incubated with 0.5 × MIC CFX (Thi et al., 2011). The cleavage of 
LexA and the concomitant derepression of the three error-prone polymerases polB, dinB, and 
umuCD have also been shown to be necessary for the increase in mutation caused by sublethal 
treatment with CFX in E. coli, P. aeruginosa and S. aureus (Cirz et al., 2005, Cirz et al., 2007, Cirz 
et al., 2006, Mo et al., 2016). Further to this, the reduction of mutation induced by CFX seen in 
SOS response-depleted strains was also observed in SOS response-depleted hypermutator 
species of E. coli (E. coli with mutations in mismatch repair) (Cirz & Romesberg, 2006), suggesting 
the MMR was not involved in the restoration of CFX-induced mutations. Although the 
involvement of the error-prone polymerases would explain the increase in SNPs and small 
deletions or insertions seen here, the larger mutations such as the large deletions or the 
loops/amplifications are unlikely to be caused by the error-prone polymerases. In fact, induction 
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of recA-mediated homologous recombination by sublethal CFX is only partially dependent on 
SOS induction (Lopez & Blazquez, 2009), and recombination between divergent sequences 
induced by treatment with sublethal concentrations of CFX has been shown to be independent 
of SOS induction (Lopez et al., 2007). In this case, there is some suggestion that the 
recombination is induced by the RecBCD and RecFOR pathways (Lopez et al., 2007). Overall, 
more work is needed to fully explain how the deletions and duplications/amplifications reported 
here have arisen. However, there is no reason to suspect the DNA gyrase-mediated IR is not 
involved. 
 
6.4 Conclusions 
QIAR assay 
Treatment of E. coli MG1655 with sublethal concentrations of CFX has resulted in an increase 
in resistance to non-quinolone antibiotics. This was not seen when the competitive DNA gyrase 
inhibitor CouA1 was used, nor was it demonstrated with Amp or Kan. Other quinolones including 
SFX, NFX and OA also induced resistance to non-quinolone antibiotics, however MFX did not. 
The Redx compound 5931, which inhibits DNA gyrase by stabilising the cleavage complex was 
demonstrated to induce resistance to other antibiotics although not to the same level as the 
quinolones suggesting the stabilisation of the cleavage complex may be important. Treatment 
of the Keio collection strain parent E. coli BW25113 with sublethal CFX also showed an increase 
in resistance to non-quinolone antibiotics. When the quinolone-resistant E. coli MLS83L strain 
(MG1655 with the GyrAS83L mutation) was tested with sublethal CFX, there was no increase in 
resistance. The hyper-recombination mutants when overexpressed on plasmids did not show 
much difference in resistance over the overexpressed wild-type GyrA and the overexpressed 
I203V/I205V mutant showed a greater increase in resistance over the chromosomally expressed 
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I203V/S204R/I205V protein (NGB345 strain). However, all of these strains when treated with 
sublethal CFX showed resistance to non-quinolone antibiotics. 
Whole genome sequencing 
Whole genome sequencing revealed a number of SNPs and small deletions that explained 
most of the resistance seen. It also showed large-scale genomic modifications that explained 
two of the Cam-resistance mutations. The cause of these large-scale chromosomal modifications 
is unknown and more work here is needed, but DNA gyrase-mediated IR has not been ruled out 
as a potential mechanism. 
 
6.5 Future work 
This part of my PhD work has the most unresolved questions. So much so, that a new PhD 
student will be taking up some of this work from October. 
Firstly, all of the assays done here need to be repeated with a wild-type nfo MG1655 strain. 
I would reassess the antibiotics used in the second selection step and perhaps look to include 
more clinically-relevant antibiotics such as rifampicin or vancomycin. I would also try with the 
antimicrobial peptide microcin B17, which targets DNA gyrase and stabilises the cleavage 
complex but seemingly not in the same way as quinolone antibiotics. Further repetitions of the 
other quinolone and non-quinolone antibiotics need to be done to get a true reflection of the 
induced resistance profile. This is also true for the other strains of E. coli and I would like to 
include some clinically isolated strains in the experiments. I would like to continue to work on 
getting the hyper-recombination mutations into the MG1655 chromosome and to test these 
fully. I would also like to design an assay that would allow us to measure mutation rates either 
by Delbruck and Luria fluctuation assays or through mutation accumulation studies (Pope et al., 
2008). 
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Secondly, I would like to try and work out the mechanism behind the increase in resistance 
after sublethal treatment by CFX. I would like to systematically delete genes or pathways 
involved in SOS response, non-homologous end joining, and other DNA repair pathways 
including the RecBCD and FOR pathways to see how these affect the increase in resistance. 
Thirdly, I would like to confirm and establish what the amplifications are by PCR or long-read 
sequencing. I would also further evaluate the WGS data and try and evaluate the deletion and 
amplification junctions to see if any further information about the likelihood that they are as a 
result of DNA gyrase-mediated IR can be obtained. I would also send more strains for WGS to 
see if the genome modifications continue to occur and do long-read WGS alongside de novo 
assemblies on these to see if any other rearrangements can be discerned. 
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Chapter 7: Discussion and Conclusions 
7.1  Discussion 
IR assays 
λ-based assays 
This project began with attempts to re-establish the assays that were done by Ikeda et al. 
(Ikeda et al., 1982, Ikeda et al., 1984, Ikeda et al., 1980, Ikeda & Shiozaki, 1984) to further study 
the molecular and biochemical reasons for the demonstrated topoisomerase-mediated IR. 
However, the λ-based assays proved to be more problematic than anticipated. There is a notion 
that gyrase-mediated IR as described previously may be an artefact. The translocations seen 
may have been due to the high concentrations of DMSO in the packaging extracts (Kobayashi & 
Ikeda, 1977) and the involvement of gyrase and topoisomerases in IR may be more subtle or 
indirect. 
Non-λ assays 
At the same time, I also worked on optimising a separate non-λ assay to study 
topoisomerase-mediated IR. Despite this assay appearing to be a simpler system in theory, in 
practise it has proved to be more complicated. This complication arose from the DNA substrates 
used in the assay. In particular, the pBR322* plasmid substrate which, due to it being a high-
copy number plasmid, results in a cotransformants that make it difficult to identify 
recombinants. In spite of this difficulty, the non-λ assay still has the potential to be a good system 
for studying IR, particularly if a better DNA substrate can be found. The λ-based assays also still 
have the potential to work as there are still avenues of enquiry that have not been fully explored. 
Both the λ-based and non-λ assays had to be put aside due to time constraints and other assays 
proving more successful. 
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Hyper-recombination mutants 
Ashizawa et al. (1999) identified mutations in GyrA that conferred a hyper-recombination 
phenotype in their assay (in vivo). These were I203V/I205V, L488P and L492P. The L492P mutant 
was purified and tested in an in vitro supercoiling assay. The authors suggested that the reason 
for the hyper-recombination phenotype was that these mutations were causing spontaneous 
double-stranded breaks (DSBs) in the chromosome. This was due to the mutations causing 
instability in the GyrA dimer, or by these mutations causing a defect in the cleavage or religation 
reaction by the enzyme. I had always planned to purify these mutants and use them in the IR 
assays as well as characterise them using biochemical activity assays. However, when the IR 
assays were put aside, I worked on characterising the in vitro activity of all three mutants. 
In Chapter 4, I show that contrary to the phenotype suggested by Ashizawa et al. (1999), 
here none of the mutations increased the amount of natural cleavage of the enzyme, nor were 
there any defects in religation. Moreover, the mutations do not appear to destabilise the GyrA 
dimer. The I203V/I205V mutations seem to reduce the activity the enzyme all round, while the 
L488P and L492P mutations appear to affect the stability of exit gate of the enzyme. How these 
mutations would induce a hyper-recombination phenotype is not immediately obvious. In fact, 
the in vitro activities of these mutants seem counter to a hyper-recombination phenotype. 
I203V/I205V mutations 
To rationalise the unexpected phenotype seen with these mutations, I suggest that the 
reduced activity seen with the I203V/I205V mutations could potentially cause downstream 
effects leading to an accumulation of DSBs and induction of the SOS response. Here, a build-up 
of positive supercoils during replication and transcription could result in replication fork collapse 
and pausing or stalling of both the replication machinery and RNA polymerase. Both of these 
situations have been demonstrated to lead to an increase in DSBs and induction of the SOS 
response (Lilley et al., 1996, Michel et al., 2004, Seol & Neuman, 2016). Alternatively, this could 
also result in a loss of superhelical density in the chromosome. This could affect replication and 
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transcription which may trigger a general stress response (Peter et al., 2004) leading to the 
phenotype described by Ashizawa et al (1999). The I203V/I205V mutant could have a particularly 
severe phenotype when the temperature is increased, as is seen with in the Ashizawa et al. 
(1999) study where the lysogens were shifted to 42°C for induction of the lytic cycle. Transient 
relaxation of DNA has been demonstrated after heat shock at 42°C in vivo, followed by increased 
negative supercoiling (decrease in linking number) upon the shift to higher temperatures 
(Camacho-Carranza et al., 1995, Mizushima et al., 1993, Rui & Tse-Dinh, 2003). Although 
increased relaxation of chromosomal DNA has been shown to increase expression of the 
subunits of DNA gyrase (Dorman & Dorman, 2016, Menzel & Gellert, 1983, Snoep et al., 2002), 
it is not known whether the increase in supercoiling post heat shock is due to an increase in the 
amount of DNA gyrase or whether there is an increase in the activity of the enzyme. In 
Streptococcus sp., there was no significant increase in the presence of gyrA or gyrB transcripts 
at 40°C, suggesting no increase in the expression of these genes at higher temperature (Smoot 
et al., 2001). This may suggest that there is more reliance on the activity of the enzyme at higher 
temperatures, which would amplify the effects of the I203V/I205V mutant leading to DSBs and 
the hyper-recombination phenotype seen by Ashizawa et al. (1999). 
L488P and L492P mutations 
With the L488P and L492P mutants, again a seemingly contradictory in vitro phenotype was 
seen with very low natural cleavage activity observed. However, in comparison to the 
I203V/I205V mutations, these mutants did show a more severe phenotype. The L488P and 
L492P mutations appear to cause defects in the exit or C-gate in GyrA. This could either be by 
interfering with the transduction of information from the DNA-gate to the C-gate, or by causing 
the gate to remain in a closed conformation or to dwell primarily in an open conformation. There 
is little information on how the opening of the C-gate is controlled. It has been demonstrated 
that DNA cleavage and strand passage will occur when the C-gate of DNA gyrase and topo II is 
cross-linked (Roca, 2004, Roca et al., 1996, Williams & Maxwell, 1999b). Moreover, when the C-
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gate in topo II was truncated so that it was thought to be unable to close, there was a loss of 
activity by two orders of magnitude (Martinez-Garcia et al., 2014). This truncated mutant was 
used to demonstrate that the C-gate is necessary for the type IIA topoisomerases to do topology 
simplification (Martinez-Garcia et al., 2014). Topology simplification is the observation that the 
type IIA topoisomerases are able to reduce the level of crossings of DNA through relaxation, 
decatenation and unknotting, beyond thermal equilibrium (Rybenkov et al., 1997). They showed 
that the distribution of topoisomers after relaxation with the truncated C-gate resembled that 
of those after relaxation with topo I, which cannot do topology simplification (Martinez-Garcia 
et al., 2014). They also demonstrated that this truncated topo II could not mediate reverse 
strand passage (Martinez-Garcia et al., 2014). This suggests that the DNA-gate does not readily 
open in this mutant. A similar observation was made by Williams et al. (1999a) who showed a 
75 – 90% reduction in the relaxation of negative supercoils by DNA gyrase when the DNA-gate 
was cross-linked. Relaxation of negative supercoils by gyrase has been demonstrated to occur 
by a reverse-strand passage mechanism (Williams & Maxwell, 1999b). Taking all of this into 
consideration, I suggest that the L488P and the L492P mutations cause the C-gate to dwell in an 
open conformation. I also propose that the reason that Martinez-Garcia et al. (2014) required 
so much more enzyme to see relaxation activity with their truncated topo II was because the 
DNA-gate did not open frequently due to the open C-gate. I also suggest that the DNA-gate may 
have been forced open occasionally. In this case the dimers of the truncated topo II may have 
stayed together due to the N-gate of topo II not being a separate subunit and the fact that the 
NTDs of topo II have been shown to wrap around each other upon dimerisation and strand 
passage (Schmidt et al., 2012). This is unlike DNA gyrase in which the N-gate is made by GyrB, 
which is a separate subunit to GyrA which makes up the DNA-gate and C-gate (Reece & Maxwell, 
1991a, Reece & Maxwell, 1989). Studies have suggested that having two of the three protein 
interfaces closed during the “two-gate mechanism” of strand passage provides stability to the 
enzyme. This prevents the enzyme complex from dissociating during the catalytic cycle which 
would result in DNA DSBs and chromosome fragmentation (Roca, 2004, Roca et al., 1996, 
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Rudolph & Klostermeier, 2013, Williams & Maxwell, 1999b). Thus, in gyrase, if the DNA-gate was 
forced open when the C-gate was also open, this could lead to both subunits dissociating, 
carrying with it the cleaved DNA. This would cause DSBs which would potentially explain the 
hyper-recombination phenotype. 
Subunit exchange 
In Chapter 5, we demonstrated that GyrA, GyrA59 and GyrB can form higher-order 
oligomeric species. GyrA and GyrA59 form multimers in steps of two, whereas GyrB in steps on 
one. The full-length DNA gyrase was also shown to associate in higher-order species, however, 
the stoichiometry of this was not ascertained. The subunits in these higher-order species were 
also demonstrated to be labile and subunit exchange was possible under certain conditions from 
within the multimeric species. This was demonstrated by mixing GyrA with GyrA59 and GyrB and 
incubating them together over at least 18 h. Heterodimers of GyrA and GyrA59 as well as other 
multimeric species were visible at the 18 h time point. This observed subunit exchange occurred 
in the presence of DNA, however, no increase was visible when ciprofloxacin (CFX) was added 
alone or with DNA. The presence of ATP considerably reduced subunit exchange, even in the 
presence of DNA or DNA and CFX, suggesting that the nucleotide contributes to the stability of 
the subunits. Still, this stabilisation by ATP did not entirely preclude exchange between the GyrA 
and GyrA59 subunits as after 48 h there was evidence that heterodimers were formed. This 
raised the question of what effect a high ADP concentration would have on this observed subunit 
exchange. The ATP:ADP ratio has been demonstrated to drop in E. coli in the transition to 
stationary phase before ATP levels recovered in stationary phase (Buckstein et al., 2008). This 
has been demonstrated to have a concomitant relaxation of the chromosome during this time, 
until ATP levels recover (Reyes-Domínguez et al., 2003, Gutiérrez-Estrada et al., 2014, Hsieh et 
al., 1991, van Workum et al., 1996). The return to negative supercoiling when the ATP levels 
recovered was shown to be reliant on the pool of gyrase already present as no increase in the 
expression of the enzyme was detected (Reyes-Domínguez et al., 2003). The relaxation has also 
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been shown to be a direct response to the decrease in ATP:ADP ratio and gyrase was implicated 
in this decrease (van Workum et al., 1996). Taken together, this may suggest that subunit 
exchange could potentially occur in vivo, providing that gyrase associates in these higher-order 
oligomers in vivo as well. GyrA has been previously demonstrated to associate in a hexamer, 
however, this was an asymmetric unit in a crystal of the B. subtilis GyrA subunit (Rudolph & 
Klostermeier, 2013). An interesting feature of this hexameric asymmetric unit is that the DNA-
gate and C-gate of each monomer makes a protein contact with DNA-gate and C-gate of two 
other monomers, in a domain swapping fashion (PDB: 4DDQ). Nonetheless, higher-order 
multimers of GyrA or DNA gyrase have not been demonstrated in vivo. 
Heterodimers of the human topo II isoforms, topo IIα and topo IIβ have been identified in 
vivo and have been found to be active in vitro (Biersack et al., 1996, Gromova et al., 1998). 
However, these have been suggested not to form as a result of subunit exchange and no 
oligomers of the two enzymes were detected (Biersack et al., 1996, Gromova et al., 1998). 
Contrary to this, yeast topo II was demonstrated to form multimers in vitro. The degree of 
multimerisation was concentration dependent, although the multimers were not restricted to 
high concentrations (Vassetzky et al., 1994). When the multimeric species was isolated, it was 
found to be catalytically active, and arguably, more active than the dimeric species (Vassetzky 
et al., 1994). Further to this, another study showed that more than one human topo IIα dimer 
will bind one DNA crossing using atomic force microscopy (AFM) (Alonso-Sarduy et al., 2011). 
Evidently there is no clear consensus in the literature about the formation of higher-order 
oligomers of topoisomerase subunits. This may be due to different methods of detection or 
differing experimental conditions. Vassetzky et al. (1994) have shown that the multimers 
observed with yeast topo II are dependent on a number of factors. Salt concentrations (NaCl) 
above 150 mM were shown to disrupt multimers as was the addition of CaCl2, however in 
contrast, CuSO4 was demonstrated to increase the formation of multimers (Vassetzky et al., 
1994). Furthermore, the level of phosphorylation of topo II was also demonstrated to be 
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important in the formation of multimers; phosphorylation with casein kinase II increased 
aggregation by 20% (Vassetzky et al., 1994). 
When the GyrA and GyrA59 subunits were incubated with GyrB, DNA and ATP under 
supercoiling assay conditions (Chapter 2), there is evidence of a tetrameric species that appears 
to be a heterodimer (GyrA/GyrA59) with the GyrA59 homodimer (GyrA592), that is A592 +AA59. 
This would imply that low levels of subunit exchange are occurring during the catalytic cycle in 
the presence of ATP. This appears contrary to work done previously by Tennyson and Lindsley 
(1997) who showed that eukaryotic topo II is a stable dimer and no subunit exchange occurred 
during the catalytic cycle of the enzyme. It also appears contradictory to work done by Gubaev 
et al. (2016), who demonstrated that there was no subunit exchange visible between subunits 
of DNA gyrase. Both of these studies used two different assays, one using fluorescence and the 
other using inactivated subunits that upon exchange would result in a loss of activity. Two 
further points on those that I have raised in Chapter 5 with regards to these conflicting results. 
The first is that Tennyson and Lindsley (1997) purified and stored the subunits of their subunit 
exchange immunoprecipitation assay in 500 mM NaCl, which, based on the work by Vassetzky 
et al. (1994), would result in a loss of multimers. Based on the work presented here, I suggest 
that subunit exchange occurs within these multimers, the loss of which would result in no 
subunit exchange, as demonstrated by Tennyson and Lindsley (1997). The second point is from 
a discussion with Thomas Germe (JIC). He suggested that based on my multimer theory, and the 
domain swapping seen in the GyrA crystals by Rudolph and Klostermeier (2013) that the 
inactivated subunits could still be active if they formed multimers. With regards to the assay 
presented in Tennyson and Lindsley (1997), subunit exchange could still be occurring in the 
multimers, however, there would be no loss in activity if the multimers contained at least two 
wild-type subunits. With regards to the work by Gubaev et al. (2016), again, if the enzyme was 
to found to be active in multimers, then subunit exchange could still occur without the loss of 
activity. Furthermore, this may also explain the extraordinary results obtained by Gubaev et al. 
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(2016) who proposed that DNA gyrase can negatively supercoil DNA with only one catalytic 
tyrosine. This, of course, is all speculative as there is no evidence that type IIA topoisomerases 
typically function in multimers, and the conventional view is that type II topoisomerases function 
as dimers (Higgins et al., 1978, Klevan & Wang, 1980, Sugino et al., 1980, Vos et al., 2011). I’m 
not necessarily disputing this fact as, although higher-order oligomers are found, dimers are still 
the primary species. However, while not conclusive evidence that this is typical, multimers of 
topo II have been demonstrated to be catalytically active and more than one unit of topo II has 
been observed at DNA crossings previously (Vassetzky et al., 1994, Alonso-Sarduy et al., 2011). 
QIAR 
In Chapter 6, I outlined data showing that treating E. coli with sublethal concentrations of 
CFX can cause resistance to other, non-quinolone antibiotics. This was not seen when I ran the 
assay with the β-lactam ampicillin (Amp) or the aminoglycoside kanamycin (Kan). Nor was it seen 
when E. coli were sublethally treated with the aminocoumarin coumermycin A1 (a non-
quinolone, DNA gyrase inhibitor). This suggested that the stabilisation of cleavage was important 
to this increase in the frequency of resistance. This was corroborated by other cleavage-
stabilising compounds, namely three other quinolones, oxolinic acid, norfloxacin and 
sparfloxacin, and a compound from our collaborators Redx Anti-Infectives, RedX05931. 
Interestingly, moxifloxacin did not appear to show the same increase in resistance as seen with 
the other quinolones. Although this may not be that surprising as it has been shown to be less 
mutagenic than other quinolones (Malik et al., 2012, Schedletzky et al., 1999). The increase in 
resistance was not seen when a strain of E. coli that has mutations in gyrA that confer quinolone 
resistance was used. This suggests that DNA gyrase plays a primary role in this development of 
resistance. Although topo IV has also been demonstrated to be a target for quinolones, DNA 
gyrase has been shown to be the primary target for CFX in E. coli (Drlica et al., 2008, Redgrave 
et al., 2014). Quinolones has have been shown to either target gyrase or topo IV or both 
depending on the species of bacteria and the quinolone itself (Aldred et al., 2014b, Ferrero et 
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al., 1994, Khodursky et al., 1995, Correia et al., 2017). Thus, this effect may be specific to this 
quinolone (CFX) in this species of bacteria (E. coli). Although these data look promising, they 
need to viewed with caution. Most of the results presented here are very preliminary and due 
to time pressures, many of these assays were only run once or twice. To make these data 
statistically robust many of these assays need to be repeated. I believe this will also provide a 
more realistic comparison with the data obtained with sublethal CFX. Overall, I think the assay 
could also be improved to make it more clinically-relevant and to facilitate further study into the 
processing of quinolones in vivo. Despite these caveats, the general trends observed here concur 
with much of the published data, with a number of studies showing that sublethal treatment 
with quinolones increase both mutation rate (Gillespie et al., 2005, Komp Lindgren et al., 2003, 
Thi et al., 2011) and mutation frequency (Andersson & Hughes, 2014, Cirz et al., 2007, Cirz et al., 
2006, Cirz & Romesberg, 2006, Kohanski et al., 2010, Martinez & Baquero, 2000, Mo et al., 2016, 
Tattevin et al., 2009). 
A proportion of resistant and non-resistant strains isolated in the assays were sent for whole 
genome sequencing (WGS) and broadly three types or mutations were observed. The majority 
of these were SNPs and small insertions or deletions (<5 bp), however there was evidence of 
greater chromosomal modifications as well, such as larger deletions (>100 bp) and gene 
amplifications (20 -45 kb). Most of the antibiotic-resistance determinants were identified as due 
to the SNPs and many of these were known variants. However, two chloramphenicol (Cam)-
resistant isolates were found to be resistant as a result of the larger chromosomal modifications, 
namely the deletion of the marR gene in one and the increase in gene copy number (due to the 
amplification) of mdfA in the other. Both of these are known to cause resistance to Cam but they 
have also been suggested to result in an increase in resistance to a number of antibiotics, 
including CFX (Alekshun & Levy, 1997, Cohen et al., 1993, Edgar & Bibi, 1997, Nicoloff et al., 
2007). 
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Based on the literature and the information on the development of mutation due to 
antibiotics therein, I propose that there are two ways resistance develops in response to 
sublethal treatment with CFX. However, these may not be mutually exclusive and are either via 
the SOS response pathway or independent of it. In response to sublethal treatment with CFX, 
the SOS response is upregulated and this results in an increase in survivability alongside an 
increase in mutagenesis (Martinez & Baquero, 2000, Torres-Barceló et al., 2015). This ultimately 
results in SNPs in the genes that confer resistance to CFX itself. When the bacteria are then 
challenged with another antibiotic, this increase in competitive ability under stress as well as the 
increase in mutability can result in SNPs that confer resistance to the secondary selection 
antibiotic. In other words, the pre-exposure to CFX, causes upregulation of a stress response 
that prepares the bacterium to survive further increased stress. Alternatively, the antibiotic-
resistance mutation to the secondary antibiotic does arise randomly in the initial incubation, but 
the fitness of the bacterium that carries this mutation is only increased upon the secondary 
selection (Martinez & Baquero, 2000). The reason that CFX-resistance mutations are not seen 
alongside other resistance mutations is probably due to a decrease in the SOS response, which 
has been found to decline as resistance to CFX is established (Torres-Barceló et al., 2015). Thus, 
the response that has increased the survivability to stress is decreased leaving the CFX-resistant 
cells susceptible to the second antibiotic. Resistance to CFX during sublethal CFX treatment was 
visible in the treated but unselected isolates that were sent for WGS. This suggests that in some 
cases the CFX resistance could have arisen during the initial sublethal incubation and the 
secondary CFX selection was not needed for development of resistance. The SOS response can 
also increase the frequency of resistance via horizontal gene transfer (HGT) (Baharoglu & Mazel, 
2014). It has been demonstrated to increase conjugational transfer of antibiotic resistance 
genes, and increase the incidence of transduction by inducing excision of prophage (Baharoglu 
et al., 2010, Baharoglu et al., 2013, Long et al., 2016). One of the large chromosomal deletions 
seen here was the excision of the e14 prophage. Although there was no gain of resistance 
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through HGT by this, it does reinforce that CFX can contribute to the transfer of resistance from 
one bacterium to another by HGT. 
The second way resistance can be induced by CFX is by recombination. This is evident by the 
deletion of marR and the amplification of mdfA seen in this work which caused resistance to 
Cam. Lopez et al. (Lopez & Blazquez, 2009, Lopez et al., 2007) has demonstrated that CFX can 
induce recombination between homologous and divergent DNA sequences. They show that this 
is mediated by RecA and RecBCD respectively. RecBCD has been demonstrated to be involved in 
the processing of quinolone-induced double-strand breaks in preparation of induction of the 
SOS response (Sutherland & Tse-Dinh, 2010). Although no insertions, inversions or 
translocations are visible in the data I have presented, this may be due to the type of sequencing 
and assemblies that were performed on the data. The lack of insertions is probably due to there 
being no exogenous source of DNA in the bacteria to insert into the chromosome. However, 
there are deletions and the potential gene amplifications present. Although there is evidence 
that SOS-induced translesion polymerases (Pol II, Pol IV and Pol V) can mediate spontaneous 
deletions, the size of these, to the best of my knowledge, is unreported (Andersson et al., 2010). 
However, in eukaryotes, the translesion polymerases have been shown to mediate deletions up 
to 200 kb (Roerink et al., 2014). Thus, it is possible that the translesion polymerases could induce 
the deletions seen here. Gene amplifications are thought to occur randomly in a population of 
bacteria and are not necessarily as a result of a stress response (Andersson & Hughes, 2009, 
Sandegren & Andersson, 2009). However, they have been found previously as the meditators of 
antibiotic resistance as they can cause an increase in gene dosage that can increase resistance 
(Brochet et al., 2008, Hjort et al., 2016, Sun et al., 2009). Gene amplifications are examples of 
adaptive evolution as they have been suggested to provide a short-term solution to selection, 
allowing time for induction of more permanent mutations or potentially the creation of novel 
biochemical solutions (for example through gene fusions) (Andersson & Hughes, 2009). Whether 
these gene amplifications are in response to treatment with CFX, or if they are already present 
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in the population and have been selected for because they decrease susceptibility to CFX, is not 
yet known. Although they were found in isolates resistant to Cam, the mdfA gene is also known 
to increase resistance to CFX (Edgar & Bibi, 1997). Many of these multidrug resistance 
mechanisms show variable resistance to different antibiotics, with some being more efficient 
against specific antibiotics than others (Nilsen et al., 1996, Alekshun & Levy, 1997, Edgar & Bibi, 
1997, Nicoloff et al., 2007). The two that feature in this work, the ones controlled by the MarR 
regulon and the mdfA gene are known to be more effective against Cam, although they do 
decrease susceptibility to CFX and tetracycline (Alekshun & Levy, 1997, Alekshun & Levy, 2007, 
Edgar & Bibi, 1997, Nicoloff et al., 2007, Swick et al., 2011). Therefore, I propose that in these 
cases the mutations are a direct response to the treatment with the sublethal CFX and the 
mitigating effect against Cam is secondary. This implies that in some cases, the quinolone-
induced antimicrobial resistance to other antibiotics is a secondary effect. This also raises the 
issue of the difference between clinical resistance versus microbiological resistance. Clinical 
antibiotic resistance is defined as a failure to clear an infection after adequate antimicrobial 
dosage and schedule are followed. It is often defined as a clinical breakpoint (Cantón & Morosini, 
2011). Microbiological resistance is defined as an acquired mechanism of resistance that makes 
an isolate less susceptible to an antimicrobial. This is regardless of the level of resistance and 
does not necessarily relate to clinical resistance (Cantón & Morosini, 2011). Thus, the resistance 
mechanism acquired against the sublethal CFX may not make the isolate clinically resistant to 
CFX. However, it may make it clinically resistant to another antibiotic, depending on the type of 
resistance. This further emphasises the importance of reducing exposure of bacterial 
communities to sublethal concentrations of quinolones. One solution that has been suggested, 
is a move away from minimum inhibitory concentration (MIC) and to focus more on a mutant 
prevention concentration (Andersson & Hughes, 2010, Andersson & Hughes, 2014, Gullberg et 
al., 2011). 
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Ultimately, the data presented here suggest that CFX can induce mutations and IR. However, 
the exact mechanism behind it has yet to be ascertained and whether DNA gyrase or topo IV are 
directly involved is unknown. 
7.2  Conclusion 
From the data presented in this thesis, the question of how DNA gyrase is involved in IR is 
still unexplained. I have shown that subunit exchange is possible but not necessarily in the way 
that was expected. I propose that type IIA topoisomerases may be catalytically active in 
multimers and subunit exchange can occur in these multimers. The hyper-recombination 
mutations gave results that did not immediately suggest a biochemical reason for their in vivo 
phenotype. Here, I suggest that the I203V/I205V mutant may be perturbing supercoiling which 
has downstream effects leading to increased recombination. While the L488P and L492P 
mutations may be disrupting the exit gate of DNA gyrase which can lead to much lower activity 
and potentially the dissolution of the subunits in extreme circumstances. The treatment of E. 
coli with sublethal CFX has shown that IR may play a role in the increase in the frequency of 
resistance, however, the role of gyrase in this is not clear. The emerging picture is a complicated 
one in that topoisomerases seem to be necessary for IR. However, the prominence of this 
involvement and the molecular details of their role in IR has evaded us. In some cases, it looks 
to be an incidental role, such as in the accumulation of SNPs that result in antibiotic resistance, 
and in others it seems to be more direct, such as in the accumulation of larger chromosomal 
modifications. These may be caused by subunit exchange under the appropriate conditions, 
however, this is merely speculation. Overall, more work is necessary to ascertain the role of 
topoisomerases in IR. 
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List of abbreviations 
A2B2: GyrA/GyrB heterotetramer (functional unit of DNA gyrase) 
ADP: adenosine diphosphate – hydrolysis product of ATP 
ADPNP: 5′-adenylyl β,γ-imidodiphosphate 
Amp: ampicillin 
AmpR: ampicillin resistance 
AP: apurinic/apyrimidinic 
ATP: adenosine triphosphate 
BN: blue-native 
bp: base pair 
CaCl2: calcium chloride 
Cam: chloramphenicol 
CamR: chloramphenicol resistant 
CFU: colony forming unit 
CFX: ciprofloxacin 
CFXR: ciprofloxacin resistant 
cour: coumermycin A1 resistance 
CD: circular dichroism 
CTD: C-terminal domain 
DMSO: dimethyl sulfoxide 
DNA: deoxyribonucleic acid 
DSB: double stranded break 
dsDNA: double-stranded DNA 
DTT: dithiothreitol 
EB: enzyme buffer 
EDTA: ethylenediaminetetraacetic acid 
EtOH: ethanol 
G-segment: gate segment 
gyrase: DNA gyrase 
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GyrA: gyrase A 
GyrA59: CTD truncation of GyrA 
GyrB: gyrase B 
h: hour/s 
HCl: hydrochloric acid 
HSP90: heat shock protein 90 
IR: illegitimate recombination 
K-PCR: KanR gene PCR product 
Kan: kanamycin 
KanR: kanamycin resistance 
kb: kilobase pairs 
KCl: potassium chloride 
kDa: kilo Dalton 
λ: bacteriophage lambda 
LB: Luria-Bertani or Lysogeny Broth Media 
Liq N2: liquid nitrogen 
Lk: linking number 
mAMSA: (9-acridinylamino) methanesulphon-m-anisidide 
Mb: megabase pairs 
MgCl2: magnesium chloride 
MgSO4: magnesium sulphate 
MFX: moxifloxacin 
MIC: minimum inhibitory concentration 
min: minute/s 
NaOAc: sodium acetate 
NaCl: sodium chloride 
nalr: nalidixic acid resistance 
(NH4)2SO4: ammonium sulphate 
NFX: norfloxacin 
NTD: N-terminal domain 
OA: oxolinic acid 
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OD600: optical density at wavelength 600 nm 
PAGE: polyacrylamide gel electrophoresis 
PCR: polymerase chain reaction 
PFU: plaque forming unit 
QIAR: quinolone-induced antimicrobial resistance 
QRDR: quinolone resistance-determining region 
RNA: Ribonucleic acid 
ROS: reactive oxygen species 
s: second/s 
ScAB: DNA gyrase supercoiling assay buffer 
SDM: site-directed mutagenesis 
SDS: sodium dodecyl sulphate 
SFX: sparfloxacin 
SHDIR: short-homology dependent illegitimate recombination 
SHIIR: short-homology independent illegitimate recombination 
SNP: single nucleotide polymorphism 
ssDNA: single-stranded DNA 
t-AML: therapy-related acute myeloid leukaemia 
Tet: tetracycline 
TetR: tetracycline resistant 
Tri: triclosan 
TriR: triclosan resistant 
topo I: topoisomerase I 
topo II: topoisomerase II 
topo III: topoisomerase III 
topo IV: topoisomerase IV 
topo V: topoisomerase V 
topo VI: topoisomerase VI 
topo VIII: topoisomerase VIII 
TOPRIM: topoisomerase-primase 
T-segment: transport segment 
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Tris.HCl: tris(hydroxymethyl)aminomethane hydrochloride 
Tw: twist 
WGS: whole genome sequencing 
WHD: winged-helix domain 
WHO: World Health Organisation 
Wr: writhe 
WT/wt: wild type 
 
 234 
 
References 
Adachi, T., M. Mizuuchi, E.A. Robinson, E. Appella, M.H. O'Dea, M. Gellert & K. Mizuuchi, (1987) 
DNA sequence of the E. coli gyrB gene: application of a new sequencing strategy. Nucleic 
Acids Res. 15: 771-784. 
Adams, D.E., E.M. Shekhtman, E.L. Zechiedrich, M.B. Schmid & N.R. Cozzarelli, (1992) The role 
of topoisomerase IV in partitioning bacterial replicons and the structure of catenated 
intermediates in DNA replication. Cell 71: 277-288. 
Ahmed, W., C. Sala, S.R. Hegde, R.K. Jha, S.T. Cole & V. Nagaraja, (2017) Transcription facilitated 
genome-wide recruitment of topoisomerase I and DNA gyrase. PLoS Genet. 13: 
e1006754. 
Ahuja, H.G., C.A. Felix & P.D. Aplan, (2000) Potential role for DNA topoisomerase II poisons in 
the generation of t(11;20)(p15;q11) translocations. Genes Chromosomes & Cancer 29: 
96-105. 
Akimitsu, N., K. Kamura, S. Toné, A. Sakaguchi, A. Kikuchi, H. Hamamoto & K. Sekimizu, (2003) 
Induction of apoptosis by depletion of DNA topoisomerase IIα in mammalian cells. 
Biochem. Biophys. Res. Commun. 307: 301-307. 
Aldred, K.J., T.R. Blower, R.J. Kerns, J.M. Berger & N. Osheroff, (2016) Fluoroquinolone 
interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against 
wild-type and resistant gyrase. Proc. Natl. Acad. Sci. USA 113: E839-846. 
Aldred, K.J., E.J. Breland, V. Vlckova, M.P. Strub, K.C. Neuman, R.J. Kerns & N. Osheroff, (2014a) 
Role of the water-metal ion bridge in mediating interactions between quinolones and 
Escherichia coli topoisomerase IV. Biochemistry 53: 5558-5567. 
Aldred, K.J., R.J. Kerns & N. Osheroff, (2014b) Mechanism of Quinolone Action and Resistance. 
Biochemistry 53: 1565-1574. 
Aldred, K.J., S.A. McPherson, C.L. Turnbough, Jr., R.J. Kerns & N. Osheroff, (2013) Topoisomerase 
IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic 
basis of quinolone resistance. Nucleic Acids Res. 41: 4628-4639. 
 235 
 
Alekshun, M.N. & S.B. Levy, (1997) Regulation of chromosomally mediated multiple antibiotic 
resistance: the mar regulon. Antimicrob. Agents Chemother. 41: 2067-2075. 
Alekshun, M.N. & S.B. Levy, (2007) Molecular Mechanisms of Antibacterial Multidrug Resistance. 
Cell 128: 1037-1050. 
Ali, J.A., A.P. Jackson, A.J. Howells & A. Maxwell, (1993) The 43-kilodalton N-terminal fragment 
of the DNA gyrase-b protein hydrolyzes ATP and binds coumarin drugs. Biochemistry 32: 
2717-2724. 
Ali, J.A., G. Orphanides & A. Maxwell, (1995) Nucleotide-binding to the 43-kilodalton N-terminal 
fragment of the DNA gyrase-b protein. Biochemistry 34: 9801-9808. 
Alonso-Sarduy, L., C. Roduit, G. Dietler & S. Kasas, (2011) Human topoisomerase II–DNA 
interaction study by using atomic force microscopy. FEBS Lett. 585: 3139-3145. 
Aminov, R., (2017) History of antimicrobial drug discovery: Major classes and health impact. 
Biochem. Pharmacol. 133: 4-19. 
Anderson, P. & J. Roth, (1981) Spontaneous tandem genetic duplications in Salmonella 
typhimurium arise by unequal recombination between rRNA (rrn) cistrons. Proc. Natl. 
Acad. Sci. USA 78: 3113-3117. 
Andersson, D.I. & D. Hughes, (2009) Gene Amplification and Adaptive Evolution in Bacteria. 
Annu. Rev. Genet. 43: 167-195. 
Andersson, D.I. & D. Hughes, (2010) Antibiotic resistance and its cost: is it possible to reverse 
resistance? Nat. Rev. Microbiol. 8: 260-271. 
Andersson, D.I. & D. Hughes, (2014) Microbiological effects of sublethal levels of antibiotics. Nat. 
Rev. Microbiol. 12: 465-478. 
Andersson, D.I., S. Koskiniemi & D. Hughes, (2010) Biological roles of translesion synthesis DNA 
polymerases in eubacteria. Mol. Microbiol. 77: 540-548. 
Andrews, J.M., (2001) Determination of minimum inhibitory concentrations. J. Antimicrob. 
Chemother. 48 Suppl 1: 5-16. 
Aplan, P.D., (2006) Causes of oncogenic chromosomal translocation. Trends in genetics : TIG 22: 
46-55. 
 236 
 
Appleyard, R.K., (1954) Segregation of New Lysogenic Types during Growth of a Doubly 
Lysogenic Strain Derived from Escherichia Coli K12. Genetics 39: 440-452. 
Aratani, Y., T. Andoh & H. Koyama, (1996) Effects of DNA topoisomerase inhibitors on 
nonhomologous and homologous recombination in mammalian cells. Mutat. Res./DNA 
Repair 362: 181-191. 
Aravind, L., L.M. Iyer, T.E. Wellems & L.H. Miller, (2003) Plasmodium biology: Genomic gleanings. 
Cell 115: 771-785. 
Aravind, L., D.D. Leipe & E.V. Koonin, (1998) Toprim--a conserved catalytic domain in type IA and 
II topoisomerases, DnaG-type primases, OLD family nucleases and RecR proteins. 
Nucleic Acids Res. 26: 4205-4213. 
Arber, W., (1983) A Beginner's Guide to Lambda Biology. In: Lambda II. R. Hendrix, J.W. Roberts, 
F.W. Stahl & R.A. Weisberg (eds). Cold Spring Harbour: Cold Spring Harbour Laboratory, 
pp. 381-394. 
Asami, Y., D.W. Jia, K. Tatebayashi, K. Yamagata, M. Tanokura & H. Ikeda, (2002) Effect of the 
DNA topoisomerase II inhibitor VP-16 on illegitimate recombination in yeast 
chromosomes. Gene 291: 251-257. 
Ashizawa, Y., T. Yokochi, Y. Ogata, Y. Shobuike, J. Kato & H. Ikeda, (1999) Mechanism of DNA 
gyrase-mediated illegitimate recombination: Characterization of Escherichia coli gyrA 
mutations that confer hyper-recombination phenotype. J. Mol. Biol. 289: 447-458. 
Ashour, M.E., R. Atteya & S.F. El-Khamisy, (2015) Topoisomerase-mediated chromosomal break 
repair: an emerging player in many games. Nat. Rev. Cancer 15: 137-151. 
Avalos, E., D. Catanzaro, A. Catanzaro, T. Ganiats, S. Brodine, J. Alcaraz & T. Rodwell, (2015) 
Frequency and Geographic Distribution of gyrA and gyrB Mutations Associated with 
Fluoroquinolone Resistance in Clinical Mycobacterium Tuberculosis Isolates: A 
Systematic Review. PLoS ONE 10: e0120470. 
Azarova, A.M., R.K. Lin, Y.C. Tsai, L.F. Liu, C.P. Lin & Y.L. Lyu, (2010) Genistein induces 
topoisomerase IIbeta- and proteasome-mediated DNA sequence rearrangements: 
Implications in infant leukemia. Biochem. Biophys. Res. Commun. 399: 66-71. 
 237 
 
Baba, T., T. Ara, M. Hasegawa, Y. Takai, Y. Okumura, M. Baba, K.A. Datsenko, M. Tomita, B.L. 
Wanner & H. Mori, (2006) Construction of Escherichia coli K-12 in-frame, single-gene 
knockout mutants: the Keio collection. Mol. Syst. Biol. 2: 2006.0008-2006.0008. 
Bae, Y.S., M. Chiba, M. Ohira & H. Ikeda, (1991) A shuttle vector for analysis of illegitimate 
recombination in mammalian cells: effects of DNA topoisomerase inhibitors on deletion 
frequency. Gene 101: 285-289. 
Bae, Y.S., I. Kawasaki, H. Ikeda & L.F. Liu, (1988) Illegitimate recombination mediated by calf 
thymus DNA topoisomerase II in vitro. Proc. Natl. Acad. Sci. USA 85: 2076-2080. 
Bagel, S., V. Hullen, B. Wiedemann & P. Heisig, (1999) Impact of gyrA and parC mutations on 
quinolone resistance, doubling time, and supercoiling degree of Escherichia coli. 
Antimicrob. Agents Chemother. 43: 868-875. 
Baharoglu, Z., D. Bikard & D. Mazel, (2010) Conjugative DNA Transfer Induces the Bacterial SOS 
Response and Promotes Antibiotic Resistance Development through Integron 
Activation. PLoS Genet. 6: e1001165. 
Baharoglu, Z., E. Krin & D. Mazel, (2013) RpoS Plays a Central Role in the SOS Induction by Sub-
Lethal Aminoglycoside Concentrations in Vibrio cholerae. PLoS Genet. 9: e1003421. 
Baharoglu, Z. & D. Mazel, (2014) SOS, the formidable strategy of bacteria against aggressions. 
FEMS Microbiol. Rev. 38: 1126-1145. 
Baird, C.L., M.S. Gordon, D.M. Andrenyak, J.F. Marecek & J.E. Lindsley, (2001) The ATPase 
reaction cycle of yeast DNA topoisomerase II. Slow rates of ATP resynthesis and P(i) 
release. J. Biol. Chem. 276: 27893-27898. 
Baker, N.M., S. Weigand, S. Maar-Mathias & A. Mondragon, (2011) Solution structures of DNA-
bound gyrase. Nucleic Acids Res. 39: 755-766. 
Bakthisaran, R., R. Tangirala & C.M. Rao, (2015) Small heat shock proteins: Role in cellular 
functions and pathology. Biochim. Biophys. Acta 1854: 291-319. 
Baldi, M.I., P. Benedetti, E. Mattoccia & G.P. Tocchini-Valentini, (1980) In vitro catenation and 
decatenation of DNA and a novel eucaryotic ATP-dependent topoisomerase. Cell 20: 
461-467. 
Baldwin, E.L. & N. Osheroff, (2005) Etoposide, topoisomerase II and cancer. Curr. Med. Chem.: 
Anti-Cancer Agents 5: 363-372. 
 238 
 
Bansal, S., D. Sinha, M. Singh, B. Cheng, Y.C. Tse-Dinh & V. Tandon, (2012) 3,4-dimethoxyphenyl 
bis-benzimidazole, a novel DNA topoisomerase inhibitor that preferentially targets 
Escherichia coli topoisomerase I. J. Antimicrob. Chemother. 67: 2882-2891. 
Basu, A., A.C. Parente & Z. Bryant, (2016) Structural dynamics and mechanochemical coupling in 
DNA gyrase. J. Mol. Biol. 428: 1833-1845. 
Basu, A., A.J. Schoeffler, J.M. Berger & Z. Bryant, (2012) ATP binding controls distinct structural 
transitions of Escherichia coli DNA gyrase in complex with DNA. Nat. Struct. Mol. Biol. 
19: 538-546, s531. 
Bates, A.D., J.M. Berger & A. Maxwell, (2011) The ancestral role of ATP hydrolysis in type II 
topoisomerases: prevention of DNA double-strand breaks. Nucleic Acids Res. 39: 6327-
6339. 
Bates, A.D. & A. Maxwell, (2005) DNA Topology, p. 216. Oxford University Press, New York. 
Bates, A.D. & A. Maxwell, (2007) Energy Coupling in Type II Topoisomerases: Why Do They 
Hydrolyze ATP?†. Biochemistry 46: 7929-7941. 
Bates, A.D., M.H. O'Dea & M. Gellert, (1996) Energy coupling in Escherichia coli DNA gyrase:  the 
relationship between nucleotide binding, strand passage, and DNA supercoiling. 
Biochemistry 35: 1408-1416. 
Bauer, D.L.V., R. Marie, K.H. Rasmussen, A. Kristensen & K.U. Mir, (2012) DNA catenation 
maintains structure of human metaphase chromosomes. Nucleic Acids Res. 40: 11428-
11434. 
Beattie, T.R., N. Kapadia, E. Nicolas, S. Uphoff, A.J.M. Wollman, M.C. Leake & R. Reyes-Lamothe, 
(2017) Frequent exchange of the DNA polymerase during bacterial chromosome 
replication. eLife 6: e21763. 
Bellon, S., J.D. Parsons, Y.Y. Wei, K. Hayakawa, L.L. Swenson, P.S. Charifson, J.A. Lippke, R. Aldape 
& C.H. Gross, (2004) Crystal structures of Escherichia coli topoisomerase IV ParE subunit 
(24 and 43 kilodaltons): a single residue dictates differences in novobiocin potency 
against topoisomerase IV and DNA gyrase. Antimicrob. Agents Chemother. 48: 1856-
1864. 
 239 
 
Belova, G.I., R. Prasad, I.V. Nazimov, S.H. Wilson & A.I. Slesarev, (2002) The domain organization 
and properties of individual domains of DNA topoisomerase V, a type 1B topoisomerase 
with DNA repair activities. J. Biol. Chem. 277: 4959-4965. 
Benson, D.A., M. Cavanaugh, K. Clark, I. Karsch-Mizrachi, D.J. Lipman, J. Ostell & E.W. Sayers, 
(2013) GenBank. Nucleic Acids Res. 41: D36-D42. 
Berger, J.M., S.J. Gamblin, S.C. Harrison & J.C. Wang, (1996) Structure and mechanism of DNA 
topoisomerase II. Nature 379: 225-232. 
Bergerat, A., B. de Massy, D. Gadelle, P.C. Varoutas, A. Nicolas & P. Forterre, (1997) An atypical 
topoisomerase II from Archaea with implications for meiotic recombination. Nature 386: 
414-417. 
Bergerat, A., D. Gadelle & P. Forterre, (1994) Purification of a DNA topoisomerase II from the 
hyperthermophilic archaeon Sulfolobus shibatae. A thermostable enzyme with both 
bacterial and eucaryal features. J. Biol. Chem. 269: 27663-27669. 
Bernard, P. & M. Couturier, (1992) Cell killing by the F plasmid CcdB protein involves poisoning 
of DNA-topoisomerase II complexes. J. Mol. Biol. 226: 735-745. 
Bernard, P., K.E. Kézdy, L. Van Melderen, J. Steyaert, L. Wyns, M.L. Pato, P.N. Higgins & M. 
Couturier, (1993) The F Plasmid CcdB Protein Induces Efficient ATP-dependent DNA 
Cleavage by Gyrase. J. Mol. Biol. 234: 534-541. 
Biersack, H., S. Jensen, I. Gromova, I.S. Nielsen, O. Westergaard & A.H. Andersen, (1996) Active 
heterodimers are formed from human DNA topoisomerase II alpha and II beta isoforms. 
Proc. Natl. Acad. Sci. USA 93: 8288-8293. 
Binaschi, M., G. Capranico, L. Dal Bo & F. Zunino, (1997) Relationship between lethal effects and 
topoisomerase II-mediated double-stranded DNA breaks produced by anthracyclines 
with different sequence specificity. Mol. Pharmacol. 51: 1053-1059. 
Birch, R.G. & S.S. Patil, (1985) Preliminary characterization of an antibiotic produced by 
Xanthomonas albilineans which inhibits DNA synthesis in Escherichia coli. Microbiology 
131: 1069-1075. 
Bisacchi, G.S., (2015) Origins of the Quinolone Class of Antibacterials: An Expanded “Discovery 
Story”. J. Med. Chem. 58: 4874-4882. 
 240 
 
Blanc-Potard, A.-B., G. Labesse, N. Figueroa-Bossi & L. Bossi, (2005) Mutation at the “Exit Gate” 
of the Salmonella Gyrase A Subunit Suppresses a Defect in the Gyrase B Subunit. J. 
Bacteriol. 187: 6841-6844. 
Blattner, F.R., G. Plunkett, 3rd, C.A. Bloch, N.T. Perna, V. Burland, M. Riley, J. Collado-Vides, J.D. 
Glasner, C.K. Rode, G.F. Mayhew, J. Gregor, N.W. Davis, H.A. Kirkpatrick, M.A. Goeden, 
D.J. Rose, B. Mau & Y. Shao, (1997) The complete genome sequence of Escherichia coli 
K-12. Science 277: 1453-1462. 
Blázquez, J., A. Couce, J. Rodríguez-Beltrán & A. Rodríguez-Rojas, (2012) Antimicrobials as 
promoters of genetic variation. Curr. Opin. Microbiol. 15: 561-569. 
Bodley, A.L., H.C. Huang, C. Yu & L.F. Liu, (1993) Integration of simian virus 40 into cellular DNA 
occurs at or near topoisomerase II cleavage hot spots induced by VM-26 (teniposide). 
Mol. Cell. Biol. 13: 6190-6200. 
Boles, T.C., J.H. White & N.R. Cozzarelli, (1990) Structure of plectonemically supercoiled DNA. J. 
Mol. Biol. 213: 931-951. 
Bolla, J.-M., S. Alibert-Franco, J. Handzlik, J. Chevalier, A. Mahamoud, G. Boyer, K. Kieć-
Kononowicz & J.-M. Pagès, (2011) Strategies for bypassing the membrane barrier in 
multidrug resistant Gram-negative bacteria. FEBS Lett. 585: 1682-1690. 
Bollimpelli, V.S., P.S. Dholaniya & A.K. Kondapi, (2017) Topoisomerase IIβ and its role in different 
biological contexts. Arch. Biochem. Biophys. 633: 78-84. 
Bonde, M.T., M.S. Klausen, M.V. Anderson, A.I.N. Wallin, H.H. Wang & M.O.A. Sommer, (2014) 
MODEST: a web-based design tool for oligonucleotide-mediated genome engineering 
and recombineering. Nucleic Acids Res. 42: W408-W415. 
Boros, I., G. Pósfai & P. Venetianer, (1984) High-copy-number derivatives of the plasmid cloning 
vector pBR322. Gene 30: 257-260. 
Brazas, M.D., E.B.M. Breidenstein, J. Overhage & R.E.W. Hancock, (2007) Role of Lon, an ATP-
Dependent Protease Homolog, in Resistance of Pseudomonas aeruginosa to 
Ciprofloxacin. Antimicrob. Agents Chemother. 51: 4276-4283. 
Brenner, S., A.O. Stretton & S. Kaplan, (1965) Genetic code: the 'nonsense' triplets for chain 
termination and their suppression. Nature 206: 994-998. 
 241 
 
Brenner, S. & A.O.W. Stretton, (1964) The amber mutation. Journal of Cellular and Comparative 
Physiology 64: 43-49. 
Briñas, L., M. Zarazaga, Y. Sáenz, F. Ruiz-Larrea & C. Torres, (2002) β-Lactamases in Ampicillin-
Resistant Escherichia coli Isolates from Foods, Humans, and Healthy Animals. 
Antimicrob. Agents Chemother. 46: 3156-3163. 
Brochet, M., E. Couvé, M. Zouine, C. Poyart & P. Glaser, (2008) A Naturally Occurring Gene 
Amplification Leading to Sulfonamide and Trimethoprim Resistance in Streptococcus 
agalactiae. J. Bacteriol. 190: 672-680. 
Brody, H., A. Greener & C.W. Hill, (1985) Excision and reintegration of the Escherichia coli K-12 
chromosomal element e14. J. Bacteriol. 161: 1112-1117. 
Bron, S., (1990) Plasmids. In: Molecular biological methods for Bacillus. C.R. Harwood & S.M. 
Cutting (eds). New York: John Wiley & Sons, pp. 75 - 174. 
Brown, E.D. & G.D. Wright, (2016) Antibacterial drug discovery in the resistance era. Nature 529: 
336-343. 
Brown, P. & N. Cozzarelli, (1979) A sign inversion mechanism for enzymatic supercoiling of DNA. 
Science 206: 1081-1083. 
Browne, F.A., C. Clark, B. Bozdogan, B.E. Dewasse, M.R. Jacobs & P.C. Appelbaum, (2002) Single 
and multi-step resistance selection study in Streptococcus pneumoniae comparing 
ceftriaxone with levofloxacin, gatifloxacin and moxifloxacin. Int. J. Antimicrob. Agents 
20: 93-99. 
BSAC, (1991) A guide to sensitivity testing. Report of the Working Party on Antibiotic Sensitivity 
Testing of the British Society for Antimicrobial Chemotherapy. J. Antimicrob. Chemother. 
27 Suppl D: 1-50. 
Buckstein, M.H., J. He & H. Rubin, (2008) Characterization of Nucleotide Pools as a Function of 
Physiological State in Escherichia coli. J. Bacteriol. 190: 718-726. 
Buhler, C., J.H. Lebbink, C. Bocs, R. Ladenstein & P. Forterre, (2001) DNA topoisomerase VI 
generates ATP-dependent double-strand breaks with two-nucleotide overhangs. J. Biol. 
Chem. 276: 37215-37222. 
 242 
 
Bullock, P., J.J. Champoux & M. Botchan, (1985) Association of crossover points with 
topoisomerase I cleavage sites: a model for nonhomologous recombination. Science 
230: 954-958. 
Burlison, J.A., L. Neckers, A.B. Smith, A. Maxwell & B.S.J. Blagg, (2006) Novobiocin:  Redesigning 
a DNA Gyrase Inhibitor for Selective Inhibition of Hsp90. J. Am. Chem. Soc. 128: 15529-
15536. 
Bush, K., P. Courvalin, G. Dantas, J. Davies, B. Eisenstein, P. Huovinen, G.A. Jacoby, R. Kishony, 
B.N. Kreiswirth, E. Kutter, S.A. Lerner, S. Levy, K. Lewis, O. Lomovskaya, J.H. Miller, S. 
Mobashery, L.J.V. Piddock, S. Projan, C.M. Thomas, A. Tomasz, P.M. Tulkens, T.R. Walsh, 
J.D. Watson, J. Witkowski, W. Witte, G. Wright, P. Yeh & H.I. Zgurskaya, (2011) Tackling 
antibiotic resistance. Nat Rev Micro 9: 894-896. 
Bush, N.G., K. Evans-Roberts & A. Maxwell, (2015) DNA Topoisomerases. EcoSal Plus 6. 
Calderwood, S.K., (2016) A critical role for topoisomerase IIb and DNA double strand breaks in 
transcription. Transcription 7: 75-83. 
Camacho-Carranza, R., J. Membrillo-Hernández, J. Ramírez-Santos, J. Castro-Dorantes, V. 
Chagoya de Sánchez & M.C. Gómez-Eichelmann, (1995) Topoisomerase activity during 
the heat shock response in Escherichia coli K-12. J. Bacteriol. 177: 3619-3622. 
Campbell, A., (1971) Genetic Structure. In: The Bacteriophage Lambda. A.D. Hershey (ed). Cold 
Spring Harbor: Cold Spring Harbor Laboratory, pp. 13-44. 
Campoy, S., A. Hervàs, N. Busquets, I. Erill, L. Teixidó & J. Barbé, (2006) Induction of the SOS 
response by bacteriophage lytic development in Salmonella enterica. Virology 351: 360-
367. 
Candel, F.J. & M. Peñuelas, (2017) Delafloxacin: design, development and potential place in 
therapy. Drug Des. Dev. Ther. 11: 881-891. 
Cantón, R. & M.-I. Morosini, (2011) Emergence and spread of antibiotic resistance following 
exposure to antibiotics. FEMS Microbiol. Rev. 35: 977-991. 
Capranico, G., J. Marinello & G. Chillemi, (2017) Type I DNA Topoisomerases. J. Med. Chem. 60: 
2169-2192. 
 243 
 
Capranico, G., S. Tinelli, C.A. Austin, M.L. Fisher & F. Zunino, (1992) Different patterns of gene 
expression of topoisomerase II isoforms in differentiated tissues during murine 
development. Biochim. Biophys. Acta 1132: 43-48. 
Carter, P., (1986) Site-directed mutagenesis. Biochem. J. 237: 1-7. 
Carucci, D.J., M.J. Gardner, H. Tettelin, L.M. Cummings, H.O. Smith, M.D. Adams, S.L. Hoffman & 
J.C. Venter, (1998) The malaria genome sequencing project. Expert Rev Mol Med 1998: 
1-9. 
Casali, N., (2003) Escherichia coli Host Strains. In: E. coli Plasmid Vectors: Methods and 
Applications. N. Casali & A. Preston (eds). Totowa, NJ: Humana Press, pp. 27-48. 
Cebrián, J., A. Castán, V. Martínez, M.J. Kadomatsu-Hermosa, C. Parra, M.J. Fernández-Nestosa, 
C. Schaerer, P. Hernández, D.B. Krimer & J.B. Schvartzman, (2015) Direct evidence for 
the formation of precatenanes during DNA replication. J. Biol. Chem. 290: 13725-13735. 
Champoux, J.J., (1981) DNA is linked to the rat liver DNA nicking-closing enzyme by a 
phosphodiester bond to tyrosine. J. Biol. Chem. 256: 4805-4809. 
Champoux, J.J. & R. Dulbecco, (1972) An activity from mammalian cells that untwists 
superhelical DNA--a possible swivel for DNA replication (polyoma-ethidium bromide-
mouse-embryo cells-dye binding assay). Proc. Natl. Acad. Sci. USA 69: 143-146. 
Chan, P.F., T. Germe, B.D. Bax, J. Huang, R.K. Thalji, E. Bacqué, A. Checchia, D. Chen, H. Cui, X. 
Ding, K. Ingraham, L. McCloskey, K. Raha, V. Srikannathasan, A. Maxwell & R.A. 
Stavenger, (2017) Thiophene antibacterials that allosterically stabilize DNA-cleavage 
complexes with DNA gyrase. Proc. Natl. Acad. Sci. USA 114: E4492-E4500. 
Chan, P.F., J. Huang, B.D. Bax & M.N. Gwynn, (2014) Recent Developments in Inhibitors of 
Bacterial Type IIA Topoisomerases. In: Antibiotics: Targets, Mechanisms and Resistance. 
C.O. Gualerzi, L. Brandi, A. Fabbretti & C.L. Pon (eds). Weinheim, Germany: Wiley-VCH 
Verlag GmbH & Co, pp. 263 - 297. 
Chang, A.C. & S.N. Cohen, (1978) Construction and characterization of amplifiable multicopy 
DNA cloning vehicles derived from the P15A cryptic miniplasmid. J. Bacteriol. 134: 1141-
1156. 
 244 
 
Chatterji, M., S. Unniraman, A. Maxwell & V. Nagaraja, (2000) The additional 165 amino acids in 
the B Protein of Escherichia coli DNA gyrase have an important role in DNA binding. J. 
Biol. Chem. 275: 22888-22894. 
Cheng, B., I.F. Liu & Y.C. Tse-Dinh, (2007) Compounds with antibacterial activity that enhance 
DNA cleavage by bacterial DNA topoisomerase I. J. Antimicrob. Chemother. 59: 640-645. 
Cheng, B., S. Shukla, S. Vasunilashorn, S. Mukhopadhyay & Y.C. Tse-Dinh, (2005) Bacterial cell 
killing mediated by topoisomerase I DNA cleavage activity. J. Biol. Chem. 280: 38489-
38495. 
Chiba, M., H. Shimizu, A. Fujimoto, H. Nashimoto & H. Ikeda, (1989) Common sites for 
recombination and cleavage mediated by bacteriophage T4 DNA topoisomerase in vitro. 
J. Biol. Chem. 264: 12785-12790. 
Cho, H.S., S.S. Lee, K.D. Kim, I. Hwang, J.S. Lim, Y.I. Park & H.S. Pai, (2004) DNA gyrase is involved 
in chloroplast nucleoid partitioning. Plant Cell 16: 2665-2682. 
Cirz, R.T., J.K. Chin, D.R. Andes, V. de Crecy-Lagard, W.A. Craig & F.E. Romesberg, (2005) 
Inhibition of mutation and combating the evolution of antibiotic resistance. PLoS Biol. 
3: e176. 
Cirz, R.T., M.B. Jones, N.A. Gingles, T.D. Minogue, B. Jarrahi, S.N. Peterson & F.E. Romesberg, 
(2007) Complete and SOS-mediated response of Staphylococcus aureus to the antibiotic 
ciprofloxacin. J. Bacteriol. 189: 531-539. 
Cirz, R.T., B.M. O'Neill, J.A. Hammond, S.R. Head & F.E. Romesberg, (2006) Defining the 
Pseudomonas aeruginosa SOS response and its role in the global response to the 
antibiotic ciprofloxacin. J. Bacteriol. 188: 7101-7110. 
Cirz, R.T. & F.E. Romesberg, (2006) Induction and inhibition of ciprofloxacin resistance-
conferring mutations in hypermutator bacteria. Antimicrob. Agents Chemother. 50: 220-
225. 
Clarke, D.J., A.C. Vas, C.A. Andrews, L.A. Diaz-Martinez & J.F. Gimenez-Abian, (2006) 
Topoisomerase II checkpoints: universal mechanisms that regulate mitosis. Cell Cycle 5: 
1925-1928. 
 245 
 
Clavijo, B., G. Garcia Accinelli, J. Wright, D. Heavens, K. Barr, L. Yanes & F. Di Palma, (2017) 
W2RAP: a pipeline for high quality, robust assemblies of large complex genomes from 
short read data. bioRxiv. 
Cobbe, N. & M.M.S. Heck, (2000) Review: SMCs in the World of Chromosome Biology— From 
Prokaryotes to Higher Eukaryotes. J. Struct. Biol. 129: 123-143. 
Cohen, S.P., H. Hächler & S.B. Levy, (1993) Genetic and functional analysis of the multiple 
antibiotic resistance (mar) locus in Escherichia coli. J. Bacteriol. 175: 1484-1492. 
Collin, F., S. Karkare & A. Maxwell, (2011) Exploiting bacterial DNA gyrase as a drug target: 
current state and perspectives. Appl. Microbiol. Biotechnol. 92: 479-497. 
Confalonieri, F., C. Elie, M. Nadal, C. de La Tour, P. Forterre & M. Duguet, (1993) Reverse gyrase: 
a helicase-like domain and a type I topoisomerase in the same polypeptide. Proc. Natl. 
Acad. Sci. USA 90: 4753-4757. 
Conrad, T.M., A.R. Joyce, M.K. Applebee, C.L. Barrett, B. Xie, Y. Gao & B.Ø. Palsson, (2009) 
Whole-genome resequencing of Escherichia coli K-12 MG1655 undergoing short-term 
laboratory evolution in lactate minimal media reveals flexible selection of adaptive 
mutations. Genome Biol. 10: R118. 
Corbett, K.D., P. Benedetti & J.M. Berger, (2007) Holoenzyme assembly and ATP-mediated 
conformational dynamics of topoisomerase VI. Nat. Struct. Mol. Biol. 14: 611-619. 
Corbett, K.D. & J.M. Berger, (2003) Structure of the topoisomerase VI-B subunit: implications for 
type II topoisomerase mechanism and evolution. EMBO J. 22: 151-163. 
Corbett, K.D. & J.M. Berger, (2005) Structural dissection of ATP turnover in the prototypical GHL 
ATPase TopoVI. Structure 13: 873-882. 
Corbett, K.D., A.J. Schoeffler, N.D. Thomsen & J.M. Berger, (2005) The structural basis for 
substrate specificity in DNA topoisomerase IV. J. Mol. Biol. 351: 545-561. 
Corbett, K.D., R.K. Shultzaberger & J.M. Berger, (2004) The C-terminal domain of DNA gyrase A 
adopts a DNA-bending β-pinwheel fold. Proc. Natl. Acad. Sci. USA 101: 7293-7298. 
Correia, S., P. Poeta, M. Hébraud, J.L. Capelo & G. Igrejas, (2017) Mechanisms of quinolone 
action and resistance: where do we stand? J. Med. Microbiol. 66: 551-559. 
 246 
 
Corvec, S., N. Caroff, E. Espaze, J. Marraillac & A. Reynaud, (2002) −11 Mutahon in the ampC 
Promoter Increasing Resistance to β-Lactams in a Clinical Escherichia coli Strain. 
Antimicrob. Agents Chemother. 46: 3265-3267. 
Costenaro, L., J.G. Grossmann, C. Ebel & A. Maxwell, (2005) Small-angle X-ray scattering reveals 
the solution structure of the full-length DNA gyrase a subunit. Structure 13: 287-296. 
Costenaro, L., J.G. Grossmann, C. Ebel & A. Maxwell, (2007) Modular structure of the full-length 
DNA gyrase B subunit revealed by small-angle X-ray scattering. Structure 15: 329-339. 
Cove, M.E., A.P. Tingey & A. Maxwell, (1997) DNA gyrase can cleave short DNA fragments in the 
presence of quinolone drugs. Nucleic Acids Res. 25: 2716-2722. 
Cowell, I.G. & C.A. Austin, (2012) Mechanism of generation of therapy related leukemia in 
response to anti-topoisomerase II agents. Int. J. Env. Res. Public Health 9: 2075-2091. 
Crisona, N.J., T.R. Strick, D. Bensimon, V. Croquette & N.R. Cozzarelli, (2000) Preferential 
relaxation of positively supercoiled DNA by E. coli topoisomerase IV in single-molecule 
and ensemble measurements. Genes Dev. 14: 2881-2892. 
Critchlow, S.E. & A. Maxwell, (1996) DNA Cleavage Is Not Required for the Binding of Quinolone 
Drugs to the DNA Gyrase−DNA Complex. Biochemistry 35: 7387-7393. 
Cunningham, E.L. & J.M. Berger, (2005) Unraveling the early steps of prokaryotic replication. 
Curr. Opin. Struct. Biol. 15: 68-76. 
Daley, J.M., C. Zakaria & D. Ramotar, (2010) The endonuclease IV family of apurinic/apyrimidinic 
endonucleases. Mutat. Res. - Rev. Mut. Res. 705: 217-227. 
Dalhoff, A., (2012) Global Fluoroquinolone Resistance Epidemiology and Implictions for Clinical 
Use. Interdisciplinary Perspectives on Infectious Diseases 2012: 37. 
Daniels, D.L., J.L. Schroeder, W. Syzbalski, F. Sanger & F.R. Blattner, (1983) A Molecular Map of 
Coliphage Lambda. In: Lambda II. R.W. Hendrix, J.W. Roberts, F.W. Stahl & R.A. Weisberg 
(eds). Cold Spring Harbour: Cold Spring Habour Laboratory, pp. 469 - 517. 
Dao-Thi, M.-H., L. Van Melderen, E. De Genst, H. Afif, L. Buts, L. Wyns & R. Loris, (2005) Molecular 
basis of gyrase poisoning by the addiction toxin CcdB. J. Mol. Biol. 348: 1091-1102. 
 247 
 
Dar, M.A., A. Sharma, N. Mondal & S.K. Dhar, (2007) Molecular cloning of apicoplast-targeted 
Plasmodium falciparum DNA gyrase genes: unique intrinsic ATPase activity and ATP-
independent dimerization of PfGyrB subunit. Eukaryot. Cell 6: 398-412. 
Darmon, E. & D.R.F. Leach, (2014) Bacterial Genome Instability. Microbiol. Mol. Biol. Rev. 78: 1-
39. 
Datsenko, K.A. & B.L. Wanner, (2000) One-step inactivation of chromosomal genes in Escherichia 
coli K-12 using PCR products. Proc. Natl. Acad. Sci. USA 97: 6640-6645. 
Davies, J. & D. Davies, (2010) Origins and evolution of antibiotic resistance. Microbiol. Mol. Biol. 
Rev. 74: 417-433. 
Davis, R.W., D. Botstein & J.R. Roth, (1980) Advanced Bacterial Genetics: A Manual for Genetic 
Engineering, p. 254. Cold Spring Harbour Laboratory, Cold Spring Harbour. 
Deibler, R.W., S. Rahmati & E.L. Zechiedrich, (2001) Topoisomerase IV, alone, unknots DNA in E. 
coli. Genes Dev. 15: 748-761. 
Deng, S., R.A. Stein & N.P. Higgins, (2005) Organization of supercoil domains and their 
reorganization by transcription. Mol. Microbiol. 57: 1511-1521. 
Deweese, J.E., M.A. Osheroff & N. Osheroff, (2009) DNA Topology and Topoisomerases. Biochem 
Mol Biol Educ 37: 2-10. 
Digate, R.J. & K.J. Marians, (1989) Molecular cloning and DNA sequence analysis of Escherichia 
coli topb, the gene encoding topoisomerase III. J. Biol. Chem. 264: 17924-17930. 
Digate, R.J. & K.J. Marians, (1992) Escherichia coli topoisomerase III catalyzed cleavage of RNA. 
J. Biol. Chem. 267: 20532-20535. 
Dillingham, M.S. & S.C. Kowalczykowski, (2008) RecBCD Enzyme and the Repair of Double-
Stranded DNA Breaks. Microbiol. Mol. Biol. Rev. 72: 642-671. 
DiNardo, S., K. Voelkel & R. Sternglanz, (1984) DNA topoisomerase II mutant of Saccharomyces 
cerevisiae: topoisomerase II is required for segregation of daughter molecules at the 
termination of DNA replication. Proc. Natl. Acad. Sci. USA 81: 2616-2620. 
Dinardo, S., K.A. Voelkel, R. Sternglanz, A.E. Reynolds & A. Wright, (1982) Escherichia coli DNA 
topoisomerase I mutants have compensatory mutations in DNA gyrase genes. Cell 31: 
43-51. 
 248 
 
Domagala, J.M., L.D. Hanna, C.L. Heifetz, M.P. Hutt, T.F. Mich, J.P. Sanchez & M. Solomon, (1986) 
New structure-activity relationships of the quinolone antibacterials using the target 
enzyme. The development and application of a DNA gyrase assay. J. Med. Chem. 29: 
394-404. 
Dong, K.C. & J.M. Berger, (2007) Structural basis for gate-DNA recognition and bending by type 
IIA topoisomerases. Nature 450: 1201-1205. 
Dong, Y., C. Xu, X. Zhao, J. Domagala & K. Drlica, (1998) Fluoroquinolone Action against 
Mycobacteria: Effects of C-8 Substituents on Growth, Survival, and Resistance. 
Antimicrob. Agents Chemother. 42: 2978-2984. 
Dorman, C.J. & M.J. Dorman, (2016) DNA supercoiling is a fundamental regulatory principle in 
the control of bacterial gene expression. Biophys Rev 8: 209-220. 
Dörr, T., K. Lewis & M. Vulić, (2009) SOS Response Induces Persistence to Fluoroquinolones in 
Escherichia coli. PLoS Genet. 5: e1000760. 
Dove, S.L. & C.J. Dorman, (1994) The site-specific recombination system regulating expression 
of the type 1 fimbrial subunit gene of Escherichia coli is sensitive to changes in DNA 
supercoiling. Mol. Microbiol. 14: 975-988. 
Drake, F.H., G.A. Hofmann, H.F. Bartus, M.R. Mattern, S.T. Crooke & C.K. Mirabelli, (1989a) 
Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase 
II. Biochemistry 28: 8154-8160. 
Drake, F.H., G.A. Hofmann, S.M. Mong, J.O. Bartus, R.P. Hertzberg, R.K. Johnson, M.R. Mattern 
& C.K. Mirabelli, (1989b) In vitro and intracellular inhibition of topoisomerase II by the 
antitumor agent merbarone. Cancer Res. 49: 2578-2583. 
Drlica, K., (1992) Control of bacterial DNA supercoiling. Mol. Microbiol. 6: 425-433. 
Drlica, K., H. Hiasa, R. Kerns, M. Malik, A. Mustaev & X. Zhao, (2009) Quinolones: Action and 
resistance updated. Curr. Top. Med. Chem. 9: 981-998. 
Drlica, K. & M. Malik, (2003) Fluoroquinolones: Action and resistance. Curr. Top. Med. Chem. 3: 
249-282. 
Drlica, K., M. Malik, R.J. Kerns & X. Zhao, (2008) Quinolone-mediated bacterial death. 
Antimicrob. Agents Chemother. 52: 385-392. 
 249 
 
Drlica, K., A. Mustaev, T.R. Towle, G. Luan, R.J. Kerns & J.M. Berger, (2014) Bypassing 
Fluoroquinolone Resistance with Quinazolinediones: Studies of Drug–Gyrase–DNA 
Complexes Having Implications for Drug Design. ACS Chemical Biology 9: 2895-2904. 
Duderstadt, K.E., R. Reyes-Lamothe, A.M. van Oijen & D.J. Sherratt, (2014) Replication-Fork 
Dynamics. Cold. Spring. Harb. Perspect. Biol. 6: a010157. 
Durrieu, F., K. Samejima, J.M. Fortune, S. Kandels-Lewis, N. Osheroff & W.C. Earnshaw, (2000) 
DNA topoisomerase IIalpha interacts with CAD nuclease and is involved in chromatin 
condensation during apoptotic execution. Curr. Biol. 10: 923-926. 
Dutta, R. & M. Inouye, (2000) GHKL, an emergent ATPase/kinase superfamily. Trends Biochem. 
Sci. 25: 24-28. 
Echols, H., (1971) Regulation of Lytic Development. In: The Bacteriophage Lambda. A.D. Hershey 
(ed). Cold Spring Harbour: Cold Spring Harbour Laboratory, pp. 247-270. 
Echols, H., (1986) Bacteriophage λ development: temporal switches and the choice of lysis or 
lysogeny. Trends Genet. 2: 26-30. 
Edgar, R. & E. Bibi, (1997) MdfA, an Escherichia coli multidrug resistance protein with an 
extraordinarily broad spectrum of drug recognition. J. Bacteriol. 179: 2274-2280. 
Edwards, M.J., (2009) The mode of action of Simocyclinone D8; a novel inhibitor of DNA gyrase. 
In: John Innes Centre, Biological Chemistry. Norwich, United Kingdom: University of East 
Anglia, pp. 
Edwards, M.J., R.H. Flatman, L.A. Mitchenall, C.E. Stevenson, T.B. Le, T.A. Clarke, A.R. McKay, 
H.P. Fiedler, M.J. Buttner, D.M. Lawson & A. Maxwell, (2009) A crystal structure of the 
bifunctional antibiotic simocyclinone D8, bound to DNA gyrase. Science 326: 1415-1418. 
Edwards, M.J., M.A. Williams, A. Maxwell & A.R. McKay, (2011) Mass Spectrometry Reveals That 
the Antibiotic Simocyclinone D8 Binds to DNA Gyrase in a “Bent-Over” Conformation: 
Evidence of Positive Cooperativity in Binding. Biochemistry 50: 3432-3440. 
Eisen, H. & M. Ptashne, (1971) Regulation of Repressor Synthesis. In: The Bacteriophage Lambda. 
A.D. Hershey (ed). Cold Spring Harbour: Cold Spring Harbour Laboratory, pp. 239-245. 
El Sayyed, H., L. Le Chat, E. Lebailly, E. Vickridge, C. Pages, F. Cornet, M. Cosentino Lagomarsino 
& O. Espéli, (2016) Mapping Topoisomerase IV Binding and Activity Sites on the E. coli 
Genome. PLoS Genet. 12: e1006025. 
 250 
 
Elguero, M.E., M. de Campos-Nebel & M. González-Cid, (2012) DNA-PKcs-dependent NHEJ 
pathway supports the progression of topoisomerase II poison-induced chromosome 
aberrant cells. Environ. Mol. Mutag. 53: 608-618. 
Emmerson, A.M. & A.M. Jones, (2003) The quinolones: decades of development and use. J. 
Antimicrob. Chemother. 51: 13-20. 
Espeli, O. & K.J. Marians, (2004) Untangling intracellular DNA topology. Mol. Microbiol. 52: 925-
931. 
Fang, F.C., (2013) Antibiotic and ROS linkage questioned. Nat. Biotechnol. 31: 415-416. 
Feiss, M. & A. Becker, (1983) DNA packaging and cutting. In: Lambda II. R. Hendrix, J.W. Roberts, 
F.W. Stahl & R.A. Weisberg (eds). Cold Spring Harbour, New York: Cold Spring Harbour 
Laboratory, pp. 305-330. 
Feiss, M., R.A. Fisher, M.A. Crayton & C. Egner, (1977) Packaging of the bacteriophage lambda 
chromosome: effect of chromosome length. Virology 77: 281-293. 
Fernández, L. & R.E.W. Hancock, (2012) Adaptive and Mutational Resistance: Role of Porins and 
Efflux Pumps in Drug Resistance. Clin. Microbiol. Rev. 25: 661-681. 
Ferrero, L., B. Cameron, B. Manse, D. Lagneaux, J. Crouzet, A. Famechon & F. Blanche, (1994) 
Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a 
primary target of fluoroquinolones. Mol. Microbiol. 13: 641-653. 
Fisher, L.M., K. Mizuuchi, M.H. O'Dea, H. Ohmori & M. Gellert, (1981) Site-specific interaction of 
DNA gyrase with DNA. Proc. Natl. Acad. Sci. USA 78: 4165-4169. 
Flatman, R.H., A.J. Howells, L. Heide, H.P. Fiedler & A. Maxwell, (2005) Simocyclinone D8, an 
inhibitor of DNA gyrase with a novel mode of action. Antimicrob. Agents Chemother. 49: 
1093-1100. 
Fogg, J.M., N. Kolmakova, I. Rees, S. Magonov, H. Hansma, J.J. Perona & E.L. Zechiedrich, (2006) 
Exploring writhe in supercoiled minicircle DNA. J Phys Condens Matter 18: S145-s159. 
Fogg, P.C.M., H.E. Allison, J.R. Saunders & A.J. McCarthy, (2010) Bacteriophage Lambda: a 
Paradigm Revisited. J. Virol. 84: 6876-6879. 
Forterre, P., (2002) A hot story from comparative genomics: reverse gyrase is the only 
hyperthermophile-specific protein. Trends Genet. 18: 236-238. 
 251 
 
Forterre, P., G. Mirambeau, C. Jaxel, M. Nadal & M. Duguet, (1985) High positive supercoiling in 
vitro catalyzed by an ATP and polyethylene glycol-stimulated topoisomerase from 
Sulfolobus acidocaldarius. EMBO J. 4: 2123-2128. 
Foster, P.L., H. Lee, E. Popodi, J.P. Townes & H. Tang, (2015) Determinants of spontaneous 
mutation in the bacterium Escherichia coli as revealed by whole-genome sequencing. 
Proc. Natl. Acad. Sci. USA 112: E5990-E5999. 
Franklin, N., (1971) Illegitimate Recombination. In: The Bacteriophage Lambda. A.D. Hershey 
(ed). Cold Spring Harbour, New York: Cold Spring Harbour Laboratory, pp. 175 - 194. 
Freddolino, P.L., S. Amini & S. Tavazoie, (2012) Newly Identified Genetic Variations in Common 
Escherichia coli MG1655 Stock Cultures. J. Bacteriol. 194: 303-306. 
Friedman, D.I. & D.L. Court, (2001) Bacteriophage lambda: alive and well and still doing its thing. 
Curr. Opin. Microbiol. 4: 201-207. 
Friedman, D.I. & M.E. Gottesman, (1983) Lytic Mode of Lambda Development. In: Lambda II. R. 
Hendrix, J.W. Roberts, F.W. Stahl & R.A. Weisberg (eds). Cold Spring Harbor: Cold Spring 
Harbor Laboratory, pp. 21-51. 
Fu, G., J. Wu, W. Liu, D. Zhu, Y. Hu, J. Deng, X.-E. Zhang, L. Bi & D.-C. Wang, (2009) Crystal 
structure of DNA gyrase B′ domain sheds lights on the mechanism for T-segment 
navigation. Nucleic Acids Res. 37: 5908-5916. 
Fujii, N., S. Matsumoto, K. Hiroki & L. Takemoto, (2001) Inversion and isomerization of Asp-58 
residue in human αA-crystallin from normal aged lenses and cataractous lenses. 
Biochim. Biophys. Acta 1549: 179-187. 
Fukuoka, H., Y. Inoue, S. Terasawa, H. Takahashi & A. Ishijima, (2010) Exchange of rotor 
components in functioning bacterial flagellar motor. Biochem. Biophys. Res. Commun. 
394: 130-135. 
Funnell, B.E., T.A. Baker & A. Kornberg, (1986) Complete enzymatic replication of plasmids 
containing the origin of the Escherichia coli chromosome. J. Biol. Chem. 261: 5616-5624. 
Furniss, K.L., H.J. Tsai, J.A. Byl, A.B. Lane, A.C. Vas, W.S. Hsu, N. Osheroff & D.J. Clarke, (2013) 
Direct monitoring of the strand passage reaction of DNA topoisomerase II triggers 
checkpoint activation. PLoS Genet. 9: e1003832. 
 252 
 
Gadelle, D., M. Graille & P. Forterre, (2006) The HSP90 and DNA topoisomerase VI inhibitor 
radicicol also inhibits human type II DNA topoisomerase. Biochem. Pharmacol. 72: 1207-
1216. 
Gadelle, D., M. Krupovic, K. Raymann, C. Mayer & P. Forterre, (2014) DNA topoisomerase VIII: a 
novel subfamily of type IIB topoisomerases encoded by free or integrated plasmids in 
Archaea and Bacteria. Nucleic Acids Res. 42: 8578-8591. 
Ganguly, A., Y. del Toro Duany & D. Klostermeier, (2013) Reverse Gyrase Transiently Unwinds 
Double-Stranded DNA in an ATP-Dependent Reaction. J. Mol. Biol. 425: 32-40. 
Gao, W., I.R. Monk, N.J. Tobias, S.L. Gladman, T. Seemann, T.P. Stinear & B.P. Howden, (2015) 
Large tandem chromosome expansions facilitate niche adaptation during persistent 
infection with drug-resistant Staphylococcus aureus. Microbial Genomics 1: e000026. 
Gari, E., N. Figueroa-Bossi, A.B. Blanc-Potard, F. Spirito, M.B. Schmid & L. Bossi, (1996) A class of 
gyrase mutants of Salmonella typhimurium show quinolone-like lethality and require 
rec functions for viability. Mol. Microbiol. 21: 111-122. 
Gelband, H., M. Miller-Petrie, S. Pant, S. Gandra, J. Levinson, D. Barter, A. White & R. 
Laxminarayan, (2015) State of the World’s Antibiotics. In. E.a.P. Center for Disease 
Dynamics (ed). CDDEP: Washington, D.C., pp. 
Gellert, M., L.M. Fisher & M.H. O'Dea, (1979) DNA gyrase: purification and catalytic properties 
of a fragment of gyrase B protein. Proc. Natl. Acad. Sci. USA 76: 6289-6293. 
Gellert, M., K. Mizuuchi, M.H. O'Dea, T. Itoh & J.-I. Tomizawa, (1977) Nalidixic acid resistance: A 
second genetic character involved in DNA gyrase activity. Proc. Natl. Acad. Sci. USA 74: 
4772-4776. 
Gellert, M., K. Mizuuchi, M.H. O'Dea & H.A. Nash, (1976a) DNA gyrase: an enzyme that 
introduces superhelical turns into DNA. Proc. Natl. Acad. Sci. USA 73: 3872-3876. 
Gellert, M., M.H. O'Dea, T. Itoh & J. Tomizawa, (1976b) Novobiocin and coumermycin inhibit 
DNA supercoiling catalyzed by DNA gyrase. Proc. Natl. Acad. Sci. USA 73: 4474-4478. 
Gensberg, K., Y.F. Jin & L.J. Piddock, (1995) A novel gyrB mutation in a fluoroquinolone-resistant 
clinical isolate of Salmonella typhimurium. FEMS Microbiol. Lett. 132: 57-60. 
Gillespie, S.H., (2016) The role of moxifloxacin in tuberculosis therapy. Eur. Respir. Rev. 25: 19-
28. 
 253 
 
Gillespie, S.H., S. Basu, A.L. Dickens, D.M. O'Sullivan & T.D. McHugh, (2005) Effect of 
subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation 
rates. J. Antimicrob. Chemother. 56: 344-348. 
Godbole, A.A., W. Ahmed, R.S. Bhat, E.K. Bradley, S. Ekins & V. Nagaraja, (2015) Targeting 
Mycobacterium tuberculosis Topoisomerase I by Small-Molecule Inhibitors. Antimicrob. 
Agents Chemother. 59: 1549-1557. 
Goldberg, A.R. & M. Howe, (1969) New mutations in the S cistron of bacteriophage lambda 
affecting host cell lysis. Virology 38: 200-202. 
Goneau, L.W., T.J. Hannan, R.A. MacPhee, D.J. Schwartz, J.M. Macklaim, G.B. Gloor, H. Razvi, G. 
Reid, S.J. Hultgren & J.P. Burton, (2015) Subinhibitory antibiotic therapy alters recurrent 
urinary tract infection pathogenesis through modulation of bacterial virulence and host 
immunity. MBio 6. 
Goneau, L.W., N.S. Yeoh, K.W. MacDonald, P.A. Cadieux, J.P. Burton, H. Razvi & G. Reid, (2014) 
Selective Target Inactivation Rather than Global Metabolic Dormancy Causes Antibiotic 
Tolerance in Uropathogens. Antimicrob. Agents Chemother. 58: 2089-2097. 
Gonzalez, R.E., C.U. Lim, K. Cole, C.H. Bianchini, G.P. Schools, B.E. Davis, I. Wada, I.B. Roninson 
& E.V. Broude, (2011) Effects of conditional depletion of topoisomerase II on cell cycle 
progression in mammalian cells. Cell Cycle 10: 3505-3514. 
Gottesman, M.E. & M.B. Yarmolinsky, (1968) The Integration and Excision of the Bacteriophage 
Lambda Genome. Cold Spring Harbor Symp. Quant. Biol. 33: 735-747. 
Graham, J.E., K.J. Marians & S.C. Kowalczykowski, (2017) Independent and Stochastic Action of 
DNA Polymerases in the Replisome. Cell 169: 1201-1213.e1217. 
Graves Jr, J., M. Tajkarimi, Q. Cunningham, A. Campbell, H. Nonga, S. Harrison & J. E Barrick, 
(2015) Rapid Evolution of Silver Nanoparticle Resistance in Escherichia coli, p. 42. 
Greer, H., (1975) The kil gene of bacteriophage lambda. Virology 66: 589-604. 
Grenier, F., D. Matteau, V. Baby & S. Rodrigue, (2014) Complete Genome Sequence of 
Escherichia coli BW25113. Genome Announcements 2: e01038-01014. 
Gromova, I., H. Biersack, S. Jensen, O.F. Nielsen, O. Westergaard & A.H. Andersen, (1998) 
Characterization of DNA topoisomerase II alpha/beta heterodimers in HeLa cells. 
Biochemistry 37: 16645-16652. 
 254 
 
Grundström, T. & B. Jaurin, (1982) Overlap between ampC and frd operons on the Escherichia 
coli chromosome. Proc. Natl. Acad. Sci. USA 79: 1111-1115. 
Gubaev, A., M. Hilbert & D. Klostermeier, (2009) The DNA-gate of Bacillus subtilis gyrase is 
predominantly in the closed conformation during the DNA supercoiling reaction. Proc. 
Natl. Acad. Sci. USA 106: 13278-13283. 
Gubaev, A. & D. Klostermeier, (2011) DNA-induced narrowing of the gyrase N-gate coordinates 
T-segment capture and strand passage. Proc. Natl. Acad. Sci. USA 108: 14085-14090. 
Gubaev, A. & D. Klostermeier, (2014) The mechanism of negative DNA supercoiling: A cascade 
of DNA-induced conformational changes prepares gyrase for strand passage. DNA 
Repair 16c: 23-34. 
Gubaev, A., D. Weidlich & D. Klostermeier, (2016) DNA gyrase with a single catalytic tyrosine can 
catalyze DNA supercoiling by a nicking-closing mechanism. Nucleic Acids Res. 44: 10354-
10366. 
Gullberg, E., S. Cao, O.G. Berg, C. Ilbäck, L. Sandegren, D. Hughes & D.I. Andersson, (2011) 
Selection of resistant bacteria at very low antibiotic concentrations. PLoS Path. 7: 
e1002158. 
Gussin, G.N., A.D. Johnson, C.O. Pabo & R.T. Sauer, (1983) Repressor and Cro Protein: Structure, 
Function, and Role in Lysogenisation. In: Lambda II. R. Hendrix, J.W. Roberts, F.W. Stahl 
& R.A. Weisberg (eds). Cold Spring Harbour: Cold Spring Harbour Laboratory, pp. 93-
121. 
Gutiérrez-Estrada, A., J. Ramírez-Santos & M.d.C. Gómez-Eichelmann, (2014) Role of chaperones 
and ATP synthase in DNA gyrase reactivation in Escherichia coli stationary-phase cells 
after nutrient addition. SpringerPlus 3: 656. 
Gutierrez, A., L. Laureti, S. Crussard, H. Abida, A. Rodríguez-Rojas, J. Blázquez, Z. Baharoglu, D. 
Mazel, F. Darfeuille, J. Vogel & I. Matic, (2013) β-lactam antibiotics promote bacterial 
mutagenesis via an RpoS-mediated reduction in replication fidelity. Nat. Commun. 4: 
1610. 
Guyer, M.S., R.R. Reed, J.A. Steitz & K.B. Low, (1981) Identification of a Sex-factor-affinity Site in 
E. coli as γδ. Cold Spring Harbor Symp. Quant. Biol. 45: 135-140. 
 255 
 
Hallett, P., A.J. Grimshaw, D.B. Wigley & A. Maxwell, (1990) Cloning of the DNA gyrase genes 
under tac promoter control: overproduction of the gyrase A and B proteins. Gene 93: 
139-142. 
Halligan, B.D., J.L. Davis, K.A. Edwards & L.F. Liu, (1982) Intra- and intermolecular strand transfer 
by HeLa DNA topoisomerase I. J. Biol. Chem. 257: 3995-4000. 
Hamperl, S. & K.A. Cimprich, (2016) Conflict Resolution in the Genome: How Transcription and 
Replication Make It Work. Cell 167: 1455-1467. 
Han, Y.-H., M.J.F. Austin, Y. Pommier & L.F. Povirk, (1993) Small deletion and insertion mutations 
induced by the topoisomerase II inhibitor teniposide in CHO cells and comparison with 
sites of drug-stimulated DNA cleavage in vitro. J. Mol. Biol. 229: 52-66. 
Hande, K.R., (1998) Etoposide: four decades of development of a topoisomerase II inhibitor. Eur. 
J. Cancer 34: 1514-1521. 
Hartung, F., K.J. Angelis, A. Meister, I. Schubert, M. Melzer & H. Puchta, (2002) An 
archaebacterial topoisomerase homolog not present in other eukaryotes is 
indispensable for cell proliferation of plants. Curr. Biol. 12: 1787-1791. 
Hartung, F. & H. Puchta, (2000) Molecular characterisation of two paralogous SPO11 
homologues in Arabidopsis thaliana. Nucleic Acids Res. 28: 1548-1554. 
Heath, R.J., J.R. Rubin, D.R. Holland, E. Zhang, M.E. Snow & C.O. Rock, (1999) Mechanism of 
Triclosan Inhibition of Bacterial Fatty Acid Synthesis. J. Biol. Chem. 274: 11110-11114. 
Heddle, J.G., S. Mitelheiser, A. Maxwell & N.H. Thomson, (2004) Nucleotide binding to DNA 
gyrase causes loss of DNA wrap. J. Mol. Biol. 337: 597-610. 
Heide, L., (2009) The aminocoumarins: biosynthesis and biology. Nat. Prod. Rep. 26: 1241-1250. 
Hermsen, R., J.B. Deris & T. Hwa, (2012) On the rapidity of antibiotic resistance evolution 
facilitated by a concentration gradient. Proc. Natl. Acad. Sci. USA 109: 10775-10780. 
Herrero, M., R. Kolter & F. Moreno, (1986) Effects of microcin B17 on microcin B17-immune 
cells. Microbiology 132: 403-410. 
Hershey, A.D. & W. Dove, (1971) Introduction to Lambda. In: The Bacteriohage Lambda. A.D. 
Hershey (ed). Cold Spring Harbour: Cold Spring Harbour Laboratory, pp. 3-11. 
 256 
 
Hiasa, H., D.O. Yousef & K.J. Marians, (1996) DNA Strand Cleavage Is Required for Replication 
Fork Arrest by a Frozen Topoisomerase-Quinolone-DNA Ternary Complex. J. Biol. Chem. 
271: 26424-26429. 
Higgins, N.P., (2016) Species-specific supercoil dynamics of the bacterial nucleoid. Biophys Rev 
8: 113-121. 
Higgins, N.P., C.L. Peebles, A. Sugino & N.R. Cozzarelli, (1978) Purification of subunits of 
Escherichia coli DNA gyrase and reconstitution of enzymatic activity. Proc. Natl. Acad. 
Sci. USA 75: 1773-1777. 
Higgins, N.P. & A.V. Vologodskii, (2015) Topological Behavior of Plasmid DNA. Microbiol Spectr. 
3. 
Hiraga, S., H. Niki, T. Ogura, C. Ichinose, H. Mori, B. Ezaki & A. Jaffé, (1989) Chromosome 
partitioning in Escherichia coli: novel mutants producing anucleate cells. J. Bacteriol. 
171: 1496-1505. 
Hjort, K., H. Nicoloff & D.I. Andersson, (2016) Unstable tandem gene amplification generates 
heteroresistance (variation in resistance within a population) to colistin in Salmonella 
enterica. Mol. Microbiol. 102: 274-289. 
Hockings, S.C. & A. Maxwell, (2002) Identification of four GyrA residues involved in the DNA 
breakage–reunion reaction of DNA gyrase. J. Mol. Biol. 318: 351-359. 
Hohn, B., (1979) In vitro packaging of lambda and cosmid DNA. Methods Enzymol. 68: 299-309. 
Hohn, B. & T. Hohn, (1974) Activity of empty, headlike particles for packaging of DNA of 
bacteriophage lambda in vitro. Proc. Natl. Acad. Sci. USA 71: 2372-2376. 
Holmes, V.F. & N.R. Cozzarelli, (2000) Closing the ring: Links between SMC proteins and 
chromosome partitioning, condensation, and supercoiling. Proc. Natl. Acad. Sci. USA 97: 
1322-1324. 
Hooper, D.C., (2003) Mechanisms of Quinolone Resistance. In: Quinolone Antimicrobial Agents, 
Third Edition. American Society of Microbiology, pp. 
Hooper, D.C. & G.A. Jacoby, (2015) Mechanisms of drug resistance: quinolone resistance. Ann. 
N. Y. Acad. Sci. 1354: 12-31. 
 257 
 
Horowitz, D.S. & J.C. Wang, (1987) Mapping the active site tyrosine of Escherichia coli DNA 
gyrase. J. Biol. Chem. 262: 5339-5344. 
Hosfield, D.J., Y. Guan, B.J. Haas, R.P. Cunningham & J.A. Tainer, (1999) Structure of the DNA 
Repair Enzyme Endonuclease IV and Its DNA Complex. Cell 98: 397-408. 
Hou, Y., Y.P. Lin, J.D. Sharer & P.E. March, (1994) In vivo selection of conditional-lethal mutations 
in the gene encoding elongation factor G of Escherichia coli. J. Bacteriol. 176: 123-129. 
Houssaye, S., L. Gutmann & E. Varon, (2002) Topoisomerase Mutations Associated with In vitro 
Selection of Resistance to Moxifloxacin in Streptococcus pneumoniae. Antimicrob. 
Agents Chemother. 46: 2712-2715. 
Hsiang, Y.H., R. Hertzberg, S. Hecht & L.F. Liu, (1985) Camptothecin induces protein-linked DNA 
breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260: 14873-14878. 
Hsieh, L.-S., R.M. Burger & K. Drlica, (1991) Bacterial DNA supercoiling and [ATP][ADP]. J. Mol. 
Biol. 219: 443-450. 
Hsieh, T. & D. Brutlag, (1980) ATP-dependent DNA topoisomerase from D. melanogaster 
reversibly catenates duplex DNA rings. Cell 21: 115-125. 
Hsieh, T.J., L. Farh, W.M. Huang & N.L. Chan, (2004) Structure of the topoisomerase IV C-terminal 
domain: a broken beta-propeller implies a role as geometry facilitator in catalysis. J. Biol. 
Chem. 279: 55587-55593. 
Hsieh, T.J., T.J. Yen, T.S. Lin, H.T. Chang, S.Y. Huang, C.H. Hsu, L. Farh & N.L. Chan, (2010) Twisting 
of the DNA-binding surface by a beta-strand-bearing proline modulates DNA gyrase 
activity. Nucleic Acids Res. 38: 4173-4181. 
Hughes, D. & D.I. Andersson, (2012) Selection of resistance at lethal and non-lethal antibiotic 
concentrations. Curr. Opin. Microbiol. 15: 555-560. 
Ikeda, H., (1986a) Bacteriophage T4 DNA topoisomerase mediates illegitimate recombination in 
vitro. Proc. Natl. Acad. Sci. USA 83: 922-926. 
Ikeda, H., (1986b) Illegitimate recombination mediated by T4 DNA topoisomerase in vitro. Mol. 
Gen. Genet. 202: 518-520. 
Ikeda, H., (1994) DNA Topoisomerase-Mediated Illegitimate Recombination. In: Advances in 
Pharmacology. F.L. Leroy (ed). Academic Press, pp. 147-165. 
 258 
 
Ikeda, H., K. Aoki & A. Naito, (1982) Illegitimate recombination mediated in vitro by DNA gyrase 
of Escherichia coli: Structure of recombinant DNA molecules. Proc. Natl. Acad. Sci. USA 
79: 3724-3728. 
Ikeda, H., I. Kawasaki & M. Gellert, (1984) Mechanism of illegitimate recombination: common 
sites for recombination and cleavage mediated by Escherichia coli DNA gyrase. Mol. Gen. 
Genet. 196: 546-549. 
Ikeda, H., K. Moriya & T. Matsumoto, (1980) In vitro study of illegitimate recombination: 
involvement of DNA gyrase. Cold Spring Harbor Symp. Quant. Biol. 45: 399-408. 
Ikeda, H., H. Shimizu, T. Ukita & M. Kumagai, (1995) A novel assay for illegitimate recombination 
in Escherichia coli: Stimulation of λbio transducing phage formation by ultra-violet light 
and its independence from RecA function. Adv. Biophys. 31: 197-208. 
Ikeda, H. & M. Shiozaki, (1984) Nonhomologous recombination mediated by Escherichia coli 
DNA gyrase: possible involvement of DNA replication. Cold Spring Harbor Symp. Quant. 
Biol. 49: 401-409. 
Ikeda, H., K. Shiraishi & Y. Ogata, (2004) Illegitimate recombination mediated by double-strand 
break and end-joining in Escherichia coli. Adv. Biophys. 38: 3-20. 
Ikeda, H. & J.I. Tomizawa, (1965) Transducing fragments in generalized transduction by phage 
P1. I. Molecular origin of the fragments. J. Mol. Biol. 14: 85-109. 
Imlay, J.A., (2015) Diagnosing oxidative stress in bacteria: not as easy as you might think. Curr. 
Opin. Microbiol. 24: 124-131. 
Ince, D. & D.C. Hooper, (2001) Mechanisms and Frequency of Resistance to Gatifloxacin in 
Comparison to AM-1121 and Ciprofloxacin inStaphylococcus aureus. Antimicrob. Agents 
Chemother. 45: 2755-2764. 
Jain, C.K., H.K. Majumder & S. Roychoudhury, (2017) Natural Compounds as Anticancer Agents 
Targeting DNA Topoisomerases. Curr. Genomics 18: 75-92. 
Janion, C., (2008) Inducible SOS response system of DNA repair and mutagenesis in Escherichia 
coli. Int. J. Biol. Sci. 4: 338-344. 
Johnson, R.C., (2015) Site-specific DNA Inversion by Serine Recombinases. Microbiol Spectr. 3: 
1-36. 
 259 
 
Jurado, S., A. Medina, R. de la Fuente, J.A. Ruiz-Santa-Quiteria & J.A. Orden, (2015) Resistance 
to non-quinolone antimicrobials in commensal Escherichia coli isolates from chickens 
treated orally with enrofloxacin. Jap. J. Vet. Res. 63: 195-200. 
Kaiser, A.D., (1957) Mutations in a temperate bacteriophage affecting its ability to lysogenize 
Escherichia coli. Virology 3: 42-61. 
Kampranis, S.C., A.D. Bates & A. Maxwell, (1999a) A model for the mechanism of strand passage 
by DNA gyrase. Proc. Natl. Acad. Sci. USA 96: 8414-8419. 
Kampranis, S.C., N.A. Gormley, R. Tranter, G. Orphanides & A. Maxwell, (1999b) Probing the 
binding of coumarins and cyclothialidines to DNA gyrase. Biochemistry 38: 1967-1976. 
Kampranis, S.C., A.J. Howells & A. Maxwell, (1999c) The interaction of DNA gyrase with the 
bacterial toxin CcdB: evidence for the existence of two gyrase-CcdB complexes. J. Mol. 
Biol. 293: 733-744. 
Kampranis, S.C. & A. Maxwell, (1996) Conversion of DNA gyrase into a conventional type II 
topoisomerase. Proc. Natl. Acad. Sci. USA 93: 14416-14421. 
Kampranis, S.C. & A. Maxwell, (1998a) Conformational changes in DNA gyrase revealed by 
limited proteolysis. J. Biol. Chem. 273: 22606-22614. 
Kampranis, S.C. & A. Maxwell, (1998b) The DNA gyrase-quinolone complex: ATP hydrolysis and 
the mechanism of DNA cleavage. J. Biol. Chem. 273: 22615-22626. 
Karp, P., D. Weaver, S. Paley, C. Fulcher, A. Kubo, A. Kothari, M. Krummenacker, P. Subhraveti, 
D. Weerasinghe, S. Gama-Castro, A. Huerta, L. Muñiz-Rascado, C. Bonavides-Martinez, 
V. Weiss, M. Peralta-Gil, A. Santos-Zavaleta, I. Schröder, A. Mackie, R. Gunsalus, J. 
Collado-Vides, I. Keseler & I. Paulsen, (2014) The EcoCyc Database. EcoSal Plus. 
Katayama, T., T. Kubota, K. Kurokawa, E. Crooke & K. Sekimizu, (1998) The Initiator Function of 
DnaA Protein Is Negatively Regulated by the Sliding Clamp of the E. coli Chromosomal 
Replicase. Cell 94: 61-71. 
Kato, J.-i. & H. Ikeda, (1996) Construction of mini-F plasmid vectors for plasmid shuffling in 
Escherichia coli. Gene 170: 141-142. 
Keetch, C.A., E.H. Bromley, M.G. McCammon, N. Wang, J. Christodoulou & C.V. Robinson, (2005) 
L55P transthyretin accelerates subunit exchange and leads to rapid formation of hybrid 
tetramers. J. Biol. Chem. 280: 41667-41674. 
 260 
 
Kellenberger, E. & R.S. Edgar, (1971) Structure and assembly of phage particles. In: The 
Bacteriophage Lambda. A.D. Hershey (ed). Cold Spring Harbour, New York: Cold Spring 
Harbour Laboratory, pp. 271-295. 
Kelly, S.M., T.J. Jess & N.C. Price, (2005) How to study proteins by circular dichroism. Biochim. 
Biophys. Acta 1751: 119-139. 
Keren, I., Y. Wu, J. Inocencio, L.R. Mulcahy & K. Lewis, (2013) Killing by Bactericidal Antibiotics 
Does Not Depend on Reactive Oxygen Species. Science 339: 1213-1216. 
Khodursky, A.B., E.L. Zechiedrich & N.R. Cozzarelli, (1995) Topoisomerase IV is a target of 
quinolones in Escherichia coli. Proc. Natl. Acad. Sci. USA 92: 11801-11805. 
Kikuchi, A. & K. Asai, (1984) Reverse gyrase--a topoisomerase which introduces positive 
superhelical turns into DNA. Nature 309: 677-681. 
Kim, N. & S. Jinks-Robertson, (2017) The Top1 paradox: Friend and foe of the eukaryotic genome. 
DNA Repair 56: 33-41. 
Kirkegaard, K. & J.C. Wang, (1981) Mapping the topography of DNA wrapped around gyrase by 
nucleolytic and chemical probing of complexes of unique DNA sequences. Cell 23: 721-
729. 
Klevan, L. & J.C. Wang, (1980) Deoxyribonucleic acid gyrase-deoxyribonucleic acid complex 
containing 140 base pairs of deoxyribonucleic acid and an alpha 2 beta 2 protein core. 
Biochemistry 19: 5229-5234. 
Kobayashi, I. & H. Ikeda, (1977) Formation of recombinant DNA of bacteriophage lambda by recA 
function of Escherichia coli without duplication, transcription, translation, and 
maturation. Mol. Gen. Genet. 153: 237-245. 
Kohanski, M.A., M.A. DePristo & J.J. Collins, (2010) Sublethal antibiotic treatment leads to 
multidrug resistance via radical-induced mutagenesis. Mol. Cell 37: 311-320. 
Komp Lindgren, P., Å. Karlsson & D. Hughes, (2003) Mutation Rate and Evolution of 
Fluoroquinolone Resistance in Escherichia coli Isolates from Patients with Urinary Tract 
Infections. Antimicrob. Agents Chemother. 47: 3222-3232. 
Kondrat, F.D.L., W.B. Struwe & J.L.P. Benesch, (2015) Native Mass Spectrometry: Towards High-
Throughput Structural Proteomics. In: Structural Proteomics: High-Throughput 
Methods. R.J. Owens (ed). New York, NY: Springer New York, pp. 349-371. 
 261 
 
Koskiniemi, S. & D.I. Andersson, (2009) Translesion DNA polymerases are required for 
spontaneous deletion formation in Salmonella typhimurium. Proc. Natl. Acad. Sci. USA 
106: 10248-10253. 
Koskiniemi, S., D. Hughes & D.I. Andersson, (2010) Effect of translesion DNA polymerases, 
endonucleases and RpoS on mutation rates in Salmonella Typhimurium. Genetics 185: 
783-795. 
Koster, D.A., A. Crut, S. Shuman, M.A. Bjornsti & N.H. Dekker, (2010) Cellular strategies for 
regulating DNA supercoiling: A single-molecule perspective. Cell 142: 519-530. 
Kottur, J. & D.T. Nair, (2016) Reactive oxygen species play an important role in the bactericidal 
activity of quinolone antibiotics. Angew. Chem. 55: 2397-2400. 
Kozlowski, L.P., (2016) IPC – Isoelectric Point Calculator. Biology Direct 11: 55. 
Kramlinger, V.M. & H. Hiasa, (2006) The "GyrA-box" is required for the ability of DNA gyrase to 
wrap DNA and catalyze the supercoiling reaction. J. Biol. Chem. 281: 3738-3742. 
Kreuzer, K.N., (2013) DNA Damage Responses in Prokaryotes: Regulating Gene Expression, 
Modulating Growth Patterns, and Manipulating Replication Forks. Cold. Spring. Harb. 
Perspect. Biol. 5: a012674. 
Kreuzer, K.N. & N.R. Cozzarelli, (1980) Formation and resolution of DNA catenanes by DNA 
gyrase. Cell 20: 245-254. 
Kumagai, M. & H. Ikeda, (1991) Molecular analysis of the recombination junctions of lambda bio 
transducing phages. Mol. Gen. Genet. 230: 60-64. 
Kumar, R., P. Nurse, S. Bahng, C.M. Lee & K.J. Marians, (2017) The mukB-topoisomerase IV 
interaction is required for proper chromosome compaction. J. Biol. Chem. 
Lanz, M.A., M. Farhat & D. Klostermeier, (2014) The acidic C-terminal tail of the GyrA subunit 
moderates the DNA supercoiling activity of Bacillus subtilis gyrase. J. Biol. Chem. 289: 
12275-12285. 
Lanz, M.A. & D. Klostermeier, (2011) Guiding strand passage: DNA-induced movement of the 
gyrase C-terminal domains defines an early step in the supercoiling cycle. Nucleic Acids 
Res. 39: 9681-9694. 
 262 
 
Laponogov, I., D.A. Veselkov, I.M.-T. Crevel, X.-S. Pan, L.M. Fisher & M.R. Sanderson, (2013) 
Structure of an ‘open’ clamp type II topoisomerase-DNA complex provides a mechanism 
for DNA capture and transport. Nucleic Acids Res. 
Laponogov, I., D.A. Veselkov, M.K. Sohi, X.-S. Pan, A. Achari, C. Yang, J.D. Ferrara, L.M. Fisher & 
M.R. Sanderson, (2007) Breakage-reunion domain of Streptococcus pneumoniae 
topoisomerase IV: Crystal structure of a gram-positive quinolone target. PLoS ONE 2: 
e301. 
Laureti, L., I. Matic & A. Gutierrez, (2013) Bacterial Responses and Genome Instability Induced 
by Subinhibitory Concentrations of Antibiotics. Antibiotics 2: 100. 
Laurie, B., V. Katritch, J. Sogo, T. Koller, J. Dubochet & A. Stasiak, (1998) Geometry and physics 
of catenanes applied to the study of DNA replication. Biophys. J. 74: 2815-2822. 
Lázár, V., G. Pal Singh, R. Spohn, I. Nagy, B. Horváth, M. Hrtyan, R. Busa-Fekete, B. Bogos, O. 
Méhi, B. Csörgő, G. Pósfai, G. Fekete, B. Szappanos, B. Kégl, B. Papp & C. Pál, (2013) 
Bacterial evolution of antibiotic hypersensitivity. Mol. Syst. Biol. 9: 700-700. 
Lesher, G.Y., E.J. Froelich, M.D. Gruett, J.H. Bailey & R.P. Brundage, (1962) 1,8-Naphthyridone 
derivatives. A new class of chemotherapeutic agents. J. Med. Chem. 91: 1063-1065. 
Levine, C., H. Hiasa & K.J. Marians, (1998) DNA gyrase and topoisomerase IV: biochemical 
activities, physiological roles during chromosome replication, and drug sensitivities. 
Biochim. Biophys. Acta 1400: 29-43. 
Lewin, C.S., B.M.A. Howard, N.T. Ratcliff & J.T. Smith, (1989) 4-Quinolones and the SOS response. 
J. Med. Microbiol. 29: 139-144. 
Lewis, K., (2012) Antibiotics: Recover the lost art of drug discovery. Nature 485: 439-440. 
Lewis, R.J., O.M. Singh, C.V. Smith, T. Skarzynski, A. Maxwell, A.J. Wonacott & D.B. Wigley, (1996) 
The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines 
revealed by X-ray crystallography. EMBO J. 15: 1412-1420. 
Li, T.-K. & L.F. Liu, (1998) Modulation of Gyrase-Mediated DNA Cleavage and Cell Killing by ATP. 
Antimicrob. Agents Chemother. 42: 1022-1027. 
Lilley, D.M., D. Chen & R.P. Bowater, (1996) DNA supercoiling and transcription: topological 
coupling of promoters. Q. Rev. Biophys. 29: 203-225. 
 263 
 
Lima, C.D., J.C. Wang & A. Mondragon, (1994) Three-dimensional structure of the 67K N-
terminal fragment of E. coli DNA topoisomerase I. Nature 367: 138-146. 
Lin, T.-Y., S. Nagano & J. Gardiner Heddle, (2015) Functional Analyses of the Toxoplasma gondii 
DNA Gyrase Holoenzyme: A Janus Topoisomerase with Supercoiling and Decatenation 
Abilities. Sci. Rep. 5: 14491. 
Lind, P.A. & D.I. Andersson, (2008) Whole-genome mutational biases in bacteria. Proc. Natl. 
Acad. Sci. USA 105: 17878-17883. 
Linder, J.A., E.S. Huang, M.A. Steinman, R. Gonzales & R.S. Stafford, (2005) Fluoroquinolone 
prescribing in the United States: 1995 to 2002. Am. J. Med. 118: 259-268. 
Lindsley, J.E., (2001) DNA Topology: Supercoiling and Linking. In: eLS. John Wiley & Sons, Ltd, pp. 
Liu, L.F., C.C. Liu & B.M. Alberts, (1980) Type II DNA topoisomerases: enzymes that can unknot a 
topologically knotted DNA molecule via a reversible double-strand break. Cell 19: 697-
707. 
Liu, L.F. & J.C. Wang, (1978) Micrococcus luteus DNA gyrase: active components and a model for 
its supercoiling of DNA. Proc. Natl. Acad. Sci. USA 75: 2098-2102. 
Liu, L.F. & J.C. Wang, (1987) Supercoiling of the DNA template during transcription. Proc. Natl. 
Acad. Sci. USA 84: 7024-7027. 
Liu, Y. & J.A. Imlay, (2013) Cell Death from Antibiotics Without the Involvement of Reactive 
Oxygen Species. Science 339: 1210-1213. 
Livermore, D.M., (1995) beta-Lactamases in laboratory and clinical resistance. Clin. Microbiol. 
Rev. 8: 557-584. 
Lockshon, D. & D.R. Morris, (1985) Sites of reaction of Escherichia coli DNA gyrase on pBR322 in 
vivo as revealed by oxolinic acid-induced plasmid linearization. J. Mol. Biol. 181: 63-74. 
Long, H., S.F. Miller, C. Strauss, C. Zhao, L. Cheng, Z. Ye, K. Griffin, R. Te, H. Lee, C.-C. Chen & M. 
Lynch, (2016) Antibiotic treatment enhances the genome-wide mutation rate of target 
cells. Proc. Natl. Acad. Sci. USA 113: E2498-E2505. 
Long, M., (2001) Evolution of novel genes. Curr. Opin. Genet. Dev. 11: 673-680. 
 264 
 
Lopez, C.R., S. Yang, R.W. Deibler, S.A. Ray, J.M. Pennington, R.J. DiGate, P.J. Hastings, S.M. 
Rosenberg & E.L. Zechiedrich, (2005) A role for topoisomerase III in a recombination 
pathway alternative to RuvABC. Mol. Microbiol. 58: 80-101. 
Lopez, E. & J. Blazquez, (2009) Effect of subinhibitory concentrations of antibiotics on 
intrachromosomal homologous recombination in Escherichia coli. Antimicrob. Agents 
Chemother. 53: 3411-3415. 
Lopez, E., M. Elez, I. Matic & J. Blazquez, (2007) Antibiotic-mediated recombination: 
ciprofloxacin stimulates SOS-independent recombination of divergent sequences in 
Escherichia coli. Mol. Microbiol. 64: 83-93. 
Lovett, B.D., L. Lo Nigro, E.F. Rappaport, I.A. Blair, N. Osheroff, N. Zheng, M.D. Megonigal, W.R. 
Williams, P.C. Nowell & C.A. Felix, (2001) Near-precise interchromosomal recombination 
and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic 
breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) 
translocation. Proc. Natl. Acad. Sci. USA 98: 9802-9807. 
Lovett, S.T., P.T. Drapkin, V.A. Sutera-Jr & T.J. Gluckman-Peskind, (1993) A Sister-Strand 
Exchange Mechanism for Reca-Independent Deletion of Repeated DNA Sequences in 
Escherichia Coli. Genetics 135: 631-642. 
Luijsterburg, M.S., M.F. White, R. van Driel & R.T. Dame, (2008) The Major Architects of 
Chromatin: Architectural Proteins in Bacteria, Archaea and Eukaryotes. Crit. Rev. 
Biochem. Mol. Biol. 43: 393-418. 
Lynn, R., G. Giaever, S.L. Swanberg & J.C. Wang, (1986) Tandem regions of yeast DNA 
topoisomerase II share homology with different subunits of bacterial gyrase. Science 
233: 647-649. 
Madhusudan, K. & V. Nagaraja, (1996) Alignment and phylogenetic analysis of type II DNA 
topoisomerases. J. Biosci. (Bangalore) 21: 613-629. 
Malik, M., K. Chavda, X. Zhao, N. Shah, S. Hussain, N. Kurepina, B.N. Kreiswirth, R.J. Kerns & K. 
Drlica, (2012) Induction of Mycobacterial Resistance to Quinolone Class Antimicrobials. 
Antimicrob. Agents Chemother. 56: 3879-3887. 
Malik, M., S. Hussain & K. Drlica, (2007) Effect of Anaerobic Growth on Quinolone Lethality with 
Escherichia coli. Antimicrob. Agents Chemother. 51: 28-34. 
 265 
 
Malik, M., X. Zhao & K. Drlica, (2006) Lethal fragmentation of bacterial chromosomes mediated 
by DNA gyrase and quinolones. Mol. Microbiol. 61: 810-825. 
Mangiameli, S.M., C.N. Merrikh, P.A. Wiggins & H. Merrikh, (2017) Transcription leads to 
pervasive replisome instability in bacteria. eLife 6: e19848. 
Mani, R.-S. & A.M. Chinnaiyan, (2010) Triggers for genomic rearrangements: insights into 
genomic, cellular and environmental influences. Nat. Rev. Genet. 11: 819-829. 
Marianayagam, N.J., M. Sunde & J.M. Matthews, (2004) The power of two: protein dimerization 
in biology. Trends Biochem. Sci. 29: 618-625. 
Marians, K.J., (1987) DNA gyrase-catalyzed decatenation of multiply linked DNA dimers. J. Biol. 
Chem. 262: 10362-10368. 
Markham, N.R. & M. Zuker, (2005) DINAMelt web server for nucleic acid melting prediction. 
Nucleic Acids Res. 33: W577-581. 
Marshall, B., S. Darkin & R.K. Ralph, (1983) Evidence that mAMSA induces topoisomerase action. 
FEBS Lett. 161: 75-78. 
Martinez-Garcia, B., X. Fernandez, O. Diaz-Ingelmo, A. Rodriguez-Campos, C. Manichanh & J. 
Roca, (2014) Topoisomerase II minimizes DNA entanglements by proofreading DNA 
topology after DNA strand passage. Nucleic Acids Res. 42: 1821-1830. 
Martinez, J.L. & F. Baquero, (2000) Mutation Frequencies and Antibiotic Resistance. Antimicrob. 
Agents Chemother. 44: 1771-1777. 
Mathieu, A., S. Fleurier, A. Frénoy, J. Dairou, M.-F. Bredeche, P. Sanchez-Vizuete, X. Song & I. 
Matic, (2016) Discovery and Function of a General Core Hormetic Stress Response in E. 
coli Induced by Sublethal Concentrations of Antibiotics. Cell Reports 17: 46-57. 
Maxwell, A., (1997) DNA gyrase as a drug target. Trends Microbiol. 5: 102-109. 
Maxwell, A. & M. Gellert, (1984) The DNA dependence of the ATPase activity of DNA gyrase. J. 
Biol. Chem. 259: 14472-14480. 
Maxwell, A. & M. Gellert, (1986) Mechanistic Aspects of DNA Topoisomerases. Adv. Protein 
Chem. 38: 69-107. 
 266 
 
Maxwell, A. & A.J. Howells, (1999) Overexpression and Purification of Bacterial DNA Gyrase. In: 
Methods in Molecular Biology, Vol 94: Protocols in DNA Topology and Topoisomerases, 
Part 1: DNA and Enzymes. M. Bjornsti & N. Osheroff (eds). Totowa: Humana Press Inc., 
pp. 135-144. 
Maxwell, A. & D.M. Lawson, (2003) The ATP-Binding Site of Type II Topoisomerases as a Target 
for Antibacterial Drugs. Curr. Top. Med. Chem. 3: 283-303. 
Mayer, C. & Y.L. Janin, (2014) Non-quinolone Inhibitors of Bacterial Type IIA Topoisomerases: A 
Feat of Bioisosterism. Chemical Reviews 114: 2313-2342. 
McDaniel, L.S., L.H. Rogers & W.E. Hill, (1978) Survival of recombination-deficient mutants of 
Escherichia coli during incubation with nalidixic acid. J. Bacteriol. 134: 1195-1198. 
McGann, P., P. Courvalin, E. Snesrud, R.J. Clifford, E.-J. Yoon, F. Onmus-Leone, A.C. Ong, Y.I. 
Kwak, C. Grillot-Courvalin, E. Lesho & P.E. Waterman, (2014) Amplification of 
Aminoglycoside Resistance Gene aphA1 in Acinetobacter baumannii Results in 
Tobramycin Therapy Failure. mBio 5: e00915-00914. 
McGlynn, P., N.J. Savery & M.S. Dillingham, (2012) The conflict between DNA replication and 
transcription. Mol. Microbiol. 85: 12-20. 
McPartland, A., L. Green & H. Echols, (1980) Control of recA gene RNA in E. coli: Regulatory and 
signal genes. Cell 20: 731-737. 
Meczes, E.L., K.L. Gilroy, K.L. West & C.A. Austin, (2008) The Impact of the Human DNA 
Topoisomerase II C-Terminal Domain on Activity. PLoS ONE 3: e1754. 
Mehta, P., S. Casjens & S. Krishnaswamy, (2004) Analysis of the lambdoid prophage element e14 
in the E. coli K-12 genome. BMC Microbiol. 4: 4. 
Menzel, R. & M. Gellert, (1983) Regulation of the genes for E. coli DNA gyrase: homeostatic 
control of DNA supercoiling. Cell 34: 105-113. 
Meselson, M. & R. Yuan, (1968) DNA restriction enzyme from E. coli. Nature 217: 1110-1114. 
Michael, T.P., (2014) Plant genome size variation: bloating and purging DNA. Brief. Funct. 
Genomics. 13: 308-317. 
Michel, B., G. Grompone, M.-J. Florès & V. Bidnenko, (2004) Multiple pathways process stalled 
replication forks. Proc. Natl. Acad. Sci. USA 101: 12783-12788. 
 267 
 
Miki, T., Z.T. Chang & T. Horiuchi, (1984a) Control of cell division by sex factor F in Escherichia 
coli. II. Identification of genes for inhibitor protein and trigger protein on the 42.84-43.6 
F segment. J. Mol. Biol. 174: 627-646. 
Miki, T., J.A. Park, K. Nagao, N. Murayama & T. Horiuchi, (1992) Control of segregation of 
chromosomal DNA by sex factor F in Escherichia coli. Mutants of DNA gyrase subunit A 
suppress letD (ccdB) product growth inhibition. J. Mol. Biol. 225: 39-52. 
Miki, T., K. Yoshioka & T. Horiuchi, (1984b) Control of cell division by sex factor F in Escherichia 
coli. I. The 42.84-43.6 F segment couples cell division of the host bacteria with 
replication of plasmid DNA. J. Mol. Biol. 174: 605-625. 
Miller, C., L.E. Thomsen, C. Gaggero, R. Mosseri, H. Ingmer & S.N. Cohen, (2004) SOS Response 
Induction by ß-Lactams and Bacterial Defense Against Antibiotic Lethality. Science 305: 
1629-1631. 
Milne, I., G. Stephen, M. Bayer, P.J.A. Cock, L. Pritchard, L. Cardle, P.D. Shaw & D. Marshall, 
(2013) Using Tablet for visual exploration of second-generation sequencing data. Brief. 
Bioinformatics 14: 193-202. 
Mitelman, F., B. Johansson & F. Mertens, (2007) The impact of translocations and gene fusions 
on cancer causation. Nat. Rev. Cancer 7: 233-245. 
Miura-Masuda, A. & H. Ikeda, (1990) The DNA gyrase of Escherichia coli participates in the 
formation of a spontaneous deletion by recA-independent recombination in vivo. Mol. 
Gen. Genet. 220: 345-352. 
Mizushima, T., S. Natori & K. Sekimizu, (1993) Relaxation of supercoiled DNA associated with 
induction of heat shock proteins in Escherichia coli. Mol. Gen. Genet. 238: 1-5. 
Mizuuchi, K., L.M. Fisher, M.H. O'Dea & M. Gellert, (1980) DNA gyrase action involves the 
introduction of transient double-strand breaks into DNA. Proc. Natl. Acad. Sci. USA 77: 
1847-1851. 
Mizuuchi, K., M. Gellert & H.A. Nash, (1978a) Involvement of supertwisted DNA in integrative 
recombination of bacteriophage lambda. J. Mol. Biol. 121: 375-392. 
Mizuuchi, K., M.H. O'Dea & M. Gellert, (1978b) DNA gyrase: subunit structure and ATPase 
activity of the purified enzyme. Proc. Natl. Acad. Sci. USA 75: 5960-5963. 
 268 
 
Mo, C.Y., S.A. Manning, M. Roggiani, M.J. Culyba, A.N. Samuels, P.D. Sniegowski, M. Goulian & 
R.M. Kohli, (2016) Systematically Altering Bacterial SOS Activity under Stress Reveals 
Therapeutic Strategies for Potentiating Antibiotics. mSphere 1: e00163-00116. 
Mogre, A., T. Sengupta, R.T. Veetil, P. Ravi & A.S.N. Seshasayee, (2014) Genomic Analysis Reveals 
Distinct Concentration-Dependent Evolutionary Trajectories for Antibiotic Resistance in 
Escherichia coli. DNA Res. 21: 711-726. 
Mogre, A. & A.S.N. Seshasayee, (2017) Modulation of global transcriptional regulatory networks 
as a strategy for increasing kanamycin resistance of EF-G mutants. bioRxiv. 
Morais Cabral, J.H., A.P. Jackson, C.V. Smith, N. Shikotra, A. Maxwell & R.C. Liddington, (1997) 
Crystal structure of the breakage-reunion domain of DNA gyrase. Nature 388: 903-906. 
Morgulis, A., G. Coulouris, Y. Raytselis, T.L. Madden, R. Agarwala & A.A. Schäffer, (2008) 
Database indexing for production MegaBLAST searches. Bioinformatics 24: 1757-1764. 
Morrison, A. & N.R. Cozzarelli, (1981) Contacts between DNA gyrase and its binding site on DNA: 
features of symmetry and asymmetry revealed by protection from nucleases. Proc. Natl. 
Acad. Sci. USA 78: 1416-1420. 
Mustaev, A., M. Malik, X. Zhao, N. Kurepina, G. Luan, L.M. Oppegard, H. Hiasa, K.R. Marks, R.J. 
Kerns, J.M. Berger & K. Drlica, (2014) Fluoroquinolone-gyrase-DNA complexes: Two 
modes of drug binding. J. Biol. Chem. 
Naito, A., S. Naito & H. Ikeda, (1984) Homology is not required for recombination mediated by 
DNA gyrase of Escherichia coli. Mol. Gen. Genet. 193: 238-243. 
Nash, H.A., (1990) Bending and supercoiling of DNA at the attachment site of bacteriophage λ. 
Trends Biochem. Sci. 15: 222-227. 
Negrini, M., C.A. Felix, C. Martin, B.J. Lange, T. Nakamura, E. Canaani & C.M. Croce, (1993) 
Potential topoisomerase II DNA-binding sites at the breakpoints of a t(9;11) 
chromosome translocation in acute myeloid leukemia. Cancer Res. 53: 4489-4492. 
Neuman, K.C., (2010) Single-molecule measurements of DNA topology and topoisomerases. J. 
Biol. Chem. 285: 18967-18971. 
Neuman, K.C., G. Charvin, D. Bensimon & V. Croquette, (2009) Mechanisms of chiral 
discrimination by topoisomerase IV. Proc. Natl. Acad. Sci. USA 106: 6986-6991. 
 269 
 
Nichols, M.D., K. DeAngelis, J.L. Keck & J.M. Berger, (1999) Structure and function of an archaeal 
topoisomerase VI subunit with homology to the meiotic recombination factor Spo11. 
EMBO J. 18: 6177-6188. 
Nicolas, E., A.L. Upton, S. Uphoff, O. Henry, A. Badrinarayanan & D. Sherratt, (2014) The SMC 
Complex MukBEF Recruits Topoisomerase IV to the Origin of Replication Region in Live 
Escherichia coli. mBio 5: e01001-01013. 
Nicoloff, H. & D.I. Andersson, (2013) Lon protease inactivation, or translocation of the lon gene, 
potentiate bacterial evolution to antibiotic resistance. Mol. Microbiol. 90: 1233-1248. 
Nicoloff, H., V. Perreten & S.B. Levy, (2007) Increased Genome Instability in Escherichia coli lon 
Mutants: Relation to Emergence of Multiple-Antibiotic-Resistant (Mar) Mutants Caused 
by Insertion Sequence Elements and Large Tandem Genomic Amplifications. Antimicrob. 
Agents Chemother. 51: 1293-1303. 
Nilsen, I.W., I. Bakke, A. Vader, O. Olsvik & M.R. El-Gewely, (1996) Isolation of cmr, a novel 
Escherichia coli chloramphenicol resistance gene encoding a putative efflux pump. J. 
Bacteriol. 178: 3188-3193. 
Nilsson, A.I., S. Koskiniemi, S. Eriksson, E. Kugelberg, J.C.D. Hinton & D.I. Andersson, (2005) 
Bacterial genome size reduction by experimental evolution. Proc. Natl. Acad. Sci. USA 
102: 12112-12116. 
Nitiss, J.L., (2009a) DNA topoisomerase II and its growing repertoire of biological functions. Nat. 
Rev. Cancer 9: 327-337. 
Nitiss, J.L., (2009b) Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer 9: 
338-350. 
Noble, C.G. & A. Maxwell, (2002) The Role of GyrB in the DNA Cleavage-religation Reaction of 
DNA Gyrase: A Proposed Two Metal-ion Mechanism. J. Mol. Biol. 318: 361-371. 
Nolivos, S., A.L. Upton, A. Badrinarayanan, J. Müller, K. Zawadzka, J. Wiktor, A. Gill, L. 
Arciszewska, E. Nicolas & D. Sherratt, (2016) MatP regulates the coordinated action of 
topoisomerase IV and MukBEF in chromosome segregation. Nat. Commun. 7: 10466. 
Nollmann, M., N.J. Crisona & P.B. Arimondo, (2007a) Thirty years of Escherichia coli DNA gyrase: 
From in vivo function to single-molecule mechanism. Biochimie 89: 490-499. 
 270 
 
Nollmann, M., M.D. Stone, Z. Bryant, J. Gore, N.J. Crisona, S.-C. Hong, S. Mitelheiser, A. Maxwell, 
C. Bustamante & N.R. Cozzarelli, (2007b) Multiple modes of Escherichia coli DNA gyrase 
activity revealed by force and torque. Nat. Struct. Mol. Biol. 14: 264-271. 
Normark, S., T. Edlund, T. Grundström, S. Bergström & H. Wolf-Watz, (1977) Escherichia coli K-
12 Mutants Hyperproducing Chromosomal Beta-Lactamase by Gene Repetitions. J. 
Bacteriol. 132: 912-922. 
Norström, T., J. Lannergård & D. Hughes, (2007) Genetic and Phenotypic Identification of Fusidic 
Acid-Resistant Mutants with the Small-Colony-Variant Phenotype in Staphylococcus 
aureus. Antimicrob. Agents Chemother. 51: 4438-4446. 
O'Neill, J., (2016) Tackling drug-resistant infections globally: Final report and recommendations. 
In., pp. The Review on Antimicrobial Resistance. Final report. 
O'Sullivan, D.M., J. Hinds, P.D. Butcher, S.H. Gillespie & T.D. McHugh, (2008) Mycobacterium 
tuberculosis DNA repair in response to subinhibitory concentrations of ciprofloxacin. J. 
Antimicrob. Chemother. 62: 1199-1202. 
Oakley, T.J. & I.D. Hickson, (2002) Defending genome integrity during S-phase: putative roles for 
RecQ helicases and topoisomerase III. DNA Repair 1: 175-207. 
Oliphant, C.M. & G.M. Green, (2002) Quinolones: a comprehensive review. Am. Fam. Physician 
65: 455-464. 
Oram, M., A.A. Travers, A.J. Howells, A. Maxwell & M.L. Pato, (2006) Dissection of the 
Bacteriophage Mu Strong Gyrase Site (SGS): Significance of the SGS Right Arm in Mu 
Biology and DNA Gyrase Mechanism. J. Bacteriol. 188: 619-632. 
Orphanides, G. & A. Maxwell, (1994) Evidence for a conformational change in the DNA gyrase-
DNA complex from hydroxyl radical footprinting. Nucleic Acids Res. 22: 1567-1575. 
Pang, Z., R. Chen, D. Manna & N.P. Higgins, (2005) A Gyrase Mutant with Low Activity Disrupts 
Supercoiling at the Replication Terminus. J. Bacteriol. 187: 7773-7783. 
Papillon, J., J.F. Menetret, C. Batisse, R. Helye, P. Schultz, N. Potier & V. Lamour, (2013) Structural 
insight into negative DNA supercoiling by DNA gyrase, a bacterial type 2A DNA 
topoisomerase. Nucleic Acids Res. 41: 7815-7827. 
 271 
 
Parks, W.M., (2004) The interaction between DNA gyrase and the peptide antibiotic microcin 
B17. In: Biological Chemistry Department, John Innes Centre. Norwich, UK: University of 
East Anglia, pp. 188. 
Pato, M.L., (1994) Central location of the Mu strong gyrase binding site is obligatory for optimal 
rates of replicative transposition. Proc. Natl. Acad. Sci. USA 91: 7056-7060. 
Pendleton, M., R.H. Lindsey, C.A. Felix, D. Grimwade & N. Osheroff, (2014) Topoisomerase II and 
leukemia. Ann. N. Y. Acad. Sci.: 1-13. 
Peng, H. & K.J. Marians, (1993) Escherichia coli topoisomerase IV. Purification, characterization, 
subunit structure, and subunit interactions. J. Biol. Chem. 268: 24481-24490. 
Peng, H. & K.J. Marians, (1995) The interaction of Escherichia coli topoisomerase IV with DNA. J. 
Biol. Chem. 270: 25286-25290. 
Pereira, R.V., J.D. Siler, J.C. Ng, M.A. Davis, Y.T. Grohn & L.D. Warnick, (2014) Effect of on-farm 
use of antimicrobial drugs on resistance in fecal Escherichia coli of preweaned dairy 
calves. J. Dairy Sci. 97: 7644-7654. 
Pérez-Capilla, T., M.-R. Baquero, J.-M. Gómez-Gómez, A. Ionel, S. Martín & J. Blázquez, (2005) 
SOS-Independent Induction of dinB Transcription by β-Lactam-Mediated Inhibition of 
Cell Wall Synthesis in Escherichia coli. J. Bacteriol. 187: 1515-1518. 
Perez-Cheeks, B.A., C. Lee, R. Hayama & K.J. Marians, (2012) A role for topoisomerase III in 
Escherichia coli chromosome segregation. Mol. Microbiol. 86: 1007-1022. 
Peter, B.J., J. Arsuaga, A.M. Breier, A.B. Khodursky, P.O. Brown & N.R. Cozzarelli, (2004) Genomic 
transcriptional response to loss of chromosomal supercoiling in Escherichia coli. 
Genome Biol. 5: R87. 
Peter, B.J., C. Ullsperger, H. Hiasa, K.J. Marians & N.R. Cozzarelli, (1998) The Structure of 
Supercoiled Intermediates in DNA Replication. Cell 94: 819-827. 
Pitiriga, V., G. Vrioni, G. Saroglou & A. Tsakris, (2017) The Impact of Antibiotic Stewardship 
Programs in Combating Quinolone Resistance: A Systematic Review and 
Recommendations for More Efficient Interventions. Advances in Therapy 34: 854-865. 
Piton, J., S. Petrella, M. Delarue, G. André-Leroux, V. Jarlier, A. Aubry & C. Mayer, (2010) 
Structural insights into the quinolone resistance mechanism of Mycobacterium 
tuberculosis DNA gyrase. PLoS ONE 5: e12245. 
 272 
 
Pletz, M.W.R., M. Rau, J. Bulitta, A. De Roux, O. Burkhardt, G. Kruse, M. Kurowski, C.E. Nord & 
H. Lode, (2004) Ertapenem Pharmacokinetics and Impact on Intestinal Microflora, in 
Comparison to Those of Ceftriaxone, after Multiple Dosing in Male and Female 
Volunteers. Antimicrob. Agents Chemother. 48: 3765-3772. 
Pogue-Geile, K.L., S. Dassarma, S.R. King & S.R. Jaskunas, (1980) Recombination between 
bacteriophage lambda and plasmid pBR322 in Escherichia coli. J. Bacteriol. 142: 992-
1003. 
Pohlhaus, J.R. & K.N. Kreuzer, (2005) Norfloxacin-induced DNA gyrase cleavage complexes block 
Escherichia coli replication forks, causing double-stranded breaks in vivo. Mol. Microbiol. 
56: 1416-1429. 
Pommier, Y., P. Pourquier, Y. Fan & D. Strumberg, (1998) Mechanism of action of eukaryotic 
DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta 1400: 
83-106. 
Pope, C.F., D.M. O'Sullivan, T.D. McHugh & S.H. Gillespie, (2008) A Practical Guide to Measuring 
Mutation Rates in Antibiotic Resistance. Antimicrob. Agents Chemother. 52: 1209-1214. 
Postow, L., N.J. Crisona, B.J. Peter, C.D. Hardy & N.R. Cozzarelli, (2001) Topological challenges to 
DNA replication: conformations at the fork. Proc. Natl. Acad. Sci. USA 98: 8219-8226. 
Postow, L., C.D. Hardy, J. Arsuaga & N.R. Cozzarelli, (2004) Topological domain structure of the 
Escherichia coli chromosome. Genes Dev. 18: 1766-1779. 
Pruss, G.J., S.H. Manes & K. Drlica, (1982) Escherichia coli DNA topoisomerase I mutants: 
Increased supercoiling is corrected by mutations near gyrase genes. Cell 31: 35-42. 
Rajan, R., A. Osterman & A. Mondragón, (2016) Methanopyrus kandleri topoisomerase V 
contains three distinct AP lyase active sites in addition to the topoisomerase active site. 
Nucleic Acids Res. 44: 3464-3474. 
Rajan, R., B. Taneja & A. Mondragon, (2010) Structures of minimal catalytic fragments of 
topoisomerase V reveals conformational changes relevant for DNA binding. Structure 
18: 829-838. 
Rau, D.C., M. Gellert, F. Thoma & A. Maxwell, (1987) Structure of the DNA gyrase-DNA complex 
as revealed by transient electric dichroism. J. Mol. Biol. 193: 555-569. 
 273 
 
Rau, M.H., R.L. Marvig, G.D. Ehrlich, S. Molin & L. Jelsbak, (2012) Deletion and acquisition of 
genomic content during early stage adaptation of Pseudomonas aeruginosa to a human 
host environment. Environ. Microbiol. 14: 2200-2211. 
Rawdon, E.J., J. Dorier, D. Racko, K.C. Millett & A. Stasiak, (2016) How topoisomerase IV can 
efficiently unknot and decatenate negatively supercoiled DNA molecules without 
causing their torsional relaxation. Nucleic Acids Res. 44: 4528-4538. 
Redgrave, L.S., S.B. Sutton, M.A. Webber & L.J. Piddock, (2014) Fluoroquinolone resistance: 
mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol. 22: 
438-445. 
Reece, R.J. & A. Maxwell, (1989) Tryptic fragments of the Escherichia coli DNA gyrase A protein. 
J. Biol. Chem. 264: 19648-19653. 
Reece, R.J. & A. Maxwell, (1991a) DNA gyrase: Structure and function. Crit. Rev. Biochem. Mol. 
Biol. 26: 335-375. 
Reece, R.J. & A. Maxwell, (1991b) Probing the limits of the DNA breakage-reunion domain of the 
Escherichia coli DNA gyrase A protein. J. Biol. Chem. 266: 3540-3546. 
Reisinger, V. & L.A. Eichacker, (2007) How to analyze protein complexes by 2D blue native SDS-
PAGE. Proteomics 7 Suppl 1: 6-16. 
Reyes-Domínguez, Y., G. Contreras-Ferrat, J. Ramírez-Santos, J. Membrillo-Hernández & M.C. 
Gómez-Eichelmann, (2003) Plasmid DNA Supercoiling and Gyrase Activity in Escherichia 
coli Wild-Type and rpoS Stationary-Phase Cells. J. Bacteriol. 185: 1097-1100. 
Richardson, S.M., C.F. Higgins & D.M. Lilley, (1984) The genetic control of DNA supercoiling in 
Salmonella typhimurium. EMBO J. 3: 1745-1752. 
Rickenberg, H.V. & G. Lester, (1955) The preferential synthesis of beta-galactosidase in 
Escherichia coli. Journal of General Microbiology 13: 279-284. 
Robert, T., A. Nore, C. Brun, C. Maffre, B. Crimi, V. Guichard, H.-M. Bourbon & B. de Massy, 
(2016a) The TopoVIB-Like protein family is required for meiotic DNA double-strand 
break formation. Science 351: 943-949. 
Robert, T., N. Vrielynck, C. Mézard, B. de Massy & M. Grelon, (2016b) A new light on the meiotic 
DSB catalytic complex. Semin. Cell Dev. Biol. 54: 165-176. 
 274 
 
Roca, J., (2004) The path of the DNA along the dimer interface of topoisomerase II. J. Biol. Chem. 
279: 25783-25788. 
Roca, J., J.M. Berger, S.C. Harrison & J.C. Wang, (1996) DNA transport by a type II topoisomerase: 
Direct evidence for a two-gate mechanism. Proc. Natl. Acad. Sci. USA 93: 4057-4062. 
Rocha, J.C., F.F. Busatto, T.N. Guecheva & J. Saffi, (2016) Role of nucleotide excision repair 
proteins in response to DNA damage induced by topoisomerase II inhibitors. Mutat. Res. 
- Rev. Mut. Res. 768: 68-77. 
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Appendix I: Plasmid and DNA Substrate Maps 
 
 
Figure XI: DNA map of Cam Frag. Linear DNA substrate of 1869 bp containing the 
chloramphenicol resistance cassette (CamR – in red) from pACYC184, the strong-gyrase binding 
site from pBR322 (pBR322 SGS – dark blue) and the Mu strong-gyrase binding site (Mu SGS – 
petrol blue). 
 
 
 
Figure XII: DNA map of the MiniCircle. Circular DNA substrate of 2012 bp containing the 
chloramphenicol resistance cassette (CamR – in red) from pACYC184, the strong-gyrase binding 
site from pBR322 (pBR322 SGS – dark blue) and the Mu strong-gyrase binding site (Mu SGS – 
petrol blue). It also contains the E. coli AttR site (orange) as a result of the manufacturing 
process. 
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Figure XIII: Plasmid map of pACYC177. It has the P15A Origin (green) with an ampicillin 
(AmpR – pink) and kanamycin (KanR – yellow) resistance cassettes. The purple indicates TN3 
inverse repeats and the black line indicates the ApaLI restriction site. 
 
 
Figure XIV: Plasmid map of pACYC184. It has the P15A Origin (green) with a 
chloramphenicol (CamR – red) and tetracycline (TetR – royal blue) resistance cassettes. 
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Figure XV: Plasmid map of pBR322*. It has the ColE1 Origin (grey) (with a single point 
mutation to increase copy number) with an ampicillin (AmpR – pink) resistance cassette. The 
tetracycline (TetR – royal blue) resistance cassette has been inactivated by a deletion between 
bp 42 and 139 (indicated by the red cross). The black lines indicate the ApaLI restriction sites. 
 
 
Figure XVI: Plasmid map of pGDV1. It has the palA Origin (green) with a chloramphenicol 
(CamR – red) resistance cassette and the pUC18 multiple cloning site (pUC18 MCS in dark blue). 
 290 
 
 
Figure XVII: Plasmid map of pIR. It has the ColE1 Origin (grey) (with a single point mutation 
to increase copy number) and the origin from pSC101 (light blue and RepA darker blue) with 
a chloramphenicol (CamR – red) resistance cassette from pACYC184. There are two the Mu 
strong-gyrase binding site (Mu SGS – petrol blue) around the CamR cassette. The black lines 
indicate the ApaLI and NheI restriction sites. 
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Figure XVIII: Plasmid map of pKD46. It has the origin from pSC101 (light blue and RepA 
darker blue) with an ampicillin (AmpR – pink) resistance cassette. The AraC protein is indicated 
in purple. The Lambda Red proteins, Gam (light green), Beta (mid green) and Exo (dark green) 
proteins are under the inducible arabinose promoter (Para in mauve). 
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Figure XIX: Plasmid map of pLysS. It has the P15A Origin (green) with a chloramphenicol 
(CamR – red) resistance cassette. The tetracycline (TetR – royal blue) resistance cassette have 
been inactivated by a 634 bp insertion. 
 
 
Figure XX: Plasmid map of pPH3. It has the pBR322 Origin (grey also known as the ColE1 
origin) with an ampicillin (AmpR – pink) resistance cassette. The LacIq gene is indicated in dark 
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blue. The gyrA gene is indicated in mustard yellow (GyrA) under control of the inducible tac 
promoter (Ptac - mauve). 
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